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Abstract 
Abstract 
The field of metabonomics is beginning to grow rapidly due to the ability to analyse 
biofluids, providing a `snapshot' of biological processes that have happened (cf. 
proteomic/transcriptomic studies, which predict what may happen), making it possible 
to profile responses over time. The work described in this thesis was motivated by 
the aim of profiling clinical urine samples obtained from fracture patients, with a view 
to identifying potential biomarkers related to failed fracture healing. This led to the 
need to develop and evaluate metabonomic approaches, specifically a orthogonal 
separation approach complementary to the commonly-used reversed phase (RP) 
separation methods, namely hydrophilic interaction liquid chromatography (HILIC). 
Urine samples from healthy volunteers were collected and used to develop an LC- 
MS `metabonomic toolbox'. This development evaluated various aspects of a 
metabbnomic study that are commonly poorly reported within the literature: study 
design, sample collection storage and handling considerations, data extraction, 
normalisation and scaling methods, and multivariate data analysis tools. 
From the literature, the commonly-used method of normalising to creatinine was 
found to be unsuitable due to perturbations in the urinary excretion of creatinine due 
to factors such as illness. Methods used to evaluate system stability were also 
developed and added to the `toolbox'. HILIC was successfully used as a separation 
technique orthogonal to RP, producing comparable results but using different 
metabolites; this highlights the fact that much potential information is possibly being 
lost when only RP-LC-MS methods are used for analysis. The need to use both 
modes of ionisation polarity were also addressed for an increased coverage in 
biofluid metabolite profiles. 
The knowledge gained in the development of the `metabonomic toolbox' was used for 
the analysis of clinical urine samples. Despite the lack of properly time-setted 
samples and none of the recruited patients suffering delayed fracture healing, 
potential metabolites related to fracture healing were found. However, the samples 
were very different to previously-analysed samples from healthy volunteers; they 
showed very large amounts of protein, which had a large range of molecular weights. 
These were identified proteomically. 
Finally, ESI-Q-o-ToF MS/MS, MALDI-ToF/ToF MS/MS and racemic amino acid 
analysis were used for the structural determination of a pseudomonad biosurfactant, 
which was identified, unexpectedly, as the cyclic lipopeptide white line inducing 
principle, WLIP. 
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Chapter One: Introduction 
1.1. Overview 
The work described in this thesis was motivated by the original aim of profiling clinical 
urine samples obtained from fracture patients, in research originated in collaboration 
with Smith & Nephew, UK. This led to the work described in this thesis being 
primarily focussed upon investigating certain aspects of, and developing further 
methods for, liquid chromatography-mass spectrometric metabonomic studies. As 
the field of metabonomics is relatively young (Nicholson, 1999) compared to other 
better established `omic' techniques, there was (and still is) a need to consider many 
different aspects of the experimental approach that are not always covered within the 
literature, so that a robust `metabonomic toolbox' can be created and utilised for the 
study of the clinical urine samples, with the original hope of identifying candidate 
biomarkers for further study. 
In addition to the metabonomic studies of human urine samples, the same methods 
as are used for metabonomic studies were exploited for the structural identification of 
a biosurfactant from a soil bacterial isolate. 
1.2. Introduction 
The human skeletal system consists of 206 bones (upon maturity) that function to 
support, protect and store. Whilst being strong, bones can fracture; given the nature 
of human activity bone fractures will and do occur. Most fractures that occur within 
the human body will heal successfully given some degree of medical intervention, 
however, there are occasions where a fracture will fail to heal successfully (delayed 
or non-union) and require further medical attention. The number of non-unions has 
been described as "alarming"; in the United States alone there were nearly 100,000 
non-union treatments performed in 2003 (Jones, 2005). 
Metabolic bone diseases such as Paget's', osteoarthritis2 and osteoporosis3 are a 
common cause of pathological fractures in the elderly. Over three million people 
suffer from osteoporosis in the UK, and as a result there are over 200,000 fractures 
annually (NHS-Direct). Studies have utilised biofluids such as serum and urine to try 
1 Increased and irregular bone formation leading to larger, weaker bones. 2 The most common type of arthritis, primarily affecting joints. 
3 Bone structure becomes porous (osteoporosis literally means 'porous bones'). 
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and find indicators of metabolic bone disease, with a view to the possibility of earlier 
diagnosis and treatment of these pathological bone diseases 
The overall processes behind the biochemistry of bone formation and resorption 
(bone turnover) are reasonably well known, but in-depth knowledge is lacking; 
numerous studies are currently trying to gain a further insight into the complex 
processes involved in bone turnover (Fisher et al., 2005; Heer et al., 2005; Mandelin 
et al., 2005; Leu et al., 2006; Nancollas et al., 2006; Viguet-Carrin et al., 2006). 
Many studies have identified biomarkers in both serum and urine that have been 
used to monitor bone turnover (Calvo et al., 1996; Eyre, 1996; Woitge et al., 1998; 
DeLaurier et al., 2004; Miller, 2005; Weisman and Matkovic, 2005). However, it has 
been noted that no single biomarker can provide a reliable results for monitoring 
bone turnover (Calvo et al., 1996). As analytical techniques such as gas 
chromatography-mass spectrometry (GC-MS), high performance liquid 
chromatography-mass spectrometry (HPLC-MS) and nuclear magnetic resonance 
(NMR) provide increased selectivity and sensitivity over more traditional assay based 
techniques, they will become an increasingly important techniques for biomarker 
analysis and identification. 
Pathological bone fractures, which are caused by metabolic bone diseases, have 
received most of the attention in the literature on bone turnover studies; osteoporosis 
being the predominant disease is therefore the most studied. Many potential serum 
biomarkers such as osteocalcin, alkaline phosphatase, pyridinoline, 
deoxypyridinoline, tartrate resistant acid phosphatase, hydroxylysine glycosides and 
urinary biomarkers including pyridinoline, deoxypyridinoline, osteocalcin or cross- 
linking telopeptides have been identified as biochemical markers that are suitable for 
use in the management of osteoporosis (Ebeling and Akesson, 2001). Research has 
shown that recently sustained pathological fractures influence the levels of 
biochemical markers of bone turnover (Obrant et al., 2005); given that the levels of 
biomarkers can be profiled for fractures that are a result of a metabolic bone disease, 
there is good reason to propose that the biochemical response to a non-pathological 
fracture may also be profiled in a similar way. 
Since this study was commissioned, there have only been a handful of papers 
published that study non-pathological fractures and their delay or failure to heal. Of 
these papers none studied urine as a biofluid, all having chosen to concentrate on 
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serum. Zimmermann et al., (Zimmermann et al., 2005) concentrated on the 
transforming growth factor family, and in particular TGF-(31 as a marker of delayed 
fracture healing, whilst Henle et al., (Henle et al., 2005) studied matrix 
metalloproteinases and failed fracture healing. These studies were designed to look 
at specific compounds within serum; as serum is a homeostatically controlled biofluid 
there may be more hope for the analysis of urine, which is a biofluid that should 
contain biomarkers that have been removed from serum as they are no longer 
required, and are therefore a functional end-point. 
One area of analytical science that is suitable for the analysis of biofluids, and has 
seen substantial growth are the related fields of metabonomics and metabolomics. 
These `omic' technologies typically involve a less targeted approach to analysis, 
being hypothesis forming, rather than hypothesis driven. They utilise analytical 
methodologies such as capillary electrophoresis (Pisitkun et al., 2006; Ullsten et al., 
2006; Monton and Soga, 2007), gas chromatography (Kopka, 2006) and high 
performance liquid chromatography (Plumb et al., 2005; Wilson et al., 2005; Lenz 
and Wilson, 2007), which are typically coupled to a mass spectrometer, or use NMR 
(Robertson et al., 2000; Constantinou et al., 2005; Bertram et al., 2007) (or recently 
HPLC-NMR-MS (Bajad et al., 2003)). These methods typically provide separation of 
the complex biofluid matrix components, and their subsequent detection (and ideally 
quantification). 
Techniques such as NMR and HPLC-MS create vast amounts of data, which have 
been called mega-variate data, which would be impossible to visually interpret. 
Thankfully, methods such as multi-variate data analysis (MVDA) which encompass 
techniques such as principal component analysis (PCA) and partial least squares - 
discriminant analysis (PLS-DA) have been developed, which allows the comparison 
of large datasets with few observations (samples) and many thousands of variables. 
The dimensionality of datasets is reduced before any differences (such as 
metabolites or groups of metabolites that are related to the condition being 
investigated) can be pinpointed and subjected to further investigation (Dunn and 
Ellis, 2005; Wilson et al., 2005; Chen et al., 2007). 
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1.3. The skeletal system 
The skeletal system performs a vital role within the human body; it supports muscle, 
which allows locomotion (mechanical role), affords protection for vital organs and 
stem cells (protective role) and also provides a large reserve of ions (metabolic role). 
The body stores a total of about 1000 g of calcium and 600 g of phosphate, 99 and 
65 % of which respectively, is housed within the skeletal system (American Society 
for Bone and Mineral Research, 1999). 
1.3.1. Bone remodelling 
Bone is a living tissue and as such is in a dynamic state as it is continually being 
formed by osteoblasts and broken down by osteoclasts (figure 1.3.1); this is known 
as bone turnover. As the skeleton is in a dynamic state, it can continually adapt to 
changes in its physiological and mechanical environment, i. e. periods of heavy, 
repeated stress on the skeleton would cause more bone to be laid down, whereas 
long periods of inactivity can cause bone to be resorbed, weakening the skeleton. 
Bane king ceis 
o ýý Bane irrig ce>s 
Non- 
mineafised 
bane 
New bane 
ald bone 
Figure 1.3.1. A schematic representation of the components involved in the bone 
remodelling process. Courtesy of Leah Etheridge, Dept. Biology, University of York, 
UK. 
The process of bone turnover is highly complex and is still not fully understood. In 
order to maintain bone (dynamic tissue) it is removed by resorption so that new bone 
can be laid down in its place. Osteoclasts are giant nucleated cells that contain four 
to twenty nuclei; parathyroid hormone (PTH) is released by the parathyroid gland. 
This induces the production of vitamin D3 [1,25(OH)2 vitamin D3], which in turn 
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induces the differentiation of marrow monocytes, from bone marrow, into osteoclasts. 
Each resorptive site only contains one or two osteoclasts that secrete a range of 
enzymes which function to digest the bone and release the stored calcium and other 
minerals into the blood stream. The secretion of tartrate resistant acid phosphatase 
(TRAP) lowers the pH at the resorptive site. TRAP actively digests the hydroxyapatite 
crystals that are linked to collagen; collagenase digests the exposed collagen fibres, 
leaving a site that is now ready for new bone to be laid down. 
Normally, bone formation only occurs at a site that has previously undergone bone 
resorption and typically deposits around 0.55 µm of new bone per day (American 
Society for Bone and Mineral Research, 1999). Osteoblasts are formed by the 
proliferation of stem cells (found in bone marrow), which is induced by a drop in the 
serum levels of PTH, caused by an increase in the hormone oestrogen. Whereas 
osteoclasts are few in number at a resorptive site, osteoblasts form clusters of 100 to 
400 cells and are rich in alkaline phosphatase, and secrete type I collagen that 
matures and allows the deposition of minerals. 
Bone matrix is a two-phase system; collagen provides ductility and the ability to 
absorb energy whereas minerals provide rigidity. Collagen has a triple helix structure 
formed by three alpha polypeptide chains; these are laid down and arranged in fibrils 
in concentric strands. Depending upon the type of collagen, each chain generally 
consists of a tight triple helix afforded by a Gly-X-Y triplet (where X is usually proline 
and Y hydroxyproline). Glycine is an absolute requirement as it is the smallest amino 
acid, and so can occupy the centre of the triple helix structure, making possible the 
tight helix structure (Viguet-Carrin et al., 2006). The collagen fibrils are roughly 300 
nm in length and are capped by N- and C-terminal propeptides' that function to allow 
the association of newly synthesised procollagen chains. 95 % of collagen content in 
bone comprises type I collagen (and also accounts for - 80 % of the total protein 
content in bone); type III and V collagens are present at. low levels and function to 
modulate the diameter of the type I collagen fibrils. 
Collagen is initially un-mineralised. As bone matures, hydroxyapatite crystals are 
deposited and the bone becomes calcified, increasing the stiffness. Further stability 
is derived from inter and intramolecular cross-links as the N- and C-terminal 
1 The prefix pro- refers to an inactive protein or peptide. They can be activated by posttranslational 
modification (a chemical modification). 
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telopeptides1 are oxidatively deaminated. This results in cross links being formed 
through condensation with a lysyl or hydroxylysyl side chain on an adjacent collagen 
fibril. 
The three dimensional architecture of bone, its shape and geometry and the intrinsic 
properties of the matrix (mineral and collagen), give the skeleton the capacity to 
resist mechanical forces. However, the amount of force that a bone can withstand 
before giving way and causing a fracture is dependent upon the quality and quantity 
of bone tissue that is laid down. 
1.3.2. Fractures 
Bone is anisotropic in nature, meaning that it has different mechanical properties 
when it is loaded along its different axes; bones are typically strongest when weight 
is applied along their length. Fractures occur when too much pressure is loaded onto 
any one of the axes, or a combination of axes. Pathological fractures are caused by 
diseases such as osteoporosis2 and Paget's3; bones are weaker and more likely to 
suffer from a fracture due to the inherent bone structure being degraded. The 
majority of fractures are not a result of a pathological disease; they are caused by 
either direct or indirect forces that result in the fracture being classed as one of three 
types (Wraighte and Scammell, 2006). 
Transverse fractures (figure 1.3.2a) are a result of a direct force or bending and are 
considered to be a simple fracture as they are typically stable, which favours union of 
the broken bone. They may require some kind of external fixation such as a plaster 
cast to ensure that there is minimal movement. Oblique and spiral fractures (figures 
1.3.2b and c respectively) are usually caused by compression/loading and torsional 
forces; these types of fractures are inherently less stable than transverse fractures 
and can suffer from bone shortening and/or displacement. All three types of fractures 
can become more complex when multiple bone fragments are present; these 
fractures are referred to as comminuted4 fractures. 
1 The prefix telo- means 'at the end'. 
2A metabolic bone disease where the structure of bone becomes porous (osteoporosis literally means 
orous bones'), it typically affects those over the age of 45. 
Paget's is a metabolic bone disease where bone cells begin to form bone in an uncontrolled and 
irregular pattern, causing poor bone structure, it typically affects those over the age of 45. 
4 Many broken, splintered or crushed bone fragments. 
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(a) (b) (c) 
Figure 1.3.2. Diagram to illustrate the three types of non-pathological fractures: (a) 
transverse fracture. (b) oblique fracture, (c) spiral fracture. 
1.3.3. Fracture healing 
Bone has the amazing ability to successfully repair itself and heal without leaving any 
visible signs of scarring. There are two types of fracture healing, primary and 
secondary. Primary fracture healing can take place after reduction and rigid internal 
fixation that leaves the fracture surfaces unable to move. However, there has to be a 
direct bony union. More commonly, secondary fracture healing occurs. Secondary 
fracture healing affords some controlled movement, as there is relative stability; the 
fracture is usually cast in a plaster cast or is externally fixed. 
Fracture treatment in the UK follows the RIP (reduction, immobilisation and 
physiotherapy) model (Wraighte and Scammell, 2006). Reduction is only undertaken 
if there is any significant displacement of the fracture and is typically used when 
oblique or spiral fractures occur. Manipulative reduction involves the reversal of 
direction that initially caused the fracture in an attempt to re-align the fractured 
bones. If a fracture is considered to be stable then a plaster cast can be used but 
7 
Chapter One: Introduction 
must be moulded properly to avoid any subsequent re-displacement of the bones. 
Plaster casts cannot, however, prevent any shortening of the bone. Less stable 
fractures can be externally fixed but are often accompanied by internal fixation 
devices. Once any reduction and/or immobilisation technique has been carried out, 
the healing process can begin. 
Site of fracture 
Dead bone 
f-- Haematoma 
(b) 
New bone Granulation tissue 
(c) 
Granulation tissue 
New bone 
Figure 1.3.3. Diagram to represent the secondary fracture healing process: (a) 
formation of a haematoma at the fracture site, (b) inflammation stage, (c) final repair 
stage. 
Primary healing requires direct bony union and absolute stability; this is only 
achieved through reduction and rigid internal fixation, usually with some 
compression. As there is no motion, there is very little (if any) strain present. The gap 
between the bone ends is less than 200 pm. This allows osteoclasts to "... tunnel 
across the fracture line... " (Wraighte and Scammell, 2006). Osteoblasts can follow, 
laying down the bone matrix to establish continuity. However, primary healing is a 
slow process as it is basically an extension of normal bone turnover. The bones must 
remain internally fixed until the healing process has finished and the remodelling is 
complete. 
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Secondary healing is the most common form of fracture healing and occurs when 
there is controlled movement of the fracture; the bone is relatively stable and is 
usually supported by an external fixation device such as a plaster cast. Secondary 
healing follows four phases that overlap. 
The first phase involves the formation of a haematoma' at the site of the fracture, 
causing the periosteum2 to tear. The ends of the bone die due to the formation of the 
haematoma, killing the osteocytes; osteoclasts begin to resorb the dead bone at the 
fracture site (figure 1.3.3a). The haematoma is gradually replaced by granulation 
tissue (fracture callus) during the inflammation stage (figure 1.3.3b). Granulation 
tissue is an intermediary between the formation of bone; unlike bone, granulation 
tissue can withstand high degrees of strain (osteoblasts can only withstand strains of 
less than 1 %). Granulation tissue increases in size, which has the effect of 
stabilising the fracture. As soon as the strain drops below 10 % (the fracture begins 
to stabilise) the granulation tissue begins to be replaced by forming cartilage, 
signalling the onset of the repair stage (figure 1.3.3c). Continuity between the bones 
is achieved when the cartilage bridges the gap and an external callus is formed. 
Upon further stabilisation of the fracture (when the stress is less than 1 %), the 
cartilage is gradually replaced with woven bone by the osteoblasts, which go on to 
replace all of the cartilage and callus with woven bone. The final step in secondary 
fracture healing is the longest and may take several years to complete. Lamellar 
bone is created from the weaker woven bone that was laid down previously. The 
bone shape begins to return but is based upon the stresses under which the bone 
has been placed during the whole repair process. Eventually, when the osteoblasts 
and osteoclasts begin to once more work in unison, the bone has healed and 
typically bears no scar tissue or evidence that a fracture has even occurred. 
1.3.4. Factors that affect healing 
There are many factors that can affect the rate at which a fracture heals, and also 
whether a fracture heals at all. Many fractures take longer than expected to heal, 
termed delayed union, whilst others fail to heal at all and are classed as non-union. 
Age has a large effect upon the rate of healing as young people, especially children, 
tend to heal at a much faster rate than older. Over the age of 40 to 50 there is an 
A collection of blood as the result of haemorrhage/internal bleeding. 
2A layer of irregular tissue membrane that covers the outer surface of bone (not at joints). 
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increased risk of fractures due to pathological disease. These fractures are likely to 
take much longer to heal than the non-pathological fractures that are common to the 
younger age groups. Other factors such as gender may play a part, but lifestyle 
differences may account for the delayed or non-union of fractures. People who 
smoke, drink and eat excessively or poorly are at a higher risk of fractures that fail to 
heal successfully (Wraighte and Scammell, 2006). 
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1.4. Metabolism 
Metabolism is the word used to describe many biological processes that are the 
means by which the body can synthesise many compounds and also generate 
energy. The synthesis of compounds is termed anabolism, and requires energy; this 
energy is generated by catabolism, where large molecules are broken down to 
generate smaller molecules, releasing energy in the process. Hormones typically 
control both anabolism and catabolism. The process of metabolism (both anabolic 
and catabolic) can be summarised as primary or secondary metabolism depending 
upon the function: primary metabolism (or basic metabolism) refers to any metabolic 
processes that are necessary to keep a cell alive (e. g. energy production, 
biosynthesis of molecules), whereas secondary metabolism relates to compounds 
that are produced/broken down, but are not important for the survival of the cell itself. 
However, secondary metabolism is important for an organism as a whole, as 
secondary metabolites are produced to enhance survival (their absence may not 
immediately result in death, but prolonged absence would). Molecules are typically 
synthesised from fats, carbohydrates and proteins (obtained from food) by enzymes. 
Many metabolic pathways interlink, and need to be able to detect the function or 
status of other pathways for efficient metabolism. 
One important factor that is gaining interest in the field of metabolism (and 
metabonomics/metabolomics) is gut microflora (Nicholson, J et al., 2002; Nicholson, 
Jeremy K. and Wilson, 2003; Nicholson, J et al., 2004; Nicholson, J et al., 2005; Gill 
et al., 2006; Bertram et al., 2007; Goodacre, 2007; Rezzi et al., 2007a; Rezzi et al., 
2007b). Nicholson et al., and Gill et al., report that the human intestinal tract is home 
to some 10 to 100 trillion (1014) microbes, which are essential for function (Nicholson, 
J et al., 2005; Gill et al., 2006). Given that the human base pair genome stands at 
2.85 billion, the estimated >_100 times greater number of genes contained within the 
human gut dwarfs this value. Gut microflora (microbiome) have been shown to 
enhance the metabolism of amino acids, glycans and xenobiotics, as well as the 
synthesis of vitamins (Gill et al., 2006). 
Whilst much more research is required to understand the effects of age, diet and 
pathological status upon the gut microbiome, Bertram et al. have shown that diet 
strongly affects the gut microbiome (Bertram et al., 2007). Rezzi et al. have observed 
that the gut microbiome, once considered to be relatively stable, are more related to 
diet than once previously thought (Rezzi et al., 2007a; Rezzi et al., 2007b). 
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As the gut microbiome also varies upon demographic profile (personal conference 
notes), it is clear that metabolites are very varied, and largely influenced by many 
factors. 
1.4.1. Renal handling and urinary excretion 
The kidney is a key organ in the regulation of metabolic products, as it is the route by 
which they can be excreted. Kidneys regulate the composition of the blood by 
maintaining the appropriate composition of many ions, removing waste compounds 
such as urea, ammonia and xenobiotics, and regulating the pH. Compounds can be 
modified to either make them more soluble (e. g. sulfonation, alkylation, acetylation or 
glucuronidation where a compound is bound to glucuronic acid via a glycosidic 
bond), or to contain a functional marker group to allow excretion rather than 
retention. 
(e) 
fib, 
Figure 1.4.1. A schematic of a nephron from a kidney: (a) capillaries, (b) glomerulus 
and glomerular capillaries, (c) descending loop of Henle, (d) ascending loop of Henle, 
(e) distal tubule to the bladder. 
In the nephron (figure 1.4.1), blood received from the heart gets filtered under 
pressure in the glomerulus, creating a filtrate. The glomerulus acts as a physical and 
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electrical charge barrier to most plasma proteins, although some do pass into the 
proximal tubule (figure 1.4.1c and d) dependent upon their size and concentration in 
plasma (Christian and Watson, 2004). The filtrate consists of water, ions such as 
sodium, potassium and chloride, glucose, amino acids and small proteins (less than 
40 kDa (Gonzalez-Buitrago et al., 2007)). The loop of Henle consists of transporters, 
which are selective for specific molecules. The descending loop of Henle has 
transporters that are specific for glucose and sodium, creating a concentration 
gradient that causes water to be passively reabsorbed in the ascending loop of Henle 
by osmosis; low molecular weight proteins can be degraded in the proximal tubule 
(figure 1.4.1 c and d), either being reabsorbed or passed to the bladder. Other 
molecules can be actively or passively absorbed; the majority of glucose, amino 
acids and inorganic salts are reabsorbed, leaving a filtrate that consists of any 
excess molecules and waste products or compounds. The final filtrate passes 
through the distal tubule (figure 1.4.1 e) to the bladder to form urine. 
As urine is one of the body's waste excretion methods, urine should contain a wealth 
of metabolites that are related to many processes within the body, meaning that the 
study of urine should enable a picture of what has gone on in the body to be 
explored; Goodacre describes the study of such biofluids as "... the way forward... " 
(Goodacre, 2007), although this is nothing new as metabolites in urine have been 
used to detect diabetes, pregnancy and liver function to name but a few. 
Given that the bone remodelling process causes secretion of compounds related to 
this process into the bloodstream, serum has been analysed for biomarkers of the 
remodelling process (Chapurlat et al., 2000; Ebeling and Akesson, 2001; Igarashi 
and Yamaguchi, 2002; Henle et al., 2005; Zimmermann et al., 2005). As the kidneys 
filter blood around 25 times a day, urine might be expected to contain excreted 
biomarkers relating to the bone remodelling process. 
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1.5. Metabonomics 
The field of systems biology has given rise to an impressive array of 'omes' and 
`omics', such as the genome, transcriptome, proteome and metabolome along with 
their studies giving genomics, transcriptomics, proteomics and 
metabolomics/metabonomics. The ultimate goal of these technologies has to be the 
complete understanding of a biological system from the genome right down to the 
metabolome, and also how each of these different `omes' relates to one another 
given the bigger picture; this is clearly a long way from being reality, but with 
continual developments in both technology and its application, it may one day 
become feasible. 
Within the scientific community there has been much debate with respect to what to 
name the field related to the metabolome, or indeed the metabonome. 
`Metabolomics' versus `metabonomics' may at first appear to merely be a case of 
semantics, but there are significant differences that emerge between the way the two 
terms are used in the literature, even though some prefer to use the terms 
interchangeably. 
The term 'meta bonomics' was coined by J. K. Nicholson et al. in 1999 (Nicholson et 
al., 1999), and was defined as "... the quantitative measurement of the multi- 
parametric metabolic response of living systems to pathophysiological stimuli or 
genetic modification... " with metabonomics being derived from the Greek "meta" and 
"nomos" meaning changes and rules/laws respectively (Lindon et al., 2004). 
`Metabolomics' first appeared in 2000 and was coined by O. Fiehn et al., (Fiehn et 
al., 2000) and was defined as "... the quantitative measurement of all low molecular 
mass metabolites in an organism's cells at a specific time under specific 
environmental conditions... ". The main noticeable difference is that metabonomics is 
concerned with dynamic changes within a system that is a response to some sort of 
stimulus, whereas metabolomics looks at a `snap-shot of the cellular metabolome' 
(Tang and Wang, 2006). The two terms are sometimes differentiated between based 
upon the analytical method utilised; metabolomics initially utilised hyphenated mass 
spectrometry techniques, whereas metabonomics utilised NMR based techniques, 
however, this is clearly an out-dated way of differentiating between metabonomics 
and metabolomics as is shown in the papers by Wilson et al., and Lindon et al., 
(Lindon et al., 2004; Wilson et al., 2005). Other arguments amount to metabolomics 
(and the metabolome) relating to plant and microbial systems whereas 
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metabonomics (and the metabonome) relate to animal models (Tang and Wang, 
2006). Whichever definitions people use to decide if their study is metabolomics or 
metabonomics based, it is academic and arguments only detract from the science 
that is being carried out. Studies in the field of metabolomics and metabonomics are 
increasing steadily as is shown by a PubMed search' (figure 1.5.1). Metabolomics 
appears to be the favoured term used but may be caused by the fact that many 
people (incorrectly) choose to use the terms interchangeably; the field in general is 
still lagging behind that of proteomics which is still receiving much attention, although 
it may be beginning to reach its maturity as the 'hype' dies down (2430 PubMed 
citations for `Proteomics' in 20071). 
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Figure 1.5.1. Graph to illustrate the increasing number of papers published citing 
`metabolomics' or 'meta bonomics'. 
For the purpose of this study, it was chosen to use the term `metabonomics', based 
upon the fact that that human clinical urine samples that were not from one given 
time, and the body's response to a stimulus, in this case bone fractures, were 
studied. 
Metabonomics can provide a real biological endpoint2; other 'omic' techniques such 
as proteomics and transcriptomics are very useful, but cannot provide any biological 
endpoint markers that could be used to relate to a specific disease or the effects of 
drug metabolism. The genome, proteome and metabonome/metabolome are all 
1 http: //www. pubmed. com accessed November 2007. 
2 Metabonomic analyses of biofluids such as urine can provide a snapshot of biological processes that 
have happened, whereas proteomic/transcriptomic studies can only predict what may happen. 
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related to one another (figure 1.5.2), and as such, environmental factors could affect 
each level either directly or indirectly through a knock-on effect. Through the process 
of homeostasis, the body automatically attempts to maintain a constant internal 
environment, even when disease, drugs or toxins affect concentrations and fluxes of 
endogenous metabolites. In order to maintain this constant internal environment, 
increased levels of endogenous metabolites and any exogenous metabolites are 
eliminated through the body's waste (urine and faeces). Many biofluids contain a 
wealth of information, but some such as blood may not be the best to use when real 
biological endpoints are sought as blood is a homeostatically controlled biofluid, the 
composition of which is therefore heavily regulated. There are other 'exotic biofluids' 
that can be sampled such as saliva, semen, bile etc., (Mukhopadhyay, 2006) but the 
biofluid that receives the most attention for good reason in metabolomic and 
metabonomic studies is urine. 
Genome 
Figure 1.5.2. Diagram to represent the relationship between the genome, proteome 
and the metabolome, and how environmental factors affect each one. 
Initial urinary metabonomic studies focussed upon the use of 'H NMR as the 
analytical platform (Nicholson et al., 1999; Lenz et al., 2000; Robertson et al., 2000). 
NMR requires very little sample preparation and is also a non-destructive technique, 
which can be useful if samples are precious. As urine is primarily water, special 
pulses have to be applied to the sample in order to suppress the overwhelming signal 
that would otherwise be present in the spectra, meaning increased analysis times. 
Even though NMR is a reasonably fast technique and shows fantastic reproducibility, 
when compared to MS techniques it shows significantly lower sensitivity. Given that 
there are estimates of 2,000 to 20,000 human metabolites' (compared to an 
1 The Human Metabolome Database Project has recently catalogued 2500 metabolites in the first draft 
of the human metabolome. (http: //www. hmdb. ca, accessed 
November 2007). 
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estimated 30,000 genes and 1,000,000 proteins (Schmidt, 2004)) it would appear 
that profiling metabolites would be comparatively easy. However, there is a large 
dynamic range in concentrations of endogenous metabolites that range from 
femtomolar (and lower) to millimolar; coupled to the fact that the chemical complexity 
(lipids, sugars, amino acids, nucleotides, sulfates and many more atomic 
arrangements) and biological variation between samples can be large, this only 
serves to further complicate the analysis of biofluids. NMR can fail to detect many 
metabolites that are present due to `... NMR-invisible moieties... ' (Williams et al., 
2005). It is not to say that NMR is a redundant technique though, as it can often 
provide information that other techniques cannot, as well as being a complementary 
technique to MS that can allow a more comprehensive picture of the components 
present within a biofluid, and the metabonomic question being posed to be revealed 
(Kenney and Shockcor, 2003; Williams et al., 2005; Forshed et al., 2006). 
Many metabonomic studies now utilise mass spectrometry coupled to some sort of 
separation technique. The technology has vastly improved in terms of sensitivity, 
selectivity, resolution, reproducibility and price over the last decade (Plumb et al., 
2003; Drexler et al., 2004; Villas-Boas et al., 2004; Beattie et al., 2005; Idborg eta!., 
2005b; Wilson et al., 2005; Kopka, 2006; Lu et al., 2006; Lutz et al., 2006). Mass 
spectrometry coupled to gas chromatography (GC) provided a sound basis for the 
analysis of metabolites from plant samples after derivatisation (Gullberg et al., 2004) 
as GC affords very long columns (typically in the range of 30 to 60 meters) with very 
high separation efficiencies due to the large number of theoretical plates. However, 
complex sample matrices such as urine and blood do not contain large numbers of 
volatile metabolites and therefore require derivatisation. The process of derivatisation 
means that the chemical structure of metabolites is being altered; given that not all 
components are amenable to derivatisation means that a substantial amount of 
potentially important metabolic information may not be detected. Other separation 
techniques such as capillary electrophoresis (CE) afford high levels of separation 
efficiency as well as being able to cope with `dirty' samples, reducing the amount of 
sample preparation needed' (Ullsten et a!., 2006; Monton and Soga, 2007). Coupling 
CE to ESI-MS has proven to be a problem; there are commercially available sources 
that allow the 'easy' coupling of CE to ESI-MS, but the technique suffers from poor 
reproducibility due to CE. The future may hold great promise for CE-MS with further 
development, but at present is not reliable enough for large scale, high throughput 
1 This was found to be contradictory to the results of E. Edwards from the JTO group (Edwards, 2007). 
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metabonomics experimentation. By far the most common separation technique used 
in MS metabonomics is reversed-phase liquid chromatography. 
HPLC can separate a wide range of complex compounds; it is a liquid method and 
therefore does not require compounds to be volatile in order to be analysed. 
Compounds often require little or no preparation prior to their injection onto the 
column where they are separated based upon their partitioning behaviour between 
the liquid mobile phase, and the solid stationary phase. The performance of modern 
HPLC columns is far lower than that of GC columns, typical analytical column sizes 
of 4.6 x 100 mm can only resolve an upper limit of around 300 theoretical peaks 
(Sumner, 2006). This poor peak capacity can be increased by coupling columns 
together or by decreasing the particle size; this is at the expense of higher 
backpressures, which presents a technical challenge when designing HPLC systems. 
Recently, monolithic columns have begun to make their mark as they afford higher 
flow rates, meaning faster separations (Ishizuka et al., 2002; Ikegami and Tanaka, 
2004; Svec, 2004), they have also been applied to metabonomic studies (Tolstikov et 
al., 2003; Wilson et al., 2005). Correctly so, hydrophilic interaction chromatography 
(HILIC) is beginning to make an impact on metabonomic research (Tolstikov et al., 
2003; Idborg et al., 2005a; Kind et al., 2007), as it is selective towards polar analytes 
(which should be present in large amounts in aqueous biofluids). HPLC appears as 
though it may be superseded by ultra-performance liquid chromatography (UPLC, or 
small particle liquid chromatography as it should properly be called). UPLC utilises 
smaller particle and column sizes, typically sub 2 pm diameter particles, and a 
column length of 3 cm x2 mm for traditional packed style columns (monolithic 
columns can also be used on UPLC systems). As the columns are much smaller than 
traditional HPLC columns, UPLC requires much greater backpressures of around 
12,000 psi to be obtained (compared to - 6000 psi for traditional HPLC systems). 
The result of this new technology is a vast increase in the column efficiency and the 
number of compounds detected. Wilson et al., showed that traditional HPLC-MS 
allowed the detection of - 1,500 ions in 10 min, whereas capillary HPLC-MS could 
detect twice as many ions in the same time and UPLC-MS over 5,000 ions in only 
five minutes (Wilson et al., 2005). Even with these developments in HPLC, we are 
still a long way from satisfying the complete picture of the metabonome as many 
metabolites may fail to be detected. A recent analytical development involving LC 
coupled to NMR and MS (LC-NMR-MS) is emerging and is a promising field for 
metabonomic studies (Burton et al., 1997; Bajad et al., 2003; Bollard et al., 2005). 
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Whichever analytical platform is used, vast amounts of data are typically produced; 
once called multivariate data, megavariate data is now far too large to be analysed 
without the use of complex statistical methods. The overwhelming majority of 
metabonomic studies use a statistical method called principal components analysis 
(PCA). PCA is a descriptive technique and serves to show any trends or similarities 
inherent in the data. Another statistical method that is commonly employed is partial 
least squares - discriminant analysis (PLS-DA). This is a discriminative technique as 
it utilises a priori knowledge of group classification. 
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1.5.1. Sample collection and preparation 
Biofluids are generally easy to obtain, with blood (invasive collection) and urine (non- 
invasive collection) the most widely analysed. A biofluid only provides a `snapshot' of 
the metabolome at a specific time point, and as such is representative of the system 
under investigation at that time. To avoid subsequent changes (metabolic reactions, 
chemical modifications and microbial growth) the biofluid should ideally be flash 
frozen using liquid nitrogen and be stored at a suitable temperature (-20 °C, or better 
-80 °C). Studies (LeBeau et al., 2001; Schneider et al., 2002; Fura et al., 2003) have 
shown that freezing can alter the levels of endogenous metabolites, as can repeated 
freeze/thaw cycles; even though freezing is detrimental to the stability of endogenous 
metabolites, the effects are minimal (compared to storage above freezing) and the 
concentrations of endogenous metabolites appears to stabilise after two weeks 
(Schneider et al., 2002). 
Samples may require preparation prior to analysis such as acid hydrolysis, 
derivatisation, dilution or centrifugation depending upon the analytical platform 
chosen. Analysis by GC requires analytes to be volatile and thermally stable. Some 
compounds therefore require derivatisation. Whilst the derivatisation of compounds in 
biofluids may allow analysis by GC and increase the detection of some compounds, 
the derivatisation process is not 100 % efficient; many compounds may not be 
completely derivatised, and some may not be derivatised at all. Non-volatile 
compounds that are not derivatised may not be detected using GC; therefore when 
analysing the metabolome of a biofluid, there are compounds that cannot be 
detected. GC is biased against non-volatile, high molecular weight compounds. 
Most biofluids are analysed using HPLC-MS due to the ease of sample preparation 
and the possibility of online coupling of the HPLC to the MS using liquid introduction 
interfaces. Samples are typically extracted using solid phase extraction or liquid- 
liquid extraction when identifying specific metabolites. Typically, biofluids can be 
analysed directly (after only centrifugation or dilution) for unbiased analyses, avoiding 
the unwanted exclusion of metabolites when study of the whole metabolome is 
required. 
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1.5.2. Sample variation 
Biological samples are subject to biological and analytical variation. Biofluids such as 
blood and urine exhibit a large diurnal variation (Ebeling and Akesson, 2001; Wilson 
et al., 2005); physiological factors such as state of health, age, diet, stress or diurnal 
cycles (Antti et al., 2004) affect the composition and result in variation between 
samples. Analytical variation, whilst being accepted as less influential than biological 
variance, contributes to overall variation; sample storage, treatment, preparation and 
instrumental variation may all affect the data recorded. 
Together, biological and analytical variance affects the ability to obtain reproducible 
data; controlling the variation in a sample is challenging. Analytical variation can be 
minimised by ensuring each sample is treated in as similar a manner as possible, but 
being analysed in a random order to spread any variation across the dataset. 
Biological variance is harder to control; inclusion/exclusion criteria can be used, as 
can regulating the diet and lifestyle, although this is easier said than done when 
using human volunteers. The inclusion of internal standards, or the pooling of 
samples, is another way of accounting for biological and analytical variation. 
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1.5.3. Standards and normalisation 
The inclusion of an internal standard allows analytical variation to be accounted for, 
but has to be carefully considered. An ideal internal standard should not co-elute with 
other compounds in the biofluid being analysed, and not cause ion suppression in the 
ionisation process during LC-MS analysis. 
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Figure 1.5.3. A schematic representing the breakdown of creatine to form creatinine. 
Adenosine diphosphate (ADP) is phosphorylated to adenosine triphosphate (ATP) by 
the removal of a phosphate group from N-phosphocreatine. 
Biological variation is a much harder variable to control, especially in biofluids such 
as urine and serum. Creatinine is an endogenous metabolite that is excreted in urine; 
it is produced as a waste breakdown product during the synthesis of the body's 
energy source, adenosine triphosphate (ATP) (figure 1.5.3). The level of creatinine in 
an individual's urine is relatively stable and related to the individual's muscle mass. 
Creatinine has been utilised in many studies (Woitge et al., 1999; Schneider et al., 
2002; Schoenau and Rauch, 2003; Felitsyn et al., 2004; Huskovä et al., 2004; Idborg 
et al., 2004; Svoboda and Kasai, 2004; Obrant et al., 2005) and is often used to 
express the concentrations of urinary metabolites (urinary metabolite : creatinine 
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ratio). When statistical analysis of data is undertaken, to account for concentration 
variance between samples, the data can be normalised to the intensity of the peak 
corresponding to creatinine in the MS chromatogram. 
It is common in NMR metabonomic studies to normalise the data based upon the 
total signal intensity (Kenney and Shockcor, 2003; Antti et al., 2004; Williams et al., 
2005). Using the total intensity normalisation method accounts for any variation in the 
concentration of individual urine samples, and removes the need for any internal 
standard to be included. More recently, LC-MS metabonomic studies have begun to 
use the total ion counts of individual samples to normalise the data to account for any 
concentration differences and analytical variation (Plumb et al., 2005; Williams et al., 
2005). Many papers do not report how they normalise their data, but it appears that it 
is increasingly common to use the total ion count over creatinine (personal 
conference notes). Creatinine, whilst a good indicator of basal metabolism and 
individual muscle mass, may be perturbed by illness and other factors (Schneider et 
al., 2002), meaning that utilising it for normalisation may not be as desirable as first 
thought. It is clear that the area of normalisation requires further in-depth study to 
determine the suitability of the different normalisation methods that are currently 
used. 
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1.5.4. Statistical analysis 
Modern analytical techniques generate vast amounts of high-dimensional data (e. g. a 
30 min LC-MS acquisition generates -- 50 MB of data, so 200 samples would be 10 
GB of data! ), far more than can be dealt with manually. Thankfully, with the 
computing power now available, complex algorithms can be utilised to analyse these 
large, complex datasets. The field of chemometrics is defined as "... the science of 
relating measurements made on a chemical system or process to the state of the 
system via the application of mathematical or statistical methods... " (International 
Chemometrics Society). There are many different statistical methods that can be 
employed in order to analyse the megavariate data from metabonomic experiments. 
The most common tools are the descriptive principal components analysis (PCA) and 
the discriminative partial least squares - discriminant analysis (PLS-DA), soft 
independent modelling by class analogy (SIMCA) or more recently orthogonal partial 
least squares - discriminant analysis (OPLS-DA) (Nicholson et al., 1999; Granger et 
al., 2003; Idborg et al., 2004; Wilson et al., 2005). Whichever statistical approach is 
chosen, the user must be aware of the possible errors that can occur. There are 
typically two types of error that are considered, types I and II (or a and ß errors 
respectively). A type I error is a `false positive', this is when the hypothesis tested is 
rejected, although it is correct; a type II error, or a `false negative', occurs when the 
hypothesis tested was not rejected when it was false. 
1.5.4.1. Principal component analysis 
Principal components analysis is an unsupervised technique; it does not require any 
prior knowledge, as it is a descriptive technique. PCA was first described in 1901 by 
Karl Pearson (Pearson, 1901) but was only able to be used for two to three variables 
due to the complex calculations involved; in 1933, Hotelling published practical 
computing methods, although these could not be realised until the advent of the 
modern computer (Hotelling, 1933). The early use of statistics could only cope with 
`long and thin' data matrices, whereas today's data uses `short and fat' data matrices 
as modern analytical techniques typically record many variables for few samples (or 
observations). 
The function of PCA is to simplify, or reduce the dimensionality, of large amounts of 
data; data are broken down into two smaller tables, the scores and loadings. Scores 
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summarise the observations' and enable any patterns or trends inherent in the data 
to be visualised, whilst the loadings summarise the variables2 and help to explain the 
position of the observations in the scores plot. PCA generates principal components 
(PCs) that are linear combinations of the original data. The first principal component 
accounts for the greatest amount of variation within the data; successive principal 
components account for the maximum variation possible that has not already been 
accounted for by the previous PC. Each observation is represented by a point in 'n - 
1' dimensional space, where n= the number of variables (figure 1.5.4a). A line that 
accounts for the greatest amount of variation is fitted through the origin of the data (if 
the data have been mean centred) and is termed the first PC (figure 1.5.4b). The 
second principal component is orthogonal to the first, and accounts for the next 
largest amount of variation within the data (figure 1.5.4c). For a PC 1 vs. PC 2 plot, 
all of the points are projected onto a plane (figure 1.5.4c), this is termed the scores 
plot (figure 1.5.5a). 
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Figure 1.5.4. Schematic demonstrating how data are treated for PCA analysis, each 
blue dot represents an observation (an individual sample). (a) Each observation 
exists in n-1 dimensional space. (b) A line accounting for the greatest variation in the 
data is fitted, PC 1. (c) A subsequent line accounting for the next greatest variation is 
orthogonally placed. 
Residual values based upon each point's distance in (n - 1) dimensional space from 
the plane (figure 1.5.4c) can help to identify outliers, as can the use of Hotelling's T2 
tool which is used to show a 95 % confidence limit within which data that fits the 
model well should appear, illustrated by the oval ring in the scores plot (figure 
1.5.5a). Outliers can be easy to find, but can cause problems as the PCs are skewed 
1 'Observations' relate to each sample analysed. For example: each urine sample analysed would be 
classed as an observation when their resulting data is analysed statistically. 
2A 'variable' is a compound detected in one or more 'observation' (a variable would be an m/z value 
and a retention time, along with the relative intensity for each observation (or sample). This 
nomenclature shall be used whenever data are analysed statistically. 
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by the presence of an outlier and are therefore not a true representation of the data. 
However, to justify the removal of an outlier there should be sound scientific 
reasoning. 
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Figure 1.5.5. (a) Scores plot with three groups of data, clustering separately. (b) 
Loadings plot showing which factors are responsible for the clustering, the positions 
of which relate to the clustering observed in the corresponding PCA score plot (a). 
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Loadings determine how observations positions in the scores plot relate to the 
variables that were used. Loadings plots allow the user to interpret the scores plot, as 
the loadings relate to each variable. Loadings are calculated by relating the angles 
between each PC and the variable axis. The cosine of each angle is taken with 
respect to each axis and a loadings vector is generated (figure 1.5.6). If a particular 
variable has a strong influence then the cosine is close to 1 as the cosine of 0 is 1 
(the angle of the component to the variable is close to 0 degrees); conversely, if a 
component has very little influence then the loading will be close to zero as the 
variable is nearly orthogonal (cosine of 90 degrees is 0). The loadings scale runs 
from -1 to +1 giving negative loadings, which correspond to a cosine of 180 degrees. 
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Figure 1.5.6. Diagram illustrating how loadings are determined from the 
observations. 
The `goodness' of a PCA model can be determined by utilising internal cross- 
validation (CV). It is also useful to ensure that the model is not being over-fitted, 
given that there are up to (n - 1) PCs available. Internal CV works by removing 
observations (and their corresponding variable values) and using the developed 
model to predict the position of the removed observations in the scores plot. This is 
repeated as many times as there are removed observations. If the new model 
component that is generated enhances the predictive power, then that component is 
retained. There is a trade off between the fit of a model and its predictive ability; the 
R2 value is the 'goodness' of a fit, whilst the Q2 value the `goodness' of prediction. 
The optimal number of PCs can be determined by the relationship between the R2 
and Q2 values. If, as shown in figure 1.5.7, the R2 and Q2 values are close then that 
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PC can be considered to exhibit a good fit. When the number of PCs increases, so 
does the complexity of the model. When the Q2 value tails off, the model is beginning 
to become over-fitted and too complex. The ellipse in figure 1.5.7 highlights the 
optimal number of components; any further PCs would be over-fitted, as the Q2 
values decrease rapidly. 
1 
0 
Figure 1.5.7. Diagram to show how the fit of a model and its predictive ability must 
be controlled with respect to the number of PCs used. 
1.5.4.2. Partial least squares - discriminant analysis 
Partial least squares - discriminant analysis (PLS-DA) is a regression analysis, and 
as such is a discriminative function which seeks to separate two or more groups 
based upon a priori knowledge (Wold et al., 2001). As with PCA, PLS-DA represents 
each observation with a point in multi-dimensional space. PLS-DA seeks to obtain 
the greatest separation, which is obtained using the prior class knowledge. However, 
it can only be used to separate groups when there is a difference, which is why it is 
useful to analyse data with PCA first. 
In contrast to PCA, where all of the data are extracted into a single X matrix (the 
explanatory variables), PLS-DA allows the comparison of two blocks of data, X and 
Y, where the Y matrix contains `dependent' data, indicating class belonging. Latent 
variables (LVs, equivalent to PCs) are generated using both the X and Y matrices. 
PLS-DA seeks to maximise any inherent differences between the pre-defined classes 
in the Y matrix. Using this class knowledge, it is possible for PLS-DA to predict the 
class of one of the pre-defined classes in the Y matrix. Internal CV is once more 
essential in ensuring that any developed model is not being over-fitted. 
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Using PLS-DA to classify unknowns to groups requires that the model is trained on a 
representative dataset; the developed model should subsequently be tested (external 
CV) with data (an external test set) that were held back and not used to develop the 
discriminative model, and the developed model judged upon its classification 
success. The variables that are most influential and cause the separation of the 
groups can be found by using the loadings plots or by analysing the coefficients. 
1.5.4.3. Soft independent modelling by class analogy 
Soft independent modelling by class analogy (SIMCA) is useful when there are too 
many independent classes for PLS-DA (PLS-DA falls down when there are too many 
groups), but lacks any information on why the groups are different. SIMCA generates 
a localised PCA model for each defined group and is able to work with overlapping 
groups. Again, as with PLS-DA, there has to be a training set and a test set if a 
useful model is to be developed. The `localised' PCA models use residuals to 
determine which observations belong to which group. It is these residual values that 
are used to predict classes for the new (and test) data. 
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1.6. High performance liquid chromatography 
The development of high performance liquid chromatography dates back to 1906 
when Mikhail Tswett used glass columns of 50-500 cm in length, and 1-5 cm in 
diameter, to separate chlorophyll solutions in carbon disulfide (Tswett, 1906). Modern 
HPLC is a technique used to separate compounds within a solution according to a 
specific property, such as hydrophobicity/hydrophilicity. The compounds within a 
solution are separated according to the basis of their partitioning behaviour between 
a stationary phase and a mobile phase. The principle of partitioning can be shown as 
the equilibrium of a compound (C) between the mobile and stationary phases: 
C (Mobile Phase) C (Stationary Phase) Equation 1.6.1 
The equilibrium shown above (equation 1.6.1) can be described by a partition 
coefficient, which is defined as: 
[C (Stationery Phase)] 
kD 
C (Mobile Phase)] 
Equation 1.6.2 
A solution containing a mixture of compounds to be separated is injected' into a flow 
of liquid (mobile phase) that is pumped through a column containing a solid medium 
(stationary phase). When compounds come into contact with the stationary phase, 
they distribute between the stationary phase and mobile phase (equation 1.6.1). The 
mobile phase is continually passing thorough the column, causing compounds to 
distribute between the mobile and stationary phase many different times. 
Compounds with a higher kD (equation 1.6.2) spend a larger amount of time in the 
stationary phase, therefore taking longer to elute from the column than compounds 
with lower kD values; this is the basis upon which compounds are separated. 
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Figure 1.6.1. A schematic diagram illustrating how three different components 
migrate through a column and separate over time, as each different compound has a 
different partition coefficient. As each compound elutes from the column, they are 
detected using UV, with the area of each peak being proportional to the 
concentration. 
Figure 1.6.1 shows the separation of three compounds overtime. The compounds 
each migrate through the column at different rates, each having different partition 
coefficients (kD), before being eluted from the column and detected (here using UV). 
The resulting separation of the analytes produces a chromatogram containing peaks 
with areas that are related to the concentration of each of the separated compounds. 
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(0 
Figure 1.6.2. A schematic illustrating the chromatogram of a mixture of two 
compounds, A and B. tn, = unretained compound (dead volume); tRA = retention time 
of compound A, tRB = retention time of compound B; WA = baseline width of peak A 
and WB = baseline width of peak B, calculated by the intersection of an extension of 
tR B their point of inflection (shown); At = tR -A 
The capacity factor of a compound (k') can be used to describe the migration rate of 
a compound on a column, and is calculated according to equation 1.6.3 (using the 
terms shown in figure 1.6.2), which uses a compound's retention time (tR) and also 
the time that the mobile phase takes to pass through the column (tn, ). 
A 
k'A 
= 
tR - tm 
tm 
Equation 1.6.3 
The capacity factor for two compounds can be used to describe the selectivity factor 
(a), a measure of peak separation: 
kA 
a= 
kB 
Equation 1.6.4 
The efficiency and resolution that can be obtained using a column is of importance, 
and can be calculated using the peak widths, retention times and column length 
(figure 1.6.2). The efficiency of a column is measured by the number of theoretical 
plates, N, and is calculated using equation 1.6.5 (where HM = half maximum): 
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N =16 
tR 
A=5.545 
tR 
A 
WA WA(HM) 
2At 
R= 
WA + WB 
Equation 1.6.5 
Equation 1.6.6 
Resolution, R, can be calculated by the ability of a column to separate two peaks 
(equation 1.6.6 and figure 1.6.2). 
The ability of a column to separate two compounds is dependent upon any `band 
broadening' that occurs during separation, and leads to a reduced efficiency as fewer 
compounds can be separated. Plate height, H, can be used to describe the 
performance of a column independent of the columns length: 
H= 
L 
N 
Equation 1.6.7 
A column can be. considered to have a number of `theoretical plates' where the 
separation of a compound can be described as a series of independent, consecutive 
equilibration events occurring between the stationary phase and mobile phase. Each 
plate is the distance required for an `equilibration event' to occur; therefore the 
greater the number of plates, the more efficient the column. Plate height is 
dependent upon the linear flow rate, u, of the mobile phase, and can be explained 
using the van Deemter equation: 
H=A+B+Cu 
u 
Equation 1.6.8 
Where `A' relates to eddy diffusion, `B' to longitudinal diffusion and `C' to mass 
transport; these terms are described in further detail below: 
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0 Eddy diffusion (A) can be summarised as the different path lengths that 
compounds can take in a column. Whilst each molecule of a compound may 
start at the same position, they take different paths through the column as the 
mobile phase flows around the particles; this causes band broadening, but is 
independent of the velocity of the mobile phase. 
0 Longitudinal diffusion (B) creates band broadening, as molecules of a 
compound move from an area of high concentration (the centre of an analyte 
band) to an area of low concentration (the edges of the band). The extent of 
the diffusional band broadening depends upon the amount of time each 
compound spends on the column, thus band broadening is inversely 
proportional to the flow rate of the mobile phase. 
0 Mass transport (C) is the main factor that contributes to band broadening, 
particularly for silica particle based chromatography. During separation, 
molecules are partitioned between the stationary and mobile phase, 
depending upon their interaction with the stationary phase; this is much faster 
than the diffusion of a molecule into and out of a pore within a silica particle 
where there is no mobile phase flow. Due to the difference in partitioning and 
diffusion, band broadening occurs. The effects of mass transport are 
proportional to the velocity of the mobile phase, meaning that lower flow rates 
lead to better equilibration between partitioning and diffusion, leading to less 
band broadening. 
Various aspects of an LC system can be altered to increase the resolution and 
efficiency. The mobile phase composition can be altered to change the capacity 
factors of compounds. Gradient mobile phases change the composition of solvents 
over time, enabling a decrease in the capacity factor of compounds that are strongly 
retained, thus decreasing analysis time. Reducing particle sizes increases the 
surface area of the stationary phase, which leads to an increase in resolution and 
separation efficiency; although this is at the expense of backpressure, as increased 
pressure is required to force the mobile phase through a more tightly packed 
stationary phase. To decrease eddy diffusion, the internal diameter of a column can 
be reduced, giving better peak shapes. However, less analyte can be loaded onto a 
column with a small internal diameter compared to columns with a larger internal 
diameter. 
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The most commonly used separation mode is reversed phase (RP) chromatography, 
where components are separated based upon their hydrophobicity with the most 
hydrophobic compounds eluting last. The majority of RP columns utilise derivatised 
silica particles, typically (although not exclusively) with n-octyl and octadecyl 
functional groups, where a predominantly aqueous based mobile phase is used. 
1.6.1. Monolithic columns 
An important development in RP column technology has been the introduction of 
monolithic columns (Svec and Frechet, 1992). The word monolith derives from the 
Latin monolithus, meaning single stone; the stationary phase in a monolithic column 
differs greatly from a traditional packed silica-based column as they consist of a 
single, porous piece of polymerised material as the stationary phase. The porous 
nature of a monolithic column means that the mobile phase can pass through with 
less hindrance than a traditional packed column; this leads to a substantial decrease 
in back pressure, meaning that higher flow rates can be used (and therefore faster 
separation achieved). As the mobile phase flows through a highly porous structure, 
the mass transfer process is no longer limited by diffusion into pores on silica 
particles, but now occurs primarily by convection. 
The use of monolithic columns has allowed a reduction in analysis time and an 
increase in sensitivity and stability to be obtained for proteomic experiments 
(Premstaller et al., 2001; Wienkoop et al., 2004; Chen et al., 2005; Rodrigues, 2005; 
Ault, 2007; Sumpton, 2007). However, despite the use of monolithic columns for 
proteomic studies, their uptake has been much slower for metabonomic studies 
where only a handful of studies have discussed or utilised this type of stationary 
phase (Pham-Tuan et al., 2003; Tolstikov et al., 2003; Dunn and Ellis, 2005; Wilson 
et al., 2005; Cubbon et al., 2007). Due to the success of monolithic columns for 
proteomic research within the JTO group (Robinson and MacDonell, 2004; 
Rodrigues, 2005; Ault, 2007; Sumpton, 2007), a monolithic C18 column was used for 
all RP separations presented within this thesis. 
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1.6.2. Hydrophilic interaction chromatography 
The use of RP within the field of metabonomics is widespread, and may be caused 
by scientists using technologies that have been commonplace. However, for a field 
such as metabonomics, this could be a critical mistake given that many biofluids are 
predominantly aqueous and are thus likely to contain a wealth of polar content (that 
is poorly retained when using RP stationary phases, as discussed in chapter 3.2). 
The lack of `normal phase' separation use for metabonomic studies can be 
accounted for by its poor reproducibility and separation efficiencies (hence the 
popularity of RP stationary phases), but more importantly its incompatibility with MS 
due to the solvents typically employed (e. g. hexane). The void in polar analyte 
separation has been filled by the recent introduction of hydrophilic interaction liquid 
chromatography (HILIC). The principle of HILIC was first described in 1952 by 
Samuelson and Sjöström for the separation of monosaccharides using Amberlite 
IRA-4001 as a stationary phase (Samuelson and Sjöström, 1952), but the acronym 
and the functional stationary phase used today was first suggested by Alpert et al. 
(Alpert, 1990). 
H3 ;+ 
ýko 
CH3 0 
Figure 1.6.3. The zwitterionic bonded stationary phase for HILIC. 
Figure 1.6.3 shows the bonded stationary phase for HILIC, a zwitterionic functional 
group with a net charge of zero; there are two functional ion exchange groups that 
are pH independent2. HILIC is thought to work by the hydrophilic partitioning of 
compounds into the water rich stationary phase, and also weak electrostatic 
interactions (Hemström and Irgum, 2006). HILIC is an orthogonal separation method 
to RP (Wang et al., 2005), and as such the solvent strength is opposite to that of RP. 
The use of HILIC for metabonomic studies is not common at the present time, but a 
handful of studies (Idborg et al., 2005; Kind et al., 2007; Mawhinney et al., 2007) 
have shown that this technique shows great promise, and was therefore the focus of 
research within this thesis (chapter three). 
1 Amberlite IRA400 is an anionic exchange resin. 
2 Counter ions come from buffer contained within the mobile phase. The stationary phase remains 
hydrated. 
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1.7. Mass spectrometry 
1.7.1. History 
Mass Spectrometry (MS) began with experiments in 1899 by J. J. Thompson 
(Thompson, 1899); by 1913 he had described how rays of positive electricity could 
be applied to chemical analyses. Coming up to its centenary, MS has seen 
exponential growth in both its use and development; MS is widely used to aid the 
identification and quantification of unknown substances and to probe their physical 
and chemical properties, all with a high degree of sensitivity and selectivity. 
Sample Ion Mass 
introduction generation analyser ' 
Detectorr 
Figure 1.7.1. A schematic highlighting the components of an MS system. 
Data 
system 
The general principles of MS are shown in figure 1.7.1. Sample is introduced and 
transferred into the gas phase, creating positive or negatively charged gas phase 
ions. Ions are then separated according to their mass to charge ratio (m/z), and then 
detected, with ions' abundance being measured. The ionisation process can be at 
atmospheric pressure or under vacuum, while the mass analyser is under vacuum, 
as the gas phase ions require a mean free path so that they can traverse space. MS 
is a destructive analytical technique. However, utilising the latest techniques allows 
nanograms or less of an analyte to be used for analysis. 
1.7.2. Ionisation methods 
1.7.2.1. Electron ionisation 
Electron impact was first used by Dempster et al. in 1921 to study the isotopes of 
lithium and magnesium (Dempster, 1921). This method was subsequently improved 
by Bleakney (Bleakney, 1929) and then Nier (Nier, 1947), and is now referred to as 
electron ionisation (EI). 
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Figure 1.7.2. Schematic of an electron ionisation source. 
Figure 1.7.2 shows a schematic of an El source. The sample is introduced as a 
vapour into the source under vacuum; this is to ensure that unwanted ion-molecule 
collisions do not occur as well as maintaining a mean free path. Heating a cathode 
element causes the emission of electrons, which are accelerated into the source by 
an accelerating potential of ca. 100 V. The electrons then traverse the source. 
The interaction of the electron beam and the gaseous sample may cause the ejection 
of an electron from the sample to create a positively charged radical ion (equation 
1.7.1). This is achieved by the electron beam being associated with a particular 
wavelength, A, where h= Planck's constant, m= mass of electron and u= velocity 
(equation 1.7.2). 
M+ e- -'M+' +2e- 
A_ 
h 
my 
Equation 1.7.1. 
Equation 1.7.2. 
The typical kinetic energy of 70 eV used in the El source corresponds to a 
wavelength of 140 pm. This is sufficient to cause excitations within the gaseous 
sample that can cause the expulsion of an electron. 
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Figure 1.7.3. Ion intensity as a function of electron energy. The maximum ion 
intensity is less than 70 eV. 
The typical energy of 70 eV is used, as this is in the plateau region, away from the 
sharp drop in ion intensity at lower electron energies (figure 1.7.3). This allows a 
reproducible spectrum to be obtained, which is helpful for the comparison of spectra 
from different instruments, making the use of spectral libraries for the identification of 
unknowns feasible. Most molecules only require around 10 eV of energy to become 
ionised, but the number of ions generated is insufficient to gain any structural 
information. Using 70 eV produces ions with excess energy; this excess energy 
causes the fragmentation of the ion, which is useful, as structural information can be 
determined from the fragments obtained. One drawback of this fragmentation caused 
by the excess energy is that the molecular ion is not always observed. 
1.7.2.2. Chemical ionisation 
Chemical Ionisation (CI) was developed by Munson and Field in 1966 and is a softer 
ionisation technique than El, as ions are generated with little excess energy (Munson 
and Field, 1966). Cl therefore produces an easily recognisable MH+ peak. Ions are 
produced by the collision of a primary ion (formed in the source) with a molecule 
introduced into the source, the source being at a suitable pressure that allows 
collisions between the primary ions and gaseous sample to occur. 
A reagent gas, such as methane, is introduced into the source and is ionised by EI to 
create the primary ions; these primary ions collide with the gaseous sample 
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introduced into the source. A plasma is subsequently created where many different 
reactions can occur, causing both positive and negative ions to be formed by proton 
transfer, hydride abstraction, adduct formation or charge transfer. 
1.7.2.2.1. Methane as a reagent gas 
The reagent gas is ionised by means of a reaction with an electron beam, as in an El 
source, which creates a radical cation that can react further (equation 1.7.3): 
CH4 + e- --> CH4+* + 2e- 
CH4+' -> CH3+ +H' 
CH4+' - CH2+' + H2 
Equation 1.7.3. 
As the concentration of methane within the source is higher than that of the analyte, 
the most likely collision is the methane radical cation with methane (equation 1.7.4): 
CH4+" + CH4 - CH5+ + CH3" Equation 1.7.4. 
Collisions of methane with CH4+' or its breakdown product occur (equation 1.7.5): 
CH3+ + CH4 - C2H5+ + H2 
CH2+' + CH4 -' C2H3+ + H2 +H* 
C2H3+ + CH4 - C3H5+ + H2 
Equation 1.7.5. 
The reaction of CH5+ with the analyte molecule, M, ionises M by proton transfer 
(equation 1.7.6): 
CH5+ +M --' MH+ + CH4 
Equation 1.7.6. 
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1.7.2.2.2. Proton Transfer 
Proton transfer is the most common ionisation reaction that occurs within the plasma 
and is effectively an acid/base reaction. The reagent gas forms a Brönsted acid, eg. 
CH4+', which donates a proton to the Brönsted base (the analyte molecule, M). The 
energetics of the acid/base reaction can be controlled by the use of different reagent 
gases such as ammonia and isobutane. 
1.7.2.2.3. Adduct formation 
Given the wide range of reactions that can occur in the plasma, adducts can be 
formed by a third body collision. A protonated molecule, [M+H]+, can form an adduct 
with another analyte molecule, M (or indeed a different analyte molecule, N), or 
fragment ions, F+; these reactions are useful in aiding the confirmation of the 
protonated molecule peak, or for assessing the purity of a compound by assessing 
the different molecular peaks in a spectrum (equation 1.7.7). 
MH+ +M- (2M + H)+ 
F++M-j(F+M)+ Equation 1.7.7. 
MH++N-(N+MH)+ 
1.7.2.2.4. Charge transfer 
As with El, radical cations can be obtained upon the use of rare gases. Xenon gas 
can be ionised to produce a radical cation that subsequently reacts with the analyte 
molecule, M, to transfer a charge. Xenon radicals transfer less energy to the analyte 
molecule compared to methane gas, meaning less fragmentation of the molecule 
occurs (equation 1.7.8). 
Xe+e- -> Xe+' +2e- Equation 1.7.8. 
Xe+' +M- M+' + Xe 
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Matrix Assisted Laser Desorption Ionisation (MALDI) is an ionisation technique that 
utilises short, intense laser pulses to produce gas phase ions from a mixture of an 
analyte with a matrix. Two groups developed different methods of laser desorption 
ionisation. Tanaka et al. used a fine cobalt powder in a glycerol matrix with the 
analyte added to it; a nitrogen laser at 337 nm was used to irradiate the mixture, 
producing intact ions that are generally singly charged species, the cobalt powder 
was used to reflect the laser irradiation onto the analyte (Tanaka et al., 1988). Karas 
et al. developed a similar method, where the laser irradiation used does not directly 
cause the ionisation of the analyte (Karas et al., 1987). They added picomolar 
amounts of an analyte to a solution containing an excess of an organic matrix that 
absorbs strongly at the wavelength of the laser. The mixed solution was spotted onto 
a target plate and allowed to dry, forming crystals. Laser radiation was directed onto 
the spot, where the organic matrix absorbs the laser energy. Tanaka was 
controversially awarded the Nobel Prize in 2002 for his work, but it is the technique 
described by Karas et al. that is generally used today. 
Laser irradiation 
... 
Desorption 
" 
" 
" 
H+ 
Proton transfer 
Figure 1.7.4. MALDI ionisation. The formation of gas phase ions from analyte 
dissolved in a liquid matrix by laser irradiation. 
The mechanisms of ion formation by MALDI are not fully understood, but it is 
generally accepted that upon laser pulsing (106 to 1010 W cm"2 of energy deposited) 
the matrix absorbs the laser radiation, causing rapid heating and subsequent 
expansion of the matrix and analyte into the gas phase in a plume. The matrix 
molecules are electronically excited, and can either transfer a proton to or from the 
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analyte molecule, yielding [M+H]+ or [M-H]-. Figure 1.7.4 shows the desorption of the 
analyte surrounded by matrix, but in addition other processes also take place, such 
as the ejection of single molecule aggregates and clusters of the matrix (which are 
evident in the resulting spectrum). 
MALDI is a soft ionisation technique that produces almost exclusively protonated 
(cationised) molecules. It is also a very sensitive technique, as millimolar (and lower) 
concentrations are typically spotted onto a target for analysis. MALDI allows the 
study of large, involatile and thermally labile species and is commonly used for the 
analysis of biological molecules. Its pulsed nature makes it a suitable ionisation 
device for time of flight mass analysis (section 1.7.3.7). 
1.7.2.4. Electrospray ionisation 
Developed by Fenn et al. in 1988 (Fenn et al., 1989), electrospray ionisation (ESI) 
was based on a concept proposed in 1968 by Dole et al. (Dole et al., 1968). ESI has 
since become one of the most versatile and widely used methods for the ionisation of 
an analyte. Initially, ESI was used for the analysis of proteins, but as interest 
increased, its applications widened to synthetic polymers and small molecules. Its 
broad applicability and high sensitivity were further enhanced by the ease with which 
it could be hyphenated to HPLC and capillary electrophoresis (CE). 
Potential gradient 
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Figure 1.7.5. Schematic of an electrospray ionisation source. 
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The analyte is dissolved in a suitable solvent, placed in a syringe, and pumped into 
the capillary by the use of a syringe driver. Alternatively, sample can be received 
from the output from HPLC or CE. A high voltage is applied to the capillary tip, 
creating a potential gradient between the capillary end and the orifice (figure 1.7.5). 
Given that the ESI source is at atmospheric pressure and the mass analyser is under 
vacuum, a series of lenses and skimmers exist, that act as a physical barrier; 
roughing pumps and turbo pumps are used to create a vacuum in the analyser. 
The voltage (0.5-5 kV) is required to induce charge accumulation at the end of the 
capillary, meaning that the liquid eluting from the capillary is highly charged. The 
potential has the effect of inducing a Taylor cone; this occurs at a specific voltage, 
the onset voltage, where surface tension is overcome causing the release of a plume 
of small charged droplets. At any voltage lower than the onset voltage, droplets are 
not emitted, as the charge is not sufficient to break the surface tension. Depending 
on the flow rate, sometimes a nebulising gas is applied around the capillary, which 
aids in the formation of the Taylor cone and the emission of droplets. The fine plume 
of charged droplets can be subjected to a flow of heated nitrogen gas, the drying gas, 
which causes the solvent to evaporate; the drying gas is not always heated and is 
sometimes not used at all, this is dependent on the flow rate and the source used. 
The formation of gas phase ions is proposed to occur by one of two mechanisms. 
Dole, who proposed the concept of an ESI source proposed the charge residue 
model (CRM) (Dole et al., 1968), whilst Iribarne and Thomson proposed an ion 
evaporation model (IEM) (Iribarne and Thomson, 1976). 
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Figure 1.7.6. (a) The charge residue model, as proposed by Dole, (b) the ion 
evaporation model, as proposed by Iribarne and Thompson. 
q2 = 81r2£0YD3 Equation 1.7.8. 
The Rayleigh limit (equation 1.7.8, where q= charge, co = permittivity of environment, 
y= surface tension, D= diameter of a droplet) occurs by the desolvation from the 
drying gas, causing the evaporation of the solvent, which decreases the volume of 
the droplet, causing charge to develop at the surface of the droplet. The CRM (figure 
1.7.6a) suggests that at the Rayleigh limit, the charges on the droplet coulombically 
repel each other and subsequently overcome the surface tension, causing a 
coulombic explosion. This explosion releases smaller droplets, which subsequently 
undergo the same process until single ions are produced. 
The IEM (figure 1.7.6b) involves desolvation by the drying gas; as the droplet shrinks 
due to the solvent evaporating, charge accumulates on the surface causing 
coulombic repulsion to occur. At the Rayleigh limit, instead of an explosion, ions are 
directly released from the surface of the droplet. 
If an analyte has ionisable sites, then it is usually protonated (deprotonated in 
negative mode). However, if the analyte lacks any ionisable sites it can still be 
ionised through the adduction of anions/cations such as sodium, potassium, 
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ammonium, chloride and acetate to name but a few. Large molecules tend to have 
more than one ionisable site, which can lead to multiply charged ions, and given that 
in a mass spectrometer, the mass to charge ratio is measured, the analysis of very 
high molecular weight compounds using ESI is possible. 
ESI is very sensitive to flow. At very low flow rates (nL min-) the sensitivity is much 
greater than at high flow rates (mL min"'). This has led to the development of various 
ESI sources to incorporate the vast diversity in obtainable flow rates. The various 
types of ESI source available are important as the flow rates used may be varied 
depending upon the amount of available sample, and whether the source is being 
coupled to HPLC or CE. 
1.7.2.4.1. Nanospray 
Wilm and Mann worked on the concept of the miniaturisation of the ESI source, 
initially developing a micro-electrospray source, which was later to be renamed the 
nano-electrospray source (Wilm and Mann, 1994). The setup is similar to that shown 
in figure 1.7.5, but there is reduced drying gas flow and no need for a nebulising gas. 
Nanospray uses a capillary with an internal diameter of 1-2 pm, compared to that of 
20-100 pm for ESI. Only 0.2 to 2 pL of sample solution is loaded onto the capillary, 
which can provide around 30 minutes of analysis time whilst only consuming -1 pL of 
sample. The capillary is positioned around 1-5 mm directly in front of the orifice, but 
slightly off-axis, with a potential being applied to the capillary. The potential alone is 
sufficient to induce the formation of a Taylor cone with a flow rate in the region of 20 
nL min-' (ESI originally used 1-10 pL s-1). 
Nanospray produces droplets that are less than 200 nm in diameter, compared to 
around 1 pm for droplets produced by ESI. The small and monodisperse droplets 
have a high surface to volume and charge to volume ratio, meaning that the 
generation of gas phase ions is almost instantaneous. Given the size of the droplets, 
Dole's charge residue process is the most plausible, as only one molecule per 
droplet is possible, meaning that only one fission step can occur (compared to 
multiple in ESI). Nanospray is up to 500 times more efficient at ion generation than 
ESI (Juraschek et al., 1999), and generally has a better signal to noise ratio and a 
reduced amount of clustering due to the direct emission of ions, which creates a 
higher tolerance to salts. 
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1.7.2.4.2. High flow rate ESI 
The ESI source used for this study was the Applied Biosystems TurbolonSpray 
(figure 1.7.7). Ionisation efficiency is increased at high flow rates (5-1000 pL min-) 
with a solvent composition that can vary from 100 % aqueous to 100 % organic. The 
main function is to allow the direct coupling to HPLC using analytical columns without 
the need for reduced flow or splitting of the flow post HPLC. 
Nebulising 
gas ', ' 
HPLC outlet 
Drying 
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Figure 1.7.7. 
study). 
The Applied Biosystems TurbolonSpray source (used for ESI in this 
The ionisation efficiency for high flow rates is increased by the addition of a second 
drying gas (figure 1.7.7). The capillary is set at 45° to the orifice and is offset so that 
the Taylor cone is not directed directly into the orifice. Perpendicular to the Taylor 
cone is the additional drying gas, which aids in the desolvation of the spray from the 
capillary. The additional drying gas can be heated to a temperature of 500 °C. 
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1.7.2.5. Atmospheric pressure chemical ionisation 
Atmospheric Pressure Chemical Ionisation (APCI) is a soft ionisation technique that 
is appropriate for coupling to HPLC; it is used for the analysis of compounds that are 
not ionised efficiently by other methods. Unlike Cl, which uses an electron beam, 
APCI uses a corona discharge to produce primary ions from the nebulising gas, 
which reacts with solvent molecules, forming reagent ions (secondary ions). 
Ionisation is achieved by proton transfer or abstraction from the secondary ions, and 
gas phase ions can also adduct to the analyte. 
Nebulising 
gas Heated sheath Skimmer 
Analyte 
Quadrupole 
Corona ýJº 
Orifice Vacuum 
Drying gas 
Figure 1.7.8. Schematic of the APCI source. 
The main features of an APCI source are shown in figure 1.7.8. The analyte, 
dissolved in a suitable solvent, is passed through a capillary and nebulised by 
nitrogen gas at high pressure. The sheath around the capillary is heated, causing the 
nebulised solvent to vapourise. A corona discharge needle produces electrons, when 
the vapourised sample comes into contact with the corona discharge needle, 
ionisation occurs. 
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1.7.3. Mass analysers 
In the mass analyser, ions are separated according to their mass to charge (m/z) 
ratio. Magnetic sector instruments were the first type of mass spectrometers (MS) 
used. Along with quadrupole MSs, these are scanning analysers, meaning that ions 
of different m/z ratios are transmitted over a period of time. Later inventions such as 
time of flight (ToF) separate ions in time, and ion traps (IT) in space. 
1.7.3.1. Resolution and mass accuracy 
A mass spectrometer's resolution and mass accuracy are of great importance if it is 
to provide reliable data that can be used for the identification of unknown compounds 
(Balogh, 2004). Mass accuracy is typically measured in parts per million (ppm) and is 
calculated using equation 1.7.9: 
Error (ppm) = 
bm 
x106 
m 
Equation 1.7.9. 
There are two methods for determining the resolution of an MS. Initially, resolution 
was defined as the ability of an MS to resolve two peaks of similar mass. With that 
definition, two peaks were usually considered resolved if the valley between the 
peaks is equal to or less than 10 % of the lowest intensity peak, as shown in figure 
1.7.9a. Figure 1.7.9b shows the full width half maximum (FWHM) method, which is 
now the most commonly chosen method of reporting a peak's resolution. 
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Figure 1.7.9. (a) Two peaks are considered resolved, as the valley is at 10 % of the 
intensity of the weaker peak. The resolution, R, is given by the mass, m (where z= 
1), divided by the change in mass, bm (R = m/bm); (b) The full width half maximum 
(FWHM) definition takes the peak width at half maximum, or 50 % of the relative 
intensity. 
1.7.3.2. Magnetic sector analysers 
Magnetic sector instruments were the first type of commercially available mass 
spectrometer. Ions are generated (usually by EI) and subsequently accelerated from 
the source. The ions gain kinetic energy through the acceleration, which is given by 
equation 1.7.10 (where z= number of charges, e= charge of an electron, Vacc _ 
accelerating potential, m= mass and v= velocity of an ion. ) 
mv2 
ze Vacc =2 Equation 1.7.10. 
Magnet , -'ý . 
r f. % % 
'sue,. 
Detector 
Source 
Figure 1.7.10. A magnetic sector instrument. The magnetic field has a strength of B, 
given in Tesla; the ions traverse the field through a radius, r. 
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Once the ions have left the source, they enter the mass analyser region (figure 
1.7.10) where they traverse the magnetic field. The motion of the ion through the field 
is given by equation 1.7.11 (where B= magnet strength, in Tesla, r= radius, z= 
number of charges, e= charge of an electron, v= velocity of an ion), which, when 
combined with equation 1.7.10, forms equation 1.7.12: 
mv2 
= Bzev r 
m B2r2e 
Z 2V 
Equation 1.7.11. 
Equation 1.7.12. 
Equation 1.7.12 shows that by varying the values of B or V, different m/z values can 
traverse the field to reach the detector. Scanning is carried out as an exponential 
function beginning with the high masses. Magnetic sector instruments have a 
constant resolution over all masses, which means at lower masses, there is a low bm 
(greater separation) compared to a high öm for high masses. If the scanning were to 
be constant and not exponential, then not all of the ions at lower masses would be 
transmitted; hence the exponential scanning allows the detection of all of the ions at 
lower masses. The exponential scan mode function is given by equation 1.7.13 
(where m= mass at time t, mo = starting mass at t= 0) : 
m= moe-k` Equation 1.7.13. 
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1.7.3.3. Quadrupole analyser 
In 1953, Paul and Steinwedel developed the principle of the quadrupole which was 
subsequently developed and refined and is now an integral part of many modern 
mass spectrometers (Paul and Steinwedel, 1953). 
0 U 
i 
.......... 
- (U -V cos (tt) 
Figure 1.7.11. Schematic of a quadrupole. U= DC potential, V= amplitude, w= 
angular frequency (2rrv, where v= frequency). 
Quadrupoles consist of 4 parallel rods (figure 1.7.11) that have a circular or 
hyperbolic cross section. Opposite rods are electronically connected to one another; 
one pair is connected to a positive potential + (U - Vcoswt), and the other pair to a 
negative potential - (U - Vcoswt). U is a direct current (DC) component which is 
variable; an alternating radio frequency (RF) with amplitude V, and frequency w, is 
applied. The RF potentials that are applied to the two sets of rods are 1800 out of 
phase. Ions enter the quadrupole at a constant velocity where they are subjected to 
the alternating RF field, which is superimposed onto a constant field, the positive and 
negative DC potentials. Ions oscillate through the quadrupole along the z axis; 
depending on the ion's mass, the potentials U and V and the RF frequency applied. 
Ions of a certain m/z ratio have a stable trajectory and therefore pass through the 
quadrupole. Ions which do not have a stable trajectory are not transmitted as they 
are attracted towards the rods where they collide, losing their charge. Altering the DC 
and RF potentials, but maintaining a constant DC/RF ratio, allows the successive 
transmission of ions with different m/z ratios. 
E. Mathieu developed equations in 1866 that described vibrations across a stretched 
membrane; the equations were found to be applicable to the motion of an ion and are 
therefore used to determine the parameters required to allow an ion of a particular 
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m/z to be transmitted through the quadrupole with a stable trajectory (equation 
1.7.14, where z= charge on ion, e= charge of electron, m= mass, w= angular 
frequency, ro = radius from z-axis to quadrupole (diameter is 2ro)). 
8zeU 4zeV 
a =22 and qu = Equation 1.7.14. 
mw ro mcw2ro2 
From equation 1.7.14, a mass stability diagram (figure 1.7.12) can be created. The 
areas where an ion is stable in the x and y dimensions according to the solutions to 
the Mathieu parameters are circled. The areas of ion stability can be used to provide 
mass discrimination; not all of the areas are commonly used in mass spectrometry 
due to the high potentials that are required. Therefore most mass spectrometers 
utilise the area that lies on the q axis, as the potentials are suitable for use within a 
quadrupole. 
au 
able along x-axis 
able along y-axis 
Figure 1.7.12. Mathieu stability diagram for a quadrupole. Circled areas indicate 
where ions are stable in a quadrupolar field. Inset is an expansion of the area that is 
utilised in most mass spectrometers. Above the qu-axis corresponds to +U, and 
below to -U. 
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Providing that an ion's trajectory does not exceed the fixed ro value (where it would 
collide with a quadrupole and discharge) its trajectory is stable along the length of the 
quadrupole (z-axis) and is transmitted; when an ion moves away from the z axis of 
the quadrupole the potential field that the ion experiences is greater, causing the ion 
to be focussed back to the centre along the z-axis. 
A 
V 
Figure 1.7.13. Stability areas for positive ions of different masses (m, and m2) as a 
function of au and qu. Ions have a stable trajectory if the scan line (A and B) passes 
through the stability area; mass resolution is achieved by operating the scan line 
close to the apices of the stability areas, line A. 
Figure 1.7.13 illustrates how ions of different m/z values can be transmitted through a 
quadrupole, giving mass discrimination. Mass separation is achieved by altering the 
U and V values whilst maintaining a constant ratio between the two (U/V). Ions that 
have au and qu values that fall within the stable region are transmitted through the 
quadrupole; ions whose au and q values lie outside the stable region have unstable 
trajectories and discharge against a rod. 
The scan lines A and B (figure 1.7.13) both pass though the stability areas for two 
ions of different m/z values, m, and m2, meaning that both ions are transmitted 
through the quadrupole. Line B has a shallow gradient and does not allow mass 
discrimination as both ions of m, and m2 have stable trajectories and are detected 
together and therefore not resolved. Line A has a steep gradient and passes through 
the apices of the stability areas for the two ions; these ions are resolved and 
discrimination between the two masses is now possible. 
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A quadrupole's resolution is controlled by altering the DC component, U. A high UN 
ratio has a higher resolution but reduced transmission; initial ion velocities (amount of 
kinetic energy) and the position of entry into the quadrupole means that operating 
close to the boundaries of stability are impractical, hence why quadrupoles usually 
only operate at unit resolution. 
1.7.3.4. Quadrupoles as a collision cell - MS/MS 
Soft ionisation techniques such as ESI, MALDI and APCI only produce mainly 
protonated molecules with little, if any, fragmentation. For structural information to be 
obtained, a molecule must be fragmented to yield structurally informative fragment 
ions. Molecules can be fragmented by their collision with an inert gas. Jennings and 
McLafferty described the concept of colliding ions with a collision gas in the 1960s 
(Jennings, 1968; McLafferty, 1968); originally called collision activated dissociation 
(CAD), it is now commonly referred to as collision induced dissociation (CID). If an 
ion collides with an inert gas then part of its kinetic energy is converted into internal 
energy. This internal energy, if sufficient, induces fragmentation. 
If a quadrupole is operated in RF only mode (U = 0), provided that V is still within the 
area of stability, all ions have a stable trajectory and pass through the quadrupole; 
they are thus focussed along the z-axis. Ions that enter an RF only quadrupole can 
fragment through metastable dissociation, or by their collision with an inert gas 
present at a low pressure, CID; when ions fragment within an RF only quadrupole it 
is referred to as a collision cell. 
The coupling of two mass analysers, such as quadrupoles, separated by a collision 
cell, allows the analysis of individual components from a mixture. The coupling of 
mass analysers creates a tandem mass spectrometer that is tandem in space; 
tandem in time instruments are described later (section 1.7.3.7). Tandem mass 
spectrometry enables a series of experiments that allows a wide range of information 
about an ion to be obtained (figure 1.7.14). 
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Figure 1.7.14. Summary of the four tandem mass spectrometry experiments. (a) 
product ion experiment. (b) precursor ion experiment. (c) neutral loss experiment. (d) 
selected reaction monitoring. 
1.7.3.4.1. Product ion experiment 
A product ion experiment (figure 1.7.14a) is where a precursor ion is selected in the 
first mass analyser and transmitted to the collision cell, where it fragments by 
metastable dissociation or by CID. The fragments are analysed in the second mass 
analyser, yielding the product ion spectrum. 
1.7.3.4.2. Precursor ion experiment 
The precursor ion experiment (figure 1.7.14b) is conceptually the opposite of a 
product ion scan. The second mass analyser is set to only allow ions of a specific 
m/z ratio to be transmitted. Ions are scanned through the first mass analyser and are 
fragmented in the collision cell; the detector gives a response if an ion transmitted 
through mass analyser one fragments to the product ion m/z value set in mass 
analyser two. 
56 
Chapter One: Introduction 
1.7.3.4.3. Neutral loss experiment 
A neutral loss experiment (figure 1.7.14c) identifies a precursor ion that loses a 
specific neutral fragment, such as water. As with the precursor ion experiment, the 
first mass analyser sequentially allows ions through to the collision cell to undergo 
fragmentation. Any product ion that has a mass corresponding to the constant mass 
difference gives a response at the detector. 
1.7.3.4.4. Selected reaction monitoring 
Selected reaction monitoring (figure 1.7.14d) records a specific precursor ion giving a 
specific fragment ion. The first mass analyser transmits specific precursor ions that 
are subsequently fragmented in the collision cell. The second mass analyser is set to 
transmit specific fragments; a signal is only given if the selected precursor ion yields 
the correct fragment ion. 
1.7.3.5. Ion traps 
The quadrupole Ion Trap (IT) was described by Paul et al. in 1953, and initially 
adopted by physicists to investigate the properties of trapped ions (Paul and 
Steinwedel, 1953). The initial problems of poor resolution, mass range and the ability 
to study (trap) only one m/z value at a time due to `mass selective stability' were 
eventually overcome by the work by Stafford's group (Stafford, 2002). Stafford 
developed the `mass selective instability mode', meaning that ions could be trapped 
and sequentially ejected from the trap and detected; the addition of helium gas to the 
trap was found to vastly improve the peak shape and resolution. 
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End cap electrodes 
Ions -- -- -> Detector 
Figure 1.7.15. A schematic of an ion trap. The ring electrode utilises a fundamental 
RF whereas the end caps utilise variable RF for the excitation or ejection of ions. 
Typical ion trap geometries are less than 1 cm3. 
The ion trap (figure 1.7.15) consists of a ring electrode and two end caps which are 
all hyperbolically shaped. Ions are received from a multipole (which has focussed the 
ions) where they enter the trap through the end cap (when a repelling potential on the 
gate lens is dropped) and are subjected to a multipole field. As with quadrupoles, 
ions are only stable within a certain field that is determined by solutions to the 
Mathieu equations. Since the ion trap is cylindrical with respect to the ring electrode, 
the x and y coordinates can be reduced to r2 (x2 +/=r 2). 
The stability of an ion can be expressed using only the z and r coordinates. The 
application of DC (U) and RF (V) is required and is applied in the Mathieu parameters 
(equation 1.7.15, where w= 2rrf). 
qz = 
4eV 
and aZ =- 
8eU Equation 1.7.15. 
mro 
2(02 
mr02(0 
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Figure 1.7.16. (a) The stability diagram for ions in an ion trap. Blue areas indicate 
stability on the r-axis (between the ring electrode) and the yellow areas indicate 
stability on the z-axis (between the end caps). The area of stability circled is the one 
generally utilised and is expanded and shown in (b). 
For an ion to be stable in an ion trap, it must be stable on both the r and z axis. The 
three areas of this stability are shown in figure 1.7.16a; the area circled (and shown 
in figure 1.7.16b) is the only one that can be practically utilised, as the parameters 
that would be required to use the other areas cannot be used as arcing between the 
ring and end cap electrodes would occur. The mass selective instability mode allows 
the maximum number of ions possible to be trapped; this is operated with no DC 
potential, meaning that U=0 and therefore aZ = 0. As aZ = 0, the ions in the trap 
effectively `sit' on the qZ axis with ions of high mass at low q, values and ions of low 
mass at high q values. 
1.7.3.5.1. Injection and trapping of ions 
The gate lens at the entrance of the ion trap is pulsed from positive to negative (in 
positive mode) to allow a packet of ions from a quadrupole to enter the trap. The ions 
are subjected to an RF field that is applied to the ring electrode; the RF frequency is 
held constant but its amplitude (V) can be varied (discussed later). The RF field 
increases linearly from the centre of the trap, which causes the ions to be focussed 
into the centre of the trap, where they oscillate in a 'figure of eight' pattern (figure 
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1.7.15). Helium is an inert gas that is introduced at low pressures into the trap to aid 
focussing of the ions, as it reduces their excess kinetic energy by `collisional cooling'. 
The number of ions that enters the trap has to be carefully controlled to avoid a 
phenomenon called the `space charge effect'. Ions need to be at a concentration 
where ions do not 'see' one another, effectively existing in infinite space without 
interaction with another ion. Too many ions result in the ions being able to 'see' one 
another, causing a distortion of the quadrupole field and consequent loss of mass 
accuracy and resolution. 
1.7.3.5.2. Ion ejection 
A simple MS experiment requires the ejection and detection of the ions that are 
stored in the trap. Figure 1.7.16b shows a qZ value of 0.908, this is called the qeject 
and the q value at which ions stored in the trap become unstable in the axial direction 
(between the end caps) but remain stable in the radial direction (between the ring 
electrode). The ions are ejected from the trap when they reach this value by ramping 
the RF amplitude (V), but due to the geometry of the trap, only 50 % of the ions reach 
the detector as the ions pass towards both end caps, only one of which leads to the 
detector in the most commonly used IT design. 
In order to eject the ions, the RF amplitude (V) is sequentially ramped causing the 
ions to become unstable and be ejected in order of increasing m/z value. There is a 
problem that arises which means there is a limit to the potential that can be applied to 
the trap before arcing between the electrodes occurs; ions of a high mass are 
therefore not excited enough to become unstable and therefore remain in the trap 
(figure 1.7.17a, i, ii, iii). 
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Figure 1.7.17. An expansion of the qZ axis to illustrate the problem of high mass ions 
remaining in the trap at the maximum RF amplitude. (a) i) The ions are collisionally 
cooled and focused and are at a low qZ value. ii) The RF amplitude has been 
increased, the low mass ions (pink) begin to move along the qZ axis as they become 
excited and unstable. iii) The amplitude has been increased to its maximum, the low 
mass ions have been ejected whereas the high mass ions remain in the trap. (b) A 
secular frequency creates an area of instability at lower qZ values (red elipse). i) The 
ions are cooled and focussed in the centre of the trap. ii) An increase in amplitude 
has ejected the ions of a low mass and intermediate mass (green) through the area 
of instability. iii) At maximum amplitude, all of the ions have been ejected from the 
trap by the creation of the area of instability at a qZ value sufficient to allow the high 
mass ions to be ejected. 
Trapped ions of a given m/z oscillate at a specific frequency, called the secular 
frequency. When ions are excited by a secular frequency, they gain energy, 
becoming unstable and move towards the end caps. Figure 1.7.17b, i, ii, iii, shows how 
the application of a secular frequency creates a `hole' where ions can be ejected from 
the trap and detected at a qZ values lower than 0.908; the position of the `hole' 
depends upon the amplitude of the frequency that is applied. This technique is called 
resonance ejection and is used to extend the mass range of the ion trap. 
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1.7.3.6. Ion traps as a collision cell - MS/MS and MS" 
Ion traps are tandem in time and allow not only for MS/MS experimentation, but for 
successive MS steps creating MSn capacity, thus allowing in-depth fragmentation of 
an analyte. MS" involves the selection of a particular m/z value, so that that only ions 
of selected m/z are present within the trap. The ions are then fragmented by collision 
induced dissociation (CID) and the fragments ejected (or specific fragments isolated 
in the trap and subjected to further CID). 
1.7.3.6.1. Ion isolation 
To produce a spectrum with a fragmentation that is specific for ions of a particular 
m/z value, ions of a specific m/z value must first be isolated in the trap. Once an ion 
has been chosen, for example the ion at m/z 573 in figure 1.7.18a, ions of other m/z 
values in the trap are ejected by the application of a multi frequency resonance RF 
across the end caps (except at the frequency that corresponds to the selected ion). 
The isolated ion is then isolated in the trap. 
(a) 
(b) 
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Figure 1.7.18. The isolation of an ion of a specific m/z value and the expulsion of 
ions of other m/z values. (a) A mass spectrum with the selected ion highlighted in 
green. The blue shading represents the multi frequency resonance RF that is applied 
to the end caps. (b) A simplified representation showing that the frequency is not 
applied to the q,, that corresponds to the selected ion (red). 
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1.7.3.6.2. Collision induced dissociation 
Once ions of a particular m/z have been isolated in the trap, an RF waveform that is 
specific to the isolated ions is applied to the end caps (lower RF than causes ejection 
to occur); this is sometimes referred to as a `tickle voltage'. The ions begin to 
oscillate in the trap and gain kinetic energy, the ions then collide with the helium gas 
causing some of the kinetic energy to be converted into internal energy, inducing 
fragmentation by CID. After CID has occurred, the precursor ion and its fragments 
are focussed into the centre of the trap before they are sequentially ejected and 
detected. 
q = 0.908 
I 
Fragment ions 
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Figure 1.7.19. Low mass cut off. Fragment ions of 25 % or less of the isolated ions 
m/z value are ejected and not detected. 
One limitation caused by fragmenting an ion is that not all of the fragment ions 
generated are stable in the q direction, causing them to be expelled from the trap 
during the CID process. In order to effectively fragment an ion in a trap it has to be 
set at a q of -0.25, at which the `low mass cut off' typically results in ions of less 
than 25 % of the initial parent ions m/z value to be ejected without detection (figure 
1.7.19). 
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1.7.3.7. Time of flight analyser 
Initially, Time of Flight (ToF) mass spectrometers were linear and first described by 
Stephens in 1946 (Stephens, 1946). The resolution and accuracy of the first 
instruments was low, but the advent of delayed extraction and reflectron increased 
both the resolution and mass accuracy greatly. 
1.7.3.7.1. Linear ToF 
A linear ToF is essentially a long tube under vacuum (figure 1.7.20). Ions are 
accelerated from the source by an electric field into a field free region; the ions 
traverse the field free region and are detected. A pulsed ion source such as MALDI is 
well suited to use with a ToF analyser as it produces discrete packets of ions; the 
starting time of the ions acceleration into the field free region can easily be recorded. 
Detector 
MALDI -25 kV 
source 
+25 kV 
ý.. _.. -. _- . -.. _.. _ _.. _.. ý d 
Figure 1.7.20. A schematic of a linear ToF. Ions are generated and accelerated into 
a field free region, d, where the time taken for ions to traverse this region is recorded 
and their mass determined. 
All ions of same charge gain the same kinetic energy. The velocity depends upon the 
mass, equation 1.7.16. Ions of a different mass therefore separate in space and time 
in a ToF analyser. If an ion's 'time of flight' can be recorded, then its mass can be 
determined. An ion leaves the source with a kinetic energy (Ek) described by 
equation 1.7.16 (where m= mass, q= total charge (q = ze), v= velocity, V= applied 
potential): 
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Ek = qV = 
mv 
2 
Equation 1.7.16. 
2 
t= Equation 1.7.17. 
V 
2 
t2 =m 
d 
Equation 1.7.18. 
z 2Vse 
Equation 1.7.18 is a combination of equations 1.7.16 and 1.7.17, and shows that 
measuring the time that it takes a particular ion to traverse the field free region allows 
its m/z value to be determined. The time taken to record a full spectrum, even at low 
resolution, was enough to ensure ToFs found wide application in research and were 
therefore developed to increase the resolution and accuracy that could be obtained. 
1.7.3.7.2. Delayed extraction 
MALDI forms discrete packets of ions that allow a definitive start time to be recorded 
compared to a continuous ionisation source such as ESI; ions are continuously 
formed and as such a definitive starting time cannot be recorded. The problems of 
low mass accuracy and resolution in linear ToFs are caused by the generation of 
ions of the same m/z value but different kinetic energies. The spread of kinetic 
energy causes ions of the same m/z to reach the detector at different times, as 
shown by the ions in figure 1.7.20. 
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Figure 1.7.21. Factors that reduce mass accuracy and resolution in ToFs: (a) 
temporal distribution, ions are formed at different times, (b) spatial distribution, ions 
are formed at different locations, (c) kinetic energy distribution, ions gain different 
amounts of kinetic energy. 
Temporal distribution (figure 1.7.21 a) involves the formation of ions at different times 
during the ablation process in MALDI; the ions arrive at the detector at slightly 
different times because of their different time of formation. The formation of ions at 
different locations either within the matrix or plume gives rise to a spatial distribution 
(figure 1.7.21 b); ions that remain in the accelerating field (between the grids) for 
longer periods of time gain more kinetic energy than ions that spend less time in the 
accelerating field. The range of kinetic energies that is imparted to the ions (figure 
1.7.21c) causes their arrival at the detector at different times; a combination of all 
three distributions causes a decrease in mass accuracy and resolution. 
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Figure 1.7.22. A linear ToF with a DE source. The two acceleration grids are initially 
at ground, the ions expand into a field free region before the acceleration potential is 
applied to the ions. 
Delayed extraction (DE) was developed to try and correct for the kinetic energy 
spread and temporal distribution of ions with the same m/z value. Linear ToFs were 
modified (figure 1.7.22) to include a DE source. The ions initially expand into a field 
free region (the grids are temporarily held at earth); ions of greater kinetic energy 
move further towards the detector than those with less. After a short delay, the 
extraction potential is applied (to two grids); ions with a lower kinetic energy remain 
closer to the grids and are subsequently accelerated more than the ions with higher 
kinetic energy that are further away from the grids which are accelerated to a lesser 
degree. The DE of ions has the effect of correcting for the initial kinetic energy 
spread by focussing ions of the same m/z onto the detector, increasing the resolution 
and mass accuracy. 
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1.7.3.7.3. Reflectrons 
Mamyrin et al. first proposed the use of an electrostatic reflector or reflectron in 1973. 
A reflectron is a series of grids and ring electrodes that create an ion mirror or 
retarding field. The purpose of a reflectron is to correct for any initial energy 
dispersion that ions may have; as the energy dispersion is corrected for and the flight 
path is doubled, the resolution and mass accuracy are improved but at the cost of 
mass range and sensitivity. 
Reflectron (ion mirror) 
+1 kV 
Source """""""""""""""" 
.................... 
" 
" .. 
" Low KE ion """""""""""""""" 
Detector 0 High KE ion 
Figure 1.7.23. A schematic of a ToF analyser with a reflectron. The length of the ion 
path is doubled due to the ion's paths being inverted. KE = kinetic energy. 
Ions with high kinetic energy penetrate the reflectron more than an ion with low 
kinetic energy (figure 1.7.23). The ions do not gain or lose any kinetic energy as a 
result of the reflectron, it merely corrects for the difference in energy. Ions of high 
kinetic energy spend less time in the field free region and more in the reflectron, 
conversely low kinetic energy ions spend more time in the field free region and less 
in the reflectron; the result is that ions of the same m/z but different kinetic energies 
arrive at the detector at the same time. 
The combination of delayed extraction and reflectrons in some ToFs has been used 
in order to gain greater resolution. The reflectron can only account for the kinetic 
energy spread of ions; DE can correct for spatial and temporal distribution, causing 
ions affected by these factors to be focussed, allowing an increase in the resolution 
as the ions reach the detector with less spread in time. 
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1.7.3.7.4. Orthogonal acceleration ToF (Applied Biosystems QStar Pulsar 1) 
ToFs require discrete packets of ions, so a continuous ionisation source such as ESI 
requires the continuous ion beam to be pulsed to create discrete packets of ions. 
One way to create a pulsed ion beam is to effectively store the ions before creating a 
pulse that allows the stored ions to enter the ToF, or alternatively to pulse the ion 
beam into the ToF which is orthogonal to the ion beam (figure 1.7.24). 
Ions -- 
QO {! ST 
Collision cell 
(Q2) 
Pusher Detector 
--------- 
Grid o'o 
Puller 
Reflectron 
o 
iiý Curtain gas Skimmer 
Figure 1.7.24. A schematic of the Applied Biosystems QStar Pulsar i. ST = Stubbies, 
a small quadrupole. 
Ions enter the orthogonal acceleration ToF (oa-ToF) where they are focussed by an 
RF only quadrupole, QO which transmits all ions (figure 1.7.24); the ions are then 
transferred to the high vacuum area of the MS. The voltage that is applied to QO and 
ST is held at a constant fraction of the RF voltage that is applied to Q1, the mass 
filter quadrupole which has no DC potential applied for MS. The collision cell contains 
a collision gas at low pressures; the cell is operated in RF mode, which is stepped 
over several ranges to transmit a wide range of m/z values to the ToF. The ions enter 
the ToF where they are orthogonally `pushed' by an accelerating voltage, creating a 
discrete packet of ions, which allows a starting time for the time of flight to be 
recorded. The ions enter the field free region where they are separated according to 
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their m/z value before being detected; ions with a large m/z have a longer flight time 
than ions with a low m/z value. 
1.7.3.7.4.1. MS/MS 
oa-ToF is tandem in space as it has two mass analysers that are separated by a 
collision cell. The first mass analyser is a quadrupole that operates in RF only mode 
for MS, but uses a DC potential to allow mass discrimination. The second mass 
analyser is a ToF and is not a scanning analyser, which means that oa-ToF is only 
capable of precursor and product ion experiments. 
For product ion experiments, Q1 (figure 1.7.24) is operated in mass discrimination 
mode to allow ions of a particular m/z value to be transmitted to the collision cell. The 
ions enter the collision cell where they collide with a collision gas and fragment by 
CID; if a potential is applied to the exit lens of the collision cell then the ions are 
stored before being passed to the pusher where they are orthogonally pushed into 
the ToF. 
The precursor ion experiment involves Q1 scanning ions through into the collision 
cell where they are fragmented using CID. The ToF is set to only give a signal if 
fragment ions of a particular m/z value are detected. If the correct fragment ions are 
detected, then the precursor ion is identified. 
1.7.3.8. MALDI-ToF/ToF (Applied Biosystems 4700 proteomics analyser) 
The Applied Biosystems 4700 proteomics analyser is a MALDI linear tandem ToF 
mass spectrometer, which can perform high energy CID MS/MS experiments. The 
MALDI source utilises a Nd: YAG solid state laser, with a repetition rate of 200 Hz, 
and is equipped with delayed extraction optics. For MS, ions are extracted with a 
high potential (ca. 20 kV) and pass through the MS1 region, the collision cell and the 
MS2 region (figure 1.7.25); the ions' time of flight are calculated when they reach 
either the linear or reflectron detectors, depending upon which mode is chosen. 
For tandem MS experiments, the ions are subjected to DE and then accelerated 
using a high potential into MS1, where the timed ion selector is used to select a 
precursor ion. The timed ion selector is a dual stage electrode, where the first 
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electrode is switched on, retarding all ions; as the time of flight that corresponds to 
the precursor ion being selected occurs, the voltage is dropped allowing the 
transmission of the precursor ions before the second electrode is turned on to repel 
any subsequent ion transmission. The retarding lens decelerates the transmitted 
precursor ion to an energy of -1 keV where it enters the collision cell, which now 
contains a collision gas. After the precursor ion has been subjected to CID, the 
fragment ions are re-accelerated in the second source; pulsed ion acceleration 
provides a start point for ToF measurement of the fragment ions. 
Timed ion Target 
Nd: YAG selector gas 
Reflectron 
detector 
laser ; -; 
MS 1 MS 2 
'i 0000 aooo uii 
uuý ppoo ; ooao _ iii 
........... 
DE-MALDI 
Source 
Beam 1 Collision 
ion optics cell 
Retarding 
lens 
Reflectron 
111111111111111111 
1111111111111 
2nd source Beam 2 
ion optics 
Linear 
detector 
Figure 1.7.25. A schematic of an Applied Biosystems 4700 proteomics analyser with 
ToF/ToF optics. 
1.7.3.9. Detectors 
Given that ions can be separated according to their m/z value by mass analysers, 
they need to be detected for any structural information to be obtained. Initially, ions 
used to be detected directly by a photographic plate or a Faraday cup. Ions of the 
same m/z would reach the plate at the same place (the intensity of the spot would be 
proportional to the intensity); a scale could be applied that would determine the m/z 
of the spots. Faraday cages cause an ion to discharge upon a collision; the current of 
the discharge is amplified and then detected. Modern mass spectrometers use 
electron multipliers, photomultipliers or array detectors such as the microchannel 
plate. 
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1.7.3.9.1. Electron multiplier 
Positive or negative ions are attracted towards a conversion dynode where they 
impact causing the emission of secondary particles (figure 1.7.26). The secondary 
particles (electrons) are accelerated into a horn shaped device where they collide 
with a cathode, releasing more electrons which go on to collide again and again with 
further cathodes, causing a cascade of electrons. The cascade of electrons travels 
towards ground where their current can be measured (it is proportional to intensity). 
Typical amplification can reach 107; electron multipliers are commonly used for 
quadrupole and ion trap instruments. 
Ion 
Conversion 
dynode 
Current 
Figure 1.7.26. A schematic of an electron multiplier. 
1.7.3.9.2. Photomultiplier 
Ions are converted into electrons by their collision with a conversion dynode, as in an 
electron multiplier. The secondary particles are accelerated towards a 
phosphorescent screen, from which photons are emitted on impact of the electrons 
(figure 1.7.27). The photons are detected by a photomultiplier. The lifetime of a 
photomultiplier is longer than that of an electron multiplier as it is sealed in glass, 
preventing contamination; however the amplification is less, at 104 to 105. 
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Figure 1.7.27. A schematic of a photomultiplier. 
1.7.3.9.3. Microchannel plate 
Electrons 
Photons 
The microchannel Plate (MCP) is a plate that consists of many small (4-25 pm 
diameter) glass tubes (figure 1.7.28a), that have a geometry (figure 1.7.28b) which 
allows a cascade of electrons to occur (analogous to electron multipliers). Both faces 
of the disk are coated in metal so that each channel is electronically connected, with 
a potential difference applied across the plate. Ions of the same m/z value can arrive 
at a different location on the plate but can still all be detected at the same time with a 
typical amplification of 106. The connection of plates in series (figure 1.7.28 c-d) can 
increase the amplification up to 108. MCPs are commonly used in ToFs as they allow 
the simultaneous detection of ions over space. 
(a) 
(b) (c) 
Figure 1.7.28. (a) The microchannel plate detector. (b) Continuous dynode electron 
multiplier geometry. (c-d) The connection of MCPs together to increase the 
amplification of ion current. 
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1.8. Aims 
This thesis describes the application of LC-MS for the analysis of human urine 
samples. The objectives of the research described in this thesis were to critically 
assess current LC-MS metabonomic methodologies alongside a new separation 
method, hydrophilic interaction chromatography (HILIC), in an attempt to increase the 
coverage of metabolites within human urine samples. A further objective was to 
analyse an extract of Pseudomonas chlororaphis PCL 1391 using the same 
analytical methods as a metabonomic study, but in a completely different manner. 
Chapter Three thus discusses and evaluates the various analytical platforms 
available for metabonomic studies, comparing and contrasting different separation 
methods, ionisation methods and detection methods. It describes considerations 
involved in sample collection, storage and manipulation, as well as subsequent 
extraction of raw LC-MS data and the related statistical analysis of these data and 
their assessment and development. The main focus of the work described in Chapter 
Three is the development of HILIC as a complementary orthogonal separation 
method to reversed phase for an increased coverage of urinary compounds, and a 
proposal of the required elements of a robust LC-MS `metabonomic toolbox'. 
Chapter Four uses the methods discussed and developed in Chapter Three for the 
analysis of clinical urine samples obtained from patients who had suffered a fracture. 
Chapter Five discusses the structural determination of a Pseudomonad biosurfactant 
using ESI-MS(MS), MALDI-ToF/ToF and racemic amino acid analysis. 
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Chapter Two: Experimental methods 
2.1. Urine collection 
2.1.1. Samples collected from volunteers within the Department of Chemistry, 
University of York, UK 
An e-mail was sent to all academic, administrative and Ph. D. student members of the 
Department of Chemistry, University of York, UK, asking for volunteers to donate two 
urine samples. All potential volunteers were made aware of the purpose for collecting 
their urine samples (for the development of a `metabonomic toolbox'), and were 
guaranteed anonymity. They were informed that they would have to collect the first 
void of the day, and any subsequent void after 15: 00 on the same day, with a 
preference for `mid-stream' urine. Volunteers anonymously collected sealed bags 
containing two randomly labelled sample tubes (Bibby Sterilin), further instructions 
and two further sealable bags in which to place their filled sample tubes. The only 
information that was requested was gender, age (age groups were acceptable) and if 
they were a smoker; no restrictions were placed upon volunteers diet or lifestyle. 
Volunteers were asked to place their filled sample tubes into one of three boxes 
spread across the department within two hours of donation; all samples were 
transferred to -80 °C storage within two hours of donation, indicated by the majority 
of samples still being warm upon collection of the boxes. A total of 62 samples were 
donated, 39 from males and 23 from females. All data relating to the samples is 
presented in appendix A. 
2.1.2. Clinical urine sample collection 
Full ethical approval was obtained for the collection of urine samples from patients 
suffering bone fractures. A registrar orthopaedic surgeon collected clinical urine 
samples from patients suffering a fracture who were admitted to York District Hospital 
NHS Trust's accident and emergency department between October 2004 and 
February 2005. The inclusion criteria was that patients were between the ages of 18- 
45 to reduce any chance of pathological fractures or incomplete skeletal 
development; initially only long bone fractures were considered, but due to the lack of 
long bone fractures, the study was opened up to wrist and ankle fractures. Further 
exclusions were patients who had suffered multiple injuries, had malignancy, head 
injuries, spine/foot/hand fractures, pregnant or nursing mothers and any unconscious 
patients. A total of 61 patients were deemed suitable for inclusion into the study (45 
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males and 16 females); of these, 11 declined consent stating either lack of interest or 
a needle phobia', with a further two patients withdrawing consent at a later date, and 
one being transferred into the care of another health trust. This left a total of 48 
patients (36 males and 12 females, with an age range of 19 to 47 years old; average 
age = 29.5, standard deviation = 8.2), who each donated between one and four urine 
samples, ranging from a period of t=0 (time of fracture) to 133 days (19 weeks) after 
the initial fracture (average =6 weeks). 
A total of 12 different fracture types were included in the study, with the largest 
sample cohort being ankle fractures (51 urine samples). All obtained data relating to 
the clinical urine samples are presented within appendix B. 
2.2. Sample storage 
2.2.1. Samples collected from volunteers within the Department of Chemistry, 
University of York, UK 
Upon collection, donated urine samples were stored at -80 °C for a period of four 
weeks before being subject to further manipulations (section 2.3), and stored at -80 
°C after these manipulations. 
2.2.2. Clinical urine samples 
Clinical urine samples were stored at -80 °C at Smith & Nephew, York Science Park, 
UK. Samples were aliquotted (section 2.3) and stored at -80 °C until transport to the 
Department of Chemistry on dry ice for analysis. 
2.3. Sample manipulations 
All urine samples were defrosted at room temperature before being aliquotted into 
microcentrifuge vials (Sarstedt) and re-frozen at -80 °C prior to any further sample 
preparation and analysis. The samples collected from within the department were 
Serum samples were also collected for a parallel study by Smith & Nephew into serum markers related 
to fracture repair; any patients with needle phobia were excluded from the trial. 
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used to create a pooled reference sample by transferring 1 mL from each sample into 
a beaker before mixing and aliquotting this pooled reference sample. 
2.3.1. Samples separated using RP 
For analysis using RP-LC-MS, all urine samples were defrosted at room temperature 
before being centrifuged at 10,186 xg for 8 min (GenFuge 24D, Progen). The 
supernatant was collected and passed through a 0.45 pm PVDF syringe filter (VWR) 
into sample vials fitted with 250 pL deactivated glass inserts (Agilent Technologies), 
ready for analysis. 
2.3.2. Samples separated using HILIC 
For analysis using HILIC-MS, all urine samples were defrosted at room temperature 
before being mixed in a 1: 1 ratio with MeCN (Fisher Scientific). The samples were 
then centrifuged at 10,186 xg for 8 min (GenFuge 24D, Progen). The supernatant 
was collected and passed through a 0.45 pm PVDF syringe filter (VWR) into sample 
vials fitted with 250 pL deactivated glass inserts (Agilent Technologies), ready for 
analysis. 
2.3.3. Sample re-analysis using RP (clinical samples) 
To precipitate and remove the protein present in the clinical urine samples prior to 
RP-LC-MS analysis, the samples were treated as described in section 2.3.2. 
2.4. HPLC separations 
2.4.1. RP separation 
Urine samples were separated on a 100 x 4.6 mm Chromolith RP18e column 
(Merck), along with a guard column (5 x 4.6 mm), on an an Agilent 1100 LC (Agilent 
Technologies). Mobile phase A was 0.1 % (v/v) formic acid (Fisher Scientific), while 
mobile phase B was MeCN (Fisher Scientific) modified by the addition of 0.1 % (v/v) 
formic acid (Fisher scientific). The gradient started with 5% mobile phase B, 
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increasing to 20% B at 9 min, and then to 95% B at 21 min. The mobile phase was 
held isocratic for 3 min before returning to the starting conditions within 3 min (total 
run time was 30 min). The injection volume was 20 pL, and the column was eluted at 
a flow rate of 600 pL min-'. 
2.4.2. HILIC separations 
Urine samples were separated using a 3.5 pm, 100 x 4.6 mm ZIC-HILIC column 
(SeQuant), along with a guard column (20 x 2.1 mm), on an an Agilent 1100 LC 
(Agilent Technologies). Three gradients were developed, with gradient three (section 
2.4.2.3) being used for all HILIC separations in this thesis. 
2.4.2.1. Gradient 1 
Mobile phase A consisted of 0.1 % (v/v) formic acid (pH 4, Fisher Scientific), while 
mobile phase B consisted of MeCN (Fisher Scientific) modified by the addition of 0.1 
% (v/v) formic acid (Fisher Scientific). The gradient started with 5% mobile phase A 
increasing linearly to 20 % over a period of 9 min, with a further increase to 95 % 
over 12 min before being held isocratic for 3 min before returning to the starting 
conditions within 3 min. The mobile phase was kept at 5%A for the remaining time 
to allow equilibration (total run time was 30 min). The injection volume was 20 pL, 
and the column eluted at a flow rate of 600 pL min-'. 
2.4.2.2. Gradient 2 
Mobile phase A consisted of 0.1 % (v/v) formic acid (pH 4, Fisher Scientific), while 
mobile phase B consisted of MeCN (Fisher Scientific) modified by the addition of 0.1 
% (v/v) formic acid (Fisher Scientific). The gradient started with 5% mobile phase A 
increasing linearly to 95 % over a period of 15 min. The mobile phase was held 
isocratic for 4 min before returning to the starting conditions within 30 s. The mobile 
phase was kept at 5%A for the remaining time to allow equilibration (total run time 
was 30 min). The injection volume was 20 pL, and the column eluted at a flow rate of 
600 pL min-'. 
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2.4.2.3. Gradient 3 
Gradient 3 used the same parameters as shown in section 2.4.2.2 with the only 
difference being the addition of 5 mM ammonium acetate (Fisher Scientific) to mobile 
phase A. 
2.5. LC-MS(MS) analysis 
2.5.1. ESI parameters 
A TurbolonSpray source (Applied Biosystems) was used for all ESI analyses. The LC 
outlet from an Agilent 1100 series HPLC was directly coupled with no splitting. The 
capillary voltage was held at ±2500 V depending upon the ionisation mode; N2 
nebulising gas, 3.3 L min-'; and N2 drying gas, 6.0 L min-' at 300 °C. 
2.5.2. APCI parameters 
The LC outlet from an Agilent 1100 series HPLC was directly coupled to an APCI 
source (Applied Biosystems) with no splitting. The nebulising current was held at ±2 
(arbitrary units) depending upon the ionisation mode; N2 nebulising gas, 3.8 L min"'; 
and N2 drying gas, 1.5 L min-' at 425 °C. 
2.5.3. MS parameters 
ESI and APCI Q-o-ToF MS experiments were performed using an Applied 
Biosystems QStar pulsar / quadrupole orthogonal time of flight tandem MS. The MS 
was operated in full scan mode with m/z range of 40-1000 using the following 
parameters (depending upon the ionisation polarity being used): focussing potential = 
±145 V; declustering potential = ±45 V; declustering potential 2= ±15 V; quadrupole 
2 gas pressure =2 (arbitrary units). For positive ionisation mode the following 
additional parameters were used: mirror = +985 V; liner = -400 V; plate = +330 V; 
grid = -400 V; offset = -11.3 V, and for negative ionisation mode: mirror = -985 V; 
liner = +400 V; plate = -330 V; grid = +410 V; offset = -25.4 V. Data were recorded 
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using the Analyst QS v1.1 software (Applied Biosystems). 
2.5.4. MS/MS parameters 
All CID tandem MS experiments used the same conditions as those in section 2.5.3 
(except the quadrupole 2 gas which was set at 5 (arbitrary units)). In addition to these 
conditions, the independent data acquisition setting was used with the following 
settings: the four most intense peaks were selected for CID at collision energies of 20 
and 25 (arbitrary units), with dynamic exclusion set to 120 s to prevent the re- 
analysis of precursor ions already selected for CID. An `include list' was used to 
include any ions that should be automatically selected for CID should they appear in 
an MS survey `scan'. 
2.6. Data extraction and normalisation 
2.6.1. Data extraction 
Raw LC-MS data were exported using the metabolomics export script (Applied 
Biosystems). Peaks files were created prior to generating a 3D data matrix of m/z 
and tR versus intensity for each sample analysed. The following settings were used: 
tR tolerance, 0.5 min; LC peak width (min/max), 0.1/10 min; intensity threshold, 10 
counts s-1 for positive ionisation mode and 1 count s-1 for negative ionisation mode; 
mass accuracy, 200 ppm; maximum peak number, 5000. The data were exported as 
a text file (ASCII format), ready for import into Excel (Microsoft) for further data 
manipulation and the addition of sample information. 
2.6.2. Normalisation 
Extracted data were imported into Excel (Microsoft) and were either normalised to 
creatinine intensity or total ion count, depending upon the experiment. Normalisation 
to creatinine was performed by finding the most intense creatinine value, and dividing 
all other observations (samples) creatinine intensity by this value. The resulting scale 
factor for each observation was then used to multiply each variable within that 
observation. 
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Normalisation to total ion count was performed by summing the intensities of all 
variables for each observation (sample), with the resulting value for each observation 
being divided by the largest total ion count value. The resulting scale factor for each 
observation was then used to multiply each variable within that observation. 
All resulting data were saved as a text file in the ASCII format. 
2.7. Statistical analysis 
All statistical analyses used the SIMCA-P+ statistical software versions 11 and 11.5 
(Umetrics). 
2.7.1. Data import 
All datasets were imported as text files into SIMCA-P+, where they were transposed 
so that each column represented an observation. Any information such as sample 
name, sample data etc. were assigned one of the following formats: primary 
observation ID; secondary observation ID; X variable (all of the variable intensities), 
and Y variable (discriminatory variables). Once all formats were set, the resulting 
imported data were ready for statistical analysis. 
2.7.2. Principal component analysis 
For principle component analysis (PCA), all Y variables were excluded from the data 
and the resulting X matrix scaled using either mean centering, pareto scaling or unit 
variance. The number of principal components (PCs) developed was determined by 
R2 and Q2 values; these values relate to the explained variation and give an 
indication of the fit of the model and its predictive ability. Internal cross-validation 
(CV) was used to determine an optimal balance between fit and predictive ability and 
to determine the number of components used for each model. Data points in the 
resulting scores plot can be coloured according to any secondary observation IDs set 
(section 2.7.1). 
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2.7.3. Partial least squares 
For partial least squares (PLS) analysis -2/3 of any dataset were used for PLS model 
development (with the remaining -r1/3 being held back to form an external test set, 
section 2.7.4), with aY variable being included to indicate class belonging. The X 
matrix was scaled using either mean centering, pareto scaling or unit variance. The 
number of latent variables (LVs) developed was determined using the R2 and Q2 
values, as described in section 2.7.2. Variable importance for projection (VIP) scores 
were used to identify and assess unimportant variables that did not add any 
predictive ability to the developed model. Any unimportant variables were removed 
and the model rebuilt with the process repeated. Once a satisfactory PLS model has 
been built, the resulting scores plot can be coloured according to any secondary 
observation IDs or Y variables set (section 2.7.1). 
2.7.4. External classification 
To determine the `true' predictive ability of any developed PLS model, the remaining 
-1/3 of a dataset were imported as a secondary dataset and manipulated according to 
section 2.7.1, before being selected as a prediction dataset. The resulting predicted 
Y variable values were used to indicate the external classification rate based upon 
their closeness to their actual Y variable values. 
2.8. Proteomics 
2.8.1. Bradford assay 
Each of the clinical urine samples were diluted by adding 5 pL to 995 pL of HPLC 
grade water (Fisher Scientific). Eight diluted bovine serum albumin standards (0,50, 
125,250,500,750,1000 and 1500 pg/mL) were created. 10 pL of each of the 
standards and diluted clinical urine samples were pipetted into 96-well microtitre 
plates (Corning Inc. ). 200 pL of Coomassie brilliant blue dye (Sigma) was added to 
each of the standards or samples. A photometer microplate reader (Dionex 
Technologies) set to measure absorbance at 570 nm was used to determine protein 
concentration. 
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2.8.2.1-D gel electrophoresis 
For the separation of urinary proteins using 1-D SDS-PAGE analysis, 18 pL of diluted 
clinical urine samples (5 pL in 1000 pL water) and MW marker standards (Invitrogen) 
were added to 7.5 pL of NuPAGE buffer (Invitrogen) and 4.5 pL of 2- 
mercaptoethanol (Invitrogen), giving a total volume of 30 pL. These solutions were 
incubated at 75 °C for 10 mins before 20 pL of each sample were loaded onto a 1-D 
NuPAGE 4-12 % Bis-Tris 1 mm 10-well gel (Invitrogen). The gel was run at a 
constant voltage of 200 V for ca. 50 min. Once completed, the gel was washed in 
water for 20 min before being stained overnight using Coomassie brilliant blue dye 
(Sigma). 
2.8.3. In-gel tryptic digestion 
Protein bands were excised from the stained gel, chopped into smaller segments 
and placed into 0.5 mL microcentrifuge vials (Sarstedt). Each of the excised gel 
pieces were washed twice using 20 mM ammonium bicarbonate (Sigma) in MeCN 
(Fisher Scientific) for 20 min. The gel pieces were then washed for 5 min using 
MeCN, before being dried for 20 min in a SpeedVac (Savant) and then incubated at 
65 °C for 1h in 10 mM dithioerythritol (Sigma) in 100 mM ammonium bicarbonate. 
The gel pieces were then subsequently washed with 100 mM and then 25 mM 
ammonium bicarbonate for 15 min before being washed with MeCN for 5 min. The 
gel pieces were dried in a SpeedVac for 20 min before being digested overnight by 
incubating the gel pieces at 37 °C with 10 pL of 0.02 pg/pL trypsin (porcine trypsin, 
Promega) in 20 mM ammonium bicarbonate. The supernatant from each 
microcentrifuge vial was then extracted using C18 ZipTips (Millipore) before 0.5 pL 
was spotted onto MALDI plates, ready for analysis. 
2.8.4. MALDI-ToF/ToF analysis 
The 4700 proteomics analyzer (Applied Biosystems) was used to analyse the 
digested proteins from the clinical urine samples. To each of the spotted digested 
samples, 0.5 pL of a-cyano-4-hydroxycinnamic acid (Sigma) in 0.1 % TFA (Sigma) 
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were spotted and allowed to air dry. First, MS spectra were recorded for each sample 
spot to identify the ten most intense peaks for subsequent MS/MS analysis, using 
1500 laser shots and accumulating the resulting data. MS/MS data were acquired 
using the default 1 kV MS/MS method, with a maximum of 2000 laser shots being 
allowed for each spectrum; air was used as the collision gas. 
2.8.5. Protein identification by database searching 
Data obtained from MS/MS analyses were submitted for database searching using 
an in-house MASCOT server (Matrix Science). GPS Explorer v3.6. (Applied 
Biosystems) was used to submit the data for database searching using the following 
parameters: MS/MS ion search; trypsin enzyme; monoisotopic mass values; 
unrestricted protein mass; 200 ppm mass tolerance; ±0.1 Da fragment mass 
tolerance. All searches were performed against the NCBInr protein sequence 
database (06 July 2007 build). 
2.9. Lipopeptide analysis 
2.9.1. Sample information 
A HPLC fraction obtained from an ethyl acetate extract of Pseudomonas chlororaphis 
PCL 1391 spent growth medium was provided by the Department of Biology, 
University of Leiden, the Netherlands. The fraction was reconstituted in 300 pL of 
MeOH (Fisher Scientific) before being diluted to 25 % using MeOH modified by the 
addition of 0.1 % (v/v) formic acid (Fisher Scientific) for further analysis. 
2.9.2. ESI-MS(MS) analysis 
The same parameters were used as shown in section 2.5.3 and 2.5.4. 
2.9.3. MALDI-ToF/ToF analysis 
The same parameters were used as shown in section 2.8.4. 
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2.9.4. Chemical methods 
To cleave the ester bond to create a linear lipopeptide, 10 pL of diluted sample was 
added to a 1: 1 mixture of 35 % ammonia solution (Sigma) and MeOH, and left 
overnight at room temperature. The sample was reduced to dryness using a 
SpeedVac and reconstituted in MeOH with 0.1 % (v/v) formic acid. 
The above procedure was also undertaken using a 1: 1 mixture of 35 % ammonia 
solution and BuOH (Fisher Scientific). 
2.9.5. Racemic amino acid analysis 
Racemic amino acid analysis was performed with the assistance of Dr. Kirsty 
Penkman (Department of Chemistry, University of York). 10 pL of stock lipopeptide 
was added to 200 pL of 7M HCI (Fisher Scientific), the vial flushed with N2 gas, and 
then placed in an oven (Binder Ovens) for 24 h at 110 °C, to hydrolise the peptide 
bonds, releasing free amino acids into solution. The hydrolysed sample was reduced 
to dryness in a SpeedVac before being rehydrated in 40 pL 0.01 M HCI and 1.5 mM 
sodium azide (Sigma), containing the non-protein amino acid L-homo-Arg at a 
concentration of 0.01 mM. 
The rehydrated solution was analysed using RP-HPLC (C18 HyperSil BDS column, 5 
x 250 mm, Agilent 1100 series LC, Agilent Technologies) where 2 pl of sample was 
injected and mixed online with 2.2 pl of derivitising reagent (260 mM N-Iso-L-butyryl 
L-cysteine (Sigma), and 170 mM o-phthaldialdehyde (Sigma) in 1M potassium borate 
buffer (Sigma), adjusted to pH 10.4 with potassium hydroxide pellets). Mobile phase 
A consisted of 23 mM sodium acetate tri-hydrate, 1.5 mM sodium azide, 1.3 pM 
EDTA, adjusted to pH 6.00 with 10% acetic acid and sodium hydroxide (all Sigma), 
mobile phase C was methanol and mobile phase D was MeCN. Initially 95% A and 
5% C was used at a flow rate of 0.56 ml min-', changing to 50% C and 2% D after 95 
min. Fluorescence detection used a Xenon-arc flash lamp at a frequency of 55Hz, 
with excitation wavelength of 230nm and emission wavelength of 445nm. 
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The work presented in this section formed part of the following publication: 
"Hydrophilic Interaction Chromatography for Mass Spectrometric 
Metabonomic Studies of Urine" 
Simon Cubbon, Timothy Bradbury, Julie Wilson, and Jane Thomas-Oates 
Analytical Chemistry, Volume 79, Number 23, pages 8911 - 8918. 
Chapter Three: Development of a `metabonomic toolbox' 
3.1. Introduction 
One of the earliest metabolite profiling experiments was performed by Pauling et al, 
in 1971 (Pauling et al., 1971); they quantitatively studied around 250 substances in a 
sample of breath and 280 substances in a sample of urine vapour using gas-liquid 
chromatography. The field now known as metabonomics, defined by Nicholson et al. 
in 1999 (Nicholson et al., 1999), is in its infancy today, and is very rapidly 
changing/developing direction. Many overlapping fields of medicine/biology, 
analytical science and statisticians are all bringing many different ideas to 
metabonomic studies; the literature is currently very patchy as some details are just 
not reported, so it cannot be found if the details were, or were not considered, or how 
they were undertaken. These problems are further confounded, as some 
considerations that are important to analytical scientists may be very different from 
those that are important to medics (e. g. replicates, appropriate controls, sample 
storage and analytical conditions). The metabolomics standards initiative (MSI) 
steering group (Sansone et al., 2007) seeks to standardise most aspects of 
metabolomic (metabonomic) experiments. However, as the MSI has only just 
published some draft guidelines (Metabolomics volume 3,2007), the existing 
literature studies are likely to be non-standard. 
It is therefore of great importance that all aspects of a metabonomic study are 
carefully considered and controlled to stand any chance of obtaining results that are 
both robust and informative. The main goal of a metabonomic study is to obtain as 
much information as possible. This may encompass the use of several different 
analytical platforms, as well as considering and employing methods specific to each 
analytical platform. The only fixed aspect of the study which is the subject of this 
PhD. was the use of HPLC-MS as the analytical platform, hence the need to develop 
LC methods that allow for the separation, and subsequent detection, of as broad a 
range of compounds within human urine samples as is possible. 
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3.1.1. Aims 
The purpose of the work described in this chapter was to develop a robust LC-MS 
platform for the analysis of human urine samples, as well as the full consideration 
and development of all components of every step of a metabonomic study, as shown 
in figure 3.1.1. 
Design of experiment II* Sample collection il* 
Which analytical platform? 
Data extraction fII it 
Data normalisation 
Making sense of the results 
Figure 3.1.1. Schematic representation of the steps involved in a metabonomic 
study. 
As the analytical platform was fixed (LC-MS was chosen as the platform for this 
study), the methods that were available at the start of this work, along with the 
problems associated with LC-MS are first highlighted. This is followed by the results 
of my in-depth study of all of the aspects involved in a metabonomic study (figure 
3.1.1). 
Considering all of the points of a metabonomic study should allow the development 
of a robust LC-MS method (or a metabonomic toolbox) that can be effectively used 
within a broader experimental protocol. To increase the coverage of the metabolite 
content within human urine, a hydrophilic interaction liquid chromatography method 
(HILIC) was developed and compared to the performance of a traditional reversed 
phase (RP) approach. 
System stability? 
Sample preparation/storage 
411 Sample analysis 
Careful model development 
II* Statistical analysis II$ t 
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3.2. Analytical Platform Considerations 
3.2.1. Introduction 
The analytical platforms used for this study were an Agilent 1100 series HPLC 
coupled to an Applied Biosystems QStar Pulsar i ESI-Q-o-ToF, however, other 
analytical platforms are available and should be compared to the platforms used here 
to allow the relative advantages and disadvantages for each to be assessed, as 
these can have a dramatic effect on the results obtained. The majority of 
metabonomic studies began using ' H-NMR, although LC-MS is now becoming more 
commonplace (Lenz and Wilson, 2007). Whichever platforms are utilised for a 
metabonomic study, no one single analytical technique can be considered to provide 
a completely comprehensive picture of the compounds contained within a biofluid. 
3.2.2. Analytical platforms and separation techniques 
Early metabonomic studies used'H-NMR as their analytical platform. 1H-NMR is a 
very reproducible technique that suffers less analytical bias than other platforms due 
to its universal detection of compounds, providing that they contain a proton. As LC- 
MS systems increased in reliability, and the field of metabonomics evolved, the 
increased sensitivity (superior to that of NMR) and stability afforded by the latest LC- 
MS platforms has led to its increased usage within the field. 
There are many different MS platforms available; the Q-o-ToF instrument used in this 
study has the capability to provide tandem MS data with resolutions approaching 
10,000 with a mass accuracy typically better than 20 ppm. However, the data 
collection rate is rather slow (typically 1s per `scan') compared to other MS 
techniques. Triple quadrupoles (QqQ) can also perform tandem MS (along with other 
MS experiments) but have lower levels of resolution and mass accuracy compared to 
ToFs. Ion traps (IT) can perform successive CID experiments, however, they typically 
have to perform many CID steps to gain similar data to those in a single step on a Q- 
o-ToF. IT's resolution and mass accuracy are poor compared to a Q-o-ToF, which is 
not desirable for accurate mass measurements - something that can be important for 
metabonomic studies. A recent `enhancement' of the IT is the orbitrap; it combines a 
linear IT with a subsequent IT where ions are maintained within the trap; their mass 
being recorded by the cyclic motion of ions passing between the ends of the trap. 
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This technique affords very high resolution, mass accuracy, data acquisition rates 
and in-depth structural characterisation properties comparable with a traditional IT. 
Whichever MS detection technique is used, some form of front-end separation is 
required for complex biofluid matrices. 
Gas chromatography (GC) coupled to MS was the traditional approach to 
metabonomic studies due to its high resolving power and reproducibility. Since as 
much information as possible is desired for metabonomic studies, GC as a 
separation method is largely unsuitable for biofluid analysis (Kopka, 2006). This is 
due to the fact that compounds need to be volatile in order to be separated and 
therefore analysed. As urine predominantly contains compounds of a polar nature, 
the majority of these would fail to be detected using GC as a separation technique. 
Derivatisation can be carried out in order to increase the number of volatile 
components, but can be a lengthly process that is not 100 % efficient and also 
changes the chemical structure of compounds being derivatised. Given the nature of 
metabonomic studies, high throughput experimentation is often required which 
cannot be obtained using GC due to the lengthly analysis times. 
One separation method which is gradually gaining more attention for metabonomic 
studies is capillary electrophoresis (CE) (Wang and Liao, 2004; ladarola et al., 2005; 
Pisitkun et al., 2006; Ullsten et al., 2006). CE has the ability to separate components, 
in urine for example, using an aqueous medium with only small injection volumes (in 
the nL range, compared to µL range used for GC and LC). Despite the apparent 
benefits that CE should offer as a separation technique, it has failed to make any 
appreciable mark in metabonomic research. Only a handful of papers have utilised 
CE (some coupled to MS) successfully (Ullsten et al., 2006; Monton and Soga, 2007; 
Soria et al., 2007), and even then the systems were targeted and therefore not 
comprehensive. The reasons behind the apparent failure of CE-MS to make 
headway in metabonomic research may be due to the poor reproducibility of 
migration times, as well as the problems associated with joining the capillary to an 
ES source successfully. Work previously carried out within the JTO and associated 
groups (Emma Edwards, Ed Bergstrom, Cristina Soria and Julie Wilson) has 
highlighted CE's current unsuitability for metabonomic studies. Undertaking statistical 
analysis using data generated by CE proved to be near impossible due to large 
deviations in migration time, baseline shifts, capillary degradation and instability of 
the capillary interface. As the technology advances, CE may become a viable 
89 
Chapter Three: Development of a 'metabonomic toolbox' 
separation technique, but for now appears to be inappropriate for the separation of 
biofluids in large-scale metabonomic experiments. 
Separation using HPLC is now the most common method currently employed for the 
separation of components in biofluids prior to analysis by MS (Bajad and Shulaev, 
2007; Chen et al., 2007; Hodson et al., 2007; Lenz and Wilson, 2007; Wagner et al., 
2007). Using such a separation technique can reduce (but not remove) the effects of 
matrix suppression (Taylor, 2005; Chambers et al., 2007) when coupled to an 
ESI/APCI interface. Matrix suppression can reduce the number of compounds that 
can be detected within a sample, thus reducing the coverage of compounds present 
and increasing the selectivity of LC-MS as a metabonomic platform. Despite LC 
being the most common separation method used for MS studies, many fail to 
appreciate the importance of choosing a column, as this dictates the bias towards 
particular classes of compounds that can be retained and therefore detected. The 
overwhelming majority of metabonomic studies utilise a reversed phase approach; 
this discriminates against polar compounds, which are likely to be the main 
components of biofluids, due to their aqueous nature. Some studies have utilised 
hydrophilic interaction LC (HILIC) (ldborg et al., 2005; Hemström and Irgum, 2006; 
Mawhinney et al., 2007) as a complementary separation method. The development 
of a HILIC separation approach is assessed in section 3.6. 
Whilst reasonable analysis times can be obtained using HPLC', development of this 
method called ultra-performance LC (UPLC), which should perhaps more correctly 
be called small particle LC, is gaining attention within the literature (Wilson et al., 
2005; Crockford et al., 2006; Nordstrom et al., 2006; Bruce et al., 2007; Lenz et al., 
2007; Rainville et al., 2007). UPLC uses sub 2 pm particles, which enable far 
superior separation and resolution than particle sizes typically used in HPLC (> 2 pm) 
(Churchwell et al., 2005; Plumb et al., 2005; Wilson et al., 2005). HPLC has a 
maximum pumping pressure of less than 400 bar, whereas UPLC typically uses 
pressures that can exceed 700 bar (Churchwell et al., 2005), which is required when 
using sub 2 pm particles. At such high pressures, run times can be reduced to a 
fraction of those used in HPLC separations, whilst maintaining a greater resolving 
1 Monolithic columns (chapter one) have allowed reductions in analysis time and increases in sensitivity 
and stability to be obtained for proteomic experiments (Premstaller et al., 2001; Wienkoop et al., 2004; 
Chen et al., 2005; Ault, 2007; Sumpton 2007); their uptake in metabonomics seems much slower. 
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power and increasing the possibility of allowing the detection of more compounds 
(Churchwell et al., 2005; Plumb et al., 2005; Wilson et al., 2005). 
Using UPLC separation methods does discriminate against certain MS platforms due 
to the peak widths that can be obtained (less than 1s at half-height). For example, 
the Q-o-ToF used in this study typically has an acquisition speed of 1 s, meaning that 
some peaks may go undetected. Lenz et al. utilised an orthogonal ToF MS with 
UPLC separation, obtaining peak widths of -3 s at half-height (Lenz et al., 2007); this 
would still be too short for tandem MS experiments where the total acquisition times 
can approach 10 s (again for the Q-o-ToF used in this study). 
3.2.3. Ionisation methods 
The output of CE and LC is in liquid form, and MS requires gas phase ions; as such, 
there are different sources that can generate gas phase ions from liquid. The most 
common and universal interface is electrospray ionisation (ESI) and its related 
techniques (micro ESI and nano ESI), the use of which is dependent upon the flow 
rate from CE/LC. The largest problem with ESI is the fact that it suffers from matrix 
effects (Taylor, 2005); this is where co-eluting compounds compete for the `ion- 
stream', generally resulting in a decrease in ionisation efficiency for some 
compounds (or the enhancement of other compounds). Whilst the exact mechanism 
of matrix effects are unknown, it is postulated that polar compounds fail to reach the 
surface of the charged droplets formed, therefore not being transferred into the gas 
phase (Bonfiglio et al., 1999; King et al., 2000). Given that most biofluids contain a 
high proportion of polar content, then the use of ESI as an ionisation method seems 
perhaps not ideal. APCI is a complementary method of ionisation that is analogous to 
ESI. 
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Figure 3.2.1. A comparison of the different methods of ionisation for the two 
complementary ionisation methods: ESI and APCI. 
Figure 3.2.1 compares the two mechanisms of ionisation in ESI and APCI. ESI 
creates many small, charged droplets. The polar more contents tend towards the 
centre of a droplet, away from the charged surface where the more hydrophobic 
content resides, therefore having a greatly reduced chance of being transferred into 
the gas phase as an ion. Conversely, APCI generates neutrals first, meaning that a 
mixture of polar and non-polar neutrals is created. After the generation of neutrals, 
molecules are charged (creating gas phase ions) by the production of electrons at a 
corona discharge needle, which in turn allows proton transfer (or adduction) to occur. 
This ionisation method does not discriminate against polar compounds to the extent 
that ESI does, therefore allowing greater ionisation efficiency for polar compounds. 
A recent advance by Shimadzu is the development of a dual APCI/ESI source which 
allows both methods of ionisation to occur at the same time, should increase the 
overall ionisation efficiency over a broad range of compounds, from highly polar to 
non-polar, thus making it potentially highly suitable for LC-MS metabonomic studies 
(Shimadzu). 
One final ionisation source that has recently been reported for use in metabonomic 
studies is desorption-ESI (DESI) (Pan et al., 2007). DESI-MS works by 'firing' a 
stream of gas phase ions (generated by ESI of a suitable solvent) at a target with a 
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sample on it, where secondary ions are formed by collisions of primary ions with the 
sample deposited on the target. Whilst this is a crude method where many non- 
volatile compounds may fail to be ionised (personal conference notes), Pan et al. 
have shown that the technique can provide a rapid analysis of many samples 
(acquisition times of less than 1 min per sample). This work parallels the work of 
Pauling et al. in 1971, which was one of the first metabolite profiling experiments 
undertaken (Pauling et a!., 1971). Despite this ionisation method being `snubbed' at 
conferences (personal conference notes) for its poor coverage of the metabolite 
content within biofluids, therefore technically not being a method suitable for 
metabonomics by definition, this simple approach may actually yield relevant 
biomarkers. Research by Willis et a!. showed that dogs could be trained to identify 
patients with bladder cancer "... on the basis of urine odour more successfully than 
would be expected by chance alone... " (Willis et a!., 2004). This suggested that 
volatile compounds related to tumours were present within the urine from cancer 
patients. There are many other stories of animals being able to detect illnesses much 
before any medical symptoms can be detected (BBC, 2007). As much of the 
research within the field of metabonomics concerns illnesses, as is so often the case 
with nature, maybe science can learn a lesson that sometimes simple methods may 
produce the best results? 
3.2.3.1. APCI validation 
In order to make a comparison of APCI and ESI sources for analyses of human urine 
samples, the only APCI source available for the Applied Biosystems QStar Pulsar i 
Q-o-ToF was used to analyse the urine samples obtained from volunteers from the 
Department of Chemistry, University of York. The urine samples were analysed using 
all of the considerations laid out in this chapter. From the first instance the APCI 
source proved unsuitable for metabonomic experiments, as any of the settings with 
respect to the positioning of the corona and nebulising source could not be 
maintained throughout data acquisition, due to the poor design of the source. 
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Figure 3.2.2. PLS scores plot for a gender response variable from positive mode RP- 
LC-APCI-MS data.  = samples from male volunteers, f= samples from female 
volunteers. 
Urine samples from volunteers within the Department of Chemistry were first 
analysed using RP-LC-APCI-MS. The PLS scores plot from analysing the positive 
mode RP-LC-APCI-MS data shows no clearly definable clusters based upon gender 
(figure 3.2.2). Clustering according to gender should have been observed, as was 
seen for PLS analysis of the same samples using RP-LC-ESI-MS (section 3.6), but 
proved impossible to obtain. This failure to obtain suitable data could be caused by 
the fact that the APCI source used was unable to cope with long data acquisition 
times (two to three days), as the corona discharge needle quickly became 
excessively dirty with deposits being formed, greatly reducing the ionisation efficiency 
over time; this was further highlighted when the urine samples were analysed using 
negative mode RP-LC-ESI-MS, as the corona again formed heavy deposits, 
completely reducing the ionisation efficiency, causing no data to be obtained for 
these analyses. The inability of the APCI source to produce robust data, along with 
the fact that any settings were hard to maintain with respect to the positioning of the 
corona and nebulising source made its further use impractical. Had a better APCI 
source been available, then APCI may have been appropriate for metabonomic 
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studies on the Q-o-ToF, especially in conjunction with a separation technique such 
as HILIC. 
3.2.4. Conclusions 
Given the vast array of different analytical techniques available for metabonomic 
studies, making the correct choice to obtain a `global fingerprint' of biofluid 
components is easier said than done. Despite this study being restricted to HPLC- 
ESI-Q-o-ToF MS, it is a platform that has the potential to provide sufficient, high 
quality, reliable data. As no single technique can provide a comprehensive analysis, 
combining platforms such as LC-NMR-(ESI/APCI)MS (Burton et al., 1997; Bajad et 
al., 2003) and fusion of complementary data (Kenney and Shockcor, 2003; Forshed 
et al., 2007a; Forshed et al., 2007b; Lenz et al., 2007; Zhengzheng and Daniel, 2007) 
should become the rule, rather than the exception. 
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3.3 Sample collection and analysis 
3.3.1 Introduction 
The design and implementation of a metabonomic study has to be very carefully 
considered if a successful output stands any chance of being achieved; that is 
achieving the original goals, or answering a hypothesis generated by analysing the 
data obtained. From the initial design of a study, to collecting the samples, and then 
their subsequent processing prior to analysis requires many different steps and 
challenges, all of which can have a considerable effect upon the end result. 
The main goal of a metabonomic study should be to produce a robust and 
comprehensive fingerprint of the biofluid chosen (Wilson et al., 2005; Lenz and 
Wilson, 2007; Sangster, TP et al., 2007), however, this is much easier said than 
done. Ideally, a broad range of analytical platforms (and techniques specific to each 
platform) should be encompassed to allow this idea of a `global' fingerprint to, at the 
very least, be considered. In reality, many studies, including this one, are limited by 
the available analytical platforms, amount of biofluid available, money and most 
important of all, time. 
3.3.2 Aims 
The aim of this section is to compare some of the methods currently used within the 
literature, and to highlight some of the many aspects of sample collection and 
analysis, which are all too often omitted from metabonomic studies. The data 
presented within this section was obtained by the analysis of urine collected from fit 
and healthy volunteers from the Department of Chemistry, University of York (unless 
otherwise stated). This section comprises initial considerations for sample collection, 
sample storage and pre-treatment, sample treatment prior to analysis, sample 
stability during analysis, repeat/blank injections, random analysis and importantly, 
system stability. 
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3.3.3 Results and discussion 
To begin a metabonomic study, it needs to be decided what question is trying to be 
answered; it is of no use collecting a biofluid from exclusively healthy 
donors/volunteers/animals if biomarkers related to kidney disease are sought for 
example (Dihazi and Muller, 2007). A carefully designed plan for collecting the 
desired biofluid should first be constructed. For the initial development work 
undertaken for this thesis, a broad cross section of urine samples that would ideally 
not be perturbed by influences of illness were sought. This was to both aid the 
development of a robust LC-MS system, highlighting some of the pitfalls that can be 
encountered with metabonomic studies, and to develop complementary LC 
techniques to attempt to increase the coverage of the urinary fingerprint by LC-ESI- 
MS methods (see section 3.6 - HILIC development). 
Members of the Department of Chemistry, University of York, UK, were contacted by 
e-mail requesting their help by donating two urine samples to aid methodology 
development. It was stressed that anonymity would be maintained throughout. Any 
volunteers were able to collect a sealed pack containing two randomly numbered 
sterile 25 mL sample tubes, two sealable bags and an instruction sheet informing 
them once more of anonymity and how to collect/deposit the donated urine samples. 
Volunteers were asked to provide the two mid-stream urine samples from the same 
day, the first being the first void of the day, and the second being any void after 15: 00 
(but before 18: 00). 
The only information requested from the volunteers was gender, time of collection, 
age and whether they were a smoker or not. All volunteers were advised that if they 
felt uncomfortable with providing age then they could provide an age range, similarly, 
they did not have to declare being a smoker if they did not wish to do so. After each 
sample was donated, the volunteers were asked to deposit them into one of three 
large, sealed, red boxes across the department as soon after donation as possible 
(confirmed by all samples still being warm upon collection). Any deposited samples 
were recorded and immediately stored at -80 °C until all samples were collected 
(appendix A contains all recorded data from the collection of these samples). 
The careful consideration of what samples were required, and their prompt collection 
and storage, is the initial priority towards obtaining good data. 
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3.3.3.1 Sample storage, stability and preparation 
Many metabonomic studies require time setted data, and as such, many samples are 
required to be stored for some time before all samples can be analysed. Some 
studies have added preservatives prior to storage, such as sodium azide', to inhibit 
bacterial growth (Saude and Sykes, 2007); immediate storage at -80 °C should be 
sufficient to inhibit bacterial growth (Lauridsen et al., 2007). The addition of 
preservatives prior to storage may have adverse effects upon the composition of the 
samples, and was therefore not used with samples collected for this study. 
Studies into the effects of urine storage at various temperatures have all come to the 
same general conclusions (LeBeau et al., 2001; Schneider et al., 2002; Fura et al., 
2003; Gika et al., 2007). Storing urine at room temperature without first filtering 
caused the concentration of some compounds such as benzoate, lactate and 
creatine to fluctuate, meaning that the urine samples were subject to degradation. 
Filtering the urine samples prior to storage at room temperature diminished the 
effects of degradation of benzoate and lactate, but failed to have any appreciable 
effect upon stopping the concentration of creatine from fluctuating (Saude and Sykes, 
2007). This suggests that filtering samples removes possible causes of degradation 
(such as bacteria) and can increase the stability of urine stored at room temperature. 
Whilst filtration may exclude some compounds from the samples (e. g. large proteins), 
filtering has a two-fold benefit, also removing sediment. 
Despite the centrifugation of urine samples collected from volunteers within York 
Chemistry Department at 10,186 g for 8 min, it was noticed that particulate matter still 
remained in some of the urine samples; injecting these samples onto an LC column 
would have quickly degraded its performance, as interparticulate spaces (or the 
guard column) could easily have become blocked, therefore increasing back 
pressure. Because of this, all samples were filtered through 0.45 µm PVDF syringe 
filters, removing any particulate matter and also helping to increase the stability of the 
samples at room temperature prior to analysis. Whilst the work by Saude and Sykes 
showed that for the short term (i. e. less than 8 hours), samples should be reasonably 
stable at room temperature and are therefore fine to be racked for analysis, it would 
be more suitable to store the samples in a temperature controlled rack to try and 
1 Sodium azide (NaN3) is a biocide that inhibits bacterial growth of gram-negative bacteria. 
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diminish any degradation of compounds as much as possible (as was done by Gika 
et al. ). 
A study comparing endogenous urinary metabolites stored at room temperature and 
at -80 °C reported that the concentration of all metabolites studied altered 
significantly at room temperature, but remained reasonably stable over a four week 
period of storage at -80 °C (Saude and Sykes, 2007). Gika et al. reported that over a 
period of four weeks, storage at either -20 or -80 °C did not highlight any appreciable 
differences when the data collected from the LC-MS analysis of urine samples were 
compared by PCA. They do however, correctly point out that this is a `blunt analysis 
tool', and that some metabolites which do not have large influences upon the 
developed PCA model (heavily dependent upon the scaling method utilised) could in 
fact be subject to degradation, and not be highlighted by a change in the observed 
clustering shown by the PCA scores plot (Gika et al., 2007). 
As a result of earlier studies (LeBeau et al., 2001; Schneider et al., 2002; Fura et al., 
2003), it was decided that any samples collected for this study should be stored at - 
80 °C and allowed a period of at least four weeks for any degradation of urinary 
components to become consistent across the cohort, and only centrifuge and filter 
prior to analysis. More recent research specifically tailored for metabonomic 
experiments confirmed that the original choice to just store samples at -80 °C, and to 
centrifuge and filter prior to analysis were optimal (Gika et al., 2007; Saude and 
Sykes, 2007). 
After an initial four week storage period, aliquotting the urine samples collected from 
the Department of Chemistry into smaller portions was required to prepare aliquots 
for subsequent analysis and so minimise the number of freeze/thaw cycles required. 
Whilst Saude and Sykes recommend that the number of freeze/thaw cycles are kept 
to a minimum, Pisitkun et al. showed that up to four freeze/thaw cycles had little 
effect upon the composition of urine, and Gika et al. (again from PCA results) 
showed that up to nine freeze/thaw cycles did not effect clustering (Pisitkun et al., 
2006; Gika et al., 2007; Saude and Sykes, 2007). Despite the apparent stability of 
urine to freeze/thaw cycles, stored urine samples should be treated identically, and 
all possible manipulations should be undertaken at the first freeze/thaw cycle when 
samples are aliquotted; this should hopefully decrease the chances of any 
unnecessary degradation of urinary compounds. 
99 
Chapter Three: Development of a 'metabonomic toolbox' 
3.3.3.2 System Stability 
Metabonomic studies were initially carried using NMR analytical platforms (Nicholson 
et al., 1999; Lenz et al., 2000; Robertson et al., 2000). NMRs are renowned for their 
reproducibility, not only from day to day, but also from laboratory to laboratory. These 
high levels of reproducibility are very desirable for metabonomic experiments. 
However, despite poorer levels of reproducibility, LC-MS metabonomic studies are 
becoming more common due to its higher sensitivity which should be more 
compatible for the large dynamic range and chemical complexity seen in a urine 
matrix (Want, EJ et al., 2005; Wilson et al., 2005; Want, E. J. et al., 2007). This is 
not to say that NMR is a redundant technique though; not everything can be detected 
by LC-MS (especially when ESI is utilised). NMR should be seen as a 
complementary method of analysis for metabonomic studies. However, it still remains 
that many changes within biofluids may be below the LOD obtainable from NMR 
studies. 
As LC-MS systems exhibit less reproducibility than NMR systems, the resulting data 
produced should be carefully scrutinised. There are many methods that can be used 
to increase and monitor the stability of an LC-MS system. 
LC-MS systems generally require some time to allow the whole setup (both the LC 
and MS side) to equilibrate. It is good practice to allow an LC column to equilibrate by 
first running a gradient (no sample injection) to condition the column. This initial 
gradient also allows the ESI chamber to heat up to the selected desolvation 
temperature (300 °C for all experiments described within this chapter), and 
electronics/optics to stabilise. 
During the aliquotting of samples collected from within the department, ca. 100 µL 
from each sample was held back to create a `pooled' sample that was representative 
of all the samples to be analysed. In order to evaluate system stability over a whole 
run, pooled samples were randomly included throughout any run with at least three 
pooled samples being run back to back at the beginning of the run, before the 
analysis of individual samples. 
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Figure 3.3.1. Five positive mode RP-LC-MS TICs from aliquots of pooled urine. The 
first three samples (A - C) were from run back to back at the beginning of data 
acquisition, with the remaining samples (D - E) being analysed throughout the run. 
Hashed red arrows indicate deviation from sample A. Inset shows a magnified 
portion of the TICs, highlighting a minor deviation in retention time. 
The data presented within figure 3.3.1 show five TIC traces from five replicate 
injections from pooled urine aliquots of the collected urine set from the Department of 
Chemistry. The first three traces were from back to back injections after the first initial 
conditioning gradient. The TIC traces generally appear to exhibit the same trend 
throughout the whole 30 min acquisition (only 20 min shown as this was the 
information rich section of TICs). The most noticeable deviations are for TIC A, the 
first sample analysed, and are highlighted by the hashed red arrows; all samples 
show some minor deviation in intensity. Inset into figure 3.3.1 is a magnified section 
of a low intensity peak at ca. 17.2 min. The first TIC (A) gave a retention time for this 
peak at 17.15 min, with the second subsequent TIC (B) at 17.18 min; despite the 
peak from TIC B having a retention time equal to all subsequent TICs, the intensity is 
slightly higher (and higher still for TIC A). The last sample from the back to back 
pooled urine injections (C) show a retention time of 17.18 min, which is consistent 
with the two further sample TICs (D & E) from pooled samples which were analysed 
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after individual samples had been analysed; the intensity of the three peaks (C to E) 
is also consistent. 
As the first and second TICs from the pooled urine aliquots differ from any 
subsequent pooled urine TICs, this suggests that the LC-MS system does indeed 
require time to equilibrate. The difference in retention time shown from 17.15 to 17.18 
min between the first and third (and subsequent) TICs correspond to <2 s, which is 
not a substantial deviation in retention time. To investigate these effects further, and 
to elucidate how different any eluting compounds were from TIC to TIC of the pooled 
urine aliquots, PCA was used to analyse the resulting data. 
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Figure 3.3.2. PCA scores plot using one principal component (y axis) comparing 
data from six LC-MS analyses of pooled urine aliquots. 
Figure 3.3.2 shows the resulting scores plot from the PCA analysis of six replicate 
LC-ESI-MS runs of pooled urine aliquots, with only one principal component being 
developed for the model (t[1] on the y axis). Point number one corresponds to the 
first injection, and resides just outside the green line, meaning that for this data point, 
it is over two standard deviations outside the average of the analysed data. All 
subsequent samples data (points two to six) are well within the two standard 
deviation lines and illustrate how each sample analysis was, statistically at least, 
equivalent to one another. 
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From the TIC traces (figure 3.3.1) and the PCA analysis of resulting LC-MS data from 
the analysed pooled urine samples, it is clear that the LC-MS system requires one to 
two samples to be injected and separated to enable the system to equilibrate. The 
reason why the LC-MS system does not produce reproducible results from the offset 
may lie with the chromatography itself. The LC column may require certain binding 
sites to be masked, or may just require conditioning to the type of compounds that 
are being analysed. The MS optics and electronics may heat up at the start of data 
acquisition, and therefore require a short period to reach equilibrium. 
The above data highlight the fact that LC-MS systems should be allowed to 
equilibrate by the injection of at least two pooled (or some other well defined 
standard) samples before analysis of samples from the test cohort. The inclusion of a 
pooled sample at random points throughout data acquisition can also act to serve as 
a marker for system stability, as the resulting TIC traces should be representative of 
stabilised TIC traces obtained at the beginning of data collection. PCA analysis of all 
pooled samples would easily highlight any anomalous pooled sample analyses, 
which would serve to identify any test sample data acquired around the anomalous 
pooled sample result that may need to be re-acquired, with this work coming to the 
same conclusions as Gika et al. and Sangster et al. (Sangster, T et al., 2006; Gika et 
al., 2007) (this PCA analysis could also be carried out on-line, immediately warning 
the operator of any deviation of system stability). 
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One further way to evaluate the ongoing stability and repeatability of an LC-MS 
system is to analyse a sample from the test cohort twice, with a number of other 
samples analysed inbetween each analysis. This method serves not only to evaluate 
the stability of the system, but to also evaluate the reproducibility of sample 
preparation methods, as any errors should become evident when the resulting data 
were processed. 
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Figure 3.3.3. PLS scores plot of positive mode RP-LC-MS data separated according 
to gender. The model utilised two latent variables and was optimised to methodology 
outlined in section 3.5. 
The data presented in figure 3.3.3 shows a PLS scores plot for the data from 
samples collected within the Department of Chemistry, separated according to 
gender using two latent variables. There is clear separation between samples 
donated by males and females, as was expected. The four points (all female) that lie 
outside the 95 % confidence margin (represented by the ellipse) were only found to 
be marginal outliers (see section 3.5). Four pairs of points correspond to the analysis 
of duplicate aliquots of four different samples, randomised throughout analysis. 
Samples 18a and 18b were analysed with ten other samples inbetween, which 
corresponds to 6.3 h between each sample being analysed; 7a and 7b had 11 
samples analysed inbetween, corresponding to 7.0 h between each sample; 58a and 
58b had 9 samples run inbetween, meaning 5.7 h inbetween each sample, and 
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samples 44a and 44b had 13 samples analysed inbetween, meaning 8.2 h lapsed 
between the replicate sample analysis. 
Each of the four pairs of points show the duplicate analyses residing within the same 
area on the PLS scores plot. Obviously, if the LC-MS system were highly 
reproducible, one would expect the two points to overlap exactly. The reason that 
each of the pairs of points are slightly offset from one another, can be explained by 
the ESI process. ESI is relatively unstable with respect to absolute reproducibility; 
minor fluctuations in the efficiency of ionisation occur. These fluctuations in ionisation 
efficiency can cause fluctuations with the recorded intensity of signal for compounds 
eluting when a fluctuation occurs. These minor variations in intensity can be 
translated into minor deviations from the values seen for a replicate analysis within 
the PLS scores plot, hence an imperfect overlap. Despite these minor variations, the 
observed overlap does suggest that the system as a whole was providing results that 
were repeatable. 
3.3.3.3. Sample Carryover 
Sample carryover can be a problem, as highly retained compounds may fail to elute 
during an LC run, and subsequently elute early during the analysis of a successive 
sample. Sample carryover is therefore an effect that is not desired for metabonomic 
studies as it could give rise to spurious results. To try and combat this problem, all 
LC gradients used for analysis within this project had extended wash cycles at the 
end of each gradient (see section 3.6 for more details). 
To evaluate the possibility of sample carryover, blank runs were randomly carried out 
during LC-MS data acquisition; this involved a gradient being run without the injection 
of any urine samples; only a 1: 1 mixture of McCN: H20 was injected. Any sample 
carryover from the previous sample injection should be visible in the resulting TIC 
trace of the blank run. 
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Figure 3.3.4. Two TIC traces from a positive RP-LC-MS analysis. The blue trace 
corresponds to a sample run before a blank gradient with no sample injection was 
recorded (red trace). 
Figure 3.3.4 shows comparison of a sample TIC and a subsequent blank injection of 
solvent; the red trace corresponds to the blank while the TIC from the sample that 
was recorded immediately before it, is shown by the blue trace. The baseline from 
the blank gradient does not show any appreciable deviation from the 1000 cps 
intensity value seen for both the sample (first two minutes, corresponding to the dead 
volume) and the blank. There is a sharp dip in intensity for both traces evident at ca. 
27 min, which may be caused by a persistent contaminant eluting from the column 
which causes suppression of ionisation (matrix effects); this could also be true for the 
only minor peak shown at ca. 29 min. The peak present in the blank TIC corresponds 
to a mass of 84.95 Da, and was also present in every TIC trace for all other blanks, 
pooled samples and samples, suggesting that it is a persistent contaminant in 
solvent. Clearly, the adopted cleaning strategy was sufficient to avoid sample 
carryover. 
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3.3.3.4. Random sample analysis 
Over time as many samples are analysed the levels of contaminants may alter, or 
more typically, the LC-MS system may develop a systematic drift. If all samples 
within a group were analysed consecutively, then any trends could falsely aid 
discrimination between different groups. Therefore, when performing a metabonomic 
study (or indeed any study) involving many samples, which is aimed at trying to 
elucidate some underlying factors, samples should be analysed in a random order. 
3.3.4. Conclusions 
To obtain results that enable robust statistical models to be generated, one has to 
ensure that all sources of possible error, or unwanted perturbations to data are 
controlled as much as is possible to ensure that the phrase `rubbish in = rubbish out' 
does not become a reality. 
All studies should begin with careful planning and preparation before samples are 
collected. The work presented within this section shows that a carefully constructed, 
logical approach to sample collection and data acquisition is required. From the 
literature, it is recommended that samples should be frozen at -80 °C as soon as 
possible, and be left for a period of at least one month before being aliquotted to 
allow the degradation of any compounds to be consistent across the sample cohort; 
the data presented herein suggest that this was suitable. Freeze/thaw cycles should 
be kept to a minimum, meaning that any sample manipulation should be undertaken 
during aliquotting to ensure that all samples are treated equally and subjected to the 
same minimal levels of freeze/thaw cycles and manipulations. 
As the goal of a metabonomic study is to obtain as representative a picture of the 
compounds present within the chosen biofluid as possible, any sample pre-treatment 
which could exclude compounds should be avoided unless absolutely necessary; this 
includes common clean-up steps such as SPE. Prior to analysis, samples should be 
centrifuged and filtered (minimal loss of compounds) to remove any particulate 
matter. 
Representative pooled samples should be created during sample aliquotting. Pooled 
samples should be analysed first (minimum of three) to allow the LC-MS system to 
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come to equilibrium. Throughout data acquisition, further random analysis of pooled 
samples, and also replicate analysis of some samples should be carried out make it 
possible to check whether the LC-MS system as a whole remains stable. The 
inclusion of blank runs where no sample is analysed should be undertaken to ensure 
that sample carryover does not occur. The random analysis of samples is an 
absolute must, especially given that scientists are creatures of habit and like things to 
be ordered! Randomisation of samples across the whole data acquisition helps to 
avoid any time related shifts in intensity of contaminants and to minimise the effects 
of any instrument drift. 
Overall, from sample collection, storage and pre-treatment, to its analysis, there are 
many different steps that are required in order to generate robust, reproducible 
(within run), and hopefully, meaningful results from an LC-MS analysis. 
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3.4 Data extraction 
3.4.1 Introduction 
Once the experimental data has been collected, one crucial step remains before the 
data can be statistically analysed: data extraction. This involves converting individual 
LC-MS data files into a single file that contains details of m/z and tR along with 
intensity for each component detected across all of the sample cohort. Whilst this 
step may appear to be trivial, it is of great importance that raw data (here, LC-MS 
data) be carefully extracted with much consideration for the many parameters that 
can be applied. It is pointless ensuring that raw LC-MS data was rigorously collected 
so that it was the best available, if poorly chosen parameters or data extraction 
algorithms are chosen. 
Unfortunately, there are relatively few data extraction algorithms available, as LC-MS 
vendors try to `force' the user to utilise their software. Some freely available data 
extraction software programs, such as XCMS (Smith et al., 2006), are available. 
However, non-proprietary extraction programs still require raw data to be extracted 
into a user-friendly format such as NetCDF, mzXML or mzData. Raw data files 
obtained from an Applied Biosystems QStar, used for obtaining all data presented in 
chapters three and four, are stored in a complex binary wiff format file. 
ProteomeCommons. org are currently offering a $1000 bounty for someone to create 
a wiff reader, thus highlighting the problem of non-standardised raw data output files. 
As the raw data generated for chapters three and four would have required 
converting from wiff into another file format before being extracted for statistical 
analysis, possibly losing data, it was decided to use the Applied Biosystems 
proprietary software, Metabolomics Export Script v1.0.0.3. 
Problems that are associated with LC-MS raw data extraction (and that/those from 
other separation/detection methods) are typically peak picking errors that are caused 
by peak shapes, shifts of retention times, mass and signal intensity, all of which can 
cause errors when peak picking parameters are poorly selected (Sangster et al., 
2007). 
The Metabolomics Standards Initiative (Fiehn et al., 2007; Sansone et al., 2007) aims 
to address some of the above issues relating to data extraction, along with the more 
important problem of standardising the raw mass spectrometric data reporting file 
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format by publishing a series of papers on standard reporting features (Metabolomics 
volume 3,2007). 
3.4.2 Aims 
The aims of this section were to explore problems that are encountered when using 
data extraction software, along with investigating some possible solutions and areas 
of new research, which should hopefully aid a more accurate representation of 
extracted raw LC-MS data. 
3.4.3 Results 
The metabolomics export script works by generating peaks files (containing 
information about each detected ion) from each sample's raw LC-mass spectrometric 
data file (wiff format). The generated peaks files are then converted into aligned 
peaks files based upon many parameters that are chosen. The most critical of 
parameters relate to the retention time tolerance, mass accuracy and LC peak 
window size. 
The retention time tolerance relates to how much retention time a particular m/z 
value can differ by and still be considered as deriving from the same peak. Studying 
TICs highlighted that the LC-MS system used in this study performs well, as there 
are not any notable deviations in retention time (this can be seen in figure 3.3.1 
(section 3.3), where TICs from pooled samples are overlaid to provide an idea of 
system stability). A retention time tolerance setting of 0.5 min (giving ± 0.25 min) was 
found to be more than sufficient, and is similar to that reported within the literature 
from groups who have also used the metabolomics export script (Gika et al., 2007; 
Sangster et at., 2007). 
Working alongside the retention time tolerance to determine what forms a peak, the 
mass tolerance setting is another important setting. As all of the datasets within 
chapters three and four average ca. 100 samples, the recording of all the data for 
each ionisation mode or separation method took around three days (each LC-MS run 
averages around 35 mins when the conditioning gradient and syringe cleaning step 
are included). During the three days of data acquisition, the mass spectrometer 
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cannot be expected to maintain a high level of mass accuracy (i. e. less than 10 ppm 
for a well calibrated QStar ToF MS). Without accounting for any drift in mass 
accuracy, extracting the raw data could force some genuine peaks to go undetected 
as their mass `drifts' past the tolerance set within the metabolomics export script. 
When accounted for, any drift within mass accuracy was not considered to be a 
problem. This was because there are known compounds (e. g. creatinine, hippurate) 
within urine which can be used to re-calibrate the recorded LC-MS data. A mass 
accuracy setting of 500 ppm was used within the metabolomics export script. This is 
equal to ± 0.08 Da at m/z 150, which should be sufficient to cover any drift 
encountered for a ToF MS. 
The last critical parameter, the LC peak window, is designed to remove any noise 
from each data file. Originally, this parameter was set to values of 0.1 and 3 min for 
the minimum and maximum values respectively. This meant that any peaks narrower 
than 0.1 min or wider than 3 min would not classify as a peak and therefore not be 
extracted. Upon studying the resulting extracted data matrix from the analysis of 
urine samples collected from within the Department of Chemistry, University of York, 
some abnormalities within the data were noticed. 
/Sample 
Name 
S1 
- 
S2 
- 
S3 
- 
S4 
- 
S5 
- 
S6 
- 
S7 
- 
S8 
- 
S9 
- 
/Yvar 1 1 2 1 2 2 1 2 1 
Nariablelist 
114.06 2.80 531.82 591.60 0.00 94.85 0.00 817.46 983.54 545.83 967.21 
114.08 3.20 0.00 0.00 232.85 0.00 641.14 0.00 0.00 0.00 0.00 
114.05 3.55 114.69 140.83 123.88 956.34 920.74 401.18 821.17 677.70 549.12 
Figure 3.4.1. An excerpt of the extracted data matrix where each column represents 
a sample, and each row a concatenated m/z and tR value (other than headers). 
The two highlighted cells within figure 3.4.1 are the only peak areas extracted for that 
specific variable (114.08_3.20); all other samples apparently yielded no peak at all 
for this variable. Examining the variable in the row above (114.06_2.80) shows that 
two corresponding cells are empty, meaning that no peaks have been extracted for 
this variable (1 14.06_2.80) for those particular samples (S_3 and S_5 from the 
`/Sample Name row'). As the missing peak values for the first variable (114.06_2.80) 
correspond to the two values for the second variable (shaded cells, 114.08_3.20), 
this highlighted the fact that there must be some problem with the parameters used 
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for extracting the data. Upon analysis of the raw data, it was noticed that there were 
slightly broader peaks (not returning to baseline) for the above extracted values at 
m/z 114. Increasing the LC peak window extraction parameters to 0.1 and 20 min for 
minimum and maximum values respectively caused the above effect to disappear. 
Because of the above problem, considering how extraction algorithms may treat 
peaks highlights some potentially important issues. 
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Figure 3.4.2. An extracted ion chromatogram of the peak cluster at m/z 114, 
highlighted within the previous figure. (a) XIC of m/z 114 from positive mode RP-LC- 
MS (b) Possible assignment of 4 peaks within the XIC (c) Peak area assignment not 
based on Gaussian peak distribution (d) Peak area assignment based upon 
Gaussian peak distribution. 
The XIC of mass m/z 114 (figure 3.4.2a) does not correspond to a single, Gaussian 
shaped peak. There are two well definable peaks present, with a small hump on the 
tail of the second peak, which could correspond to another, lower intensity peak. 
Figure 3.4.2b illustrates how there could be up to four peaks contributing to the XIC 
trace shown. The most intense peak (blue) has a slight shoulder, which could 
correspond to another peak (red), or could just be caused by peak tailing. Extraction 
algorithms may not be able to distinguish between peaks of close m/z values and 
retention times (without some form of dynamic algorithm that can utilise peak shape), 
even when given suitable parameter values. When peaks are extracted within the 
metabolomics export script, it is hard to know how they are being treated; does the 
extraction algorithm just drop a line to the baseline when a valley is found (figure 
3.4.2c), or does the algorithm try and force Gaussian style peaks (figure 3.4.2d)? 
Analysing the raw data does not give any clues as to which method the 
metabolomics export script uses, as the resulting extracted data matrix was scaled 
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by an unknown factor, meaning that peak areas from raw data do not directly 
correlate with their extracted peak areas. 
One further problem that may not be addressed by many extraction algorithms for 
LC-MS data, is baseline shifting. Where does, and should, a baseline be when 
extracting data? This baseline problem has been identified and addressed for NMR 
data (Chang et al., 2007), but does not appear to have been addressed within the 
literature for LC-MS studies, something which requires attention. 
Many metabolomic NMR studies choose to bin their spectra into 0.04 ppm bins (Antti 
et al., 2004; Constantinou et al., 2005; Williams et al., 2005; Kochhar et al., 2006), 
thereby reducing the relative resolution. Worryingly, 0.04 ppm bins correspond to 250 
fixed bins over a0- 10 ppm range to coincide with the fact that Microsoft Excel 
cannot cope with more than 256 columns; the fact that something as trivial as the 
number of available columns within one particular computer program dictates the 
method that has come to be accepted for a whole metabonomic study seems a little 
bizarre. Conversely, the metabolomics export script in effect utilises movable bins 
with no fixed m/z width (other than that constrained by carefully chosen parameters). 
As fixed bins have the potential to split peaks across two bins, novel methods such 
as using wavelet transforms (Davis et al., 2007) which are an adaptive binning 
process are now being reported for use with NMR data. Many of these new 
applications for NMR (adaptive binning, baseline correction) should hopefully cross 
the boundary and find a much-needed application in LC-MS data extraction and 
processing. 
3.4.4 Conclusions 
Despite the limited choice of data extraction software available, the metabolomics 
export script that was used for extracting all of the data within chapters three and four 
currently offers the best chance of obtaining useful LC-MS metabonomic data, 
provided that: the parameters used are suitable for the data being extracted and that 
once extracted, the data is carefully scrutinised for any errors, such as those pointed 
out within this section. Sangster et al. has published work which also highlights some 
of the problems that have been found within this section when using the 
metabolomics data export script, and has shown that an improvement to the original 
algorithm provided better statistical results over the previous algorithm (Sangster et 
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aL, 2007). Despite some improvements to data extraction algorithms, it is clear that 
this vital step within the field of metabonomic studies (be it NMR or MS research) 
requires much more attention than it is currently receiving. As the field of 
metabonomics expands, and a greater cross section of scientists begin to co-operate 
on projects (e. g. chemists, biologists and importantly, statisticians and computer 
scientists) it is hoped that greater emphasis is placed on correctly extracting raw 
data. 
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3.5. Multivariate data analysis 
3.5.1. Introduction 
Metabonomic studies which involve a reasonable sized study of ca. 100 samples 
generate vast amounts of high dimensionality data; this is further increased when 
studies utilise multiple separation methods, e. g. reversed phase and hydrophilic 
interaction chromatography, different ionisation methods (ESI, APCI, positive and 
negative ionisation), or indeed different detection platforms (MS and/or NMR). Given 
that resulting datasets contain large amounts of data, which may or may not be 
linked, it is impossible to manually interpret these vast sets of data. Whilst it is 
recommend that data are at the very least `visually checked' initially, the subsequent 
analysis has to involve some kind of multivariate data analysis. 
As modern computing power and storage capacity is cheap and easily obtainable, 
the field of metabonomics greatly utilises chemometrics to try and elucidate any 
useful information from the mountains of data that can all too easily be generated. 
There are many different statistical approaches that can be employed in order to 
analyse what has been described as `megavariate' rather than multivariate data 
(Griffin and Bollard, 2004) from metabonomic experiments. The overwhelming 
majority of studies use descriptive and discriminative statistics, these predominantly 
being principal components analysis (PCA) and partial least squares (PLS) 
respectively (Lu et al., 2006; Lutz et al., 2006; Ullsten et al., 2006; Gu et al., 2007; 
Hodson et al., 2007; Katajamaa and Oresic, 2007; Kell, 2007; Lenz and Wilson, 
2007; Pizzolato et al., 2007; Sanchez-Ponce and Guengerich, 2007; Trygg et al., 
2007; Zhengzheng et al., 2007). There are many other statistical methods that are 
available (genetic algorithms and ANOVA to name but two); whichever is chosen, the 
user must be acutely aware that statistics can (and does) show you what you want to 
see. 
Many metabonomic studies use both PCA and PLS without much consideration for 
both how to use the statistical methods, and what the resulting outputs mean. Kell 
summarises this rather eloquently: "... the literature is full of complete rubbish 
resulting from a combination of over-optimism in the face of ostensibly positive 
findings, statistical ignorance and the fear of journals to scrutinise data too carefully 
lest they find something unpleasant... " (Kell, 2007). 
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3.5.1.1. Aims 
Obviously, there is no substitute for `good' data to begin with, and it is with this in 
mind that great care has been taken with statistical analyses by investigating the 
many parameters (most of which are rarely, if ever, reported within the literature) and 
the effects that they have upon the resulting data. This work aimed to define optimal 
statistical settings using urine samples collected from healthy volunteers within the 
Department of Chemistry, University of York, UK. A thorough analysis of the 
collected data is reported in this chapter (chapter 3.6. ) using the developed optimised 
methods presented herein. 
3.5.1.2. Results 
All data presented within this section (unless otherwise stated) was generated by the 
analysis of urine samples collected from healthy volunteers within the Department of 
Chemistry, University of York. 
3.5.1.2.1. Initial data analysis: principal components analysis 
After `looking' at the raw data to ensure that nothing appears to be out of place (e. g. 
abnormal TICs or UV chromatograms), the initial steps should involve a global view 
of the data. That is, the data is analysed using an unbiased method. PCA is such a 
method as it is unsupervised; it does not require a priori knowledge of class 
belonging. The dataset(s) as a whole are considered and represented within a 
matrix, X. PCA groups observations that contain similar variables. The greatest 
variation is accounted for within the first principal component (PC), with subsequent 
PCs accounting for the remaining variation within the data (each successive PC 
accounts for less variation). 
3.5.1.2.2. Outlier detection 
PCA is very useful for finding observations from the dataset which do not fit well with 
the bulk of the data. Observations that fall outside the 95 % confidence limit 
(represented by an ellipse on the scores plot, figure 3.5.1) on the scores plot, e. g. 
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point A (figure 3.5.1), are classed as outliers. Outlying points are caused by 
abnormalities within the data, such that the outlying observation contains variables 
that are not present, or are of a different magnitude to those in the bulk of the data. 
Outliers cannot just be removed from the dataset; there has to be valid justification 
for doing so first. If a point falls just outside the 95 % confidence limit, it may not be a 
strong outlier. Studying the DModX' plot (figure 3.5.2) aids in determining whether an 
observation is a weak or strong outlier. 
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Figure 3.5.1. A PCA scores plot for three different classes of hypothetical data: 1,2 
and 3. The ellipse represents the 95 % confidence limit, any data outside this can be 
classed as an outlier. 
Point A is an outlier according to the scores plot (figure 3.5.1), but according to the 
DModX plot (figure 3.5.2a) it lies in plane with the majority of the data. Whilst point B 
is not classed as an outlier on the scores plot, it is 'out of plane' with the majority of 
the data, as it has a DModX value which is higher than the critical value (95 %). 
Figure 3.5.2b and c help to illustrate how point A is in keeping with the data, whereas 
point B is not. Point A is still an outlier, but is on the same plane as the rest of group 
1 (red data points). Point B now exists outside the 95 % confidence limits (grey 
sphere) and does not lie on the same plane as the rest of group 2 (green data 
points). Justification for removing outliers can only be complete when the loadings 
1 DModX is the distance each observation is from the model plane. 
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plot (and the raw data) has been examined to elucidate what is causing the 
observations to be classed as an outlier. 
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Figure 3.5.2. (a) DModX plot highlighting two points, A and B. Point B has a DModX 
value outside the 95 % confidence limit. (b) 3D scores plot highlighting how point A is 
not significantly `different' from the rest of group 1 (red points), whereas point B has a 
large distance from group 2 (green points), hence the high DModX value. (c) 3D 
scores plot from a different angle, illustrating how point A lies `in plane' with group 1, 
and how point B lies outside the plane of group 2. 
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The loadings plot (figure 3.5.3a) corresponds to the scores plot and shows how each 
of the variables relates to any clustering exhibited within the scores plot. Points within 
the red ellipse correspond to the clustering of group 1; analysing each of the three 
points showed that point A was classed as an outlier due to having an elevated 
response for variable `g'. Points within the green ellipse cause the clustering for 
group 2, and points within the grey ellipse the clustering for group 3. Studying the 
points `e and I' did not highlight any data that could cause point B to have a high 
DModX value. However, points within the blue ellipse only gave a response for point 
B, hence causing a high DModX value. The remaining points on the loadings plot do 
not have a high bearing on the clustering as they are close to the origin, meaning that 
the relative intensities across each of the three classes must be fairly even, not 
allowing any further differences between classes to be found. Figure 3.5.3b plots the 
intensities of the two points j and h' which cause point B to have a high DModX 
value. All other data points do not have any response for the two variables j and h', 
meaning that these variables are exclusively causing the perturbation of point B. 
In order to justify removing either point A or point B, the question "what is the 
hypothesis in question or being generated? " needs to be asked. Point B, having 
different variables from the bulk of the data may derive from a sample that is 
contaminated, or it may be a perturbation that is relevant to the hypothesis being 
drawn. Point A, containing the same variables as the bulk of the dataset, may be an 
outlier as the perturbation could be caused by something which is not consistent with 
the hypothesis. 
It is only once all avenues of such investigation have been followed that an outlying 
observation can be removed from the dataset, providing that the reasons for doing so 
are justifiable. 
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Figure 3.5.3. (a) Loadings plot explaining the clustering shown in the scores plot. (b) 
A plot of the intensities for two variables, h and j. These two variables cause the high 
DModX value for point B. 
121 
(a) 
Atfm 
fa 
Ab 
j Ah fe 
Al 
f9 
Ad Ak 
Chapter Three: Development of a `metabonomic toolbox' 
3.5.1.2.3. PCA for biomarker detection? 
The greatest variation within the dataset is accounted for in PC 1. For urinary 
metabonomics, this is likely to be due to gender difference or another significant 
factor such as diurnal variation, if the samples have not been subjected to external 
perturbation (e. g. drugs). However, if drugs (or some other external stimulus) have 
been administered, PCA may show this as the greatest source of the variation and 
may also exhibit deviation from a basal state towards an affected state, and then 
subsequent return to basal state (Bollard et al., 2005). Examining the loadings plot 
indicates what variables are responsible for any separation, or deviation from the 
basal state; this can lead to biomarker identification. Usually, a bias technique (such 
as PLS) that can be externally validated is preferred over PCA, as it leads to a more 
robust statistical model with less chance of spurious variables forming the model. 
3.5.1.3. Partial least squares (discriminant analysis) 
After PCA has been used to view the data in an unbiased fashion, and any outliers (if 
present) have been investigated and treated accordingly, then PLS-DA can be used 
to investigate the dataset(s) more thoroughly. 
PLS-DA uses a priori knowledge of class belonging, that is the data which were 
represented within the `X' matrix (the explanatory variables) has each observation 
linked to a discriminatory class in a separate `Y' matrix. PLS-DA seeks to maximise 
the separation, hence `discrimination', between two or more groups as designated 
within the `Y' matrix. Importantly, PLS-DA models should only be developed using ca. 
2/3 of the available dataset; this forms the `training' set. The remaining 1/3 of the 
dataset should be held back and not be used in model development; this forms the 
external test set. 
The use of training and test sets is of paramount importance. Internal cross-validation 
(typically venetian blind) can give models which fit the data exceedingly well; given 
that there may be many thousands of variables with which a model can be built, it is 
unsurprising to note that such models are easily obtained and should be treated with 
scepticism. It is only through proper model development and external validation using 
test sets that contain data that were not used to form the discriminative model, that 
potential biomarkers can confidently be obtained. 
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3.5.1.3.1. PLS model development - problems and solutions 
In order to highlight a problem with discriminative statistics, which is one of the points 
which Kell makes (Kell, 2007), data from positive mode ESI-RP-LC-MS study of the 
urine from healthy male and female volunteers within the Department of Chemistry 
were analysed using PLS. The data were randomly assigned to one of six classes, 
meaning that the `Y' matrix did not bear any resemblance to any 'real' possible 
groupings within the `X' matrix (such as gender, diurnal variation, age etc. ) 
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Figure 3.5.4. PLS scores plot illustrating how seemingly good models can be created 
given enough variables, despite there being no basis for the grouping shown. 
Figure 3.5.4 shows the resulting PLS scores plot after PLS model development; 
internal CV values were satisfactory. Both LVs are required to separate all of the 
seven groups, but it does highlight the fact that a seemingly good PLS model can be 
built, even when there should be no relationship between the `X' and `Y' matrices. 
Given that PLS models can be developed and effectively made to show the user 
what they were asking, it is of paramount importance that any developed model is 
treated with a great deal of scepticism. The PLS scores plot in figure 3.5.4 is 
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overfitted as it was developed using all of the available variables from the dataset 
(many thousands). The variables that direct the separation shown can be listed in 
order of importance to the model, this is termed the Variable Importance for 
Projection (VIP). 
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Figure 3.5.5. Schematic representing our method of PLS model development to 
ensure robust, reliable models are developed. 
Figure 3.5.5 summarises the methods that should be followed to develop a more 
robust and significant PLS model. After the first development of a PLS model, the 
VIP list gives all of the variables with their respective score. Any variable with a VIP 
score of less than one should be removed from the model, as these are not 
considered statistically significant. A subsequent PLS model is then developed using 
only the remaining variables with VIP scores greater than one. The whole process is 
repeated until a suitable number of variables remains and the internal CV is 
satisfactory'; the number of remaining variables should be decided using `common 
sense', as if too many remain, then the developed model still has a chance of 
overfitting (I typically aim to use less than 10 variables). As the PLS model's 
' Defined by R2 and Q2 values in SIMCA. R2 is the `goodness' of fit, or the explained variance and Q2 is 
the fraction of total variation of the X matrix that can be predicted by a component (as estimated by 
internal CV). 
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complexity is reduced by reducing the number of variables, it is also worthy to note 
that excessive latent variables should not be used in a model. The general rule is the 
fewer the better (as for PCA, the most variation should be contained within the first 
few components of the model). 
Once the PLS model has been deemed satisfactory, the true test of its predictive 
power is to import a secondary dataset, the test set (figure 3.5.5). The developed 
model uses the allowed variables from the test set (as dictated by the variables in the 
model) to predict class belonging. If the model is robust, then a high external 
classification rate should be obtained. 
When the PLS model reduction scheme (figure 3.5.5) is followed using the data 
shown to generate figure 3.5.4, a meaningful model cannot be developed. This is 
because a large number of variables were removed which, whilst having a low VIP 
value, were actually all being used to predict class belonging; once these were 
removed, a working model is no longer achieved. We are unaware of any literature 
where the authors have reported use of such a scheme of discriminant model 
development within their experimental sections, other than a few papers published to 
highlight the problems of poor use of statistics (Handl et al., 2005; Broadhurst and 
Kell, 2006; Kell, 2007). 
It is therefore of the utmost importance that for any discriminative study, a rigorous 
approach such as that highlighted above, is followed to ensure that any developed 
models genuinely relate to the hypothesis, rather than to `statistical junk'. 
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3.5.2. Data normalisation and scaling 
3.5.2.1. Introduction 
Metabonomic studies that use carefully controlled animal subjects should 
theoretically have fewer issues with large biological variation between urine samples 
(than that from using human subjects). Conversely, the majority of studies where 
human volunteers are involved do not have such a luxury, as the volunteers 
generally cannot be controlled to the same degree as animal subjects. This `large 
biological variation' between subjects requires to be corrected for if statistical 
analyses are to be less biased towards the largest biological variation; generally 
related to differences in the concentration of each individual urine sample. 
Normalisation is another area that is usually vaguely described within the literature, if 
at all; data is either not normalised, scaled to creatinine or most recently to the total 
ion count (TIC). Of the literature which does report its normalisation methods, the 
most common is to use scaling to creatinine (Woitge et al., 1999; Schoenau and 
Rauch, 2003; Huskovä et al., 2004; Idborg et al., 2004; Svoboda and Kasai, 2004; 
Obrant et al., 2005). Normalisation to TIC stems from NMR studies where 
normalising data to the total signal intensity is common (Kenney and Shockcor, 2003; 
Antti et al., 2004; Williams et al., 2005). LC-MS metabonomic studies have begun to 
adopt this method of normalisation (Plumb et al., 2003; Williams et al., 2005) as a 
means of accounting for concentration differences as well as some forms of 
analytical variation. 
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Figure 3.5.6. (a) Schematic representing how normalisation to creatinine works. (b) 
Schematic representation of normalisation to total ion count. 
Figure 3.5.6 shows schematics of two normalisation techniques: the more common 
normalisation to creatinine (figure 3.5.6a), and the newer normalisation to total ion 
count (figure 3.5.6b). Normalisation to creatinine involves each sample's creatinine 
intensity being extracted (m/z 114.07 = [M + H]+ and m/z 112.05 = [M - H]" with tR for 
RP = 2.7 min and HILIC = 8.2 min), represented by each observations column letter 
in lower case with a prime (e. g. A is a'), and used to create a scale factor by scaling 
each observation's creatinine value to the same value. The scale factor is then used 
to scale each variable within the original 'X' matrix (e. g. a' scales column A variables, 
b' column B variables etc. ). Normalisation by total ion count is undertaken using a 
similar method to that of creatinine normalisation. The sum of each observation's 
intensities (represented by 1A, 113 etc. in figure 3.5.6b) is used to create a scale 
factor, by dividing each TIC value by the largest value obtained from the sum of each 
observation. As with creatinine normalisation, the generated scale factors are then 
used to scale each variable (by the generated scale factor) within the 'X' matrix. 
For both normalisation methods, the scale factors should be visually checked to first 
ensure that the values are roughly consistent with one another, and that there are no 
inconsistent values. If the scale factors are consistent, then the X matrix data can be 
normalised by the relevant scale factor. 
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3.5.2.1.1. Aims 
Reading the literature relating to creatinine synthesis and excretion prompted the 
examination of the effects of no normalisation, normalisation to creatinine and 
normalisation using total ion count upon model development. This was because 
creatinine is considered to be relatively stable and related to an individual's mass 
(see chapter 1). However, we wished to test the relevance of creatinine scaling for 
metabonomic studies using the developed LC-MS approaches. 
3.5.2.2. No normalisation 
Leaving the data `as is' and not using normalisation means that any clustering 
evident upon PCA, would most likely be linked to the concentration of each individual 
sample (dependent upon any subsequent scaling methods used, see chapter 
3.5.2.4). Whilst this may be desired for some studies, it is evident that the majority of 
metabonomic studies require some kind of normalisation to account for any biological 
(and/or analytical) variation, so that any differences in the concentrations of individual 
urine samples are not the overriding factor directing clustering. 
One method that has been used in the literature, and is technically `no normalisation', 
is 24 h urine collection. The collection of each void of urine over a 24 h period should 
remove any effects caused by diurnal variation, and also minimise the effects of 
varying concentrations. Whilst 24 h urine collection has been described as the `gold 
standard', it suffers many disadvantages (Heavner et al., 2006). Generally, 24 h 
collection is completely unfeasible for a metabonomic study as it would involve 
volunteers/'patients' completing a full 24 h collection, where the sample integrity 
could be compromised by bacterial infection and incomplete sample collection for 
example (Woitge et al., 1999; Heavner et al., 2006). However, most obvious is the 
issue of storing many volunteers/'patients' 24 h urine samples (given that the 
average human produces 1-2 L of urine daily), especially for time-set metabonomic 
studies. 
128 
Chapter Three: Development of a `metabonomic toolbox' 
3.5.2.3. Creatinine normalisation 
A thorough analysis of literature relating to normalisation by creatinine suggested that 
normalisation using creatinine may not have been as robust as once thought. Whilst 
creatinine excretion is usually consistent, some of the literature suggests that the 
levels of excreted creatinine are easily altered by internal and external factors such 
as therapeutic interventions, disease and growth (Boeniger et aL, 1993; Schoenau 
and Rauch, 2003). These findings were consistent with the worry that levels of 
creatinine may be easily perturbed, hence the need to further research the literature 
on creatinine normalisation and alternative normalisation methods. 
If creatinine levels in urine are susceptible to large fluctuations caused by disease for 
example, then using the concentration of creatinine to normalise data would seem 
rather hazardous. Heavner et al. suggests that whilst using creatinine to normalise 
data appears "... to be a valid and effective method... ", its use would not improve 
correlation to exposure to dose, and could in fact make it worse (Heavner et al., 
2006). This is backed up by research undertaken by Antti et al.. Antti dosed Sprague- 
Dawley rats with differing amounts of hydrazine' to aid the design of experiment and 
data screening for adverse drug effects (Antti et al., 2004). Upon analysis of 1H NMR 
data, the resonance at 8 3.92 increased in positive correlation with increasing 
hydrazine dose. This resonance corresponded to that of creatinine, showing that 
creatinine levels were perturbed by induced disease. This effect may not have been 
noticed had the data been normalised to creatinine. Heavner et al. also state that 
creatinine exhibits variability due to gender, age, muscularity, physical activity, diet, 
disease state, pregnancy and creatinine intake (also noted by Scheonau and Rauch 
(Schoenau and Rauch, 2003)). 
Further to creatinine being perturbed by many factors, some literature suggests that 
creatinine is not as stable as once thought. Schneider et al. describe how after 
excretion, creatinine is influenced by variations in both pH and temperature 
(Schneider et al., 2002); the levels of creatinine decreased by around 20 - 25 % 
within the first 12 days of urine storage, stabilising after this initial period. This has 
also been noted by Saude and Sykes (Saude and Sykes, 2007) who also suggested 
that many urinary metabolites' concentrations fluctuate within the first 7- 14 days of 
storage at either - 20 or - 80 °C, again stabilising after this period. 
N2H4: a hepatotoxin which induces steatosis, lipid retention. 
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With the literature proving that using creatinine to normalise urinary metabonomic 
data is not ideal, it is clear that alternative methods should be utilised. A set of 
experiments to compare no normalisation, normalisation to creatinine, or to total ion 
count were designed. These results are discussed in section 3.5.2.5. 
3.5.2.4. Scaling techniques 
In addition to normalisation, some kind of scaling should also be applied post 
normalisation. Scaling is typically used to account for the large range in the 
concentrations between metabolites excreted in urine. Metabolites with a large 
concentration are not necessarily of greater importance than metabolites with a 
significantly lower concentration; without some kind of scaling, the dominant features 
(metabolites (variables) with large concentrations) would dominate any statistical 
model developed. 
A literature search highlights that scaling is another area of metabonomic studies that 
are scantily or not reported. Only van den Berg et al. (van den Berg et al., 2006) has 
conducted a study into different scaling methods for metabonomic / genomic data 
analysed by PCA. The general conclusions from van den Berg et al. can be applied 
to PLS, but this author suggests it is an area that requires more consideration from 
both statisticians and biologists working together. 
We chose to evaluate three scaling techniques (those being the only methods 
available in SIMCA P+ v11.5, Umetrics, Sweden): mean centring (ctr), pareto (par) 
and unit variance (UV). 
ctr = 
ýxv 
-x) 
par = 
SD 
UV= Xii 
SD 
Equation 3.5.1 
Equation 3.5.2 
Equation 3.5.3 
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Equation 3.5.1 represents how mean centring works. Each variable, )ý, has the 
mean, x,, for that variable subtracted from itself. This has the effect of converting the 
mean of all of the data to zero, centring the data around the origin in PCA and PLS 
analyses. Mean centring is not a true scaling technique, because the variation is only 
between the samples themselves with no variables being scaled. However, mean 
centring forms part of both pareto and unit variance scaling, as the data is first 
centered. 
Pareto and unit variance (equations 3.5.2 and 3.5.3 respectively) both utilise mean 
centring and also the standard deviation of each variable. Standard deviation is a 
measure of the spread of the data. As pareto uses the square root of the standard 
deviation, it reduces the effect of large intensities more than small, therefore making 
intense variables less dominating. Unit variance scales each variable to have a 
standard deviation of one (dividing each sample's response for a variable by the 
standard deviation for that variable), meaning that any differences are based upon 
correlations within the data, as all variables are now equally important. 
Pareto, and especially unit variance, requires normalised data to have been carefully 
extracted (from the raw LC-MS data). If any `noise' has been extracted then these 
scaling methods would enhance this. 
3.5.2.5. Results 
In order to evaluate each normalisation and scaling technique (no normalisation, 
normalisation to creatinine, normalisation using total ion count, mean centring, pareto 
and unit variance), we used datasets generated from urine samples collected from 
volunteers within the York Chemistry Department, who considered themselves to be 
generally fit and free from disease. As mentioned earlier, creatinine has been shown 
to be easily perturbed by illness or other states; it is with this in mind that we chose 
people who should have been free from anything that would have perturbed the 
basal levels of creatinine excretion, hence allowing a comparison using normalisation 
to creatinine. 
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For both positive and negative modes of ESI, and also for two complementary 
separation methods (RP and HILIC, the development of which is described later in 
chapter 3.5.6), discriminative PLS models were developed and optimised according 
to the methodology outlined earlier (figure 3.5.5). The optimised models were then 
evaluated with -- 1/3 of the initial data which were held back to form an external test 
set. 
PCA was used to first analyse each dataset to detect any outliers; no data points 
were considered to be outliers based upon the DModX values of any points outside 
the 95 % confidence limit, thus all data were retained for PLS analysis. Table 3.5.1 
shows all of the methods used to develop models for datasets obtained using 
separation techniques, ionisation modes, normalisation methods and scaling 
methods. For this study, gender was used as the discriminatory variable within the Y 
matrix. Gender was chosen as it should be the largest discriminatory variable 
amongst healthy volunteers, and therefore allow the generation of robust PLS 
models. 
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Table 3.5.1. All methods used to develop PLS models (totalling 36) to allow the 
comparison of different normalisation and scaling techniques. 
Separation 
Method 
Ionisation Mode Normalisation 
Technique Scaling Method 
ctr 
None par 
UV 
ctr 
Positive Creatinine par 
UV 
ctr 
Total Ion Count par 
rsed Phase R 
UV 
eve 
ctr 
None par 
UV 
ctr 
Negative Creatinine par 
UV 
ctr 
Total Ion Count par 
UV 
ctr 
None par 
UV 
ctr 
Positive Creatinine par 
UV 
ctr 
Total Ion Count par 
UV 
HILIC ctr 
None par 
UV 
ctr 
Negative Creatinine par 
UV 
ctr 
Total Ion Count par 
UV 
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Figure 3.5.7. Graphical representation of external classification results for all 36 
developed PLS models (as shown in table 3.5.1). 
The urine samples from the Department of Chemistry were analysed using both 
positive and negative ionisation mode RP- and HILIC-ESI-MS (discussed later within 
the RP and HILIC development section, chapter 3.5.6). After each dataset (±RP and 
±HILIC) was extracted into an X matrix, they were left as is, normalised by creatinine 
or normalised to total ion count before being imported into SIMCA. Each dataset was 
then scaled by one of three methods (ctr, pareto or UV) to generate a discriminative 
PLS model based upon gender using the earlier developed methods (figure 3.5.5). 
Once satisfactory PLS models had been developed, external test sets were imported 
to evaluate the external classification rates, and therefore the accuracy of the 
developed models. 
Comparing the external classification results as percentages across all 36 differently 
developed models shows that each different method used gave a different external 
classification result (figure 3.5.7). Analysing the data for each different scaling 
method for all modes of normalisation shows the general trend of ctr < par < UV with 
respect to the observed classification results. This may be caused by the fact that UV 
gives each variable an equal weighting, meaning that the models have in effect 
access to lower intensity metabolites, whereas par and ctr do not. The three 
normalisation methods (none, creatinine and TIC) all show comparable external 
classification results for each of the three scaling methods, with normalisation to TIC 
performing the best when combined with UV scaling. Evaluating positive and 
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negative ionisation modes across all normalisation, scaling and separation methods 
shows us that positive ionisation mode generally allowed the development of more 
robust PLS models for discrimination by gender. 
The results presented here are in agreement with that of van den Berg et al. who 
stated "... autoscaling and range scaling seem to perform better than other 
methods... " (where autoscaling is analogous to UV). I also agree that "... data pre- 
treatment is often overlooked or is applied in an ad hoc way... " (van den Berg et al., 
2006). 
As-such, care should be taken when applying scaling methods; the results obtained 
should be carefully scrutinised to ensure that variables with the highest VIP values 
are determined and identified so that they can be linked to the question being asked 
(this is discussed later in much greater detail within the RP and HILIC method 
development section, chapter 3.5.6). 
Analysis of the normalisation results for both modes of ionisation shows that no 
normalisation led to classification rates that were broadly comparable to 
normalisation to creatinine or TIC. This shows that for discrimination by gender, 
concentration differences do not play a major role. Providing that the volunteers were 
not ill or diseased, then the results for normalisation by creatinine were very 
comparable to TIC normalisation. This was very promising as it showed that if, for 
this example, normalisation to TIC was comparable to normalisation to creatinine, 
TIC is therefore a suitable normalisation method that can be used for normalising 
urinary metabonomic data. Normalisation to TIC should remove any problems that 
are associated with normalising to creatinine (perturbations due to illness, disease 
etc. ), which could affect studies such as the clinical study (chapter four) which was 
the ultimate overall aim of the work described in this thesis. 
3.5.2.6. Conclusions 
It has been shown that careful consideration has to be given to how data are 
manipulated prior to statistical analysis. Given that many papers confirmed our 
suspicion that normalisation to creatinine should no longer be considered the `gold 
standard', we have also shown that when data are normalised using TIC, it is highly 
comparable to normalising to creatinine (at least when there are expected to be no 
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perturbations to the creatinine levels). Our results showed that scaling by UV was 
most favourable for metabonomic studies, in agreement with research by van den 
Berg et al.. 
Overall, for either positive or negative ESI, we suggest that normalisation using TIC 
followed by scaling using unit variance should be employed for urinary metabonomic 
studies. However, other scaling methods should not be discounted and should 
always, at the very least, be considered during statistical analysis. 
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3.5.3. Data fusion 
3.5.3.1. Introduction 
The goal of a true metabonomic study should be to encompass a representative 
`fingerprint' which contains the largest amount of information that is available. Studies 
may collect NMR data, along with LC/GC/CE-MS data. Mass spectrometric data 
should at the very least contain data from positive and negative ionisation modes, but 
ideally data from more separation methods (e. g. RP and HILIC for LC) or different 
ionisation methods (e. g. ESI and APCI). 
Typically, each data cohort (i. e. RP+, RP-, HILIC+, HILIC- for ESI-LC-MS) is 
statistically analysed as a separate entity. Whilst this is a necessary step, the data 
should also be analysed as a whole. Data fusion has been described in a handful of 
papers (ldborg et a/., 2005; Forshed et al., 2007a; Forshed et al., 2007b) but has yet 
to find a place as a mainstream data analysis method within metabonomic studies. 
3.5.3.2. Aims 
The aim of this `data fusion' study was to examine how fusing together four different 
LC-MS datasets (RP+, RP-, HILIC+ and HILIC-) would effect PLS model 
development. Each individual data cohort, once optimised, produces a list of VIP 
values for the variables forming the discriminative model. Developing a `fused' model 
involving several datasets should produce robust statistical models, as all variables 
across all datasets can now contribute to forming a single PLS model. 
3.5.3.3. Results 
Four sets of data were obtained by analysing the urine from healthy volunteers from 
the department, by RP and HILIC LC-MS in both positive and negative ESI modes. 
Each dataset was individually exported into Excel as a text file (in ASCII format) 
(Microsoft Excel 2004 for Mac) and normalised to TIC as described (chapter 3.5.2). 
Figure 3.5.8 illustrates how the individual datasets were concatenated together. All of 
the observations were ordered and aligned so that each column corresponds to data 
from the same urine sample. The variables for each dataset were labelled to identify 
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which dataset they belonged to (i. e. all variables from RP+ were subsequently 
labelled with `_RPpos'). The datasets were then concatenated, one below the other, 
to form one single X matrix of the data. 
I _I 
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Figure 3.5.8. Representation of data fusion of four different LC-MS datasets. 
Before PLS analysis, the data were analysed by PCA to determine if there were any 
anomalous data points. As the data appeared to be satisfactory, response variables 
based upon gender discrimination were assigned to the Y matrix. As the PLS model 
contained four times the usual number of variables, it was crucial to ensure that the 
model was optimised according to the methodology previously laid out (figure 3.5.5). 
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Figure 3.5.9. Graphical representation of external test set classification results for 
concatenated data normalised by TIC, using three scaling methods: mean centering, 
pareto and unit variance. 
The concatenated dataset was imported into SIMCA for analysis by PLS using three 
scaling methods (mean centring, pareto and UV). When satisfactory PLS models had 
been developed, external test sets were imported to evaluate the predictive ability of 
each of the three developed PLS models. What we see is that the external test set 
classification results (figure 3.5.9) from the optimised PLS models show that scaling 
to unit variance once again gave the highest classification rate, followed by pareto 
and then mean centring. UV scaling was expected to have the highest classification 
rate as each variable is given the same statistical significance, meaning that at the 
very least, the model should perform as well as the best single PLS model developed 
for the non-concatenated model. As the concatenated model contains information 
from two different separation methods and polarities, such an unbiased scaling 
method is required; each different analytical method may produce variables of 
varying intensities, which are not comparable between analytical methods. 
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Table 3.5.2. Comparison of the top five variables forming each PLS model for all 
three scaling methods. 
Scaling Rank Separation 
Method (VIP) Method Polarity 
1 RP + 
2 RP - 
ctr 3 RP - 
4 HILIC - 
5 RP + 
1 RP + 
2 RP + 
par 3 RP - 
4 RP - 
5 RP - 
1 HILIC + 
2 HILIC - 
UV 3 HILIC + 
4 RP - 
5 RP - 
Comparing the top five variables as determined from their VIP values for each 
scaling method, showed that a mixture of variables from across each of the four 
datasets formed the model (table 3.5.2). For scaling by mean centring and pareto, 
separation by reversed phase gave the top five variables (other than position four for 
mean centring which used a HILIC variable), with the positive ionisation mode 
providing the most important variable. This is interesting as it suggests that 
separation by reversed phase may give rise to variables that are more intense, and 
therefore more discriminating than HILIC variables - something which pareto scaling 
would enhance. Scaling by unit variance gave five completely different variables. The 
first three variables were from HILIC separation, with the last two from reversed 
phase separation. Once again, the top variable was from positive ionisation mode. 
A more in-depth discussion of these data fusion results, along with each variable's 
m/z and tR values, is presented in chapter 3.5.6 where the development of RP and 
HILIC LC-MS methods are discussed, along with a thorough analysis of the data 
used to develop these models. 
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3.5.3.4. Conclusions 
Whilst much information can be obtained through the statistical analysis of individual 
datasets, the concatenation (or fusion) of multiple datasets can enhance information 
obtainable from metabonomic studies. Even though the data presented here were 
purely LC-MS data, this additional method of data analysis is not exclusive to this 
analytical platform. Forshed et al. has evaluated different techniques for the fusion of 
1H-NMR data with LC-MS data (Forshed et. al., 2007a). 
Despite the example for data fusion using gender as a discriminatory factor which 
was easily modelled, we predict that data fusion may be of a greater use for more 
complex models where changes may be more subtle, or linked to a series of different 
compounds which are only detectable across different analytical platforms. Fusing 
the data and applying discriminative statistics may enable compounds which, in a 
single dataset model, would not form a robust model, to be combined with 
compounds from other datasets with similar poor classification results to form a 
single, more robust model. 
We feel that as the field of metabonomics progresses, data fusion should become a 
more common feature within the published literature. 
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3.6. Development of reversed phase and hydrophilic interaction liquid 
chromatographic methodologies for mass spectrometric metabonomic studies 
of urine 
3.6.1. Introduction 
Metabonomics comprises a suite of `omic' technologies and has seen substantial 
growth in recent years, perhaps due to its success within the pharmaceutical 
industry, where metabonomics is now used for the identification of potential markers 
of disease, efficacy and toxicity (Nicholson et al., 2002; Drexler et al., 2004; Lindon et 
al., 2004; Walgren and Thompson, 2004; Wilson et al., 2005; Robertson et al., 2007). 
It cannot be stressed enough, that a `true' metabonomic study should involve a 
comprehensive analysis with no pre-selection of analytes, in order to obtain as much 
information as possible. 'H-NMR spectroscopy is a non-discriminatory analytical 
technique (provided that there is a proton! ) and provides information about all of the 
metabolites above the limit of detection (LOD) within a biological sample. However, 
sensitivity is a problem in NMR, and metabolites present in low concentrations may 
not be detected. Mass spectrometry, on the other hand, has lower LODs (orders of 
magnitude) but is a more selective technique. When used in conjunction with HPLC, 
which is required to provide separation of the components within a chosen biofluid 
and to reduce selectivity, mass spectrometry allows detection and quantification of 
low-level metabolites (Dettmer et al., 2007). 
A comprehensive LC-MS study should utilise both positive and negative ionisation 
modes with a chromatographic method that allows the retention and separation of as 
many components as possible. However, many LC-MS metabonomic studies only 
use reversed phase chromatography, which instantly discriminates against highly 
polar analytes. Despite the fact that only non-polar and mildly polar analytes are 
retained, RP-LC-MS is still the most widely used metabonomic MS platform (Plumb 
et al., 2005; Williams et al., 2005; Wilson et al., 2005; Lu et al., 2006; Lutz et al., 
2006; Sumner, 2006; Tang and Wang, 2006; Hodson et al., 2007; Robertson et al., 
2007). As urine is predominantly aqueous, a significant proportion of the content is 
likely to be highly polar, and would typically be unretained using a traditional RP 
approach, and thus not contribute to the data obtained. 
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Hydrophilic interaction chromatography (HILIC) is analogous to normal phase 
chromatography in that it utilises a polar stationary phase, allowing the retention of 
polar analytes (Hemström and Irgum, 2006). However, unlike normal phase, HILIC 
allows the use of aqueous solvents, making this separation technique compatible 
with ESI-MS. In direct contrast to RP-LC, gradient elution HILIC begins with a low 
polarity organic solvent and elutes polar analytes by increasing the polar aqueous 
content. Compounds are retained by partitioning into a water rich layer which is 
partially immobilised on the stationary phase. MS compatible buffers are typically 
used to reduce any undesirable electrostatic interactions between the analytes and 
stationary phase (Hemström and Irgum, 2006). 
It is because of HILIC's compatibility with MS and ability to retain polar compounds, 
therefore possibly increasing the coverage of urinary compounds, that it was chosen 
to assess its suitability for application in LC-MS based metabonomic studies. 
3.6.2. Aims 
The aim of this work was to analyse urine collected from fit and healthy members of 
the Department of Chemistry, University of York, comparing a traditional RP-LC-MS 
approach with HILIC-LC-MS, using both positive and negative electrospray ionisation 
modes. Both RP and HILIC gradients were optimised to obtain a good separation of 
compounds over the analysis time. The resulting data were analysed by PCA and 
PLS to visualise the information-rich data, using the techniques developed and 
described earlier in this chapter. PLS discriminative models were developed and 
classified for gender, time of collection and age in order to compare the performance 
of HILIC-LC-MS with the traditional RP-LC-MS approach. Further to the analysis of 
each individual dataset (RP and HILIC in both ionisation modes), data fusion was 
performed to evaluate its potential for generating robust models based upon a more 
complete dataset. 
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3.6.3. Results and discussion 
3.6.3.1. RP and HILIC gradient optimisation 
So that a direct comparison could be made between reversed phase and hydrophilic 
interaction liquid chromatography separation methods, each column's dimensions 
were identical at 4.6 x 100 mm, and each gradient's total run time was set to 30 min. 
This allowed comparisons to be made under optimal developed conditions for each 
column. As RP-LC is the most commonly utilised separation method for LC-MS 
metabonomic studies, there are many gradients described in the literature that have 
been optimised. A stepwise gradient from 0% MeCN, increasing to 20 % then 95 % 
before returning to starting conditions appears to be one of the most common 
gradients described in the literature (Granger et al., 2003; Plumb et al., 2005; Gika et 
al., 2007); this gradient scheme was modified slightly to avoid a completely aqueous 
mobile phase, thus increasing ionisation efficiency and reducing viscosity (therefore 
reducing the back pressure), and is presented in table 3.6.1. 
Table 3.6.1. Gradient profile for RP-LC-MS metabonomic studies. Solvent A= H2O 
with 0.1 % v/v formic acid; B= MeCN with 0.1 % v/v formic acid. The additional steps 
from 30-35 min correspond to column washing and re-equilibration steps. 
Time min" %A%B 
0 95 5 
9 80 20 
21 5 95 
24 5 95 
27 95 5 
30 95 5 
31 0 100 
32 0 100 
34 95 5 
35 95 5 
30 min total run times were chosen to allow for as much separation as possible whilst 
allowing for a reasonable sample throughput. Obviously, non-academic institutions 
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would require much shorter analysis times, as very high throughput experimentation 
is demanded; in industry, time is money, whereas in academia, time is the students. 
1, 
Figure 3.6.1. (a) Typical UV254chromatogram obtained using RP separation of a 
urine sample. Inset shows an XIC for creatinine (m/z 114.07 = [M + H]+ with a 
retention time of 2.1 min. (b) Positive mode TIC of the same urine sample, 
normalised to the most intense peak. 
A typical RP-LC UV chromatogram is shown in figure 3.6.1 a for the separation of a 
urine sample. Despite many urinary components not having a chromophore, meaning 
that UV chromatograms do not contain many peaks, there are some intense peaks 
that are Gaussian shaped present within the chromatogram. The corresponding TIC 
(figure 3.6.1 b) is much more information rich, showing many more peaks than the UV 
chromatogram. Changing the gradient profile did not show any appreciable change to 
either the UV chromatogram or the TIC, suggesting that the gradient was suitable for 
the separation of urinary components. Both the UV chromatogram and TIC return to 
the baseline at the end of each run (only 20 min of gradient shown to highlight the 
information rich sections). The high organic content wash at the end of each run 
(table 3.6.1) was applied to remove any highly hydrophobic components, avoiding 
late eluting compounds being present in subsequent analyses. 
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Table 3.6.2. Gradient profile for HILIC-LC-MS metabonomic studies. Solvent A= 
MeCN with 0.1 % v/v formic acid; B= H2O with 0.1 % v/v formic acid. 
Time min' %A%B 
0 95 5 
9 80 20 
21 5 95 
24 5 95 
27 95 5 
30 95 5 
Only a handful of papers have been published regarding the use of HILIC (Idbarg et 
al., 2005; Kind et al., 2007; Mawhinney et al., 2007), and most of these utilise a 
gradient which was similar to that chosen for RP separation; this is because HILIC is 
in effect reversed-reversed phase, as the solvents used are the same, but the other 
way around. The first HILIC gradient used H2O and MeCN both modified by the 
addition of 0.1 % v/v formic acid (table 3.6.2). Whilst the separation achieved 
appeared to be similar to that obtained by RP-LC (figure 3.6.1a), repeat injections 
showed that retention times, peak shapes and intensities were not reproducible (not 
shown). As HILIC columns require longer equilibration times than RP-LC (Hemström 
and Irgum, 2006), a longer equilibration time was afforded at the end of the run (19.5 
to 30 min) at the expense of a shorter gradient elution profile (table 3.6.3). 
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Table 3.6.3. Gradient profile for HILIC-LC-MS metabonomic studies utilising a longer 
equilibration period (19.5 to 30 min). Solvent A= MeCN with 0.1 % v/v formic acid; B 
= H2O with 0.1 % v/v formic acid. 
Time min" %A %B 
0 95 5 
15 5 95 
19 5 95 
19.5 95 5 
30 95 5 
The resulting UV chromatogram (figure 3.6.2a) and the repeat analysis of the same 
urine sample (figure 3.6.2b) show that comparable peaks were obtained. However, 
as for the first HILIC gradient (table 3.6.2), retention times, peak shapes and intensity 
were not repeatable. The peak labelled `1' exhibited different intensities and retention 
times (tR c 3.0 and 2.4 min for the first and second analyses respectively). The 
poorly resolved peaks highlighted by arrow `2' show no comparable peak shapes or 
retention times, and the most intense peak in the UV chromatogram highlighted by 
arrow `3', despite being of comparable intensities in the two chromatograms, show a 
shift in retention time of ca. 1 min. 
These deviations in retention time, peak shapes and intensity were clearly 
unacceptable. As HILIC columns work using a zwitterionic stationary phase, and 
urine is a salty matrix, the reproducibility problems could have been caused by a 
build up of salt on the column, which was effecting how compounds were being 
retained. It was decided to add a buffer to the aqueous solvent; the addition of this 
buffer aids in stabilising the pH of the mobile phase and maintaining a constant salt 
content, buffering the zwitterionic stationary phase and avoiding any unwanted ionic 
interactions. 
The addition of 5 mM ammonium acetate to the aqueous phase of the gradient 
shown in table 3.6.3 yielded very reproducible results, as the retention times, peak 
shapes and intensities of all the peaks within the UV chromatograms were identical 
(figure 3.6.2c and d, cf. panels a and b). 
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Figure 3.6.2. (a - b) first and second UV254 chromatograms of the same urine sample 
using the gradient described in table 3.6.3, where the arrows refer to specific peaks 
(see comments within main text). (c - d) two replicate injections of the same urine 
sample using same gradient, but with the addition of 5 mM ammonium acetate to the 
aqueous phase. 
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Figure 3.6.3. (a) Typical UV254chromatogram obtained using HILIC separation of the 
same urine sample as used for figure 3.6.1. Inset shows an XIC for creatinine (m/z 
114.07 = [M + H]+ with a retention time of 8.3 min. (b) Positive mode TIC of the same 
urine sample, normalised to the most intense peak. 
The UV chromatograms and TICs shown in figure 3.6.3 possess fewer peaks than 
those of a RP analysis (cf. figure 3.6.1), however, there still appears to be an 
abundance of information present within the TIC. 
As suitable RP and HILIC gradients of comparable length were developed and 
shown to produce robust, reproducible results, the next steps allowing comparison of 
each column's ability to produce meaningful statistical results could be carried out. 
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3.6.3.2. Data acquisition and extraction 
All of the urine samples obtained from the volunteers from the Department of 
Chemistry were analysed positive and negative mode ESI and both RP and HILIC 
LC-MS methods. Before any samples were analysed, pooled urine samples were run 
to condition the LC-MS system. Throughout each of the four data acquisitions, 
pooled samples, blank runs and replicate sample analyses were carried out in 
accordance with the methodologies laid out earlier in this chapter. 
Upon extraction of the resulting data using the metabolomics export script (see 
chapter 3.4), it was noticed that for both separation methods, fewer peaks were 
extracted from negative ionisation mode compared to positive. This was not a 
surprise, as for positive ionisation mode, more compounds are generally ionised 
(general observation); however, negative ionisation mode tends to generate much 
clearer spectra than positive with fewer background peaks being observed. It was a 
surprise to find that more variables were generated from RP-LC-MS than HILIC-LC- 
MS data. This could be due to the fact that HILIC only retains mildly polar and polar 
compounds (of which it was hypothesised that there should be a substantial in urine). 
RP columns can retain mildly polar and hydrophobic compounds, but typically 
generate multiple peaks from the same compounds (due to salts); this fact may 
account for the increase in extracted data when using RP separation techniques. 
For both RP and HILIC separation, the most intense peak observed within TICs 
generally corresponded to creatinine. The intensity of the creatinine peak for each 
sample was plotted from the extracted data; this is presented in figure 3.6.4. 
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Figure 3.6.4. Graphical representation of the extracted creatinine peak intensity from 
positive mode data for both RP and HILIC separation. 
From the data presented in figure 3.6.4, it is clear that the intensity of the creatinine 
peaks are generally higher using RP separation than HILIC; this was expected as all 
samples analysed by HILIC-LC-MS were diluted 50: 50 with MeCN. It is evident that, 
on the whole, the extracted intensity of creatinine using both separation techniques 
generally follow the same trend. There are 10 samples where the difference in 
intensity does not follow the same trend as the majority of the data, with two samples 
(33 and 44) having the same intensity. The creatinine levels from HILIC-LC-MS are 
consistent across the majority of samples; it is the RP-LC-MS creatinine levels that 
appear to be lower than expected for the samples that do not follow the trend. As 
creatinine elutes from the RP column very close to the void, this apparent decrease 
in expected creatinine intensity could be due to ion suppression caused by 
particularly salty samples or co-eluting compounds which utilise the majority of the 
ion stream; this is consistent with the fact that creatinine is well retained using HILIC 
and does not exhibit any noticeable deviation from the expected intensity. 
Despite there being a few minor discrepancies between the extracted intensities for 
creatinine, it is evident that both RP and HILIC-LC-MS can produce comparable 
results in terms of detection and ionisation, based upon creatinine. 
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3.6.3.3. PCA 
Before each dataset was randomly split into training and test sets for discriminative 
analysis, they were analysed using PCA in an unbiased manner to identify any 
potential data points outside the 95 % confidence limits, which also had a large 
difference from the model (DModX in SIMCA). 
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Figure 3.6.5. PCA scores plots of the first two principal components for (a) positive 
mode RP-LC-MS analysis, (b) negative mode RP-LC-MS analysis, (c) positive mode 
HILIC-LC-MS analysis and (d) negative mode HILIC-LC-MS analysis. 
The four PCA scores plots presented in figure 3.6.5 show the first two principal 
components for each separation and ionisation method. Figure 3.6.5a shows positive 
mode RP-LC-MS data, with only a few data points outside of the 95 % confidence 
limit (shown by the ellipse), whereas for negative ionisation mode RP-LC-MS 
analysis (figure 3.6.5b) there are two data points (indicated by arrows) that are more 
substantial outliers than the other points just outside the 95 % confidence limit. For 
positive mode analysis by HILIC-LC-MS (figure 3.6.5c), the vast majority of the data 
points are within the confidence limit, with only two points outside this limit; 
conversely, negative mode HILIC-LC-MS analysis (figure 3.6.5d) shows many more 
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points outside the confidence limit, with the most extreme of these indicated by 
arrows. 
Comparing positive ionisation mode to negative for both separation methods shows 
that negative mode data appear to have more `outliers' than positive. The fact that 
there are more moderate outliers for negative mode than positive, may be accounted 
for by the fact that positive mode generates many more variables than negative. As 
models using negative mode data have fewer variables to form a model, any 
spurious variables will have a greater effect upon the model, therefore generating 
data points that appear to be outliers in the first two principal components of a PCA 
scores plot. 
Examining the distance from model (DModX) plots for each PCA model showed that 
for positive ionisation mode for both separation methods, the few data points that are 
outside of the confidence limits did not have a DModX value that was larger than the 
critical tolerance value of 0.05 (corresponding to 95 % confidence). For this reason, 
all of the data points from positive mode data (figure 3.6.5 a and c) were not classed 
as outliers, and were subsequently retained to form datasets for further analysis by 
discriminative statistics. 
The data points indicated by arrows in the negative ionisation scores plots (figure 
3.6.5 b and d) are reasonable outliers according to the confidence limits shown on 
the scores plots. When the DModX plots were examined, the data points highlighted 
by solid green arrows had DModX values which were higher than the critical value, 
meaning that these data points were not only outside the 95 % confidence limits, but 
were also not on the same plane as the bulk of the remaining data. The data point 
indicated by a hashed blue arrow (figure 3.6.5d) did not have a DModX value which 
was above the critical value meaning that this data point was only an outlier based 
upon its value for the second principal component. Studying the loadings plots for 
both negative ionisation mode scores plots failed to highlight any particular variables 
responsible for the outliers indicated, thus the outlying points must be caused by a 
combination of many variables, and are therefore not specific outliers. 
As the first few principal components failed to show any clustering based upon 
gender, time of collection, age or smoker status, and the outlying data points were 
not caused by any particular variables, all of the data points were retained and not 
discarded. However, the data points were recorded as being outliers and were to be 
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checked in any subsequent discriminative analysis to see if they once more were 
classed as outliers'. 
As none of the marked outliers were removed from either the RP-LC-MS or HILIC- 
LC-MS negative ionisation mode datasets, each of the four datasets were 
subsequently randomly split into training and test sets. For the subsequent PLS 
analyses the data were assigned the discriminatory variables gender, time of 
collection and age, and roughly one-third of the data were held back to form a test 
set. The test sets contained equal numbers of observations for gender and time of 
collection, with eight observations for each discriminatory class. For discrimination by 
age, there were fewer observations for the age groups 31-40 and 41-61 as the bulk 
of the samples donated were from the 21-30 age group (not surprising within a 
University environment). The test set therefore consisted of nine, four and three 
randomly chosen observations for the age groups 21-30,31-40 and 41-61 
respectively. The training and test sets were then normalised according to the 
methods laid out in section 3.5 before PLS analysis. 
1 Once discriminatory models were developed, the outliers indicated within figure 3.6.5 were not classed 
as outliers within any developed model. Further to this, the most 
important variables were checked to 
see if there was any correlation with the loadings plots from the 
PCA analysis; there were no 
correlations evident, suggesting that retaining these `outliers' was not 
detrimental to subsequent model 
development. 
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3.6.3.4. PLS analysis 
Each of the datasets were analysed by PCA, based on consideration of the results of 
which it was decided that all the data should remain without any data points being 
discarded. The next step to compare how HILIC separation compared to a traditional 
RP approach was to analyse each dataset using discriminative statistics. All of the 
data presented within this section were normalised to TIC and scaled using unit 
variance. However, the most important variables forming the models developed using 
no normalisation, normalisation to creatinine, as well as normalisation to TIC and all 
three scaling methods (mean centring, pareto and unit variance) as presented in 
section 3.5 are reported too for comparison. 
Development of all PLS models was undertaken using the scheme laid out in section 
3.5. The explained variation (in terms of R2 and Q2 within SIMCA P+) gave an 
indication of the fit of the model and its predictive ability (using internal venetian blind 
CV). The internal CV was used to determine the number of components in the 
developed models. VIP scores were used to ascertain the discriminating power for 
each variable, and also to identify and remove any unimportant variables that did not 
add any predictive power to a model. After the removal of unimportant variables, the 
models were re-developed and the process repeated until a satisfactory model was 
developed (typically less than 10 variables were used to form a PLS model). 
3.6.3.4.1. Positive ionisation mode data analysis 
For both separation methods, PLS plots for positive ionisation mode datasets 
afforded a clear separation in terms of discrimination by gender using LC-MS (figure 
3.6.6). It is clear that the discriminative power of the model using data from HILIC 
separation (figure 3.6.6b) is comparable to, if not better than, that produced from a 
more traditional RP separation approach (figure 3.6.6a). 
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Figure 3.6.6. PLS scores plots for a gender response variable (  = male training set, 
"= female training set, "= male external test set, s= female external test set) 
analysed in positive mode ESI-MS: (a) reversed phase data training set data. (b) 
HILIC data training set data. (c) reversed phase data with external test set overlaid. 
(d) HILIC data with external test set overlaid. 
To assess the predictive power of each developed PLS model, the external test sets 
were imported. The classification rates from the independent test sets were 94 and 
100 % for RP and HILIC datasets respectively (the lower classification rate for RP- 
LC-MS corresponds to one fewer external test set samples being correctly 
classified). Figures 3.6.6c and d show the PLS scores plots with the external test set 
data overlaid to highlight the predictive power of the developed models. Despite the 
scores plots being presented using two latent variables, both developed models for 
discrimination by gender only utilised one latent variable for prediction, with no gain 
in classification rates being observed by using two latent variables. 
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Figure 3.6.7. PLS scores plots for the response variables time of collection (a, b) 
where (f = AM training set,  = PM training set, f= AM external test set, "= PM 
external test set), and age (c, d) where (" = 21-30 age group training set, "= 31-40 
age group training set,  = 41-61 age group training set, 0= 21-30 age group 
external test set, = 31-40 external age group test set, Q= 41-61 external age group 
test set) analysed in positive mode ESI-MS with both the training and test set data 
shown. (a) FLS model for discrimination by time of collection using RP-LC-MS data, 
(b) PLS model for discrimination by time of collection using HILIC-LC-MS data, (c) 
PLS model for discrimination by age using RP-LC-MS data, (d) PLS model for 
discrimination by age using HILIC-LC-MS data. 
For further comparison of the two separation techniques using positive ionisation 
mode LC-MS, PLS was used to analyse data based on the time of sample collection 
(AM vs. PM) and age. Figure 3.6.7 shows scores plots with time of collection and age 
as discriminatory factors. Both RP-MS (figure 3.6.7a) and HILIC-MS (figure 3.6.7b) 
data exhibited good clustering for discrimination by time of collection (AM = first void 
of the day, PM = any subsequent void after 15: 00 h), although, as might be expected, 
the scores plots do show some overlap. This overlap is probably caused by the fact 
that some volunteers may not have donated the first void of the day, or may have 
donated earlier than the 15: 00 h collection time for the PM sample. Also, 
discrimination between AM/PM samples was not expected to give clear clustering, as 
some urinary profiles may not substantially differ over the course of the collection 
period. Despite the overlap, classification rates of the external test sets were 94 % for 
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RP and 87 % for HILIC. HILIC's lower classification rate was due to the fact that one 
of the samples in the external test set (a PM donation, highlighted by a red circle) lies 
well outside the 95 % confidence limit (figure3.6.7b) and was subsequently classed 
as a false positive. The PLS model for RP separation gave the highest classification 
when one latent variable was used, whereas the HILIC separation model gave higher 
classification results with two latent variables. 
For discrimination by age, the donors were split into three arbitrary classes: ages 21- 
30,31-40 and 41-61. A general trend with increasing age could be seen along the 
first latent variable for both RP and HILIC datasets, although the groups merge at 
age boundaries, as expected. This trend along the first principal component explains 
why for both RP and HILIC data models, only one latent variable was required to give 
the highest classification rates. The samples corresponding to the 21-30 age group 
are more tightly clustered those of the 31-40 and 41-61 age groups, which are less 
well defined. Classification results for the independent test sets were the poorest in 
this study, with classification rates of 71 and 86 % for RP (figure 3.6.7c) and HILIC 
(figure 3.6.7d) respectively. 
PLS models for both RP and HILIC data were able to predict samples from the 
younger age groups (21-30) reasonably well, but the models were unable to 
accurately predict samples from the older groups (31-40 and 41-61). Samples from 
the external test sets are overlaid onto the RP (Fig. 3.6.7c) and HILIC (Fig. 3.6.7d) 
scores plots and illustrate the poor prediction of class for the older age groups. 
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Table 3.6.4. Comparison of the top five variables for each developed model using 
gender as a discriminatory factor for positive ionisation mode LC-ECI-MS data, 
where GD = gender for which that variable was more discriminatory for. 
Separation Method 
ti li N Scalin Rank Ionisation on sa orma g 
Method Method Method (VIP) RP HILIC 
GD m/z tR GD m/z tR 
1 QM 310.22 15.83 QM 126.06 3.67 
2 F 229.16 3.88 QM 327.11 3.97 
ctr 3 fM 286.19 15.18 F 432.14 4.80 
4 F 290.16 8.32 QM 371.07 4.15 
5 QM 265.13 11.22 QM 126.07 5.28 
1 QM 310.22 15.83 jf F 126.06 3.67 
2 ¶F 114.06 2.63 QM 126.07 5.28 
None par 3 tM 100.09 7.57 QM 162.03 9.23 
4 QF 290.16 8.32 QM 327.11 3.97 
5 QM 286.19 15.18 jF 432.14 4.80 
1 QF 497.19 15.47 M 185.02 7.12 
2 ¶F 815.25 11.37 ji F 192.11 7.70 
UV 3 fF 83.05 9.23 M 428.01 2.63 
4 QM 182.07 5.73 QF 325.99 7.65 
5 QM 263.20 6.67 QF 206.04 2.55 
1 ji M 310.22 15.83 QM 327.11 3.97 
2 QM 114.07 3.52 QF 432.14 4.80 
ctr 3 M 286.19 15.18 QM 476.20 5.22 
4 QM 100.09 7.57 QM 371.07 4.15 
5 QM 302.24 16.12 QM 415.12 4.83 
1 QM 310.22 15.83 F 166.99 2.98 
2 QM 286.19 15.18 fr F 177.04 3.50 
Positive Creatinine par 3 F 290.16 8.32 M 529.14 4.48 
4 QM 100.09 7.57 QM 371.07 4.15 
5 M 202.11 5.75 F 401.95 7.03 
1 F 497.19 15.47 QF 182.05 2.48 
2 QF 815.25 11.37 QF 231.10 5.33 
UV 3 QF 90.05 2.70 QF 206.04 2.55 
4 jr F 492.22 15.50 QF 158.02 7.93 
5 F 290.16 8.32 F 105.02 2.73 
1 QM 114.07 3.52 QF 126.06 3.67 
2 QM 310.22 15.83 QM 529.14 4.48 
ctr 3 M 100.09 7.57 QF 166.99 2.98 
4 QF 229.16 3.88 QM 126.07 5.28 
5 QM 286.19 15.18 QF 265.08 2.92 
1 M 310.22 15.83 F 166.99 2.98 
2 QM 100.09 7.57 QF 177.04 3.50 
TIC par 3 QM 286.19 15.18 F 401.95 7.03 
4 QF 290.16 8.32 QF 265.08 2.92 
5 F 229.16 3.88 QM 126.06 3.67 
1 QF 171.10 6.92 F 206.04 2.55 
2 QF 497.19 15.47 QF 192.11 7.70 
UV 3 F 217.13 6.92 M 87.02 3.42 
4 QM 161.09 10.23 QF 325.99 7.65 
5 QF 815.25 11.37 F 182.05 2.48 
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It is evident that for positive ionisation mode, both separation methods allow the 
development of models that have comparable external classification results. Table 
3.6.4 shows the five most important variables (as determined by their VIP values) for 
the developed PLS models using gender as the discriminatory factor, for all 
normalisation and scaling methods. The shaded cells within table 3.6.4 highlight 
variables that are duplicated in other developed models for that particular separation 
method. Whilst there are some unshaded cells, meaning unique variables were used 
in that particular model, there is a large number of shaded cells for both RP and 
HILIC separation method models, suggesting that these variables are important for 
discrimination by gender. As there are only two groups to discriminate against, the 
`GD' column shows which gender each variable had an increased response for. 
The CID tandem MS analysis of the most important variables determined by PLS 
models for discrimination by gender, time of collection and age for positive (and 
negative) ionisation mode are presented in section 3.6.4. 
3.6.3.4.2. Negative ionisation mode data analysis 
Negative mode ESI-MS was also investigated for each separation method to 
determine whether further information could be obtained over that produced using 
positive mode, in order to provide as comprehensive an MS fingerprint as possible. 
Again PLS was carried out on the data sets with response variables assigned to 
gender, time of collection and age. 
160 
Chapter Three: Development of a 'metabonomic toolbox' 
4 
2 
N_ 
N0 
-4 
4 
2 
N 
(Ä C 
CL 
-9 
" (a) 
tiý On 
-6 -4 -2 0246 
tPS[1 ] 
7 
-lädb- 44 
i  
itro 
-e -6 -4 -2 02468 
tPs[1] 
4 
N 
to C 
a 
.4 
  
s ,0 
7 
0 ,0 ei ý h 
tt I 
O° 
. 
. 
6 
4 
2 
N 
NQ 
CL 
-e 
-4 
4 
2 
ý N 
NQ 
a 
-4 
4 
2 
N 
w 
-2 
-1 
(b) 
... ý. . 
" 
"ý 
-8 -6 -4 -2 02468 10 
tPsEl] 
(d) 
. 4". 
  
.. t ru 
ý 
. 
"ýti 
""" ". S 
-6 -4 -2 0246 
tPS[1] 
  
" 
ý6 "  ý 13 " d   
" 
.. s ' ° .. 
-8 -6 -4 -2 02468 -4 -2 0246 
tPS[1] tPS[1] 
Figure 3.6.8. PLS scores plots for negative mode ESI-MS with the response 
variables: gender (a, b) where (  = male training set, f= female training set, "= male 
external test set, f= female external test set), time of collection (c, d) where (f = AM 
training set,  = PM training set, f= AM external test set, "= PM external test set), 
and age (e, f) where (f = 21-30 age group training set, "= 31-40 age group training 
set,  = 41-61 age group training set, 0= 21-30 age group external test set, = 31- 
40 external age group test set, Q= 41-61 external age group test set). (a) PLS model 
for discrimination by gender using RP-LC-MS data, (b) PLS model for discrimination 
by gender using HILIC-LC-MS data, (c) PLS model for discrimination by time of 
collection using RP-LC-MS data, (d) PLS model for discrimination by time of 
collection using HILIC-LC-MS data, (e) PLS model for discrimination by age using 
RP-LC-MS data, (f) PLS model for discrimination by age using HILIC-LC-MS data. 
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PLS scores plots for separation based on gender for RP (figure 3.6.8a) and HILIC 
(figure 3.6.8b) separation methods show clustering for the two groups. The results for 
both positive (figure 3.6.6a) and negative ionisation (figure 3.6.8a) are comparable 
for RP separation. However, the defined clusters seen with the positive ionisation 
HILIC-ESI-MS data (figure 3.6.6b) are lost when the polarity of ionisation is changed 
(figure 3.6.8b). For both RP and HILIC PLS models based upon gender, the 
classification rate of the independent test set was 88 %, with both models having the 
same classification rate when either one or two latent variables were used. This 
value is lower than those achieved for positive ionisation data from both separation 
techniques, where classification rates of 94 % and 100 % were obtained for RP and 
HILIC data respectively (section 3.6.3.4.1). 
Separation based upon time of collection for RP (figure 3.6.8c) and HILIC (figure 
3.6.8d) ESI-MS data in negative mode shows comparable clustering to that in 
positive mode (figures 3.6.7a and b). However, classification of time of collection was 
worse with negative ionisation data, giving 81 % correct classification of the 
independent test sets for both separation methods. This can be compared to the 
classification rates of 94 % and 87 % achieved for RP and HILIC respectively using 
positive mode ESI-MS. Both PLS models did not increase the classification rate 
when two latent variables were used over one, as the majority of the variation can 
again be accounted for using the first latent variable. 
The final PLS models correspond to discrimination by age. As with positive 
ionisation, both RP (figure 3.6.8e) and HILIC (figure 3.6.8e) negative mode ESI-MS 
data show overlap of the age groups, with the general trend of increasing age along 
the first latent variable. With negative ionisation data, the age group 31-40 appears to 
form a tighter cluster than was observed for positive ESI-MS data (figure 3.6.7c and 
d), although the oldest age group (41-61) again shows poor clustering. Even with the 
tighter clustering of the second age group (31-40), classification of the external test 
set for both separation methods using negative ESI-MS data was poor at 64 %. For 
RP separation, the use of two latent variables increased the classification rates, but 
for HILIC separation only one latent variable was required to gain the maximum 
classification rate. 
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Table 3.6.5. Comparison of the top five variables for each developed model using 
gender as a discriminatory factor for negative ionisation mode LC-ECI-MS data, 
where GD = gender for which that variable was more discriminatory for. 
ti i Normalisation Scalin R k 
Separation Method 
on sa Ion g an 
Method Method Method (VIP) RP HILIC 
GD m/z tR GD m/z tR 
1 F 186.99 13.60 F 186.98 2.92 
2 'ft M 211.99 11.53 M 211.98 5.80 
ctr 3 ji F 191.00 4.48 QM 367.12 2.13 
4 QF 263.07 11.33 M 263.08 4.57 
5 F 178.03 11.35 F 96.95 10.73 
1 F 191.00 4.48 QF 186.98 2.92 
2 QM 211.99 11.53 QM 211.98 5.80 
None par 3 ¶F 263.07 11.33 QF 96.95 10.73 
4 QM 331.14 17.02 QM 367.12 2.13 
5 QM 465.21 17.57 QF 107.04 2.97 
1 QM 158.08 7.82 ¶F 165.03 2.93 
2 QF 101.03 3.48 QM 263.08 2.87 
UV 3 ¶F 217.04 3.40 QM 88.03 9.35 
4 QF 145.01 3.47 if F 424.98 5.80 
5 QF 304.89 2.28 QF 74.02 5.40 
1 jý F 178.03 11.35 QF 186.98 2.92 
2 QF 263.07 11.33 QM 211.98 5.80 
ctr 3 ¶M 211.98 11.53 QF 161.97 3.02 
4 QM 191.00 3.93 jr M 367.12 2.13 
5 QF 191.00 4.48 M 263.08 4.57 
1 ¶F 178.03 11.35 F 186.98 2.92 
2 F 263.07 11.33 QM 211.98 5.80 
Negative Creatinine par 3 QF 191.00 4.48 ¶M 367.12 2.13 
4 QM 211.98 11.53 jr F 107.04 2.97 
5 M 191.00 3.93 QM 263.08 4.57 
1 ¶F 101.03 3.48 QF 74.02 5.40 
2 F 145.01 3.47 QM 145.01 6.75 
UV 3 QF 78.96 4.33 F 101.02 6.75 
4 QF 495.19 15.45 M 88.03 9.35 
5 QM 158.08 7.82 QM 151.01 6.08 
1 QF 263.07 11.33 F 186.98 2.92 
2 QF 186.99 13.60 QM 367.12 2.13 
ctr 3 QM 191.00 4.48 QF 107.04 2.97 
4 jf M 211.98 11.53 QM 263.08 4.57 
5 QM 191.00 3.93 QF 191.00 7.18 
1 QF 263.07 11.33 QF 186.98 2.92 
2 QF 186.99 13.60 QF 107.04 2.97 
TIC par 3 QM 191.00 4.48 M 367.12 2.13 
4 QM 465.21 17.57 M 172.98 2.97 
5 QF 283.06 13.30 QM 167.00 7.58 
1 F 101.03 3.48 QF 184.09 2.50 
2 QF 145.01 3.47 QF 186.98 2.92 
UV 3 QM 541.22 15.23 F 74.02 5.40 
4 F 495.19 15.45 QF 101.02 6.75 
5 I_# F 260.99 10.28 IF 107.04 2.97 
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As for positive mode of ionisation, the top five most important variables for the 
developed PLS models using gender as a discriminatory variable, again using all 
normalisation and scaling methods, shows that there are relatively few unshaded 
cells (table 3.6.5). The gender for which each variable gave the most discrimination 
for are shown in the `GD' column. The CID tandem MS analysis of the variables 
generated by negative ionisation mode data for discrimination by gender, time of 
collection and age is presented in section 3.6.4. 
3.6.3.4.3. Summary of discriminative analysis of data from positive and 
negative modes of ionisation 
Table 3.6.6. Comparison of external test set classification results for reversed phase 
and HILIC separation technique data from positive and negative mode ESI-MS 
studies. The value indicates the percentage of correct classification results. 
Ionisation Mode Y variable 
Separation Method 
RP HILIC 
Gender 94 100 
Positive Time of collection 94 87 
Age 71 86 
Gender 88 88 
Negative Time of collection 81 81 
Age 64 64 
Table 3.6.6 summarises the classification results for the independent test set. The 
two different chromatographic column chemistries allow comparable classification 
rates, showing that HILIC is a suitable separation technique to be employed for the 
analysis of human urine in metabonomic studies. It is clear that, for gender, diurnal 
variation and age, the classification rates obtained using positive mode ESI-MS are 
higher than for negative mode, suggesting that positive ionisation data generate 
more robust models. However, when a metabonomic study is undertaken, a 
comprehensive picture of the components present in the sample should be sought 
and both positive and negative ionisation considered. 
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Comparing tables 3.6.4 and 3.6.5 for the variables generated for discrimination by 
gender shows that it is clear that the variables used to construct the models from the 
positive and negative ionisation mode data are all totally different, as both the m/z 
and retention times (tR) are different. This shows that different compounds are 
contributing to the developed models, highlighting the fact that both modes of 
ionisation are important in increasing the urinary metabolome coverage. Further to 
this, comparing the variables for RP-LC-MS and HILIC-LC-MS also reveals that 
different compounds are contributing to the developed PLS models. This is entirely 
consistent with the initial expectation that different compounds would be retained on 
the different columns, and again reinforcing the need to utilise complementary 
separation methods when as much information as possible is sought from urinary 
samples. 
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3.6.3.5. Data fusion 
To evaluate how fusing the four datasets (±RP and ±HILIC) together alters the 
predictive ability of a PLS model for each of the three Y variables (gender, time of 
collection and age), the datasets were concatenated together as outlined in section 
3.5. As for each individual dataset, the fused dataset was first analysed using PCA to 
identify any outliers. As for the single datasets, there was no clustering within the first 
few LVs related to gender, time of collection or age. The majority of the data points 
were within the 95 % confidence limit; only three data points were outside the 
confidence limit, but did not have a DModX value above the critical value (95 %) and 
were therefore retained for subsequent analysis. 
The fused dataset was split into a training and test set. As the training set contained 
over 15,000 variables, optimising the PLS models based upon discrimination by 
gender, time of collection and age was of paramount importance to avoid any 
overfitting. 
The PLS scores plot based upon separation according to gender shows good 
clustering (figure 3.6.9a); this is reflected in the external classification rate of 100 %. 
The external test set data points are plotted onto the scores plot, which shows two 
latent variables. To obtain the 100 % classification rate, two latent variables were 
required. 
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Figure 3.6.9. PLS scores plots for the response variables: gender (a) where (  _ 
male training set, f= female training set, "= male external test set, f= female 
external test set), time of collection (b) where (f = AM training set,  = PM training 
set, f= AM external test set, "= PM external test set) and age (c) where (f = 21-30 
age group training set, "= 31-40 age group training set,  = 41-61 age group training 
set, 0= 21-30 age group external test set, = 31-40 external age group test set, Q_ 
41-61 external age group test set). 
167 
Chapter Three: Development of a 'metabonomic toolbox' 
For discrimination by time of collection, the developed PLS model again showed 
some good clustering, but with overlap between the two groups as expected (figure 
3.6.9b). Using two latent variables did not increase the observed external 
classification rate of 90 % over using one latent variable. Similarly for discrimination 
by age, there is significant overlap between the three age groups (figure 3.6.9c). The 
21-30 age group exhibits a tight cluster between zero and minus two on the y-axis, 
with the 31-40 age group also showing little spread across the one latent variable. 
The 41-61 age group has a large spread from zero to five on the y-axis, showing 
much more variation between the samples. The external test set data (overlaid) 
shows that the 21-30 age group can be well predicted, but with increasing age the 
level of confidence in predictive ability is much lower as there is so much overlap 
between the 31-40 and 41-61 age groups; this is reflected in the external 
classification rate of 87 % (100 % for the 21-30 age group). As the 41-61 age group 
has poor clustering, only one latent variable was required, as using two did not 
increase the external classification rate. 
Table 3.6.7. Comparison of the external test set classification results for 
concatenated data and each of the four individual data sets (± RP and ± HILIC). 
Y Variable Classification Separation 
Rate (%) Method 
100 Data Fusion 
100 HILIC + 
Gender 94 RP + 
88 HILIC - 
88 RP - 
94 RP + 
90 Data Fusion 
Time of 87 HILIC + Collection 
81 HILIC - 
81 RP- 
87 Data Fusion 
86 HILIC + 
Age 71 RP + 
64 HILIC - 
64 RP - 
Table 3.6.7 compares the highest external classification results for each of the single 
datasets with the concatenated dataset. It should be expected that as the data fusion 
models use all of the available variables from each of the four single datasets, they 
should perform as well as, or better than, the best performing individual dataset. As 
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some of the original datasets had some samples missing due to insufficient urine 
donated, there were fewer samples available to form the aligned concatenated 
dataset, resulting in slightly smaller test sets, and therefore different external 
classification results. For both discrimination by gender and age, data fusion 
generated results that were equal to, or slightly better than, the best performing 
individual model. For discrimination by time of collection, the data fusion model 
performed as well as the positive ionisation mode RP dataset with only one sample 
being incorrectly classified; the decrease in classification rate was due to the 
differently sized external test set. 
Table 3.6.8. Comparison of the top five variables for each developed model 
highlighting which separation and ionisation mode generated each of the variables. 
Rank Separation Y Variable Y Variable (VIP) Method Polarity m/z tR Discriminative for 
1 HILIC + 428.01 2.63 ýF 
2 HILIC - 184.09 2.50 fm 
Gender 3 HILIC + 223.04 3.00 
4 RP - 101.03 3.48 
5 RP - 145.01 3.47 ýF 
1 RP + 121.06 3.95 f PM 
2 HILIC + 190.11 12.33 f PM 
Time of 3 RP + 114.90 2.45 f AM (PM = 0) Collection 
4 RP + 152.01 2.80 f PM 
5 RP + 283.16 5.57 iAM 
1 HILIC + 84.93 14.52 
(31-40/41-61) 
> (21-30) 
2 RP - 231.01 4.12 
(41-61) > 
(21-30/31-40) 
Age (41-61) > 3 RP + 433.23 6.42 (21-30/31-40) 
4 RP + 176.09 6.67 ft (31-40/41-61) 
5 RP + 217.13 6.92 ft(41-61) 
Each of the three developed PLS models all used a mixture of variables deriving from 
different separation and ionisation method data (table 3.6.8). The fact that each 
model utilises variables from each of the four single datasets, highlights the fact that 
by not attempting to increase the coverage of the components within a biofluid, there 
is the potential to miss many variables that may be important to a model's 
development, and therefore the question being asked. 
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3.6.4. Variable analysis using CID tandem MS 
Identifying the ions giving rise to the variables generated by each of the developed 
models in section 3.6 was carried out using CID tandem MS. A selection of four urine 
samples was chosen for analysis based upon differences in gender, time of collection 
and age. Each of the four samples were analysed using the two modes of ionisation 
and both separation methods, RP and HILIC. Each of the most important variables 
for each model were added to an `include list' within Analyst QS's independent data 
acquisition (IDA) setting, meaning that when an ion with a retention time and mass 
that corresponds to one in the `include list' is detected, it is isolated and subjected to 
CID product ion analysis. A total of the four most intense peaks could be analysed 
using two different collision energies from any one `survey scan'. 
Upon analysis of the resulting data for each of the samples from each separation and 
ionisation mode, it became clear that many of the masses added to the 'include list' 
did not fragment (or were not isolated at intensities sufficient for CID product ion 
analysis), leaving just the precursor ion present in the spectrum. Unfortunately, this is 
a problem with the QStar's Analyst QS software, where the most intense peaks are 
first selected for CID tandem MS analysis at the selected collision energies, with an 
MS 'survey scan' being run in between each tandem MS step; this can result in some 
ions not being selected for CID, despite being present on the 'include list'. 
The product ions that were generated on CID tandem MS analysis of the precursor 
ions from the variable lists, and the m/z values of ions identified as variables and 
corresponding to metabolites within the Human Metabolite Data Base (HMDB, 
(Wishart et al., 2007))' or Metlin2 database, are presented in table 3.6.9: 
1 http: //www. hmdb. ca (accessed November 2007). 
2 http: //metlin. scripps. edu (accessed November 2007). 
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Table 3.6.9. A table showing precursor ions that were isolated and subjected to CID 
tandem MS analysis, and m/z values of ions that were identified as variables and 
correspond to metabolites in either HMDB or Metlin. (n/d = not detected in CID 
analysis. n/r = not recorded, meaning no fragment ions were observed). 
Separation 
Method 
Statistical 
Model 
Ionisation 
Polarity R 
Precursor 
Ion Mass 
(Milz) 
Product Ions (miz) 
Product 
Ion 
Spectrum 
n 
Appendix 
C 
Posit e 15.47 497.2 321.1 303.2 186.1 1.0 
3.48 101.0 n1r - 
Gender i 3.47 145.0 n1r - ve Negat 15.23 541.2 429.1 145.1 2.0 
15.45 495.2 357.0 267.0 260.1 181.1 3.0 
Positive nid aid aid - 
RP Time of 2.95 173-0 n1r - Cotlection Negative 2.95 111.0 n1r - 
3.75 135.0 n1r - 
Positive 8.90 197-1 n1r - 
A 8.90 196-1 n1r - ge Negative 11.82 
1 
180.1 n1r - 
1- 3.92 391.1 
291.1 195.1 129.0 97.0 69.0 4.0 
G d 
Positive 2.55 206.0 air - er en Ne ative 5.40 74.0 n1r - 
P 9.37 290.8 n1r - 
I IC 
rime of 
ll ti C 
osit ve 9.37 206-8 n1r - H L on o ec Negative aid aid n/d - 
3.33 197-0 aid - 
Age Positive 7.50 204.0 n1r - 
Negative 5.38 275.0 n/r - 
Appendix B contains the CID tandem MS spectra of any precursor ions which 
produced fragment ions upon CID. 
As the QStar Q-o-ToF MS can only provide accurate mass measurements to 2 d. p. 
at best for a well calibrated machine', it is not possible to confidently assign atomic 
compositions to precursor (and fragment) ion masses that do not correspond to a 
metabolite within one of the databases; this is often the case with metabonomic 
studies where, without the ability to obtain accurate masses (to 4 d. p. with mass 
accuracy below 1 ppm) or have access to comprehensive databases or search 
engines (such as those used for proteomic studies), the identification of metabolites 
remains the hardest goal to achieve. 
The unidentified precursor ion at m/z 497 (appendix B1) is accompanied by a peak 2 
Th higher, suggesting the presence of chlorine in the compound. The loss of 18 Th 
from one of the fragment ions at m/z 321 is consistent with the subsequent loss of 
water from this fragment ion. 
1 Using internal standards. 
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The precursor ion at m/z 101 did not produce any structurally diagnostic fragment 
ions at either collision energy used. However, upon searching the databases, a 
matching mass was found with 2-oxobutyric acid. This metabolite is involved in the 
metabolism of the amino acids Gly, Ser and Thr, and has previously been detected in 
human urine as an endogenous metabolite (Liebich et al., 1981). Another metabolite 
that failed to produce any fragment ions, but has a mass that corresponded to a 
metabolite found upon a database search was the precursor ion at m/z 145. This 
mass could correspond to the metabolite oxoglutaric acid. Oxoglutaric acid is 
involved in the Krebs cycle and also in amino acid metabolism and is an endogenous 
metabolite found in urine (Lee et al., 1998). 
The two ions at m/z 541 and 495 (appendix B2 and 3) both produced fragment ions. 
However, their masses did not correspond to any metabolites contained within either 
of the databases, and the lack of more accurate mass data means that it is not 
possible to assign atomic compositions to the fragment ions, making it very difficult 
for a structure to be postulated. 
Guneral and Bachmann have previously detected metabolites in human urine which 
gave deprotonated molecules at m/z 173 and 135 (Guneral and Bachmann, 1994). 
These corresponded to cis-aconitic acid, related to the Krebs cycle, and threonic 
acid, a by-product of the oxidation of ascorbic acid. The ion at m/z 111 could 
correspond to uracil, a compound that has many uses within the body. Uracil is found 
in RNA, can react to form nucleosides, and has previously been detected in urine as 
an endogenous metabolite (Jiang et al., 2001; Hofmann et al., 2003). 
A metabonomic study by Williams et al. of development and ageing of rats proposed 
two possible atomic compositions of C7H1704S and C4H13N405 (RMM = 197) for an 
ion they detected in negative ionisation mode that was discriminatory of age 
(Williams et al., 2005). The ion also detected in this study at m/z 196 (table 3.6.9) in 
negative ionisation mode (corresponding to a mass of 197 Da) as an important 
variable for discrimination by age, could correspond to the same component that 
Williams et al. detected. 
The remaining precursor ion at m/z 391 (appendix B4), which produced fragment 
ions, did not correspond to any metabolites within any of the databases; without more 
accurate mass data, no atomic structure can be postulated. 
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The precursor ion of m/z 206 could correspond to an ion of the same m/z value 
detected by Lenz et al., Plumb et al., and Hodson et al. (Lenz et al., 2004; Plumb et 
al., 2005; Hodson et al., 2007). Research by Plumb et al. and Hodson et al. showed 
that an ion of m/z 206 detected in positive ionisation mode contributed significantly to 
clustering based upon discrimination according to gender (Plumb et al., 2005; 
Hodson et al., 2007). The ion observed in this study at m/z 206 was detected in the 
positive ionisation mode, and was an important variable for discrimination according 
to gender, in agreement with the results of Plumb et al. and Hodson et al. Lenz et al. 
determined that the ion of m/z 206 corresponded to the metabolite 4,8- 
dihydroxyquinoline-2-carboxylic acid, which is part of the tryptophan catabolism 
pathway (Lenz et al., 2004). 
The only remaining precursor ion that corresponded to a metabolite within either of 
the databases gave a deprotonated molecule at m/z 74, which is postulated to 
correspond to the amino acid Gly, an endogenous metabolite in human urine (Bales 
et al., 1984). 
3.6.4.1. Discussion 
Despite the lack of more accurate mass data which may have led to an increased 
confidence in the postulated metabolites identified within this study, the postulated 
metabolites that were identified as discriminatory for gender, time of collection and 
age have all previously been identified as endogenous metabolites in urine. The ion 
at m/z 206 that was highly discriminatory for gender, which has previously been 
identified as a metabolite that can be used to discriminate based upon gender in two 
studies (Plumb et al., 2005; Hodson et al., 2007), suggests that the models 
developed were robust and consistent with previously published metabonomic 
research. 
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3.7. Discussion 
The work presented in Chapter Three covers many topics that are involved in an LC- 
MS metabonomic study. The various platforms available for a metabonomic study 
were discussed and evaluated for the contributions that each method can provide. It 
is clear that whilst the majority of studies choose to focus on one particular method, 
be it LC-MS (Wilson et al., 2005; Sumner, 2006; Chen et al., 2007) or NMR (Lenz et 
al., 2000; Constantinou et al., 2005; Bertram et al., 2007), the future of metabonomic 
studies lies with the use of both NMR- and MS-based analyses where all of the data 
generated are compared together to provide the most comprehensive analysis 
possible (Forshed et al., 2007a; Forshed et al., 2007b). 
As metabonomic studies tend towards a `comprehensive' fingerprint of the biofluid 
chosen for analysis (Lenz and Wilson, 2007), the consideration of how samples are 
collected, stored and manipulated is of paramount importance. However, this is an 
area that is often overlooked or poorly considered within the literature. The results 
presented within section 3.3 are in good agreement with similar studies described in 
the literature (LeBeau et al., 2001; Schneider et al., 2002; Fura et al., 2003; Gika et 
al., 2007; Saude and Sykes, 2007). Samples should be stored, preferably at -80 °C, 
as soon as possible after collection and allowed to remain frozen for a period of at 
least one week to allow the degradation of compounds to be consistent across the 
sample cohort (Saude and Sykes, 2007), with any sample manipulation kept to an 
absolute minimum. Samples should just be centrifuged and filtered prior to LC-MS 
analysis to maximise the metabolite content of urine samples (avoiding the inevitable 
loss of analytes using extraction methods such as solid phase extraction) (Gika et al., 
2007). 
As LC-MS systems are renowned for poorer reproducibility than NMR, the system as 
a whole should be allowed to equilibrate by the analysis of a minimum of three 
reference samples (e. g. aliquots of a urine pool), and continually monitored by the 
inclusion of reference samples throughout the run; this was also proposed in very 
recently published research by Gika et al. (Gika et al., 2007). 
Despite being a vitally important step, the approaches to extraction of raw data into a 
usable format for subsequent statistical analysis has received comparatively less 
attention than the rest of the field of metabonomics. Research by Sangster et al. 
showed that problems with extraction algorithms led to problems with the resulting 
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extracted data (Sangster et al., 2007); this was also clear in this study in the results 
presented in section 3.4. 
The statistical analysis of metabonomic data (section 3.5) is one of the most 
important steps in a metabonomic study, after producing `good' data in the first 
instance. Statistical tools such as PCA and PLS have made the analysis of large, 
complex datasets easier, and available to all. Because of the ease of use of 
statistics, spurious results can be easily generated where naivety leads to the 
generation of a hypothesis being generated that is proved using poor, undeveloped 
statistical models. At the very least, discriminative models built using PLS should be 
developed using only -2/3 of the data, and subsequently refined by the removal of 
unimportant variables. Once a statistical model has been refined and developed, the 
remaining -r1/3 of the withheld data should be analysed using the developed model to 
evaluate the `true' predictive ability of the developed model. However, there are many 
other considerations that need to be evaluated when statistics are involved, ranging 
from scaling methods to normalisation. 
Many metabonomic studies have used creatinine to provide some degree of 
normalisation of differences in the concentration of urine samples prior to statistical 
analyses (Woitge et al., 1999; Schoenau and Rauch, 2003; Huskov6 et al., 2004; 
Idborg et al., 2004; Svoboda and Kasai, 2004; Obrant et al., 2005). However, 
normalisation using total ion count (originating from NMR studies (Kenney and 
Shockcor, 2003; Antti et al., 2004; Williams et al., 2005)) appears also to be 
becoming a more accepted method of normalisation in LC-MS studies (Plumb et al., 
2003; Williams et al., 2005). Reading the literature, it became very evident that very 
little consideration has been given to the consequences of using creatinine for 
normalisation, as studies into the effects of internal and external factors showed that 
excreted levels of creatinine are easily perturbed (Boeniger et al., 1993; Schoenau 
and Rauch, 2003; Antti et al., 2004; Heavner et al., 2006). This was evidence that the 
use of creatinine to provide normalisation for metabonomic studies may be an 
outdated way of doing so, and is an area that definitely requires further research. 
The main aim of Chapter Three was to evaluate a HILIC separation method for the 
retention of more polar compounds from urine samples. HILIC is an orthogonal 
separation method to RP, and was shown to provide an increased coverage of 
different metabolites from urine by the development of robust statistical models that 
used completely different variables than models developed using RP-LC-MS data. 
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This highlighted the fact that much information has potentially been missed when 
only RP as a separation method has been employed for metabonomic studies. The 
use of HILIC is quite rightly beginning to find a place in metabonomic studies (ldborg 
et al., 2005; Kind et al., 2007; Mawhinney et al., 2007) as the field demands an 
increasing amount of information from biofluids. 
Despite the lack of more accurate mass measurements, variables being identified 
and the poor success rate of CID tandem MS analysis, there were a number of 
masses that were identified from both database searches and previous metabonomic 
studies into urine samples. Each of the putative assignments correlated well with 
components previously identified in human urine, with two variables being detected in 
this metabonomic study as being important for discrimination by age and gender, that 
have also been identified in other studies. 
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3.8. Conclusions 
The work presented in this chapter has highlighted the fact that metabonomics is still 
an immature field, with much potential for important scientific discoveries to be made. 
However, due to the immaturity of the field, there is still much that needs to be 
researched and standardised if LC-MS-based metabonomics is to stand a chance of 
becoming a mature, robust and commonly utilised `omic' approach. 
It has been shown that metabonomic experiments are typically poorly reported within 
the literature, with many vitally important experimental aspects either not reported or 
not carried out at all. The recommendations from this chapter are that metabonomic 
studies are first carefully thought through before sample collection begins. When a 
study has been developed, samples should be carefully collected, stored 
appropriately for a pre-determined period of time (at least one week to allow the 
degradation of compounds to be consistent across all samples), and subjected to 
minimal freeze/thaw cycles and manipulations. 
Samples should only be centrifuged and filtered prior to analysis using LC-MS. For 
LC separation, orthogonal separation methods (RP and HILIC) should be utilised to 
increase the coverage of the urinary metabolome and thus the amount of information 
obtained. LC-MS systems should be allowed to equilibrate by the initial analysis of at 
least three reference samples (e. g. aliquots of a urine pool), and subsequently 
monitored by the inclusion of reference samples throughout the randomised urine 
samples. 
Data should be not be normalised according to creatinine concentrations, due to the 
perturbation to concentrations caused by internal and external factors (such as 
therapeutic interactions, disease and growth), but instead to total ion count. The 
resulting normalised data should be carefully analysed using both PCA and PLS 
statistical methods. The data should first be analysed using PCA to view the 
maximum variation in the dataset, and to explore any outliers that may be present. 
Subsequent discriminative analysis by PLS should be undertaken on _2/3 of the 
dataset, with any unimportant variables being removed from the model. The 
optimised PLS model should then be evaluated using the remaining _1/3 of the 
dataset that was held back and not used to build the model; this determines the 
model's 'true' predictive ability. 
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As the field develops, a more comprehensive `global' analysis of biofluids should be 
sought, where all of the data generated are integrated together and analysed as a 
whole, becoming the norm, rather than the exception. 
The conclusions from the work presented in this chapter were used for the 
subsequent LC-MS metabonomic analysis of clinical urine samples from patients 
who had suffered a fracture. 
3.8.1. Retrospective view 
From the work undertaken within this chapter, and with the knowledge gained, it has 
become clear that obtaining larger sample cohorts would be a benefit allowing a 
greater number of samples to be held back to form the external test set. Holding back 
roughly 1/3 of a small data set means that the data available to build a robust model 
may not be sufficient, let alone large enough to allow the external test set to 
thoroughly test any developed model. 
Obtaining more information from the volunteers would have allowed further 
investigation into the potential information contained within this biofluid: 
" Dietary intake prior to donation 
" Height / weight 
" Physical activity levels 
" Ethnic origin 
" Drug intake 
The use of NMR for the analysis of the samples would have allowed a further 
orthogonal detection approach, and would have allowed an interesting comparison of 
any results obtained to be undertaken. 
Collaborating with statisticians to analyse any resulting data more thoroughly would 
be of great benefit, as a more critical approach to the analysis of metabonomic data 
could then be sought. 
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4.1. Introduction 
The skeletal system within the human body performs a vital role, as it supports 
muscle, protects vital organs and stem cells, and is a vast reserve of ions. Despite 
their strength, given the very nature of human activity, bones do fail and fractures 
occur. As bones are continuously being renewed, they exhibit an amazing ability to 
repair themselves and regain their original strength, usually without scarring. In spite 
of the body's ability to repair itself after a fracture, there are times when a fracture 
takes much longer to heal than normal (delayed fracture), or may not heal at all (non- 
union). 
Fractures that are delayed or go to non-union (failed fracture healing) require further 
medical intervention, putting patients through further stress and increasing the time 
until their fracture has successfully healed. Whilst much research has been 
undertaken studying biofluids for biomarkers that relate to pathological fractures such 
as osteoporosis (Calvo et al., 1996; Woitge et al., 1998; Chapurlat et al., 2000; 
Ebeling and Akesson, 2001; Srivastava et al., 2002; Garnero and Delmas, 2003), 
there have been very few studies published regarding non-pathological fractures 
(Severns et al., 2003; Henle et al., 2005; Zimmermann et al., 2005). Of the research 
undertaken to attempt to elucidate biomarkers of bone resorption/formation, the 
overwhelming majority use serum samples and try to identify biomarkers (Chapurlat 
et al., 2000; Yu-Yahiro et al., 2001; Srivastava et al., 2002, Henle et al., 2005; Li et 
al., 2005; Asaba et al., 2006); few papers describe studies that have used urine as a 
biofluid, but those that have, are targeted studies of known breakdown products of 
large proteins e. g. telopeptides and collagen cross-links (Chapurlat et al., 2000; Yu- 
Yahiro et al., 2001; Qvist et al., 2002; Srivastava et al., 2002; Garnero and Delmas, 
2003; Lamers et al., 2005). 
To my knowledge, no research has been undertaken using a metabonomic approach 
for the analysis of clinical urine samples from patients whom have sustained a non- 
pathological fracture. In collaboration with Smith & Nephew (Research Centre, York 
Science Park, York, UK) and York NHS Hospital Trust (York, UK), urine samples 
were collected from patients who had suffered a fracture, with a view to analysing the 
samples to hopefully identify biomarkers that relate to failed fracture healing. The 
ultimate aim was to identify candidate biomarkers that could be tested as early 
urinary predictors of fracture healing in order to investigate the possibility of early 
identification of patients whose fracture will result in delayed/non-union. 
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To avoid any chance of pathological fracture patients being included in the study, or 
those with incomplete skeletal development, all recruited patients were between the 
ages of 18-45. Initially, only long bone fractures were considered, but due the slow 
recruitment of patients suffering from long bone fractures, wrist and ankle fractures 
were also included in the study as it progressed. Further exclusions were any 
patients who had suffered multiple injuries, had malignancy, head injuries, 
spine/foot/hand fractures, pregnant or nursing mothers and any unconscious 
patients. 
During the recruitment period (October 2004 to February 2005) a total of 61 patients 
were deemed suitable for inclusion into the study (45 males and 16 females); of 
these, 11 declined consent stating either lack of interest or a needle phobia', with a 
further two patients withdrawing consent at a later date, and one being transferred 
into the care of another health trust. This left a total of 48 patients (36 males and 12 
females, with an age range of 19 to 47 years old; average age = 29.5, standard 
deviation = 8.2), who each donated between one and four urine samples, ranging 
from a period of t=0 (time of fracture) to 133 days (19 weeks) after the initial fracture 
(average =6 weeks). All of the samples were labelled randomly, shuffled, 
transported from York Hospital to Smith & Nephew, where they were stored in a 
semi-organised, partially catalogued state at -80 °C until the recruitment period 
finished. 
1 Serum samples were also collected for a parallel study by Smith & Nephew into serum markers related 
to fracture repair; any patients with needle phobia were excluded from the trial. 
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Table 4.1. Summary of fracture types, breakdown by gender and number of samples 
obtained. 
Fracture Type 
I No. of 
Patients 
Gender Total No. 
of Urine Male Female Samples 
Ankle 21 15 6 51 
Wrist 10 6 4 24 
Fibula 2 2 0 5 
Radius 2 2 0 5 
Tibia/Fibula 3 2 1 4 
Tibial Plateau 1 1 0 4 
Clavicle 3 3 0 3 
Radial Head 2 2 0 3 
Ulna 1 1 0 3 
Radius/Ulna 1 1 0 2 
Gr. Tuberosity of 1 0 1 2 Humerus' 
Pilon 1 1 0 1 
Total 48 36 12 107 
The largest sample cohorts obtained were not from long bone fractures, but from 
ankle and wrist fractures (table 4.1), with a total of 51 and 24 samples obtained 
respectively. After all of the samples were collected and (de)coded, they were each 
defrosted at room temperature before being aliquotted into 0.5 mL microcentrifuge 
vials and then refrozen to await analysis by ESI-LC-MS. Some samples were of 
sufficient volume to allow up to 13 aliquots to be produced, whereas some only 
afforded three aliquots (average number of aliquots from each of 107 samples = 8). 
All obtained data relating to the clinical urine samples are presented within appendix 
C. 
1 Greater tuberosity of humerus refers to the fracture of the head of a humerus. 
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4.2. Aims 
The aim of this work was to utilise all of the developed `metabonomic tools' described 
in chapter three to comprehensively analyse the obtained clinical urine samples by 
both positive and negative ionisation modes and reversed phase and hydrophilic 
interaction LC-ESI-MS. The resulting data were analysed using PCA and PLS to 
attempt to elucidate potential biomarkers that could be putatively linked to failed 
fracture healing', hopefully generating candidates for further research into the field, 
with an envisaged end goal of developing early tests for possible failed fracture 
healing, thus allowing earlier intervention and shorter healing times. 
1 Unfortunately, post-analysis of the clinical urine samples, it was found out that none of the recruited 
patients fractures went to non-union, or suffered delayed healing. Despite this, the resulting data 
obtained was analysed to attempt to elucidate potential biomarkers that could putatively be related to 
the fracture healing process instead. 
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4.3. Results from RP-LC-ESI-MS analysis of clinical samples 
Prior to analysis by positive and negative RP- and HILIC-LC-ESI-MS, the aliquotted 
clinical urine samples were removed from storage at Smith & Nephew (-80 °C) and 
placed in a container with dry ice, for transport to the Departments of Chemistry or 
Biology. As there were limited aliquots available from the clinical samples, pooled 
urine samples were created from the urine samples collected from volunteers from 
within the Department of Chemistry. These 'pool' samples were used for system 
equilibration and ongoing system stability monitoring. All optimised methods from the 
'metabonomics toolbox' (chapter three) were employed for all analyses described 
within this section. For the RP-LC-MS analysis of clinical urine samples, each sample 
was defrosted at room temperature, vortex mixed, centrifuged and then filtered to 
remove any remaining sediment before being transferred into LC autosampler 
sample vials, ready for analysis. 
4.3.1. Positive mode RP-LC-ESI-MS analysis of clinical urine samples 
The LC-MS system was equilibrated by the injection and separation of three identical 
pooled urine aliquots. The TICs shown in figure 4.3.1 all follow the same trend, 
except the first TIC (blue line) that shows some deviations in peak intensity (indicated 
by arrows) from subsequent pooled sample TICs. The observed deviation for the first 
pooled sample was expected from previous results (chapter 3.3) as the LC-MS 
system equilibrates; as subsequent TICs all followed the same trend with no 
deviation in intensity or retention time, the system was considered equilibrated and 
thus ready for the analysis of clinical urine samples. 
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Figure 4.3.1. Five overlaid TICs from positive mode RP-LC-MS analysis of five 
pooled urine samples; three back-to-back analyses carried out at the very start of the 
analysis to monitor system equilibration, and two subsequent analyses for ongoing 
system stability monitoring. The arrows indicate areas where the first pooled samples 
TIC (blue line) deviate from subsequent TICs. 
So that samples suffered minimal possible degradation, only 10-14 samples were 
defrosted and prepared for analysis at any one time. Subsequent sample batches 
were prepared and loaded into the autosampler as the analysis proceeded. Pooled 
samples and random repeats of clinical samples were included throughout data 
collection, meaning a total of 130 samples were analysed (3.5 days of analyses). 
After the analysis of all samples, the raw data were extracted using the metabolomics 
export script (Applied Biosystems) to form a matrix for import into Excel (Microsoft 
Excel for Mac 2004), where data relating to each sample were added into a 
spreadsheet, before being subsequently imported into SIMCA P+ v11.5 (Umetrics, 
Sweden) for statistical analysis. 
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Figure 4.3.2. (a) PCA scores plot of positive mode RP-LC-MS data (  = samples 
from males, "= samples from females and "= pooled samples). (b) PCA scores 
plot of pooled samples only, the arrow indicates the first sample analysed, with the 
hashed line indicating the order of sample analysis. 
The initial PCA of all samples analysed by positive mode RP-LC-MS is shown in 
figure 4.3.2a. The PCA scores plot shows a tight cluster between 0 and -20 on both 
axes (PC 1 and PC 2), with all female data points within this cluster (red diamonds, 
masked by male data points), and the majority of the male data points (black 
squares). The remaining male data points are either outside the 95 % confidence 
limit (shown by an oval in the scores plot) or are far away from the bulk of the data in 
the tight cluster. The pooled samples (blue dots) appear to cluster apart from the 
samples analysed before any of the clinical samples (grouped at -100 on PC 1 and 
-50 on PC 2). This trend was unexpected, as the pooled samples should reside 
within the same area upon a PCA scores plot, given that they are the same sample 
just analysed a number of times. 
PCA analysis of the data from just the pooled samples displayed a 'U' shape in the 
resulting scores plot (figure 4.3.2b) when the points were joined up in order of 
analysis (shown by a hashed line). The arrow indicates the three initial equilibration 
injections, which all form a tight cluster, with subsequent pooled samples moving 
away from this point. Visual inspection of the TICs of the initial injections did not 
highlight any substantial differences (figure 4.3.1), which is why the initial samples 
form a tight cluster. However, TICs of later injections of the pooled samples illustrate 
the reason for the `U' trend observed in the scores plot. 
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Figure 4.3.3. Three TICs from positive mode RP-LC-MS analysis of pooled urine 
samples. The blue TIC was from the initial analysis, with the green and red TICs 
obtained towards the end of sample analysis. The hashed double-headed arrow 
shows a large shift in the retention time of the most intense peak, and the solid arrow 
shows the severe reduction in intensity for an intense set of peaks. 
Figure 4.3.3 shows superimposed TICs from three injections of the pooled sample. 
The blue TIC is from one of the initial injections run prior to the analysis of clinical 
samples, and the green and red TICs correspond to analyses towards the end of 
data acquisition (-3.5 days) to highlight the large shifts in retention time and peak 
intensity. The green and red TICs show a significant difference from the original TIC, 
with substantial deviation (-3 min) in retention time of the most intense peak 
indicated by the hashed double-headed arrow, and the disappearance of an intense 
set of peaks highlighted by the solid arrow. The large deviations in retention time and 
intensity occurred gradually, with a systematic drift in both the retention time and 
intensity of the peaks over the 3.5 day acquisition period; this means that some 
peaks that were present in the extracted data for the initial pooled sample injections 
would fail to be present in subsequent injections (an increasing number of peaks 
were `lost' as time progressed). The systematic deviation in retention time and peak 
intensity explains the `U' shaped trend present in the PCA scores plot for the 
analyses of the pooled sample (figure 4.3.2b). 
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The cause of the shifts in retention time and intensity was consistent with column 
degradation/contamination, which would cause large shifts in the retention time and 
peak intensities. Despite the trend observed for the pooled sample analyses, the 
male `outliers' in the scores plot in figure 4.3.2a do not correspond to samples 
analysed later in the run, nor do they follow any time related trend (sample analysis 
order shown by numbers along the x-axis in figure 4.3.4b); the random analysis of 
samples controls for this, meaning that these samples did not form part of the tight 
cluster for another reason. 
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Figure 4.3.4. (a) PCA scores plot of positive mode RP-LC-MS data (  = samples 
from males, f= samples from females), with all samples outside of the tight cluster 
labelled (see appendix B). (b) Corresponding DModX plot of the data, where data 
points above the red line (95 % confidence limit) have large distances from the 
model. 
PCA of the clinical samples (without the pooled sample data) results in more data 
points lying outside the 95 % confidence limit (figure 4.3.4a), compared to PCA of all 
analyses (figure 4.3.2a); again, there is a tight cluster containing the bulk of the data. 
When the data presented in figure 4.3.4a were viewed in 3D (not shown), the tight 
cluster containing the bulk of the data points formed along the same plane, with 13 
data points lying outside of (or close to) the 95 % confidence limit on a different plane 
to the bulk of the data. This is highlighted by the many data points above the 95 % 
confidence limit (red line) in the corresponding DModX plot (figure 4.3.4b), where the 
majority of the labelled data points correspond to those labelled in the scores plot 
(figure 4.3.4a); the few additional data points above the confidence limit correspond 
to a few samples that were not outliers in the PCA scores plot, but were slightly 'out 
of plane' from the bulk of the data. 
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Figure 4.3.5. (a) PCA scores plot of positive mode RP-LC-MS data (  = samples 
from males, f= samples from females), with all data points that were labelled in 
figure 4.3.4a removed. (b) Resulting PLS analysis of positive mode RP-LC-MS data 
(again with all data points that were labelled in figure 4.3.4a removed) for a gender 
response variable (  = samples from males, f= samples from females). 
To further investigate these trends, the data points with large DModX values (above 
the 95 % confidence limit, figure 4.3.4b) that also corresponded to the labelled data 
points in figure 4.3.4a were removed; thus PCA was performed on the data sets 
forming the tight cluster. The resulting PCA scores plot (figure 4.3.5a) shows a well 
defined trend within the data; many data points cluster together, with some data 
points tailing off at values lower than -10 along PC 1. Nothing in the information 
obtained on the patients could be used to explain the effects observed in the first two, 
and any subsequent, PCs. The clustering observed even with the `outlying' samples 
removed, shows a systematic drift of the data. This was further shown when PLS 
analysis of the whole data set (excluding pooled samples) failed to discriminate by 
gender (figure 4.3.5b); this should have been easily obtained as was shown in 
chapter 3.6. 
As for PCA, there is a cluster containing the bulk of the data (both male and female 
data points), with other data points moving away from the cluster and spreading out. 
Surprisingly, even when all variables were used to build the PLS model, there was no 
apparent clustering based upon discrimination by gender. The data points from 30 to 
110 along the first latent variable (LV) correspond to the 13 data points that had large 
DModX values and were close to, or outside of, the 95 % confidence limit in the 
original PCA scores plot (figure 4.3.4). 
Given that the data obtained were unsuitable for subsequent analysis due to the 
unacceptable drifts in both retention times and peak intensity, shown by the 
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systematic drift in the pooled urine sample injections upon PCA (figure 4.3.2b), and 
the inability to obtain clustering according to gender using PLS. The unfortunate 
conclusion was that the analysis was flawed, probably due to degradation of the 
HPLC column. Therefore, It was decided to analyse the clinical samples using a new 
RP column. 
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4.3.2. Negative mode RP-LC-ESI-MS analysis of clinical samples 
The new column (and LC-MS system) was equilibrated and tested by the analysis of 
five aliquots of the pooled urine sample before the analysis of any clinical urine 
samples. As for positive mode RP-LC-MS analysis, the first aliquot analysed 
exhibited a TIC that was marginally different from the four subsequent near-identical 
TICs (not shown). 
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Figure 4.3.6. (a) PCA scores plot of negative mode RP-LC-MS data (  = samples 
from males, "= samples from females and "= pooled samples). (b) PCA scores 
plot of pooled samples only, the solid black arrow indicates the first sample analysed 
and the hashed red arrow the sixth, with the hashed line indicating subsequent 
sample analysis. 
The PCA scores plot for the analysis of extracted negative mode RP-LC-MS data is 
shown in figure 4.3.6a, and includes both the clinical and pooled sample data. The 
pooled sample data points cluster in the lower left hand side of the scores plot, with 
far less variation between samples than for the positive mode RP-LC-MS data (figure 
4.3.2a); this suggests that whilst there is some variation between repeat injections of 
the pooled sample, on the whole, the system was more stable than observed in the 
positive mode RP-LC-MS analysis. The clinical data show two distinct clusters, a 
small tight cluster (centered around 20 and 0 on PCs 1 and 2 respectively) that 
contains the bulk of the data points (all female samples and the majority of the male 
samples), with the remaining samples forming a loose cluster between -40 and -80 
onPC1. 
Analysing the data points from the pooled urine sample injections by PCA shows a 
trend within the data (figure 4.3.6b); the first few analyses (before the analysis of any 
clinical samples, with the first sample indicated by the solid black arrow) were similar, 
due to their close proximity to one another in the scores plot. The subsequent pooled 
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urine sample data points (indicated by a hashed red arrow) show an instant shift in 
position from the initial data points; after the initial shift, a more stepwise trend is 
observed. The PCA of positive mode RP-LC-MS data from pooled samples (figure 
4.3.2b) showed a more stepwise pattern from the beginning, than that observed for 
negative mode RP-LC-MS data. 
Despite the trend observed upon PCA of the pooled sample data, the initial cluster 
observed in the PCA scores plot of all data analysed by negative mode RP-LC-MS 
was much tighter than that observed for positive mode RP-LC-MS data, suggesting 
that negative mode RP-LC-MS data analysis produced slightly more reliable results 
(the TICs over the whole run exhibited less shifting in retention time and intensity 
than for the previous analysis). Analysing the pooled sample aliquots by PCA on their 
own only gives an idea of any trends, as PCA by definition seeks to find the most 
amount of variation between data points. Given that there are many thousands of 
variables in each dataset, the pooled sample injections' data points would not overlay 
due to minor variations within the dataset; PCA maximises these variations, thus 
'increasing' the observed variation when pooled sample data are analysed using 
PCA. 
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Figure 4.3.7. (a) PCA scores plot of negative mode RP-LC-MS data (  = samples 
from males, f= samples from females), with all samples outside of the tight cluster 
labelled (see appendix B). (b) Corresponding DModX plot of the data, where data 
points above the red line (95 % confidence limit) have large distances from the 
model. 
When only the clinical sample datasets were analysed using PCA, the resulting 
scores plot (figure 4.3.7a) shows a tight cluster and a loose cluster, with samples 
spread over a broad range of values along the second PC. The majority of the 
labelled samples are outside, or very close to, the 95 % confidence limit. The labelled 
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data points all correspond to those labelled in the PCA from positive mode RP-LC- 
MS data (figure 4.3.4a). The corresponding DModX plot (figure 4.3.7b) shows many 
samples above the confidence limit; these samples correspond to those labelled in 
the corresponding PCA scores plot, again showing that these data points are 
`different' to those in the tight cluster. 
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Figure 4.3.8. (a) PLS scores plot of negative mode RP-LC-MS data for a gender 
response variable (  = samples from males, f= samples from females), with all 
clinical data points included. The shaded ellipse contains all 12 samples that are 
`different' from the bulk of the data. (b) Resulting PLS analysis of negative mode RP- 
LC-MS data (with all data from the shaded area in (a) removed) for a gender 
response variable (  = samples from males, f= samples from females). 
The PLS scores plot for negative mode RP-LC-MS data (two thirds of all clinical data 
points, but not the pooled urine injections included) shows one long cluster between - 
10 and 20 along the first LV, and a large cluster below -50 along the first LV, 
highlighted by a shaded ellipse (figure 4.3.8a). The long cluster corresponds to the 
bulk of the data and contains all of the data points that also fell within the tight cluster 
observed in the PCA scores plot (figure 4.3.7a). In contrast to the PLS analysis of 
positive mode RP-LC-MS data, the PLS scores plot of negative mode RP-LC-MS 
data shows some degree of clustering based upon gender. The data points within the 
shaded ellipse all correspond to the labelled 'outliers' within the corresponding PCA 
scores and DModX plots (figure 4.3.7a and b). 
Figure 4.3.8b shows the resulting PLS scores plot for a gender response variable 
when the initial model (figure 4.3.8a) was optimised by the removal of unimportant 
variables; there are two overlapping clusters that relate to samples obtained from 
male and female patients (in contrast to the PLS analysis of positive mode RP-LC- 
MS data, where no developed model could discriminate by gender). The data points 
from the shaded ellipse (figure 4.3.8a) no longer cluster apart from the bulk of the 
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data, but now form part of the cluster containing data points corresponding to male 
patients. 
The external classification using the third of the dataset that was held back gave an 
external classification rate of 42 %, which is very low compared to 88 % obtained 
using negative mode RP-LC-MS analysis of urine samples collected from within the 
Department of Chemistry (chapter 3.6). This suggests that the variables used to 
develop the PLS model, yielding the separation shown in figure 4.3.8b, are not overly 
predictive of gender. However, despite the poor external classification rate for 
discrimination by gender, the fact that clustering based upon a gender response 
variable was observed showed some promise for the further analysis of the clinical 
samples. 
When HILIC-MS was used for the analysis of the clinical samples (section 4.6), the 
possible cause of the issues observed during the positive and negative mode RP-LC- 
MS analyses of the clinical samples became evident, and was thus investigated 
further. 
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4.4. Proteomic analysis of clinical urine samples 
Upon preparation of the clinical samples for analysis by HILIC-ESI-MS, they were 
diluted by addition of an equal volume of MeCN for injection onto the HILIC column. 
This had the effect of producing large amounts of precipitate in the majority of 
samples, something that was not observed with any of the pooled samples, or indeed 
any other urine samples analysed during the course of my PhD. Given that the RP 
gradient used for the analysis of the clinical samples utilised MeCN to elute 
hydrophobic compounds, the clinical samples, once injected onto the column, would 
have precipitated in the same manner on the column. This is proposed to be the 
cause of the systematic degradation of column performance seen as drifts in 
retention time and peak intensity over time observed on analysis of the clinical, but 
not the healthy volunteer samples (chapter three); the effects were most likely less 
evident for the negative mode RP-LC-MS analysis as this was carried out on a new 
column, which had therefore not suffered as much on-column precipitation as the 
column used for positive mode RP-LC-MS analysis. The level of precipitation caused 
by the addition of MeCN explained why, for the clinical samples, filtering was much 
harder (sometimes impossible) due to the increased viscosity; differences in surface 
tension were also observed between the clinical and pooled samples when 
transferring filtered urine into sample vials (clinical samples had a higher surface 
tension, clinging to the vials much more than the pooled urine sample). 
To test if the precipitate was protein, 10 pL of each of a random cross section of 
clinical samples were added to 200 pL of Coomassie solution (see 4.4.1); an 
immediate change from dull red to bright blue was observed, suggesting protein was 
present. To further test whether the clinical urine samples contained protein, 1D 
Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) was run, 
with only 5 pL each from two samples loaded onto the gel. 
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Figure 4.4.1. Coomassie stained 1D SDS-PAGE of two clinical urine samples (colour 
altered for clarity, red = higher concentration of protein). 
Following Coomassie brilliant blue staining, the 1D SDS-PAGE of the two clinical 
urine samples shows a heavily overloaded gel; positively staining material in both 
lanes has spread outside of their lane due overloading (figure 4.4.1). As bands 
relating to different proteins could not be resolved, the samples required dilution 
before any protein identification could take place. To allow dilution of the clinical urine 
samples to the correct concentration for SDS-PAGE analysis, each of the clinical 
samples was analysed using a Bradford assay to determine the concentration of 
protein present. 
4.4.1. Bradford assay of clinical urine samples 
The Bradford assay was first described by M Bradford in 1976 (Bradford, 1976), and 
is a semi-quantitative colourimetric protein assay. The principle behind a Bradford 
assay is the colour shift of Coomassie (a dye) from a dull red at 465 nm, to a bright 
blue at 595 nm upon binding of protein. Coomassie binds to protein through different 
interactions such as van der Waals forces and ionic interactions; hydrophobic 
aromatic amino acids such as Phe, Try and Pro also aid in binding, as does 
hydrophilic Arg (Compton and Jones, 1985). 
As the binding of Coomassie to protein occurs in a stoichiometric manner, the 
increase in absorbance at 595 nm is proportional to the concentration of protein 
within a sample. However, time related shifts in intensity occur, so the assay must be 
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completed in a timely fashion to avoid inducing error into the results obtained. 
Bradford assays are only linear over a small range of protein concentrations; typically 
125-1500 pg/mL dependent on the protein being bound (Zor and Selinger, 1996). A 
dilution series of a random selection of clinical urine samples showed that 5 pL in 
1000 pL H2O was sufficient for the majority of samples to fall into the linear range, 
thus highlighting how concentrated the protein was in some of the clinical samples. 
Two 10 pL portions of each diluted clinical sample were loaded into wells on a 96- 
well plate (providing a duplicate), along with duplicates of eight protein standards 
ranging from 0-1500 pg/mL, meaning a total of four 96-well plates were analysed 
(each 96-well plate therefore containing a full set of standards and a subset of clinical 
urine samples). 200 pL of Coomassie was loaded into each cell containing 10 pL of 
sample or standard, and then agitated for 30 s before being analysed by UV-Vis 
absorbance at 595 nm. 
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Figure 4.4.2. Standard curves for all four 96-well plate standard protein samples. 
Figure 4.4.2 shows four standard curves used for the determination of the 
1600 
concentrations for each clinical sample present on each 96-well plate. Each of the 
standard curves goes through the origin and yields the same y= mx equation (where 
196 
. 
0V 
0 200 400 600 800 1000 1200 1400 1600 
Conc Ng/mL 
0 
o 200 400 600 800 1000 1200 1400 1600 
Conc pg/mL 
Chapter Four: Clinical urine sample analysis 
m=0.0003), as well as having R2 values greater than 0.99, indicating an acceptable 
`goodness of fit'. 
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Figure 4.4.3. A graph plotting the protein concentrations of each clinical urine 
sample, as determined using the equation from each of the standard curves (figure 
4.4.2). 
Using the four standard curve equations (figure 4.4.2) to determine the protein 
concentration for each of the clinical samples, produced the graph shown in figure 
4.4.3. There are two tiers of protein concentrations observed for the clinical samples 
(figure 4.4.3); the bulk of the samples have a total urinary protein concentration in the 
range of -150 to 250 mg/mL, which corresponds to a -40 fold increase between the 
12 samples with urinary protein concentrations below 5 mg/mL. When the total 
urinary protein concentrations were further analysed, the 12 samples with 
concentrations less than 5 mg/mL corresponded to the samples that were `outliers' in 
both the positive and negative mode RP-LC-MS data PCA and DModX plots (figures 
4.3.4 and 4.3.7). The bulk of the data in the tight clusters on the positive and negative 
mode RP-LC-MS data PCA scores plots (figures 4.3.4a and 4.3.7a) correspond to 
the clinical samples with protein concentrations above 75 mg/mL (figure 4.4.3). 
Values for normal urinary protein excretion rates reported in the literature vary 
greatly. The most common value found was -150 mg/day total urinary protein 
excretion (Pisitkun et al., 2006; Tyan et at., 2006; Gonzalez-Buitrago et al., 2007). 
This clearly means that the level of protein excretion observed for the majority of the 
clinical samples was far from normal. In order to determine if there were one or more 
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types of protein present within the clinical samples, 1D SDS-PAGE analysis of a 
cross section of samples was performed. 
4.4.2.1-D SDS-PAGE analysis of clinical urine samples 
The 1-D SDS-PAGE analysis of proteins works by using polyacrylamide gel and a 
potential gradient to separate proteins based upon their charge and molecular weight 
(size). The polyacrylamide gel is cross-linked, with pore sizes determined by the 
amount of cross-linking; larger proteins take longer to migrate than smaller proteins, 
and the molecular weight (MW) range that can be separated is determined by pore 
size. Sodium dodecyl sulfate (SDS) denatures proteins by interacting with 
hydrophobic chains, and applies an overall negative charge to the protein; the 
negative charge is proportional to the mass of the protein, which is why 
polyacrylamide gel is used to `sieve' the proteins, giving separation; further 
denaturing is achieved by the addition of 2-mercaptoethanol and heating to near 
boiling, this reduces disulfide linkages and has the effect of creating a linear shaped 
protein. 
After protein denaturing, the sample is loaded into a cell at the top of the 
polyacrylamide gel (submerged in an SDS running buffer), and then subjected to a 
voltage. The proteins migrate towards the anode at rates proportional to their charge 
and mass, with the largest proteins migrating the least due to their resistance in 
migrating through the gel structure. 
After separation is achieved, the gel is stained using Coomassie brilliant blue 
(Chrambach et al., 1967), which visualises bands of protein within the gel. MW 
markers are typically run in one of the lanes to allow the MW of protein bands 
observed to be estimated. A flow chart of the SDS-PAGE protocol used to analyse 
the clinical urine samples is summarised in figure 4.4.4: 
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7.5 pL NuPAGE Buffer 4x 
To 18 pL (max) of diluted urine add: 0. + 
4.5 pL 2-mercaptoethanol 
Incubate at 75 °C (10 min) 
1 Load 20 p l- into well 
Run SDS gel at 200 V (ca. 50 min) 
Wash in H2O (20 min) 
Stain with Coomassie (Overnight) 
Figure 4.4.4. SDS-PAGE protocol for analysis of protein. 
To obtain a representative picture of the protein content over all the clinical samples 
(to see if different proteins were present at different concentrations), three samples 
were chosen from three different protein concentration ranges for SDS-PAGE 
analysis. The most concentrated samples were F67, F94 and F78 (248,258 and 253 
mg/mL), with F11, F5 and F74 having median protein concentrations (156,79 and 
135 mg/mL) and F2, F89 ad F17 for the lowest concentration samples (5,2 and 4 
mg/mL). 
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Figure 4.4.5. SDS-PAGE analysis of six randomly chosen clinical urine samples from 
three different concentration levels. The two outside lanes on each gel contained MW 
markers, the weight of which (kDa) is labelled in the right hand lane on each gel. 
Colour altered for clarity. (a) Highest protein concentrations of 248,258 ad 253 
mg/mL for samples F67, F94 and F78. (b) Median protein concentrations of 156,79 
and 135 mg/mL for samples F11, F5 and F74. (c) Lowest protein concentrations of 5, 
2 and 4 mg/mL for samples F2, F89 and F17. 
Each of the three clinical urine samples from the three different levels of protein 
concentrations were analysed on separate gels, with MW markers used in each of 
the outside lanes to aid in estimating the MWs of the different protein bands that 
were present (figure 4.4.5). The most concentrated urine samples (figure 4.4.5a) 
show that different proteins were present in these clinical urine samples, with a MW 
spread from -25 to 250 kDa suggesting the presence of some large proteins. The 
median (-125 mg/mL) and low concentration (<5 mg/mL) cohorts (figure 4.4.5b and 
c) show the same bands are present, but at lower intensities. The most intense band 
across all samples is at -70 kDa. 
Pisitkun et al. reported "... a myriad of proteins and peptides can be detected in 
normal urine... " (Pisitkun et al., 2006); they found the presence of more than 1000 
different protein gene products and many more peptides in human urine, suggesting 
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that the presence of many proteins is normal. However, the concentrations observed 
in the clinical samples would be considered nephrotic (Dihazi and Muller, 2007). 
The majority of plasma protein should be retained, as the glomerulus acts as a 
physical and electrical charge barrier to most proteins. Any proteins that pass 
through the glomerulus into the proximal tubule are generally small proteins, less 
than 40 kDa (Gonzalez-Buitrago et al., 2007), or are those which are very 
concentrated within plasma. Despite this, lots of proteins and peptides that pass into 
the proximal tubule are scavenged/proteolysed, and therefore reabsorbed (Pisitkun 
et al., 2006); for example, the most abundant plasma protein, albumin, is reabsorbed 
at rates exceeding 99 % (Sarti et al., 2001). 
Around 30 % of urinary proteins originate from plasma, with the remaining 70 % 
coming from kidneys (Tyan et al., 2006; Dihazi and Muller, 2007). Roughly 49 % of 
protein excreted in urine is in the form of soluble proteins, 48 % consist of sediments, 
and the remaining 3% are exosomes' (Pisitkun et al., 2006). 
The next step in the proteomic analysis of the clinical urine samples was to analyse 
the bands observed in the stained polyacrylamide gels, with the intention of 
identifying the proteins present. 
1 Sub 80 nm vesicles. 
201 
Chapter Four: Clinical urine sample analysis 
4.4.3. Protein identification by MALDI-ToF/ToF analysis 
Proteomic identification is usually carried out by one of two different approaches, top- 
down and bottom-up. Top-down proteomics involves the analysis of intact proteins 
using high accuracy mass measurements and subsequent CID or other 
fragmentation method and tandem MS analyses. Bottom-up proteomics (used in this 
study) first involves the digestion (either separated or as a mixture) of proteins into 
peptide fragments (typically of 5-30 AA residues), usually using trypsin that cleaves 
on the C-terminal side of Lys and Arg (as long as they are not followed by Pro). The 
resulting peptide fragments are then analysed by MS and CID tandem MS. A 
summary of the bottom-up proteomics approach is shown in figure 4.4.6: 
Excise Band 
(Cut into small pieces) 
4' 
Coomassie Destain 
Wash with ammonium bicarbonate (25 mM) for 20 min 
Repeat once 
Wash with MeCN (5 min) 
i Dry in Speed Vac (20 min) 
i Incubate at 65 °C (1 h) 
(With 10 mM dithioerythritol in ammonium bicarbonate (100 mM)) 
4' 
Add 100 pL of 50 mM iodoacetamide 
(Incubate in dark for 30 min) 
4' 
Wash with 100 mM ammonium bicarbonate (15 min) 
i Wash with 25 mM ammonium bicarbonate (15 min) 
i Wash with MeCN (5 min) 
i Dry in SpeedVac (20 min) 
i Add 10 pL of 0.02 pg/pL trypsin 
Incubate at 37 °C (Overnight) 
4, 
Wash with 25 mM ammonium bicarbonate 
4, 
Spot onto MALDI plate for analysis 
Figure 4.4.6. Flow chart of the bottom-up proteomic analysis of proteins. 
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Whichever proteomic approach is used, a database search is undertaken to compare 
the exported MS and/or MS/MS data with data expected from tryptic peptides of any 
of the protein sequences held in a database. A common search engine called 
MASCOT, used in this study', was developed by Perkins et al. in 1999 (Perkins et 
al., 1999) as an update of the original MOlecular Weight SEarch (MOWSE) search 
engine and scoring algorithm developed in the early 1990s by Pappin et al. (Pappin 
et al., 1993). The MOWSE search engine functioned by assigning a statistical weight 
to each peptide matched, which was based upon the frequency of other peptide 
masses in a protein with a certain MW range. MOWSE now forms part of MASCOT 
and is still the basis used to assign statistical confidence in any peptides matched. 
MASCOT uses a mathematical approach to compare theoretical fragment ions to the 
fragment ions recorded; confirmation of expected protein identification is obtained by 
linking the protein identified from a database to the mass observed in the original gel, 
as well as using the significance provided by the MOWSE score returned2 and linking 
the role of the protein back to the biological system. 
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Figure 4.4.7. SDS-PAGE gel of three clinical samples F67, F94 and F78. Ten bands 
were excised for proteomic analysis using a bottom-up approach. 
Ten of the most intense protein bands from the gel shown in figure 4.4.7 were 
excised for proteomic analysis using a bottom-up approach. Before each digested 
sample was spotted onto a MALDI plate for analysis, they were extracted using C18 
ZipTips to remove any excess salts, with the aim of improving the S/N ratio. 
1 The database used for all searches was the NCBInr database, updated on 06/07/2007. 
2 An event is considered significant if it occurs at random with a frequency of 
less than 5 %, giving p< 
0.05. 
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0.5 pL of each extracted sample was spotted onto a MALDI plate and covered with 
0.5 pL of a solution of «-cyano-4-hydroxycinnamic acid and allowed to air dry. The 
resulting MS and MS/MS data were imported into GPS Explorer v3.6 (Applied 
Biosystems), which uses the MASCOT search engine to attempt to match any of the 
peptides present within each sample with those generated in silico from proteins in 
the NCBlnr database. 
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Figure 4.4.8. Probability based MOWSE score plots for each of the ten excised 
protein bands. (a) band 1, (b) band 2, (c) band 3, (d) band 4, (e) band 5, (f) band 6, 
(g) band 7, (h) band 8, (i) band 9 and (j) band 10. 
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A probability based MOWSE score plot shows any hits below the assigned 
confidence limit (p < 0.05) in a hashed green area, any other hits (red bars) above 
this green area are considered significant; the higher the MOWSE score the better. 
Each of the probability based MOWSE score plots shown in figure 4.4.8 shows hits 
above the significance level, meaning that convincing protein identifications were 
obtained from each of the ten excised bands MS and MS/MS data. 
Table 4.4.1. Summary of each protein identified by MASCOT from the ten excised 
bands, along with the estimated mass from the gel. 
Number Mass of Excised MOWSE of 
Estimated protein 
Band Protein ID from MASCOT Score peptides mass 
from from 
Label gel (kDa) MASCOT Identified (Da) 
1 Alpha-2-macroglobulin precursor 332 6 -170 164600 
2 Chain B, human complement 246 5 -115 114238 comp onent C3b 
3 Complement factor H 132 6 -150 143710 
4 Ceruloplasmin 149 5 -120 116197 
5 Transferrin 567 12 -80 79280 
Alpha-l-antitrypsin 229 7 -50 46848 6 
Immunoglobulin G 165 3 -50 52687 
7 Fibrinogen gamma chain 276 6 -48 47971 
8 Preprohaptoglobin 285 6 -40 38940 
9 Human serum albumin A 704 16 -70 67988 
10 Apolipoprotein A-I 85 3 -25 28061 
Table 4.4.1 summarises the results obtained from the bottom-up proteomic analysis 
of the most intense bands excised from the SDS-PAGE analysis of the clinical urine 
samples. From the MOWSE scores, and the closeness of each identified protein's 
mass to those observed in the gel, the protein identifications can be considered as 
confident assignments. 
Alpha-2-macroglobulin precursor (band 1) is a binding host for foreign peptides and 
particles, and also functions as a barrier against pathogens (Borth, 1992), meaning 
that the protein subunit identified (165 kDa) forms part of the body's immune 
response. Band 2 corresponds to chain B- human complement component C3b, 
which is a single chain glycoprotein that is expressed in a large number of cells, and 
also has as immunological role. C3b is involved in clearing pathogens from an 
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organism by aiding cell lysis (Hamer et al., 1998), and is mainly synthesised in the 
liver. The presence of C3b in human urine has been noted before by Pascual et al., 
where it was present in low concentrations, showing that it was released by 
glomerular podocytes' (Pascual et al., 1994). C3b is linked to both factor H and 
immunoglobulin, which were also detected in the clinical urine samples and 
correspond to excised bands 3 and 6 respectively. 
Complement H (band 3) is a crucial fluid phase regulator that interacts with C3b, 
effectively deactivating C3b's function (Jokiranta et al., 1999), thus regulating the 
body's immune response. The protein identified in band 6 corresponded to 
Immunoglobulin G, again an immune system protein. Immunoglobulin G provides the 
majority of antibody-based immunity against any invading pathogens. 
Cerruloplasmin (band 4), transferrin (band 5) and antitrypsin (band 6) are all 
glycoproteins. Cerruloplasmin is synthesised in the liver and functions to transport 
-90 % of the copper within plasma; similarly, transferrin is involved in the delivery of 
iron ions within plasma. Antitrypsin is a serine protease inhibitor that plays a key role 
in controlling the coagulation of blood, and is also related to controlling inflammation 
in the body. Linked to antitrypsin, is fibrinogen (band 7) that is also a blood clotting 
agent, which is produced within the liver. 
Preprohaptoglobin (band 8) functions to provide a physiological defence against 
haemoglobin-induced toxicity (Ngai et al., 2007). The by-product of 
preprohaptoglobin is haptoglobin, which binds to free haemoglobin to stop glomerular 
filtration of haemoglobin, preventing oxidative injury to the kidneys. 
The presence of human serum albumin (HSA) was expected once protein was 
confirmed within the clinical samples, as it is the most abundant protein present in 
serum at a concentration of -40 mg/mL HSA's function is to maintain osmotic 
pressure, and also the proper distribution of body fluids within serum; HSA also 
transports fatty acids, hormones and other physiologically important, compounds 
around the body. In each of the three gels (figure 4.4.5), the band at -70 kDa was 
the most intense, suggesting that HSA was the most abundant protein within all of 
the clinical urine samples. 
1 Glomerular epithelial cells. 
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The final protein identified was apolipoprotein A-I (band 10), which functions to 
extract cholesterol from body tissues and subsequently transport it to the liver where 
it can either be excreted or recycled (Lahoz et al., 2003). 
4.4.4. Discussion 
The results presented within this section (4.4) were certainly a surprise, given all 
previously analysed urine samples did not show any precipitation upon the addition 
of MeCN prior to analysis by HILIC-ESI-MS. Research into urinary protein is not new, 
and is typically related to some physiological process such as glomerular diseases 
where increased levels of protein are excreted into urine (Sarti et al., 2001; Christian 
and Watson, 2004; Pisitkun et al., 2006; Barratt and Topham, 2007; Dihazi and 
Muller, 2007; Gonzalez-Buitrago et al., 2007; Ngai et al., 2007). The proteins 
identified within the clinical urine samples have all previously been reported in the 
literature, suggesting that the observation of these proteins is nothing new. However, 
what was in contrast to the literature was the sheer amount of protein detected within 
the clinical urine samples. Despite the semi-quantitative nature of Bradford assays, 
the levels of protein detected here (average = 166 mg/mL) were significantly higher 
than the average value excreted daily (despite the various different values reported in 
the literature) of -150 mg/day (Pisitkun et al., 2006; Gonzalez-Buitrago et al., 2007). 
Given that a normal person produces 1-2 L of urine a day, the average protein 
concentration of 166 mg/mL found in the clinical samples would correspond to a daily 
total excretion of over 150 g/day, 1000 times the reported average daily excretion. 
However, many of the clinical samples were very concentrated from the observed 
colour (dark yellow), meaning that the patients may not have produced as much urine 
on the day of collection. 
Other than benign causes of increased levels of protein in urine, such as fever/post 
exercise and also just having an upright posture (meaning an increased amount of 
protein present in urine towards the end of the day) (Newman et al., 2000; Christian 
and Watson, 2004), a few papers have reported increases in urinary protein 
excretion caused by trauma or stress (Yu et al., 1983; DeGaudio et al., 1999; Sarti et 
al., 2001). DeGaudio et al. reported an increase in capillary permeability, and 
therefore an increase in protein excretion with trauma, that was also associated with 
a systematic inflammatory response (as found in this study by the presence of 
immune system proteins); a range of different traumas were included in the 
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DeGaudio study, bone fractures being one of them (DeGaudio et al., 1999). Yu et al. 
reported that after a severe burn, kidney function was altered, causing impaired 
glomerular filtration and also the concentrating ability of the distal renal tubule, 
causing an imbalance of H20/salt and an increase in urinary protein excretion (Yu et 
al., 1983). Research by Sarti et al. concluded that there was a direct correlation 
between surgical stress score' and capillary permeability; they state that the rate of 
albumin loss can reach 5% per hour in healthy adults, but can increase to 300 % per 
hour in adult septic shock (Sarti et al., 2001). 
Even though stress can cause an increase in the excretion of protein in urine, the 
levels observed in the clinical samples still appears to be very high. The majority of 
the clinical samples with normal levels of urinary protein (the `outliers' labelled in 
figures 4.3.4a and 4.3.7a) were obtained at time = 0, therefore possibly being 
collected before protein passed into the bladder in large amounts. The largest period 
between collected urine samples was 18 weeks for patients number 16 (sample F36 
at t= 18 weeks) and 19 (sample F43 at t= 18 weeks) who both suffered ankle 
fractures (see appendix B for full details). This should have meant that their fracture 
was well into the reparative phase and strong enough for load bearing, meaning little 
stress should have been present. However, the two samples from 18 weeks after the 
initial fracture had urinary protein concentrations of 169 and 173 mg/mL (F36 and 
F43 respectively), which is still high, suggesting that stress/trauma or some other 
physiological factor may also have been present. 
Clearly, no firm conclusions as to the reason for the high levels of protein observed 
can be drawn from the information available for each sample (appendix B), but it is 
evident that this is an area of research that requires much more consideration due to 
the lack of consistent literature. 
1 The Oxford surgical stress score is used to relate stress on a scale of 1 to 
14 (where 1= the least 
amount of stress, and 14 = the most amount of stress). 
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4.5. Re-analysis of clinical samples using RP-LC-ESI-MS 
The demonstration of protein in the majority of clinical urine samples very probably 
explains the large shifts in both retention time and peak intensity that were evident in 
both positive and negative mode RP-LC-MS data (sections 4.3.1 and 4.3.2) from the 
clinical samples, as the MeCN in the mobile phase would have caused the 
precipitation of proteins onto the column, reducing the separation efficiency of the 
column. To avoid any subsequent precipitation of any protein onto the RP column, all 
clinical samples (and pooled samples) were diluted with an equal volume of MeCN to 
precipitate the protein present, before centrifugation and filtration prior to analysis. 
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Figure 4.5.1. Three overlaid positive mode RP-LC-MS TICs of pooled urine aliquots 
from the beginning of data acquisition (blue TIC), mid-way through data acquisition 
(red TIC) and at the end of three days of data acquisition (green TIC). 
Figure 4.5.1 shows three TICs from positive mode RP-LC-MS analysis of aliquots of 
pooled urine obtained following addition of MeCN, centrifugation and filtration. The 
blue TIC corresponds to a pooled urine aliquot that was analysed before any clinical 
samples, the red TIC corresponds to the analysis of a pooled urine aliquot carried out 
mid-way through data acquisition, and the green TIC corresponds to the analysis of 
an aliquot of pooled urine run at the end of data acquisition after three days of 
continual analysis. The three TICs all follow the same trend, although there are some 
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slight shifts in retention time and peak intensity evident. The most intense peaks 
(indicated with an arrow) show a retention time of -2.75 min for the first two pooled 
samples analysed (blue and red TICs), and -2.8 min for the final TIC. This gives a 
deviation of -3 s, which is well below the retention time tolerance of ±0.5 min used 
for the metabolomics export script. Although the system appears to be much more 
stable after the precipitation of protein, the TICs shown in figure 4.5.1 exhibit fewer 
peaks than were originally observed for the pooled urine sample (without MeCN 
added) in the initial RP-LC-MS analyses (figure 4.3.1); this may be caused by using 
MeCN to precipitate protein, which could cause the co-precipitation of urinary 
metabolites. 
4.5.1. Positive and negative mode RP-LC-ESI-MS analysis 
All clinical urine samples (diluted with MeCN to precipitate protein) were re-analysed 
by positive and negative mode RP-LC-ESI-MS, with the random inclusion of aliquots 
of pooled urine and the analysis of multiple aliquots of some samples, chosen at 
random. The resulting raw data were extracted using the metabolomics export script 
(Applied Biosystems) to form a matrix for import into Excel (Microsoft Excel for Mac 
2004), where information relating to each sample were added, before being 
subsequently imported into SIMCA P+ v11.5 (Umetrics, Sweden) for statistical 
analysis. 
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Figure 4.5.2. (a) PCA scores plot of positive mode RP-LC-MS data (  = samples 
from males, f= samples from females and "= aliquots of pooled urine). (b) PCA 
scores plot of pooled samples only, the arrow indicates the first sample analysed, 
with the hashed line indicating subsequent sample analysis. (c) PCA scores plot of 
negative mode RP-LC-MS data (  = samples from males, "= samples from 
females and "= aliquots of pooled urine). (d) PCA scores plot of aliquots of pooled 
urine only, the arrow indicates the first sample analysed, with the hashed line 
indicating subsequent sample analysis. 
The PCA of both positive and negative mode RP-LC-MS data are shown in figure 
4.5.2a and c respectively. Both PCA scores plots show a tight cluster near the centre 
of each plot that contains the bulk of the data, and another cluster of 12 samples (13 
samples for figure 4.5.2a due to the analysis of two aliquots of one of the samples) 
spread out over a broad range. The pooled urine samples (blue dots) form clusters 
around the 95 % confidence limit for both positive and negative RP-LC-MS data PCA 
score plots. Compared to the initial PCA from positive mode RP-LC-MS data prior to 
protein precipitation (figure 4.3.2), the pooled urine aliquot data points exhibit a much 
tighter cluster, suggesting less variation between the samples; this further suggests 
that the precipitation of protein removed some of the original effects that were 
observed. The pooled urine samples analysed using negative mode RP-LC-MS show 
a tight cluster in the resulting scores plot (figure 4.5.2c), which, as for positive mode, 
was even tighter than the initial PCA of negative mode RP-LC-MS data (figure 
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4.3.6a). The broad cluster of samples again correspond to those clinical urine 
samples with `normal' amounts of urinary protein (< 5mg/mL), showing that despite 
the precipitation and removal of protein from all samples, these samples remain 
significantly different to the bulk of the samples. 
PCA of just the datasets from analysis of the different aliquots of the pooled urine in 
both positive and negative mode RP-LC-MS (figures 4.5.2b and d) both show a trend 
moving away from the first aliquots of pooled urine analysed (indicated by arrows). 
This implies that there were still systematic drifts evident within the data, most likely 
caused by shifts in intensity that were observed in the TICs (figure 4.5.1). However, 
as the pooled urine aliquot data points in figures 4.5.2a and c cluster tightly, this 
suggests that the replicate analysis of samples gave more similar than in the initial 
analysis, prior to protein precipitation (section 4.3.1 and 4.3.2). As too little sample 
remained for a complete re-analysis following use of alternative methods to remove 
the protein, the resulting acquired data were analysed using PLS analysis. 
For analysis using PLS, the datasets (clinical samples with protein concentrations of 
less than 5 mg/mL were removed as these influenced the PLS models) were 
assigned two sets of different Y-variables. The first Y-variable split the dataset into 
two response variables: any samples from t=0 (admittance to A&E), and all other 
post-fracture samples (t=1 to 133 days), and was termed 'frac2'. The second Y- 
variable assigned three response variables to the dataset: those samples collected at 
t=0, any samples collected within the first three weeks post-fracture (t=1 to 21 days) 
and all remaining samples from 22 to 133 days post-fracture, with the Y-variable 
being termed 'frac3'. As ankle fractures formed the largest number of fractures (21 
patients with a total of 51 samples), these were used to create a separate dataset for 
further analysis. The 'ankle' dataset were split into two response variables: samples 
from t=0 and all other samples obtained post-fracture (t=1 to 133 days). The resulting 
PLS analyses of positive and negative mode RP-LC-MS data with three different Y- 
variable-assigned datasets were optimised according to the scheme presented in 
chapter 3.5, and are presented in figure 4.5.3. 
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Figure 4.5.3. (a) PLS scores plot of positive mode RP-LC-MS data with the response 
variables 'frac2":  = samples from time = 0, "= samples from time =1 to 133 days 
post-fracture. (b) PLS scores plot of positive mode RP-LC-MS data with the response 
variables 'frac3':  = samples from time = 0, "= samples from time =1 to 21 days 
post-fracture, and "= samples from time = 22 to 133 days post fracture. (c) PLS 
scores plot of positive mode RP-LC-MS data with the response variables 'ankle':  _ 
samples from time = 0, "= samples from time =1 to 133 days post-fracture. (d) PLS 
scores plot of negative mode RP-LC-MS data with the response variables 'frac2":  = 
samples from time = 0, "= samples from time =1 to 133 days post-fracture. (e) PLS 
scores plot of negative mode RP-LC-MS data with the response variables 'frac3':  _ 
samples from time = 0, "= samples from time =1 to 21 days post-fracture, and "_ 
samples from time = 22 to 133 days post fracture. (f) PLS scores plot of negative 
mode RP-LC-MS data with the response variables 'ankle':  = samples from time = 
0, f= samples from time =1 to 133 days post-fracture. 
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Good clustering of the data was observed for separation according to `frac2' 
response variables for both positive and negative RP-LC-MS data (figures 4.5.3a and 
d). All of the samples from t=0 (black squares), and the later samples (red diamonds) 
show some degree of separation between the two different response variables when 
either polarity was used to record the RP-LC-MS data. Importing external test sets 
into each developed model gave external classification results of 25 % (using one 
latent variable (LV)) for positive mode RP-LC-MS data (figure 4.5.3a), and 35 % 
(using two LVs) for negative mode RP-LC-MS data (figure 4.5.3d). The low external 
classification rates imply that the variables used to form each model are not overly 
predictive for discrimination between the two response variables. However, as there 
is overlap between the two clusters of data, and some of the external test set 
samples had LV values that placed them in the region of overlap between the two 
clusters, this would have somewhat reduced the external classification result. 
When `frac3' response variables were assigned, the resulting PLS scores plots for 
positive and negative mode RP-LC-MS data show a general trend across the first LV, 
where samples from t=0 (black squares) cluster on the left-hand side, samples from 
t=1 to 21 days post-fracture (red diamonds) cluster around `0', and the remaining 
datasets (t=22 to 133 days post-fracture, blue circles) cluster on the right-hand side 
of the scores plots (figure 4.5.3b for positive and figure 4.5.3e for negative mode RP- 
LC-Ms data). Importing external test sets for both models generated external 
classification rates of 45 % using one LV for positive mode RP-LC-MS data, and 75 
% using two LVs for negative mode RP-LC-MS data, improving the predictive ability 
over the `frac2' model. 
The RP-LC-MS data for ankle fracture samples were assigned response variables for 
t=0 and t=1 to 133 days post fracture, due to the reduced number of samples 
available. The resulting PLS scores plots for the two ionisation mode RP-LC-MS 
datasets are shown in figures 4.5.3c (for positive mode) and 4.5.3f (for negative 
mode). Both models show clustering according to the assigned response variables, 
with samples from t=0 (black squares) clustering on the right-hand side, and samples 
from t=1 to 133 days post-fracture (red diamonds) clustering on the left-hand side. 
The external classification rates for the ankle fracture models were 90 % for positive 
mode RP-LC-MS data and 60 % for negative mode RP-LC-MS data, with both 
external classification rates being highest when one LV was utilised for prediction. 
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Table 4.5.1. Comparison of the top five variables for each developed model. Shaded 
cells show variables that are present for more than one developed model (coloured 
according to polarity). 
Separation Polarity Statistical Rank mlZ tR 
Y Variable 
Discriminative Method Model (VIP) 
for 
1 86.05 12.89 if for t=0 
2 107.95 1.33 ft fort >0 
frac2 3 105.02 14.32 if for t=0 
4 86.05 11.87 ft fort >0 
5 367.14 2.95 ft fort >0 
1 100.02 1.98 ft for t=0 
2 90.52 9.12 jt for t=0 
Positive Ankle 3 171.13 17.75 ¶ for t=0 
4 205.12 16.02 ¶ fort=0 
5 392.96 13.15 ft for t=0 
1 198.05 28.16 ft for t=0 
2 500.26 21.54 jtfort>21 
frac3 3 105.02 14.32 ft for t> 21 
4 299.11 2.90 ft fort > 21 
5 120.07 11.04 ¶ fort > 21 
RP 1 448.34 20.17 if for t=0 
2 473.02 1.57 ft for t>0 
frac2 3 528.30 21.69 ft fort =0 
4 326.11 10.19 ftfort>0 
5 446.09 10.17 ft fort >0 
1 169.00 28.87 ft for t>0 
2 448.34 20.17 ftfort=0 
Ankle 3 464.34 18.64 ft for t=0 Negative 
4 465.29 18.59 ft for t=0 
5 516.35 20.17 ft for t=0 
1 448.34 20.17 ft for t=0 
2 476.32 21.46 if fort >22 
frac3 3 477.32 21.47 
¶ for t> 22 
326.11 10.19 
1t for t=0 
4 (>0 = 0) 
5 276.02 29.04 ft for t=0 
Table 4.5.1 presents the top five variables that gave the highest VIP values for each 
of the three developed PLS models using the two ionisation polarities, along with the 
Y variable they were discriminative for. For each of the statistical models, there are 
few variables present which are consistent across each model (shaded cells). The 
CID tandem MS analyses of the most important variables generated by each PLS 
model are presented in section 4.8. 
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4.6. Analysis of clinical samples by positive and negative mode HILIC-ESI-MS 
All of the clinical samples were diluted by addition of an equal volume of MeCN, 
centrifuged and filtrated prior to analysis, then analysed by positive and negative 
mode HILIC-LC-ESI-MS, with the random injection of aliquots of a pooled urine 
sample and the random re-injection of aliquots of clinical urine samples. The resulting 
raw data were extracted using the metabolomics export script (Applied Biosystems) 
to form a matrix for import into Excel (Microsoft Excel for Mac 2004), where data 
relating to each sample were added, before being subsequently imported into SIMCA 
P+ v11.5 (Umetrics, Sweden) for statistical analysis. 
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Figure 4.6.1. Three overlaid positive mode HILIC-MS TICs of aliquots of pooled urine 
samples from the beginning of data acquisition (green TIC), mid-way through data 
acquisition (red TIC) and at the end of three days of data acquisition (blue TIC). 
Arrows indicate areas where there are changes in intensity between the samples. 
Figure 4.6.1 shows three superimposed TIC traces from positive mode HILIC-MS 
injections of aliquots of a pooled urine sample. The green TIC corresponds to an 
injection of an aliquot of pooled urine prior to the analysis of any clinical samples, the 
red TIC corresponds to the injection of an aliquot of pooled urine mid-way through 
data acquisition, and the blue TIC corresponds to the injection of an aliquot of pooled 
urine at the end of three days of data acquisition. The three TICs follow the same 
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trend, but there are some minor deviations in retention time, along with some shifts in 
the intensity of the peaks indicated by arrows. Any deviations in retention time are 
less than ±6 s, which is within the tolerance of ±0.5 min used in the metabolomics 
export script; normalising to total ion count should minimise the observed differences 
in intensity. Comparing the TICs of pooled samples from positive mode HILIC-MS 
data (figure 4.6.1) to that obtained using positive mode RP-LC-MS (figure 4.5.1), 
shows that HILIC separation provided a more `information rich' chromatogram. 
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Figure 4.6.2. (a) PCA scores plot of positive mode HILIC-MS data (  = samples from 
males, f= samples from females and "= aliquots of pooled urine). (b) PCA scores 
plot of aliquots of pooled urine only, the arrow indicates the first sample analysed, 
with the hashed line indicating subsequent sample analysis. (c) PCA scores plot of 
negative mode HILIC-MS data (  = samples from males, f= samples from females 
and "= aliquots of pooled urine). (d) PCA scores plot of aliquots of pooled urine 
only, the black arrow indicates the first sample analysed, the red arrow indicates 
subsequent samples analysed prior to the analysis of clinical samples, with the 
hashed line indicating subsequent sample analysis. 
The PCA of both positive and negative mode HILIC-MS data are presented in figure 
4.6.2a and c respectively. Both PCA scores plots show a cluster containing the bulk 
of the data, with positive mode HILIC-MS data generating a larger `linear' cluster 
(figure 4.6.2a) compared to a small tight cluster for negative mode HILIC-MS data 
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(figure 4.6.2c). The remaining clinical samples for both ionisation modes' HILIC-MS 
data form a loose cluster containing 12 data points (black squares) that, as for RP- 
LC-MS data, correspond to each of the clinical samples with low concentrations (less 
than 5 mg/mL) of urinary protein. 
The datasets for clusters of pooled samples (blue dots) for each PCA scores plot 
show some differences. Positive HILIC-MS datasets for aliquots of pooled urine show 
two distinct clusters (figure 4.6.2a), meaning that there are two types of samples that 
have some different characteristics. The negative HILIC-MS datasets for aliquots of 
pooled urine show a tight cluster with only one data point deviating from the cluster 
(blue dot in the bottom right hand corner, outside the 95 % confidence limit, of the 
scores plot shown in figure 4.6.2c). When PCA of just the aliquots of pooled urine 
sample was undertaken, those from positive mode HILIC-MS (figure 4.6.2b) show a 
`U' shaped trend from the first sample analysed (indicated by an arrow). For the PCA 
of negative mode HILIC-MS aliquots of pooled urine sample, the only observation 
present as an outlier from the tight cluster observed in figure 4.6.2c can be 
accounted for by the fact that it was the first aliquot injected before the LC-MS 
system had equilibrated (indicated by a black arrow in figure 4.6.2d). The red arrow 
in figure 4.6.2d shows the subsequent aliquots of pooled urine sample that were 
injected prior to the analysis of any clinical samples, with subsequent data points 
showing less deviation then originally observed. 
For analysis by PLS, the same response variables were assigned as for the RP-LC- 
MS data (clinical samples with protein concentrations of less than 5mg/mL were 
removed as these influenced the PLS models). The first Y-variable split the dataset 
into two response variables: any samples from t=0 (admittance to A&E), and all other 
post-fracture samples (t=1 to 133 days), and was termed `frac2'. The second Y- 
variable assigned three response variables to the dataset: those samples collected at 
t=0, any samples collected within the first three weeks post-fracture (t=1 to 21 days) 
and samples collected 22 to 133 days post-fracture, with the Y-variable being termed 
'frac3'. As ankle fractures formed the largest number of fractures (21 patients with a 
total of 51 samples), these were used to create a separate dataset for further 
analysis. The `ankle' dataset was split into two response variables: samples from t=0 
and all other samples obtained post-fracture (t=1 to 133 days). The resulting PLS 
analyses of positive and negative mode HILIC-LC-MS data with three different Y- 
variable assigned datasets were optimised according to the scheme presented in 
chapter 3.5, and are presented in figure 4.6.3. 
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Figure 4.6.3. (a) PLS scores plot of positive mode HILIC-MS data with the response 
variables `frac2":  = samples from time = 0, f= samples from time =1 to 133 days 
post-fracture. (b) PLS scores plot of positive mode HILIC-MS data with the response 
variables `frac3':  = samples from time = 0, "= samples from time =1 to 21 days 
post-fracture, and "= samples from time = 22 to 133 days post fracture. (c) PLS 
scores plot of positive mode HILIC-MS data with the response variables `ankle':  _ 
samples from time = 0, "= samples from time =1 to 133 days post-fracture. (d) PLS 
scores plot of negative mode HILIC-MS data with the response variables `frac2":  = 
samples from time = 0, f= samples from time =. 1 to 133 days post-fracture. (e) PLS 
scores plot of negative mode HILIC-MS data with the response variables `frac3':  _ 
samples from time = 0, f= samples from time =1 to 21 days post-fracture, and "_ 
samples from time = 22 to 133 days post fracture. (f) PLS scores plot of negative 
mode HILIC-MS data with the response variables `ankle':  = samples from time = 0, 
f= samples from time =1 to 133 days post-fracture. 
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Separation according to `frac2' response variable for positive and negative HILIC-MS 
data shows good clustering of the two groups (figures 4.6.3a and d). Samples 
corresponding to t=0 (black squares), and samples from any time post-fracture (red 
diamonds), show some degree of separation, although there is some overlap present 
between the two clusters. External classification of the developed models for positive 
and negative HILIC-MS data using an independent test set generated results of 60 
and 30 % for each model respectively, both using two LVs to gain maximum 
classification. 
When response variables corresponding to `frac3' were assigned, the resulting PLS 
scores plots for positive and negative mode HILIC-MS data show a general trend 
along the first LV (figure 4.6.3b and e). Samples from t=0 (black squares) cluster on 
the left-hand side, samples from t=1 to 21 days post-fracture (red diamonds) cluster 
around `0', and all remaining data (t=22 to 133 days post-fracture, blue circles) 
cluster on the right-hand side of the scores plots (figure 4.6.3b for positive and figure 
4.6.3e for negative mode RP-LC-Ms data). Importing external test sets into each 
developed model generated external classification rates of 65 % using two LVs for 
positive HILIC-MS data, and 50 % for negative mode HILIC-MS data, using one LV. 
PLS analysis of the ankle fracture sample cohort by positive and negative mode 
HILIC-MS, generated the scores plots shown in figures 4.6.3c and f. Clustering 
according to the assigned response variables t=0 (black squares) and t=1 to 133 
days post-fracture (red diamonds) was observed. The external classification rates 
were the highest obtained for any PLS model using HILIC-MS data, with 70 % for 
positive mode HILIC-MS data and 80 % for negative mode HILIC-MS data, both 
using two LVs for maximum classification. 
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Table 4.6.1. Comparison of the top five variables for each developed model. Shaded 
cells show variables that are present for more than one developed model (coloured 
according to polarity). 
Separation Statistical Rank Y Variable 
Method Polarity Model (VIP) mlZ tR Discriminative 
for 
1 198.05 3.45 ft for t>0 
2 254.14 2.35 ft for t>0 
frac2 3 168.06 2.95 ft fort >0 
4 392.03 8.92 ft fort >0 
5 198.05 5.33 ft for t>0 
1 142.09 9.38 ft fort >0 
2 350.18 6.73 Q fort >0 
Positive Ankle 3 450.30 2.90 ¶ for t=0 
4 451.31 2.90 jt for t=0 
5 86.091 19.55 ft for t>0 
1 198.05 3.45 ft for t>0 
2 254.14 2.35 ft fort >0 
frac3 3 152.06 7.57 ft for t=0 
4 239.20 7.30 jI fort < 21 
HILIC 5 796.55 6.55 
¶ for t=0 
1 448.33 2.90 fI fort >0 
2 562.33 2.90 ft for t>0 
frac2 3 276.02 5.53 ft for t=0 
4 498.32 5.88 ¶ fort >0 
5 243.06 7.38 ft for t=0 
1 448.33 2.90 ft for t>0 
2 464.31 5.52 ft for t>0 
Negative Ankle 3 464.31 3.00 ft for t>0 
4 186.12 2.63 ft fort >0 
5 562.33 2.90 ft fort >0 
1 151.06 6.93 t=0>1>2 
2 448.33 2.90 t= 0> 1>2 
frac3 3 562.33 2.90 ft fort >0 
4 498.32 5.88 ft fort >0 
5 243.06 7.38 ft for t=0 
Table 4.6.1 presents the top five variables that gave the highest VIP values that were 
generated by each of the three PLS models for each ionisation polarity, and also 
each Y variable each variable is discriminatory for. For each of the three PLS models 
developed using data obtained from positive ionisation, there are two variables that 
were consistent between each of the 'frac2' and 'frac3; models (shaded cells). For 
the models developed using negative ionisation mode HILIC-MS data, there are 
more variables that are consistent throughout the models (blue shaded cells). One 
variable at m/z 448.33 with a retention time of 2.90 min was present in all three 
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models, and also had a mass that could correspond to a variable from the negative 
mode RP-LC-MS data at m/z 448.35 (44.6 ppm difference) with a retention time of 
26.17 min. The shifts in retention time from 2.90 min (HILIC) to 26.17 min (RP) would 
appear to support the initial theory that this mass corresponds to the same 
compound, as a strongly retained compound on an RP column would be expected to 
elute very early from an HILIC column (2.90 min is close to the void). The variables 
presented in table 4.6.1 were analysed by CID tandem MS, and the results presented 
in section 4.8. 
4.7. Analysis of ±RP and ±HILIC data by data fusion 
Each of the four datasets (±HILIC- and ±RP-LC-MS) were imported into Excel 
(Microsoft Excel for Mac 2004) and concatenated one below the other, as outlined in 
chapter 3.5.3. 
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Figure 4.7.1. (a) PCA scores plot of concatenated data (  = samples from males, 
= samples from females). (b) PCA scores plot concatenated data with all samples 
having normal levels of protein (less than 5 mg/mL, corresponding to the labelled 
samples in (a)) being removed. 
Figure 4.7.1 a shows the PCA of the concatenated dataset. The bulk of the data 
cluster in a tight group near the centre of the scores plot, whilst the remaining 
samples form a loose cluster in the left hand side of the scores plot. All of the labelled 
data points correspond to clinical samples with normal urinary protein concentrations 
(less than 5 mg/mL), as was observed for the PCA of each individual dataset (±RP, 
figures 4.5.2a and c, and ±HILIC, figures 4.6.2a and c). When the samples with 
normal protein concentrations were excluded from the dataset, the resulting PCA 
scores plot (figure 4.7.1 b) shows no clear separation based upon gender (or any 
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other information available). There are only three data points outside the 95 % 
confidence limit, and none of these exhibited a large DModX value, and so remained 
to form the dataset for subsequent PLS analyses. 
For analysis by PLS, the following response variables were assigned: The first Y- 
variable split the dataset into two response variables: samples from t=0 (admittance 
to A&E), and all post-fracture samples (t=1 to 133 days), and was termed `frac2'. The 
second Y-variable assigned three response variables to the dataset: those samples 
collected at t=0, any samples collected within the first three weeks post-fracture (t=1 
to 21 days) and all samples collected 22 to 133 days post-fracture, with the Y- 
variable being termed `frac3'. As ankle fractures formed the largest number of 
fractures (21 patients with a total of 51 samples), these were used to create a 
separate dataset for further analysis. The `ankle' dataset was split into two response 
variables: samples from t=0 and all post-fracture samples (t=1 to 133 days). The 
resulting PLS analyses of the concatenated dataset with three different Y-variables 
assigned were optimised according to the scheme presented in chapter 3.5, and are 
presented in figure 4.7.2: 
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Figure 4.7.2. (a) PLS scores plot of concatenated data with the response variables 
'frac2":  = samples from time = 0, "= samples from time =1 to 133 days post- 
fracture. (b) PLS scores plot of concatenated data with the response variables 'frac3': 
 = samples from time = 0, "= samples from time =1 to 21 days post-fracture, and 
"= samples from time = 22 to 133 days post fracture. (c) PLS scores plot of 
concatenated data with the response variables 'ankle':  = samples from time = 0, 
= samples from time =1 to 133 days post-fracture. 
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PLS analysis of the concatenated data according to `frac2' response variables where 
t=0 (black squares) and t=1 to 133 days post-fracture (red diamonds) shows distinct 
clusters of the two groups (figure 4.7.2a). The external classification rate of 50 % 
using one LV was comparable to the best performing single dataset (positive mode 
HILIC-MS data at 60 %). When `frac3' response variables were assigned, the 
resulting PLS scores plot (figure 4.7.2b) shows a trend across the first LV, where 
samples from t=0 (black squares) cluster on the left-hand side, and those from t=1 to 
21 days (red diamonds) and 22-133 days post-fracture (blue dots) cluster on the 
right-hand side of the scores plot. The external classification rate of 50 % was equal 
to that for the `frac2' model, but required two LVs for the highest classification rate. 
The final PLS model was for the ankle dataset (figure 4.7.2c), where two clusters 
according to the assigned response variables were observed. Data points from t=0 
(black squares) and t=1 to 133 days post-fracture (red diamonds) cluster apart with 
no overlap. The external classification rate of 80 % using one LV was the highest 
obtained using the concatenated dataset. 
Table 4.7.1. Comparison of the top five variables for each of the three developed 
models. Shaded cells show variables that are present for more than one developed 
model (coloured according to polarity). 
Statistical Separation Rank Y Variable 
Model Method Polarity (VIP) m/z tR Discriminative for 
HILIC + 1 198.05 3.45 ft for t>0 
HILIC + 2 392.03 8.92 ft for t>0 
frac2 RP - 3 448.34 20.17 ft for t=0 
HILIC - 4 448.33 2.90 ft for t>0 
HILIC - 5 230.02 6.90 ft for t>0 
HILIC + 1 450.30 2.90 ft for t=0 
HILIC + 2 451.31 2.90 ft for t=0 
Ankle RP + 3 171.13 17.75 fj fort >0 
RP + 4 205.11 17.29 ftfort>0 
HILIC + 5 350.18 6.73 ft fort >0 
HILIC + 1 198.05 3.45 Q for t>0 
HILIC + 2 254.14 2.35 ftfort>0 
frac3 RP - 3 448.34 20.17 ft for t=0 
HILIC - 4 448.33 2.90 t=0<1<2 
HILIC - 5 243.06 7.38 ft fort < 21 
Table 4.7.1 presents the five most important variables from each of the three different 
statistical models. Each of the three models uses variables from each of the 
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separation methods and both ionisation polarities, along with the Y variable that each 
variable was discriminative for. The shaded cells represent variables that were found 
in all PLS models; each of the variables was observed in the individual PLS models 
for the separation method and polarity shown (tables 4.5.1 and 4.6.1). The CID 
tandem MS analysis of the variables presented in table 4.7.1 are discussed in section 
4.8. 
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4.8. Variable analysis using CID tandem MS 
Identifying the ions giving rise to the variables generated by each of the three 
developed PLS models (frac2, frac3 and ankle) for the two ionisation modes using 
both RP- and HILIC-MS in this chapter was carried out using CID tandem MS. A 
selection of four urine samples was chosen for analysis, based upon time of 
collection during fracture healing, and also type of fracture. As for the CID tandem 
MS analyses of data in chapter 3.6.4, the IDA setting was used in the Analyst QS 
software to analyse any variables added to the `include' list. 
When each of the variables detected was searched for in the HMDB1 (Wishart et al., 
2007) and Metlin2 databases, only one variable corresponded to a plausible 
metabolite; m/z 120 could correspond to the amino acid Thr. All other variables did 
not return any hits from either database search. The lack of more accurate mass 
measurements, along with only one potential metabolite structure from database 
searches, meant that both precursor and fragment ions shown in table 4.8.1 cannot 
be assigned atomic compositions. The only ion that was found in the literature was 
that at m/z 465, which in research by Lutz et al. (Lutz et al., 2006), was postulated to 
correspond to a glucuronidated steroid. 
1 http: //www. hmdb. ca (accessed November 2007) 
2 http: //metlin. scripps. edu (accessed November 2007) 
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Table 4.8.1. A table showing precursor ions that were isolated and subjected to CID 
tandem MS, and m/z values of ions that were identified as ariables and corresponded 
to metabolites in either HMDB or Metlin. (n/d = not detected in CID analysis. n/r= not 
recorded, meaning no fragment ions were observed). 
Separation 
Method 
Statistical 
Model 
Ionisation 
Polarity tR 
Precursor Ion 
Mass (M. -"- 
Product Ions fmiz; 
Product Ion 
Spectrum in 
A endfix D 
Positive n. '. ý NO Vd - 
frac2 
ti N 
20.17 443.4 nfr - ve ega 21. E9 528.3 478.4 155.0 113.0 1 
21.54 500.3 457.3 4392 361.2 216.1 193.0 164.0 2 
f 3 
Positive 2.90 299.1 253.1 164.9 90.1 72.1 45.0 3 RP rac 11.04 120.1 103.0 93.1 88.0 - 
Negative 21.46 476.3 279.3 253.3 5 
Positive n1d n, d r/d - 
ank e N i 20.17 516.4 448.4 427.0 385.0 249.0 205.0 155.0 6 egat ve 18.59 465.3 113.0 7 
Positive n/d n/d n/d - 
frac2 
N ti 
2.90 448.3 n/r - ega ve 2.90 562.3 448.4 113.0 8 
Positive 6.55 796.6 184.1 
HILIC frac3 2.90 448.3 yr Negative 
2.90 562.3 448.4 113.0 8 
Positive 2.90 450.3 433.2 415.3 10 
ankre N ti 2.90 443.3 n. ýr - ve ega 2.9D 562.3 448.4 113.0 8 
Appendix D contains the CID tandem mass spectrums of precursor ions that 
produced fragment ions upon CID. 
The precursor ion at m/z 528 shows a fragment ion at m/z 113 (appendix D1), 
suggesting that this compound is a glucuronide (Levsen et al., 2005). Subtracting 
176 Da (the mass increment corresponding to glucuronic acid) from the metabolites 
mass gives an RMM of 353 Da for this compound. Searching either database or the 
literature for this mass did not yield any results, making it impossible to propose an 
identity for this compound. 
Appendix D2 shows the CID tandem MS of m/z 500; the precursor ion shows a peak 
at 2 Th higher, suggesting the presence of chlorine in the structure of this compound. 
There are two losses from fragment ions that could correspond to loss of water; the 
fragment ions at m/z 457 and 216 both have peaks 18 Th less. The fragment ion at 
m/z 90 from the precursor ion at m/z 299 also loses 18Th, suggesting a loss of water 
from this ion too (appendix D3). However, no further information can be extracted 
from the data. 
The fragment ion 17 Th lower than the precursor ion at m/z 120 could correspond to 
the loss of NH3 from the compound (appendix D4). High energy CID tandem MS of 
Thr fragments to lose water from the precursor ion (giving m/z 102), then a 
subsequent loss of CO and CH202 from the fragment ion at m/z 102 to give m/z 
74 
and 56 respectively (Heerma and Kulik, 1988). However, at low energy 
CID tandem 
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MS, the loss of NH3 from peptides/amino acids is more common. No plausible loss 
could be postulated for the fragment ion 27 Th lower than the precursor ion, although 
the loss of 32 Da (fragment ion at m/z 88) could correspond to the elements of 
MeOH. 
The CID tandem MS of m/z 516 (appendix D6) shows six fragment ions. The 
fragment ion at m/z 448 could correspond to the precursor ion at m/z 448 that has 
the same retention time in negative mode RP-LC-MS data in the frac2 PLS model, 
suggesting that the ion at m/z 448 in the frac2 PLS model may be an in-source 
fragment of m/z 516. It is not possible to assign atomic compositions to the fragment 
ions, making it very difficult for a structure to be postulated. 
The presence of m/z 113 in the CID tandem MS spectrum of the precursor ion at m/z 
465 suggests that this compound may be a glucuronide (appendix D7). Lutz et al. 
used MS/MS transitions to the molecular anion of m/z 113, which is a characteristic 
fragment of glucuronic acid, to detect putative steroid glucuronides (Lutz et a/., 2006). 
A mass at m/z 465 was postulated to correspond to one of the following steroid 
glucuronides: androsterone, dihydrotestosterone, 3ß, 17ß-dihydroxy-5-androsterone 
or epiandrosterone (Lutz et al., 2006). 
The negative ion mode CID tandem MS analysis of the precursor ion at m/z 562 
(appendix D8) also produce an intense fragment ion at m/z 113, suggesting that this 
compound is also a glucuronide. The very low intensity fragment ion at m/z 448 
corresponds to a loss of 114 Th, corresponding to the neutral loss of a glucuronide 
fragment. The precursor ion eluted at 2.9 min, which is the same retention time as 
the precursor ion at m/z 448, suggesting m/z 448 may have been an in-source 
fragment of a compound with an RMM of 563 Da. Interestingly, the positive mode 
CID tandem MS analysis of m/z 450 (appendix D10) eluted at 2.9 min, the same as 
m/z 448 (postulated in-source fragment) and 562; this could mean that m/z 450 is the 
positive ion in-source fragment (loss of 114 Th, a neutral glucuronide fragment) from 
the compound with an RMM of 563 Da. The fragment ions at m/z 433 and 415 could 
correspond to further losses of NH3 and water from the positive mode in-source 
fragment. 
The final product ion at m/z 796 (appendix D9) shows one fragment ion at m/z 184, 
due to the loss of 612 Th, meaning that the product ion spectrum was very 
uninformative for this compound. 
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4.8.1. Discussion 
The CID tandem MS analysis of the most important variables from the developed 
PLS models produced some tandem MS spectra (of variable quality) containing 
fragment ions. However, the databases searched did not identify any possible 
compounds, and the lack of more accurate mass measurements means that 
assigning structures was not possible. The only tentative assignment is based upon 
work by Lutz et al. who postulated that the transition m/z 465 to 113 (as seen in the 
spectrum in appendix D7) corresponded to one of the following steroid glucuronides: 
androsterone, dihydrotestosterone, 3ß, 17ß-dihydroxy-5-androsterone or 
epiandrosterone (Lutz et al., 2006). 
It is interesting that identical retention times for many of the precursor ions (most 
important variables) in both the RP- and HILIC-MS dataset PLS models were 
observed. The fragment ion mass of m/z 448 (from the precursor ion m/z 562), 
corresponding to the loss of 114 Th (neutral glucuronide fragment) suggests that m/z 
448 (as a precursor ion) was formed as an in-source fragment of m/z 562 (also 
highlighted by the comparable importance of m/z 562 and 448 (in-source fragment) 
from the PLS models). 
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4.9. Discussion 
The original aim of the work presented in this chapter was to profile the body's 
response to long-bone fractures, specifically to attempt to find biomarkers related to 
failed or delayed fracture healing. Unfortunately, at an early stage in sampling, a lack 
of long-bone fractures led to the largest sample cohort being from patients with ankle 
fractures. 
The initial RP-LC-MS analysis of the clinical urine samples generated poor results, 
the reason for which only became apparent when the clinical samples were prepared 
for analysis by HILIC-MS. Upon addition of MeCN to the clinical urine samples, a 
large amount of precipitate formed, meaning that the RP column used would have 
been saturated with precipitate with the MeCN present in the mobile phase. The 
Bradford assay of all clinical samples confirmed that the precipitate was protein, with 
concentrations from 1-258 mg/mL (average = 166 mg/mL), compared to an average 
daily protein excretion of 150 mg (Pisitkun et al., 2006; Gonzalez-Buitrago et al., 
2007). Proteomic analysis of the clinical urine samples identified 11 proteins, some of 
which were expected, but others were not, particularly those with high MWs related 
to an immunological response. Research by Gonzalez-Buitrago et al. showed that a 
"... myriad of proteins... " have been detected in urine, meaning that the presence of 
protein should not have been a surprise (Gonzalez-Buitrago et al., 2007); what was a 
surprise was the very high levels of protein present in the clinical urine samples. After 
the precipitation of protein from the clinical urine samples, the RP- and HILIC-MS 
analyses generated much more satisfactory data for the metabonomic analysis. 
Prior to the statistical analysis of the resulting data, it was revealed that none of the 
recruited patients' fractures had gone to non-union or had suffered delayed healing. 
Despite this, the data were still analysed to see if a metabonomic approach could 
profile the body's response to fracture healing. To add to the initial disappointment, 
the cohort of clinical samples obtained contained no clear groupings of time-setted 
samples. After the initial urine samples collected at t=0, any subsequent urine 
samples were collected anything from 7 to 133 days post-fracture, with no separation 
into more discrete groups; the samples were spread more or less evenly from 7 to 
133 days. Because of this, the whole dataset was split into three groups, those at t= 
0, those under 21 days post-fracture, and all remaining samples post-fracture. For 
the ankle cohort, only two groups could be generated (those from t=0, and all other 
samples post-fracture) due to the lack of samples. 
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Statistical analysis of each of the three models generated from the two ionisation 
modes and using both RP- and HILIC-MSs data (as well as the concatenated data) 
produced some variables that were consistent across the models. 
Despite the many setbacks that limited the potential success of the work presented 
within this chapter, there were some results that show some promise for further 
analysis of clinical samples from fracture patients. Further to this, the proteomic work 
produced some very interesting results, which should be investigated further. 
4.10. Conclusions 
The work presented within this chapter used the `metabonomics toolbox' generated 
in Chapter Three in an attempt to profile the body's response to a fracture. Despite 
none of the recruited patients' fractures going to non-union, the study was flawed 
from the offset by the lack of proper time-setted samples, something which was 
beyond my control. However, after the initial cause of poor RP analyses was found to 
be caused by large amounts of protein being present in the majority of the clinical 
urine samples, subsequent RP- and HILIC-MS analyses provided some PLS models 
with reasonable external classification results, as summarised in figure 4.10.1: 
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Figure 4.10.1. A graph comparing the external classification rates for each 
developed PLS model. 
The external classification results are not as high as those presented in Chapter 
Three for the healthy volunteer samples, but the models relate to a more complex 
question than discrimination according to gender, time of collection and age, and 
would also be expected to be lower due to the lack of more discrete time-setted 
groups. Despite the high levels of protein, which was unexpected and has not been 
described in metabonomic literature before on the scale shown here, and the lack of 
many metabolite identifications (other than the possible detection of a steroid 
glucuronide), this work has produced some candidate biomarkers that could be 
related to the fracture healing process; obviously, the biomarkers are tenuous at 
best, due to the lack of clear, time-setted samples. 
This work has also highlighted the conclusions in chapter 3.3, that proper design and 
implementation of a metabonomic study is vital if the end results are to stand any 
chance of being robust and of significance for hypothesis generation. 
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4.11. Retrospective view 
Despite the original aims of the work undertaken within this chapter not being met, 
there are lessons that have been learnt. An `ideal' experimental design can be 
proposed from the shortcomings highlighted: 
" Thorough initial design of study 
" Development of correct ethical guidelines 
" Involvement of all parties before study commences 
" Recruitment of patients 
o More patients required 
o More patient information obtained (as outlined in Chapter 
3.8.1) 
" Samples collected in the same manner 
o All samples treated in the same manner 
o Frozen within the same timescale 
" Analysis of samples using a broad range of analytical methods 
" Thorough statistical evaluation of resulting data 
" Consultation with all parties of results obtained 
" Re-analysis depending upon outcome 
" Clinical testing based upon results obtained 
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Chapter Five: Lipopeptide analysis 
5.1. Introduction 
5.1.1. Introduction to Pseudomonas chiororaphis PCL 1391 and tomato foot 
and root rot 
Many plants have an intimate association with soil microorganisms in the 
rhizosphere'; some interactions can cause plant disease, whilst others can 
conversely protect against disease. Tomato foot and root rot is such a disease, which 
results in leaf yellowing, loss of turgidity and ultimately the death of the plant. Foot 
and root rot in tomato plants is caused by the fungal pathogen Fusarium oxysporum 
f. sp. radicis-lycopersici; the fungus colonises the xylem within plants and affects the 
transport of water throughout the plant, causing Fusarium wilt. The use of synthetic 
fungicides can (partially) suppress the effects of foot and root rot, however, there are 
both environmental and human/animal health questions about the desirability of long 
term usage of such synthetic fungicides. Beneficial plant-microbe interactions are 
therefore of interest, as these can provide in situ protection against pathogens, which 
could reduce man's reliance upon synthetic fungicides to aid the promotion of a 
healthy rhizosphere, increasing plant/crop productivity. 
Various strains of Pseudomonas bacteria have been shown to possess biocontrol 
properties (Thomashow and Weller, 1995; Haas and Defago, 2005); pathogens are 
generally not completely removed from the rhizosphere by the actions of the 
biocontrol agents, but show reduced growth and lack/reduction of disease symptoms. 
A bacterial library isolated from the tomato rhizosphere from a commercial field in 
Andalucia, Spain has been analysed for the potential ability to cause disruption to the 
fungal pathogen that causes foot and root rot (Chin-A-Woeng et al., 1998). The most 
active strain isolated was Pseudomonas chlororaphis PCL 1391, which was found to 
secrete many secondary antifungal metabolites (AFMs) such as hydrogen cyanide, 
chitinases, proteases and a hydrophobic compound, identified as phenazine-1- 
carboxamide (PCN) (Chin-A-Woeng et al., 1998). 
Phenazines are heterocyclic nitrogen-containing molecules that exhibit broad- 
spectrum antibiotic activity by inhibiting growth/metabolism (Turner and Messenger, 
1986), and have been shown to be toxic to many organisms including bacteria, fungi 
and algae (Toohey et al., 1965). 
1 The zone in soil immediately surrounding plant roots. 
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The effectivity of AFMs (such as PCN) for plant protection requires a delivery to the 
fungal pathogen for which bacteria need to be efficient colonisers of plant roots. More 
recently, Pseudomonas species have been shown to produce biosurfactants that are 
generally cyclic lipopeptides (CLPs) (Nielsen et al., 2002). CLPs can be likened to 
the shape of a magnifying glass, where the handle corresponds to a fatty acid (FA) 
chain, and the glass to an amphiphilic ring structure consisting of amino acids (AAs). 
CLPs are thought to aid in the biocontrol of disease by causing disruption to lipid 
membranes/outer membrane structures (Coraiola et al., 2006) by creating 
transmembrane pores, which when combined with AFMs, actively decrease fungal 
pathogen activity. CLPs have a broad range of structures (Desai and Banat, 1997), 
which explains the large and varied number of biological properties of Pseudomonas 
biosurfactants (Nielsen et al., 2002). 
5.1.2. CLP production 
Whilst the ribosomal synthesis of proteins and peptides is template driven by the use 
of messenger and transfer RNA, the synthesis of CLPs by gram negative bacteria is 
non-ribosomal, and is catalysed by large peptide synthetases (Marahiel et al., 1997; 
Nielsen et al., 2002). Polypeptide chains are `grown' using a thiotemplate 
mechanism, where 'domains' allow the sequential addition of specific AAs onto a 
growing product (lipopeptides or other antibiotics such as vancomycin). Many 
reactions, such as adenylation, thiolation, condensation and epimerisation (to name 
but a few) also occur, and allow modifications such as the cyclisation of polypeptide 
chains through the formation of an ester bond, or the addition of FA moieties 
(Marahiel et al., 1997). 
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5.1.3. CLP analysis by CID tandem MS and amino acid analysis 
Both CLPs and AFMs can be analysed using a variety of methods such as LC, 
MS(MS) (Yakimov et al., 1999; Yang et al., 2006), LC-MS(MS) (Chin-A-Woeng et al., 
1998), GC-MS (Yang et al., 2007), NMR (Ptak et al., 1980; Chin-A-Woeng et al., 
1998; Scott et al., 2007), amino acid analysis (AAA) (Rodrigues, 2005) and by 
chemical tests (Wang et al., 2003). As for metabonomics, no single technique can 
provide a complete picture of a CLP structure, rather a combination of approaches 
has to be utilised in determine to obtain the full structure. 
The analysis of peptides (such as CLPs) using MS methods is well established', with 
peptide structural information being obtained upon CID, where bond cleavage occurs 
(principally the peptide bonds). The nomenclature for the fragmentation of peptides 
was originally proposed by Roepstoff and Fohlman (Roepstorff and Fohlman, 1984), 
with a subsequent modification to the nomenclature proposed by Johnson et al. 
(Johnson et al., 1987). 
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Figure 5.1.1. Peptide fragmentation nomenclature. (Johnson et al., 1987) 
OH 
Upon fragmentation of a peptide, if the charge remains on the N-terminus, the 
resulting fragments are described as either an, bn or cn ions; if the charge remains on 
the C-terminus after fragmentation, then the ions are described as either x, yn or Zn 
ions. The subscript `n' refers to the number of AAs in the fragment. For spectra of 
1 22,062 search results for the phrase 'peptide mass spectrometry' using http: 
//www. pubmed. com 
(accessed November 2007) 
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peptides obtained by low energy CID tandem MS of protonated peptides, the ions 
that are most commonly observed, correspond to b and y fragmentation pathways 
due to the peptide bond being the weakest, and therefore the easiest to break. 
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Figure 5.1.2. Proposed formation of b and y ions by CID tandem MS from many 
papers, principally (Thorne et al., 1990; Kenny et al., 1992; Yalcin et al., 1995; 
Summerfield and Gaskell, 1997). 
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Figure 5.1.2 shows the proposed mechanism for the formation of b and y ions from 
singly protonated peptides, as developed over a range of literature, but principally 
(Thorne et al., 1990; Kenny et al., 1992; Yalcin et al., 1995; Summerfield and 
Gaskell, 1997). The use of high energy CID (> 1 keV, such as that afforded by ToF- 
ToF MS) allows the formation of other fragment ions, which arise from cleavages of 
the side chains of AAs to form dn, vn or wn fragments. 
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Figure 5.1.3. Proposed fragmentation scheme for the isomeric AAs Leu and lie, 
showing their differentiation by the formation of different wn fragment ions (Johnson 
et al., 1988). 
Under the correct conditions, the formation of wn fragment ions from the relevant yn 
ion can be very useful, as isomeric AAs Leu and Ile can be differentiated by the 
formation of different wr, fragment m/z values (figure 5.1.3). 
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There are other fragment ions that can typically be found at low m/z values in tandem 
mass spectra (below m/z 150), namely immonium ions. 
R, 
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H2N 
Figure 5.1.4. Immonium ion formation. 
NI- 
R4 
OH 
Immonium ions (figure 5.1.4) are formed by a double cleavage of the peptide chain 
(an and yn type cleavage), and are indicative of the individual AAs that form the 
peptide chain. Some immonium ions are much less stable and thus less often 
observed than others. 
0 
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The most commonly-utilised precursor ions are protonated, however, the use of 
sodiated molecules as precursors has been reported (Grese et al., 1989; Teesch and 
Adams, 1990; Lin et al., 2001; Feng et al., 2003; Newton and McLuckey, 2004; 
Bensadek et al., 2007). Metal cationised species can often be considered a nuisance 
for peptide sequencing for the following reasons as described by Bensadek et al.: 
1. Sensitivity is reduced, as the total ion signal is distributed across several 
molecular species rather than just one. 
2. Metal cationised species require increased collision energy to obtain 
fragmentation. 
3. `Suboptimal' fragmentation patterns can be obtained'. 
Despite this, many papers have reported the low energy CID tandem MS analysis 
(mainly using quadrupole ion traps) of metal cationised peptides providing diagnostic 
fragment ions (Lin et al., 2001; Feng et al., 2003; Newton and McLuckey, 2004; 
Bensadek et al., 2007). Typically, very different fragmentation spectra are obtained 
upon CID analysis of cationised species when compared to that obtained from 
protonated molecules; much simpler spectra can be obtained, as fragmentation 
usually occurs by losses from the C-terminus, yielding predominantly b ions. Simple 
spectra were obtained using an ion trap, which has MS" capabilities, repeating the 
CID process, producing structural information by sequentially generating b ions (Lin 
et al., 2001; Feng et al., 2003; Newton and McLuckey, 2004; Bensadek et al., 2007). 
Analysis using a Q-o-ToF provides a much different fragmentation spectrum when 
compared to that obtained using an ion trap; increased fragmentation is usually 
obtained as the MS/MS step allows the generation of many more fragments, 
however, this can lead to harder spectra to interpret. 
For C-terminus sequencing using cationised species, peptides of less than ten 
residues are generally used as it has been shown to be harder to obtain cationised 
species above 1 kDa using ESI. The use of MALDI has been reported for the 
ionisation of peptides up to 16 residues in length, but again, difficulty in forming 
cationised molecules generally results in protonated species fragmented instead 
(Newton and McLuckey, 2004). 
1 Meaning that fragment ions cannot be interpreted or are structurally uninformative. 
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5.1.4. Amino acid analysis 
Amino acid analysis (AAA) is a process that can determine the quantities of individual 
AAs in a sample. The sample is first hydrolysed using a strong acid for a period of 24 
h at a temperature of 110 °C. This releases free AAs into solution by hydrolysing the 
peptide bonds. After hydrolysis, the sample is dried and reconstituted in a rehydration 
fluid that contains L-homo-Arg (0.01 M) as internal standard. 
Any free AAs within the reconstituted solution cannot be detected using fluorescence 
without first being derivatised. 
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Figure 5.1.5. Reaction scheme for the derivatisation of free AAs (Bruckner et al., 
1994). 
The derivatisation is carried out prior to reversed phase analysis of the resulting 
derivatised AAs using a C18 column. Free AAs in solution are reacted with N-iso-L- 
butyryl-L-cycteine (IBLC) and o-phthaldialdehyde (OPA) (figure 5.1.5); this is carried 
out on-line within the HPLC system. This method of AAA allows the routine detection 
of the L and D isomers of the following 12 AAs: Asp, Glu, Ser, Thr, Arg, Ala, Tyr, Val, 
Met, Phe, Leu and Ile. 
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5.1.5. Aims 
The aims of this work were to identify the components in a fraction isolated using 
HPLC of an ethyl acetate extract of P. chlororaphis PCL 1391 spent growth medium, 
provided by the Department of Biology, University of Leiden, the Netherlands. This 
fraction was selected for the presence of surface tension reducing ability. Here, the 
same methods as used in a metabonomic study were exploited, but in a very 
different manner. Both ESI- and MALDI-MS and tandem MS (along with chemical 
methods) were used for structural identification. In addition, racemic amino acid 
analysis was used to provide extra information on amino acid composition of the 
compounds in the fraction. 
A 
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5.2. Results 
5.2.1. Sample information 
A sample collected following HPLC fractionation of the supernatant obtained from an 
extract of Pseudomonas chlororaphis PCL 1391 was provided by the Institute of 
Biology, Leiden University, the Netherlands. Researchers at Leiden are studying PCL 
1391 in an attempt to unravel the mode of action of the antifungal metabolite 
phenazine-1-carboxamide, which is produced by this strain of bacteria; it was 
discovered that PCL 1391 also produced an unknown biosurfactant. 
Analysis of the HPLC fraction was undertaken as part of a long-standing 
collaboration between the JTO group at the University of York and Leiden University 
in the area of plant-microbe interactions. Initial findings by Leiden suggested that the 
unknown biosurfactant may be similar to the cyclic lipopeptide massetolide C (figure 
5.2.1), as a BLAST' search in Leiden had suggested that the PCL 1391 synthase 
sequence was similar to that of the synthase that produces massetolide C. 
L-Leu 
D-a/lo-lie D-Ser 
CH3(CH2)8CH(OH)CH2CO - L-Leu - D-GIu - D-allo-Thr L-Leu 
0 D-Ser 
L-Ile 
Figure 5.2.1. Structure of the CLP massetolide C. 
1 Basic Local Alignment Search tool that finds regions of similarity between nucleotide or amino acid 
sequences. 
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5.2.2. ESI-Q-o-ToF MS analysis of PCL 1391 extract 
The HPLC fraction was received in a glass vial and had been dried under vacuum in 
a centrifugal evaporator. The sample was reconstituted in 300 pL of MeOH before a 
dilution series was created. Initial positive ion mode ESI-Q-o-ToF MS studies showed 
that a dilution to 25 % of the original stock solution gave a satisfactory signal. 
PCL 1391 had already been shown to produce the secondary antifungal metabolite 
phenazine-1-carboxamide (PCN) (Chin-A-Woeng et al., 1998), this was expected to 
be present in the reconstituted solution as it co-eluted with the unknown biosurfactant 
(shown by HPLC UV chromatograms, in Leiden). Chin-A-Woeng et al. identified PCN 
by MS and NMR; their MS/MS analysis of a protonated molecule at m/z 224 
produced two fragment ions at m/z 207 and 179, which were identified as losses of 
NH3 and the carboxamide group respectively. A peak at m/z 224 was identified in the 
ESI-MS of the reconstituted solution and was postulated to correspond to PCN, 
which has a nominal mass of 223. 
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Figure 5.2.2. Product ion spectrum of proposed PCN peak at m/z 224. 
[M + H] 
224.07 
220 
The product ion spectrum of m/z 224 contained only two fragment ion peaks (figure 
5.2.2). The peak at m/z 207 corresponds to a loss of 17 Th, which is equivalent to the 
loss of NH3; the less abundant fragment ion at m/z 179 corresponds to the loss of the 
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carboxamide group, leaving the very stable phenazine ring. These MS/MS results are 
identical to those of Chin-A-Woeng et al., suggesting that the antifungal metabolite 
PCN was present in the HPLC fraction. 
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Figure 5.2.3. ESI-MS of putative biosurfactant from PCL 1391. 
The MS obtained upon the analysis of the diluted solution also exhibits a series of 
peaks above m/z 1000 (figure 5.2.3). The signals at m/z 1126,1148 and 1164 
correspond to a protonated, sodiated and potassiated molecule of nominal mass 
1125. This was in contrast to the expected protonated molecule at m/z 1168, 
suggesting that the fractionated surfactant did not correspond to massetolide C with 
a nominal mass of 1167, but to another compound. 
Analysing the literature for other known cyclic lipopeptides (CLPs) of nominal mass 
1125 gave three possibilities (Gross et al., 2007): 
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Table 5.2.1. CLPs reported within the literature with nominal mass 1125 (Gross et 
al., 2007). Each of the three CLPs cyclise through an ester bond between the AAs in 
positions 3 and 9. The pink shaded cells highlight the only differences between the 
three CLPs. 
AA Sequence Number 
FA 
CLP 1 2 3 4 5 6 7 8 9 
Moiety 
Massetolide C101 
L-Leu o-GIu D-a//o-Thr D-Val L-Leu D-Ser L-Leu D-Ser L-Leu 
F 3-OH 
C10, 
Viscosin L-Leu D-Glu D-a/lo-Thr D-Val L-Leu D-Ser L-Leu D-Ser L-Ile 
3-OH 
White line 
inducing C, o, 
L-Leu D-Glu D-a//o-Thr D-Val D-Leu D-Ser L-Leu D-Ser L-Ile 
principle 3-OH 
(WLIP) 
(Leu = Leucine, Glu = Glutamic acid, Thr = Threonine, Ser = Serine, lie = Isoleucine. ) 
The protonated molecule observed at m/z 1126, which could correspond to 
massetolide F, viscosin, WLIP or to an as yet unreported CLP, was analysed by CID 
tandem MS to produce fragment ions to aid in elucidating the structure of the 
unknown molecule. 
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Figure 5.2.4. Product ion spectrum of the protonated molecule at m/z 1126, with both 
y and b ion AA losses identified ('AA' in the sequence indicates unknown amino 
acid). 
On CID product ion tandem MS, many fragment ions were generated across a broad 
range of m/z values, with the structural interpretation of the fragment ions not being 
straightforward due to the cyclic nature of the putative CLP at m/z 1126 (figure 5.2.4). 
Two bond cleavages must occur to generate the y and b ions, with ring opening 
occurring principally at the ester bond. Losses corresponding to the AAs Leu and/or 
Ile, Glu, Thr, Val and Ser were found within the spectrum. Starting with the 
protonated precursor ion at m/z 1126, losses corresponding to Leu/Ile, Ser, Leu/Ile, 
Ser, Leu/Ile, Val, Thr and Glu are observed, which correspond to the b ions shown 
from b8 to b, and a,. A complementary partial y ion series from y8 to y2 was also 
observed. A common feature of positive ionisation, low energy CID, is the facile loss 
of water during fragmentation across a peptide backbone (Ballard and Gaskell, 
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1993); this can account for many of the peaks 18 Th less than the b or y series ions. 
The presence of an immonium ion at m/z 86 corresponds to the isomeric AAs Leu 
and lie, further suggesting the presence of either or both of these AAs within the CLP 
structure. 
955.54 843.44 714.40 613.36 514.30 401.22 314.19 201.11 114.09 
FA Leu* Glu Thr Val Leu* Ser Leu* Ser Leu* (113) (129) (101) (99) (113) (87) (113) (87) (113) -; 
171.14 41 284.22 413.24 514.30 613.36 726.42 813.67 41 926.52 411013.61 
------------------------------- 
Figure 5.2.5. Proposed structure of fragment ions (proposed cyclisation shown by 
hashed line and values in parenthesis correspond to AA residual masses) and 
assignment of biosurfactant from the CID tandem MS analysis of m/z 1126. Leu* 
could either be Leu or Ile and FA corresponds to fatty acid. Values in bold and blue 
indicate the fragment ions present in the product ion spectrum; values in black were 
not seen. 
From the structural information obtained upon the fragmentation of the precursor ion 
at m/z 1126 (figure 5.2.4), an AA sequence was proposed (figure 5.2.5). Each of the 
three published CLP structures (table 5.2.1) are known to cyclise between the AAs in 
position nine and three (corresponding to Leu/Ile and D-alto-Thr). For an ester bond 
to be formed, an -OH group needs to be present on one of the AA side chains in 
order for condensation to occur. This means that given the proposed structure (figure 
5.2.5), cyclisation could occur through the AAs Ser or Thr in positions three, six and 
eight. Condensation through Ser in positions six and eight is unlikely due to steric 
hindrance, leaving only three as the most likely site for cyclisation. From the product 
ion spectrum (figure 5.2.4), the C-terminal fragments y8 and y7 are more intense than 
lower m/z y ions; this suggests that the cleavage between Leu-Glu (positions one 
and two) and Glu-Thr (positions two and three) was easier than that of Thr-Val 
(positions three and four). This would require cleavage of two bonds, rather than one, 
consistent with cyclisation occurring between the C-terminal carboxylic acid and the 
OH in the side chain of Thr (as in the three reported CLP structures). 
As the literature relating to sodiated peptide fragmentation suggests that the 
fragmentation obtained is simpler to interpret than protonated peptide 
fragmentation 
(Grese et al., 1989; Teesch and Adams, 1990; Ballard and Gaskell, 
1993; Lin et al., 
2001; Feng et al., 2003; Newton and McLuckey, 2004), the sodiated molecule at m/z 
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1148 was analysed by CID tandem MS to try and simplify the resulting product ion 
spectrum of the cyclic CLP. 
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Figure 5.2.6. Product ion spectrum of the sodiated molecule at m/z 1148. 
The product ion spectrum of the more intense sodiated molecule at m/z 1148 
contains many fragments across a broad range of m/z values, which at first glance 
yields an even more complex spectrum than that of the protonated molecule (figure 
5.2.4). In contrast to the literature, where sodiated peptides produce fragment ions 
almost exclusively from the C-terminus, there are many peaks present that cannot be 
readily identified, with the exception of a few b and y ions that correspond to the 
sodiated mass of the fragment ions already identified in figure 5.2.4. 
As more evidence was required to assign the structure of the CLP, and given the 
complexity of the resulting product ion spectrum from subjecting the CLP to CID 
tandem MS in its cyclic form, it was decided to open the ring to form a linear peptide, 
hopefully simplifying the resulting product ion spectrum. 
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5.2.3. ESI-Q-o-ToF MS analysis of CLP after treatment with base 
Research by Kuiper et al. into biosurfactants produced by other Pseudomonas 
strains, used MS analysis before and after mild base treatment followed, to 
demonstrate cyclisation by an ester bond (as in the structures massetolide F, 
viscosin and WLIP) and to subsequently provide a linear peptide, which provided a 
simpler tandem MS spectrum to interpret (Kuiper et al., 2004). Upon the MS analysis 
of the treated surfactant, Kuiper et al. observed an increase of 17 Da to the mass of 
the biosurfactant, consistent with the addition of ammonia across the ester bond; C- 
terminal fragment ions were also shifted by 16 Th. 
The putative CLP with nominal mass 1125 was therefore treated with mild base (1: 1 
35 % NH4OH: MeOH) overnight, which would be expected to cleave the proposed 
ester bond, creating a linear peptide with a protonated molecule at m/z 1143. 
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Figure 5.2.7. ESI-Q-o-ToF MS of CLP after treatment with ammonium hydroxide. 
The resulting MS analysis of the base treated CLP shows five intense peaks at m/z 
1126,1143,1148,1158 and 1180 (figure 5.2.7). From the previous MS analysis of 
untreated CLP (figure 5.2.3), the peaks at m/z 1126 and 1148 correspond 
to the 
protonated and sodiated molecules of cyclic CLP with nominal mass 
1125. The peak 
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at m/z 1143 is 17 Th higher that the protonated untreated CLP peak, meaning that 
despite the presence of unreacted CLP, the addition of ammonia across the ester 
bond appeared to have been partially successful. The two remaining peaks at m/z 
1158 and 1180 have an increase of 32 Th from the protonated and sodiated 
untreated CLP peaks; this has been described before by Joao Rodrigues from the 
JTO group, where an increase of 32 Th corresponded to the addition of MeOH 
across the ester bond of a related CLP, rather than ammonia as expected 
(Rodrigues, 2005). 
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Figure 5.2.8. Product ion spectrum of the CLP treated with base. 
The product ion spectrum resulting from CID tandem MS analysis of m/z 1143 (figure 
5.2.8) showed a more complex spectrum than was expected for a ring-opened CLP. 
Upon isolation of the precursor ion at m/z 1143 with no collision energy (CE) applied, 
the peak immediately disappeared to yield the peak at m/z 1126 (figure 5.2.8). When 
the CE was increased, the fragmentation was extensive, generating a spectrum 
almost identical to that of the untreated CLP at m/z 1126 (figure 5.2.4). 
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As the peak at m/z 1126 was immediately observed upon isolation of the supposed 
ring opened CLP at m/z 1143, it suggests that the increase of 17 Th was caused by 
an ammonium adduct, rather than a ring-opened compound in which ammonia is 
added across the ester bond. Kuiper et al. did not isolate an ammonia adduct, as 
subsequent CID tandem MS analysis of their treated biosurfactant showed an 
increase of 16 Th for any observed C-terminus fragment ions (Kuiper et al., 2004). 
Conversely, no change in any of the observed b and y fragment ions was observed 
here; the isobaric fragments b3 & y5, and b4 & Y6 should have not been present in the 
resulting spectrum, as the y5 and y6 fragment ions increased from m/z 514 and 613 to 
m/z 530 and 629 respectively. 
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Figure 5.2.9. Product ion spectrum of protonated lipopeptide observed at 32 Th 
higher than the cyclic lipopeptide. 
CID product ion analysis of the protonated molecule at m/z 1158 (figure 
5.2.9) 
yielded a much simpler spectrum, with easily assignable b and y ion series 
(as 
expected for a linear peptide). The increase of 32 Th arising from transesterification, 
which results in the addition of elements of methanol across the ester 
bond, can be 
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confirmed by a shift of 32 Th for each of the observed y ions. Despite the addition of 
methanol being an unintended side reaction, it was of use, providing a ring opened 
CLP. Even though incomplete b and y ion series were observed, the presence of b3_8 
and y5_7 ions aids in strengthening the proposed AA sequence assignment (figure 
5.2.5). 
CID tandem MS analysis of the sodiated ring opened CLP at m/z 1180 did not yield 
any additional information than the protonated precursor. To confirm the proposed 
AA sequence (and to attempt to elucidate the Leu/Ile uncertainty), a full range of 
fragment ions (including w ions) should be obtained to assign all of the AAs present, 
along with the FA moiety mass. For this reason, high energy CID using a MALDI- 
ToF/ToF was undertaken. 
5.2.4. High energy MALDI-ToF/ToF MS analysis of the CLP 
For analysis using high energy (HE) CID MALDI-ToF/ToF, an aliquot of both the 
untreated CLP and the CLP treated with mild base were analysed using MALDI-MS, 
using x-cyano-4-hydroxycinammic acid as the matrix. As for ESI-MS, MALDI-MS 
produced both protonated and sodiated molecules. 
HE-CID tandem MS analysis of the protonated molecule of CLP at m/z 1126 and that 
of the CLP treated with base at m/z 1158 did not yield any additional fragment ions 
than those already observed using LE-CID tandem MS. Because of this, peaks for 
the sodiated molecules were analysed to see if their resulting product ion spectra 
were more informative than those obtained at low energy using ESI-Q-o-ToF MS 
analysis. 
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Figure 5.2.10. HE-CID tandem MS analysis of sodiated CLP at m/z 1148. 
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The HE product ion spectrum from the sodiated molecule at m/z 1148 yielded a 
simpler spectrum than the LE-CID analysis, with fewer fragment ion peaks being 
observed (figure 5.1.10). Whilst this should have made interpretation easier, there 
were some fragment ions present for which no plausible structure could be proposed. 
An extensive search of the literature failed to highlight any previous studies where 
MALDI-ToF/ToF had been used for the analysis of sodiated peptides by HE-CID 
tandem MS. Following the literature on LE-CID analysis of sodiated peptides, it was 
expected that much structural information would gbe obtained, possibly from the C- 
terminus (Grese et al., 1989; Teesch and Adams, 1990; Lin et al., 2001; Feng et al., 
2003; Newton and McLuckey, 2004); however, the lack of any particularly structurally 
useful ions observed here may perhaps be accounted for by the closed ring 
structure. 
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Figure 5.2.11. HE-CID tandem MS of sodiated CLP treated with base at m/z 1180. 
Interestingly, the HE-CID tandem MS analysis of the sodiated CLP treated with base 
at m/z 1180 produced a very informative spectrum, with many C and N-terminal 
fragment ions being present across a broad range of m/z values (figure 5.2.11). HE- 
CID causes less intense ions arising by loss of water from AAs, therefore reducing 
the complexity of resulting product ion spectra. However, other so called `satellite 
ions' formed from side chain cleavages can be observed; this can be of great benefit 
when differentiation between isobaric AAs Leu and Ile is sought. 
A full series of fragment ions from the N-terminus (a, series) were obtained, which 
when combined with the near complete y,, series (from the C-terminus), shows that 
the AA sequence corresponds to that proposed earlier (figure 5.2.5). The FA moiety 
has a mass of 171 Da, which is consistent with a saturated hydroxylated C, o FA 
chain (Gross et al., 2007). 
Perhaps even more surprising from a sodiated spectrum (given the literature), was 
the presence of three fragment ions that correspond to a loss of 59 Th from y9, y5 and 
y3, which is consistent with the positioning of three Leu/Ile AAs in the proposed 
sequence (figure 5.2.5). A loss of 59 Th giving w9, w5 and w3 fragment ions, is 
consistent with side chain losses from Leu. If the AAs present were Ile, then the 
losses from they ions y9, y5 and y3 would have been 15 and 41 Th (Johnson et al., 
1988). 
257 
Chapter Five: Lipopeptide analysis 
Despite the demonstration that three out of the four possible Leu/Ile combinations 
were Leu, the remaining terminal AA was not identified due to no yi or w, peaks 
being observed in the HE-CID spectrum. In order to ascertain if the remaining AA 
was Leu or lie, it was decided to attempt to add a larger group during ester cleavage, 
with the intention of shifting the yi ion to slightly higher m/z. 
5.2.5. HE-CID MALDI-ToF/ToF tandem MS analysis of CLP treated with base 
and butanol 
The use of mild base would be expected to cleave an ester bond, adding ammonia 
across the bond and giving an increase of 17Th in the resulting MS (Kuiper et al., 
2004); in this case, however, the addition of MeOH was observed with an increase of 
32 Th being evident. In order to attempt to obtain a y, ion upon HE-CID tandem MS 
analysis of a ring opened CLP, it was decided to add a larger group that would 
hopefully allow the generation a more stable yi fragment ion. 
The CLP was treated overnight with mild base (35 % ammonium hydroxide), this time 
mixed with butanol (BuOH) instead of MeOH. An increase of 74 Th would be 
expected in the resulting MS, consistent with ring opening and the addition of BuOH 
across the ester bond. 
100 
80 
2: 1 
c 60 
c 
40 
20 C°" _ co + 
N5 r 
0 
N- 
CD 
Nl- 
CD 
CD +32 
3 
c° + NH 
1141.8 1164.6 m/Z 
# Co 
(c 
N 00 
CD Co 
1187.4 
+ 74 
00 pllý 
N 
N 
N 
1210.2 
Figure 5.2.12. MALDI-ToF/ToF MS of CLP treated with mild base and butanol. 
1233.0 
258 
Chapter Five: Lipopeptide analysis 
The resulting MALDI-MS of the CLP treated with mild base and BuOH exhibits more 
peaks than were expected. The most intense peak at m/z 1148 is consistent with 
sodiated CLP (the corresponding protonated peak at m/z 1126 has a very low 
intensity), with other sodiated molecules at 17,32 and 74 Th higher, corresponding to 
the addition of ammonia, MeOH and BuOH respectively. The addition of BuOH gave 
rise to a low intensity peak at m/z 1222, suggesting that perhaps the bulky nature of 
the alkyl chain prevented the efficient addition of BuOH across the ester bond due to 
too much steric hindrance. The peak at m/z 1180 corresponds to the addition of 
MeOH across the ester bond; as only 5 pL of a methanolic solution of CLP had been 
added to 1 mL of mild base and BuOH mixture, it was thought that BuOH would react 
with much greater efficiency. The sodiated molecule at m/z 1166 again corresponds 
to the adduction of ammonia, which has a much higher intensity than for the previous 
ring cleavage using methanol (figure 5.2.7). 
HE-CID tandem MS analysis of the three peaks at m/z 1166,1180 and 1222 failed to 
produce any spectra with increased levels of fragmentation (not shown). As the 
species deriving from the addition of BuOH was least intense, the ion was too weak 
to allow a reasonable signal to noise ratio in the product ion spectrum, meaning that 
adding a larger group did not aid in obtaining the necessary yi ion needed for 
differentiation between Leu and Ile in position nine. 
5.2.6. Amino acid analysis 
In order to fit the final pieces of the jigsaw, it was decided to use amino acid analysis 
(AAA) to elucidate both the AA composition, and to determine the configuration of 
each of the AAs (either D or L). This requires that each of the AAs present be free in 
solution; the CLP was therefore hydrolysed to free the AAs. The free AAs in solution 
were then derivatised to allow their detection using fluorescence. The RP analysis of 
the hydrolysed and derivatised AAs using the method by Penkman (Penkman, 2005) 
lasted for 95 minutes, with seven substantial peaks present in the resulting 
chromatogram (figure 5.2.13). From the three reported CLPs (massetolide F, viscosin 
and WLIP), there could have been up to nine peaks present from the different 
possible AA combinations. 
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Figure 5.2.13. Resulting UV fluorescence chromatogram from the AAA of the CLP. 
From the retention times of each of the seven substantial peaks, the following AAs 
are present within the CLP structure: D-GIu, D-Ser, D-alto-Thr, D-Val, L-Ile, L-Leu and 
D-Leu. The internal standard at 49.5 min was used to calculate the concentrations of 
each of the AAs present in order to evaluate the stoichiometry (figure 5.2.14). 
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Figure 5.2.14. Graphical representation of the amount of each AA detected. 
Despite there being some fluctuations between the absolute amounts of the AAs 
shown in figure 5.2.14, it is clear to see that two of the AAs (D-Ser and L-Leu) are 
present at higher concentrations than the other AAs. Dividing all of the amounts by 
the smallest, gives the ratio of AAs to be 1.1 : 2.0: 1.21.11.02.3: 1.2, which 
when rounded to the nearest whole number is 1: 2: 1: 1: 1: 2: 1 (totalling nine 
AAs), giving the stoichiometry to be one of each of the AAs D-Glu, D-alto-Thr, D-Val, 
L-Ile, and D-Leu with two of each of the AAs D-Ser and L-Leu; WLIP has the same AA 
composition as that determined here. 
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5.3. Conclusions 
An RP-HPLC fraction containing a surfactant (initially proposed by our collaborators 
to be similar to massetolide C on basis of the preliminary mass) and an AFM 
extracted by collaborators from the culture supernatant of Pseudomonas chiororaphis 
PCL 1391 were supplied for analysis and subsequent structural identification. CID 
tandem MS of the AFM using ESI-Q-o-ToF was consistent with phenazine-1- 
carboxamide, which has previously been reported as produced by this strain (Chin-A- 
Woeng et al., 1998). The identification of the surfactant was less straightforward than 
that of the AFM. The initial LE-CID tandem MS of the surfactant yielded substantial 
structural information consistent with a CLP, but was difficult to fully interpret due to 
the ring structure. 
Treating the CLP with mild base to cleave the ester bond gave an addition of 32 Th 
across the ester bond, which was due to the addition of methanol (Rodrigues, 2005) 
rather than ammonia as expected (Kuiper et al., 2004). LE-CID tandem MS analysis 
of the ring-opened lipopeptide gave a simpler spectrum with fewer fragment ions than 
the cyclic structure, so that structural information was incomplete. 
HE-CID-MALDI-ToF/ToF allowed differentiation between Leu and Ile for three out of 
the four possible Leu or Ile assignments from the loss of 59 Th (wn fragment ions), as 
well as providing a complete series of a,, ions and near-complete series of yn ions. 
These results were in contrast to the literature on sodiated peptides (Grese et al., 
1989; Teesch and Adams, 1990; Lin et al., 2001; Feng et al., 2003; Newton and 
McLuckey, 2004; Bensadek et al., 2007), where C-terminal fragment ions were 
reported to be the predominant species. To the author's knowledge, the observation 
of wn fragment ions from sodiated precursor ions has not previously been described 
in the literature, perhaps due to the difficulty in obtaining sodiated peptides with a 
free amino terminus, which would preferentially protonate. 
As the yi ion, which would have allowed the differentiation of the final Leu/Ile AA, 
was not observed (even after the addition of BuOH to increase the mass of the y, 
fragment ion), it was decided that AAA be used to attempt to complete the 
identification of the CLP produced by PCL 1391. 
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Table 5.3.1. Comparison of MS and AAA results. 
* Differen 
Detection Method 
Amino Acid AAA MS 
Glutamic acid 1 1 
Serine 2 2 
Threonine 1 1 
Valine 1 1 
Isoleucine 1 0 
1* Leucine 3 
fiation between one AA (elfhPr AIII º ýný. ý 
3 
nn+ An nh+ ý; jw4 -- - -- -i ---. ý ..,. ... ......,.,..... 
Table 5.3.1 shows the complementary results obtained by the MS and AAA methods. 
The use of AAA allowed the Leu/Ile in position nine to be identified as lie, as well as 
the D and L configurations of the AAs in the CLP. Combining all of the information 
obtained from both analysis methods allows the structure of the CLP to be proposed 
(figure 5.3.1). 
D-Leu 
D-Val D-Ser 
/1 
CH3(CH2)6CH(OH)CH2CO-L-Leu-D-GIu-D-a//o-Thr L-Leu 
0 o-Ser 
L-IIe 
Figure 5.3.1. Structure of the CLP as determined by MS and AAA. The position of 
the hydroxy group was not determined, but is proposed to be a 3-hydroxylated FA by 
homology. (Coraiola et al., 2006). 
The structure as proposed from MS and AAA, corresponds to the structure of white 
line inducing principle (WLIP). WLIP has previously been reported by Coraiola et al. 
(Coraiola et al., 2006) as being produced by Pseudomonas chlororaphis, having the 
ability to permeabilise membranes; something that is likely to be required if PCL 
1391 is to counteract the effects of tomato foot and root rot caused by the fungal 
pathogen Fusarium oxysporum f. sp. radicis-lycopersici. 
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6.1. Conclusions 
The primary focus of the work presented within this thesis was the development of a 
robust LC-MS `metabonomic toolbox', where all current thoughts for metabonomic 
studies were brought together and critically compared and evaluated. A to date 
rarely-used HILIC separation technique was successfully applied for the 
metabonomic analysis of both cohorts of human urine samples (those obtained from 
volunteers within the Department of Chemistry, and those from patients who had 
suffered a bone fracture), showing that different compounds were detected when 
using this method compared to the commonly-employed RP separation approach. 
This was an expected result, and confirmed the fears that the sole use of RP 
separation for metabonomic studies of urine is likely to mean that a potentially large 
wealth of information has been missed and not detected. As more metabonomic 
studies utilise a HILIC separation method, it can only be hoped that the wider 
scientific community (not restricted to metabonomics) adopts this technology to 
increase the coverage obtained for the analysis of biofluids when using LC-MS 
analytical methodologies. 
It was shown that concatenating LC-MS datasets (±RP-LC-MS and ±HILIC-MS data) 
together generated robust statistical models according to the external CV values, and 
by also comparing the individual PLS models to the concatenated PLS models. This 
is a method that shows great promise for future metabonomic studies, where LC-MS 
and NMR platforms are used (or even combined) to obtain a more representative 
picture of the compounds contained within a biofluid. The use of such a data analysis 
method may highlight potential metabolites, or groups of metabolites, that may fail to 
be found when only statistically analysing data from a single dataset (e. g. +RP-LC- 
MS); further to this, data concatenation also provides an idea of which variables are 
the most influential across all models, rather than just one. One problem that data 
fusion could encounter is the use of variables from different datasets to form a model 
when, in fact, they correspond to the same compound; the resulting variables should 
therefore be checked for any similarities in retention times and m/z values to identify 
any such variables. 
Other conclusions from the work presented in Chapter Three are that the popular use 
of normalising to creatinine could potentially skew results, as the levels of excreted 
creatinine have been shown to be easily perturbed by many factors, such as illness. 
Comparing normalisation to creatinine (from healthy volunteers) to normalisation 
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using total ion count, showed that the two methods were comparable in as much as 
the most important variables for each discriminatory model developed were 
consistent. Overall, the work presented in Chapter Three has shown that the field of 
metabonomics is still very much in its infancy and lacks a common theme whereby 
samples are carefully obtained, analysed and reported; this is something which will 
hopefully come with maturity. 
The use of the developed metabonomic toolbox for the analysis of clinical urine 
samples to profile the body's response to bone fractures (with the goal of identifying 
potential biomarkers of delayed or failed fracture healing) did develop discriminatory 
models, which highlighted potential biomarkers that could be related to the fracture 
healing process. However, the study was flawed from the offset by the lack of time- 
setted samples, and the fact that none of the patients suffered failed fracture healing. 
Drawing together the conclusions from Chapters Three and Four, as well as the 
retrospective views, highlights that careful planning is required before samples are 
collected to ensure that any subsequent analysis stands the greatest possible 
chance of being a success. 
Perhaps the most interesting piece of work from Chapter Four stemmed from the 
sample issues, which was found to correspond to very high levels of protein within 
the clinical urine samples. The protein corresponded to a broad range of molecular 
weight and function. The larger proteins corresponded were related to the body's 
immune system, which suggests that the presence of the large amounts of protein 
found in the clinical urine samples may have been caused by some kind of 
immunological response to either stress or resulting treatment. This is certainly an 
area where more research needs to be undertaken in an attempt to understand why 
so much protein was detected. 
Both Chapters Three and Four showed that the most common problem of 
metabonomic analyses is the subsequent identification of potential biomarkers 
highlighted from statistical studies. This `poor' biomarker identification could have 
been resolved by the combination of higher mass accuracy instrumentation and NMR 
after the fractionation and purification of potential biomarkers. For biomarkers that 
were proposed, the analysis of standards using LC-MS/MS would 
have confirmed if 
the proposed compounds were correct, allowing further justification to 
be sought by 
relating the identified biomarker to the biological process 
in question. 
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An additional, piece of work is also presented in this thesis. An ethyl acetate extract 
(provided by the Department of Biology, University of Leiden, the Netherlands) of 
Pseudomonas chlororaphis PCL 1391 spent growth medium, containing an unknown 
biosurfactant, was successfully analysed using ESI-Q-o-ToF MS(MS), MALDI- 
ToF/ToF MS(MS) and racemic amino acid analysis. The in-depth study elucidated 
both the amino acid sequence and the stereochemistry of the amino acids present 
within the cyclic lipopeptide. The high energy MALDI-ToF/ToF CID tandem MS 
analysis of the sodiated cyclic lipopeptide molecule generated characteristic wn 
fragments, which allowed the differentiation between the isomeric amino acids Leu 
and Ile; the use of sodium cationised non-tryptic peptides has seldom been reported 
in the literature, as sodiated tryptic peptides are commonly considered as a nuisance 
rather than a benefit. All of the analytical methods together allowed the structure of 
the cyclic lipopeptide to be postulated as corresponding to white line inducing 
principle, WLIP. 
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6.2. Future work 
Future work that could stem from the work presented in this thesis is as follows: 
0 An in-depth study into normalisation methods: is the use of normalising to 
total ion count acceptable? Are there any other endogenous metabolites that 
could be used which are not perturbed by illness or other factors? 
0 The statistical models presented within Chapters Three and Four should be 
studied in more depth. The sole use of external classification results does not 
give an in-depth view of the data; the number of variables that were used to 
develop each model should be assessed, along with their relative weightings. 
A further way of probing the variables detected is to quantify which variables 
are most persistent, not only for each model, but across all models. 
0 The refinement and development of data fusion techniques for the analysis of 
LC-MS data, and also for the inclusion of complementary NMR data is 
needed. However, LC-MS datasets cannot just be concatenated to NMR data 
as the data is different. Hierarchical analysis works by first generating PLS 
models for data which is the same, so there would be two different models for 
LC-MS and NMR data for example, and then compares the scores (linear 
combinations of the original data) from each developed model by PLS. This 
allows the comparison of two different types of data and should allow more in- 
depth metabonomic studies to be achieved where all of the data obtained 
from multiple platforms can be analysed both separately and together, 
hopefully giving a global metabolite profile. 
" The use of higher mass accuracy MS/MS and also NMR to elucidate the most 
important variables as produced by each of the developed models from both 
Chapters Three and Four. 
" The unexpectedly high levels of protein detected in the clinical urine samples 
should be investigated further. The data presented in Chapter Four should 
first be linked back to the original patient files to see if there is anything that 
can be correlated to an increase in the excretion of protein. Further simple 
tests could be carried out: for fracture patients admitted to accident and 
emergency, their levels of protein could be detected using a simple 
dip-stick 
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method. This would allow a comparison of the levels found within this study to 
other samples; it would be very interesting to see if there is a correlation, or if 
the clinical samples were unique in their protein concentrations. 
0 The study of urine samples from patients suffering a bone fracture should be 
re-designed as outlined in the conclusions/retrospective work from Chapter 
Four to obtain biofluids from patients at multiple, regularly spaced time points 
with the inclusion of more patients who suffered delayed fracture healing. It 
would also be interesting to analyse serum samples using metabonomics to 
see if the same conclusions can be drawn. 
0 The work presented in this thesis has prompted a joint study with Hull 
University into the metabonomic study of properly time-setted urine, serum, 
plasma, saliva and cancer cells from patients at various stages of colonic 
cancer. 
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Appendix A 
Randomly 
Age Number Assigned Initial Code Sex Age Smoker Time of 
Code Group Aliquots 
004 F01A FEMALE 38 NO 36-40 AM 12 
005 F01 B FEMALE 38 NO 36-40 PM 12 
019 F02A FEMALE 22 NO 21-25 AM 16 
023 F02B FEMALE 22 NO 21-25 PM 15 
018 F04A FEMALE 24 NO 21-25 AM 16 
024 F04B FEMALE 24 NO 21-25 PM 10 
007 F05A FEMALE 51-55 NO 51-55 AM 10 
015 F05B FEMALE 51-55 NO 51-55 PM 10 
051 F09A FEMALE 27 NO 26-30 AM 10 
038 F10A FEMALE 26-30 NO 26-30 AM 7 
039 F1OB FEMALE 26-30 NO 26-30 PM 10 
012 Fl 3A FEMALE 40 NO 36-40 AM 16 
013 F13B FEMALE 40 NO 36-40 PM 16 
037 Fl 5A FEMALE 47 YES 46-50 AM 16 
047 F15B FEMALE 47 YES 46-50 PM 10 
049 F20A FEMALE 24 NO 21-25 AM 10 
050 F20B FEMALE 24 NO 21-25 PM 16 
009 M01 A MALE 23 NO 21-25 AM 14 
010 M01 B MALE 23 NO 21-25 PM 10 
034 M02A MALE 39 NO 36-40 AM 14 
043 M02B MALE 39 NO 36-40 PM 15 
030 M03A MALE 34 NO 31-35 AM 12 
041 M03B MALE 35 NO 31-35 PM 11 
035 M04A MALE 42 NO 41-45 AM 10 
042 M04B MALE 42 NO 41-45 PM 10 
008 M05A MALE 41-45 NO 41-45 AM 9 
011 M05B MALE 41-45 NO 41-45 PM 10 
031 M07A MALE 35 NO 31-35 AM 10 
036 M07B MALE 35 NO 31-35 PM 14 
057 M09A MALE 22 NO 21-25 AM 10 
058 M09B MALE 22 NO 21-25 PM 12 
055 M11 A MALE 30 NO 26-30 AM 10 
056 M11 B MALE 30 NO 26-30 PM 10 
022 M12A MALE 28 NO 26-30 AM 10 
028 M12B MALE 28 NO 26-30 PM 14 
002 M13A MALE 30 NO 26-30 AM 16 
053 M13B MALE 30 NO 26-30 PM 10 
016 M14A MALE 23 NO 21-25 AM 10 
027 M14B MALE 23 NO 21-25 PM 14 
017 M15A MALE 26-30 NO 26-30 AM 14 
026 M15B MALE 26-30 NO 26-30 PM 16 
060 M20A MALE 22 NO 21-25 AM 16 
061 M20B MALE 22 NO 21-25 PM 10 
045 M21 A MALE 26 YES 26-30 AM 10 
046 M21 B MALE 26 YES 26-30 PM 8 
048 M22A MALE 36 NO 36-40 AM 10 
054 M22B MALE 36 NO 36-40 PM 10 
021 M23A MALE 52 NO 51-55 AM 10 
029 M23B MALE 52 NO 51-55 PM 14 
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Randomly Age Number 
Assigned Initial Code Sex Age Smoker Group Time of 
Code Aliquots 
032 M24A MALE 23 NO 21-25 AM 10 
044 M24B MALE 23 NO 21-25 PM 15 
062 RAND1400 MALE 25 NO 21-25 PM 14 
033 UNK2A FEMALE UNK NO UNK AM 14 
040 UNK2B FEMALE UNK NO UNK PM 14 
003 UNK4A MALE 61 NO 61-65 PM 15 
001 UNK4B MALE 61 NO 61-65 AM 9 
006 UNK5A FEMALE 45 NO 41-45 AM 16 
014 UNK5B FEMALE 45 NO 41-45 PM 10 
020 X03A MALE 25 NO 21-25 AM 10 
025 X03B MALE 25 NO 21-25 PM 14 
052 X06A FEMALE 50 YES 46-50 AM 10 
059 X06B FEMALE 50 YES 46-50 PM 10 
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9.0 
8.0 
7.0 
6.0 
5.0 
CD 
4.0 
n 
O 
3.0 
N 
2.0 
1.0 
321.09 
0.0 1111 11 1 "li 1111 
.iIý 
11 ßi 111 I 11 HI IIIII. 
80 120 160 200 240 280 320 360 400 440 480 520 
m/z 
Appendix B1. Positive mode CID tandem MS of precursor ion m/z 497 from RP-LC- 
MS data gender PLS model. The presence of peaks at 2 Da higher, suggests that 
this metabolite contains chlorine. 
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Appendix B2. Negative mode CID tandem MS of precursor ion m/z 541 from RP-LC- 
MS data gender PLS model. 
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Appendix B3. Negative mode CID tandem MS of precursor ion m/z 495 from RP-LC- 
MS data gender PLS model. 
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Appendix B4. Negative mode CID tandem MS of precursor ion m/z 391 from RP-LC- 
MS data age PLS model. 
286 
Appendices 
Appendix C 
Internal Actual Patient New Fracture Days Weeks Protein S&N SAN ID Code Type Gender Age after after Concentration Code Code Fracture Fracture (mg/mL) 
72/04 073/04 001 Fl Pilon Male 26 0 0 4 
74/04 075/04 002 F2 Ankle Male 27 0 0 5 
98/04 099/04 002 F3 Ankle Male 27 39 6 166 
76/04 077/04 003 F4 Ankle Male 47 0 0 3 
78/04 079/04 003 F5 Ankle Male 47 7 1 79 
80/04 081/04 004 F6 Ankle Male 33 0 0 nr 
100/04 101/04 004 F7 Ankle Male 33 34 5 165 
82/04 083/04 005 F8 Radius Male 35 0 0 1 
102/04 103/04 005 F9 Radius Male 35 28 4 236 
84/04 085/04 006 F10 Ankle Male 33 0 0 2 
130/04 131/04 006 F11 Ankle Male 33 40 6 156 
86/04 087/04 007 F12 Ankle Male 22 0 0 1 
132/04 133/04 007 F13 Ankle Male 22 35 5 nr 
88/04 089/04 008 F14 Ankle Male 28 0 0 1 
205/05 206/05 008 F15 Ankle Male 28 61 9 192 
193/05 194/05 008 F16 Ankle Male 28 79 11 221 
90/04 091/04 009 F17 Ankle Male 24 0 0 4 
96/04 097/04 009 F18 Ankle Male 24 22 3 160 
248/05 249/05 009 F19 Ankle Male 24 83 12 178 
92/04 093/04 010 F20 Ankle Male 20 0 0 1 
181/05 180/05 010 F21 Ankle Male 20 48 7 197 
104/04 105/04 011 F22 Ankle Female 23 0 0 179 
173/05 174/05 011 F23 Ankle Female 23 31 4 192 
195/05 196/05 011 F24 Ankle Female 23 74 11 131 
106/04 107/04 012 F25 Ankle Female 43 0 0 179 
134/04 134/04 012 F26 Ankle Female 43 29 4 198 
187/05 188/05 012 F27 Ankle Female 43 70 10 181 
108/04 109/04 013 F28 Wrist Female 24 0 0 186 
136/04 136/04 013 F29 Wrist Female 24 unk unk 183 
110/04 111/04 014 F30 Clavicle Male 35 0 0 223 
118/04 119/04 015 F31 Ankle Male 26 0 0 148 
179/05 179/05 015 F32 Ankle Male 26 33 5 186 
120/04 121/04 016 F33 Ankle Female 23 0 0 196 
135/04 135/04 016 F34 Ankle Female 23 16 2 224 
151/05 155/05 016 F35 Ankle Female 23 44 6 nr 
323/05 324/05 016 F36 Ankle Female 23 123 18 169 
122/04 123/04 017 F37 Ankle Male 35 0 0 161 
136/04 330/05 017 F38 Ankle Male 35 133 19 159 
124/04 125/04 018 F39 
Radial 
Head 
Male 20 0 0 182 
126/04 127/04 019 F40 Ankle Male 23 0 0 167 
177/05 178/05 019 F41 Ankle Male 23 28 4 170 
189/05 190/05 019 F42 Ankle Male 23 56 8 173 
345/05 346/05 019 F43 Ankle Male 23 126 18 173 
128/04 129/04 020 F44 Ankle Female 20 0 0 202 
152/05 153/05 020 F45 Ankle Female 20 35 5 175 
256/05 257/05 020 F46 Ankle Female 20 77 11 151 
209/05 210/05 021 F47 Ankle Female 23 0 0 148 
215/05 215/05 021 F48 Ankle Female 23 39 6 191 
343/05 344/05 021 F49 Ankle Female 23 95 14 nr 
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Internal Actual Patient Fracture Days Weeks Protein S&N S&N ID 
New Type Gender Age after after Concentration 
Code Code Code Fracture Fracture (mg/mL) 
207/05 208/05 022 F50 Wrist Male 23 0 0 211 
201/05 202/05 023 F51 Ankle Male 19 0 0 169 
254/05 253/05 023 F52 Ankle Male 19 35 5 172 
337/05 338/05 023 F53 Ankle Male 19 91 13 165 
166/05 167/05 024 F54 Wrist Male 20 0 0 nr 
246/05 247/05 024 F55 Wrist Male 20 29 4 217 
156/05 169/05 025 F56 Wrist Male 22 0 0 160 
197/05 198/05 025 F57 Wrist Male 22 7 1 203 
262/05 263/05 025 F58 Wrist Male 22 35 5 205 
156/05 157/05 026 Radial Male 25 0 0 204 F59 Head 
249/05 241/05 026 Radial Male 25 14 2 242 F60 Head 
160/05 161/05 027 F61 Ankle Male 24 0 0 158 
162/05 163/05 028 F62 Tib/Fib Male 26 0 0 157 
164/05 165/05 029 F63 Ankle Male 44 0 0 2 
315/05 316/05 029 F64 Ankle Male 44 50 7 185 
170/05 216/05 030 F65 Tib/Fib Male 29 0 0 164 
273/05 273/05 030 F66 Tib/Fib Male 29 21 3 238 
199/05 200/05 031 F67 Wrist Male 36 0 0 248 
303/05 304/05 031 F68 Wrist Male 36 unk unk 206 
331/05 332/05 031 F69 Wrist Male 36 unk unk 217 
158/05 159/05 032 F70 Clavicle Male unk 0 0 205 
191/05 192/05 033 F71 Tib/Fib Female 33 0 0 124 
211/05 212/05 034 F72 Ankle Male 30 0 0 3 
213/05 214/05 035 F73 Ankle Female 36 0 0 177 
301/05 302/05 035 F74 Ankle Female 36 41 6 135 
202/05 204/05 036 F75 Wrist Female 44 0 0 224 
242/05 243/05 036 F76 Wrist Female 44 unk unk 215 
266/05 267/05 036 F77 Wrist Female 44 unk unk 214 
311/05 312/05 036 F78 Wrist Female 44 45 6 253 
327/05 328/05 036 F79 Wrist Female 44 73 10 200 
185/05 184/05 037 F80 Wrist Male 42 0 0 191 
244/05 245/05 037 F81 Wrist Male 42 10 1 213 
254/05 255/05 037 F82 Wrist Male 42 24 3 218 
183/05 183/05 038 F83 Fibula Male 32 0 0 185 
301/05 301/05 038 F84 Fibula Male 32 28 4 nr 
175/05 176/05 039 F85 Ulna Male 24 0 0 183 
299/05 300/05 039 F86 Ulna Male 24 28 4 161 
335/05 336/05 039 F87 Ulna Male 24 42 6 180 
270/05 271/05 040 F88 Radius/Ulna Male 20 0 0 217 
264/05 265/05 040 F89 Radius/Ulna Male 20 18 3 2 
272/05 272/05 041 F90 Wrist Male 19 0 0 197 
321/05 322/05 041 F91 Wrist Male 19 27 4 188 
260/05 261/05 042 F92 Wrist Female 41 0 0 175 
250/05 251/05 043 
Tibial 
Plateau 
Male 38 0 0 174 
F93 
317/05 318/05 043 
Tibial 
Plateau 
Male 38 8 1 258 
F94 
347/05 348/05 043 
Tibial 
Plateau 
Male 38 15 2 180 
F95 
333/05 334/05 043 
Tibial 
Pl teau 
Male 38 43 6 235 
F96 a 
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Internal Actual Patient Fracture Days Weeks Protein 
S&N S&N ID New Type Gender Age after after Concentration 
Code Code Code Fracture Fracture (mg/ml-) 
268/05 269/05 044 F97 Radius Male 30 0 0 177 
325/05 326/05 044 F98 Radius Male 30 13 2 233 
339/05 340/05 044 F99 Radius Male 30 41 6 192 
258/05 259/05 045 F100 Fibula Male 25 0 0 195 
305/05 306/05 045 F101 Fibula Male 25 7 1 201 
341/05 342/05 045 F102 Fibula Male 25 35 5 180 
274/05 274/05 046 F103 Wrist Female 32 0 0 206 
307/05 308/05 046 F104 Wrist Female 32 unk unk nr 
Gr. 
274/05 314/05 047 Tuberosity Female 40 0 0 217 
F105 of Humerus 
Gr. 
317/05 320/05 047 Tuberosity Female 40 48 7 200 
F106 of Humerus 
309/05 310/05 048 F107 Clavicle Male 34 00 193 
Where unk = no data available, and nr = not recorded due to lack of sample. 
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Appendix D1. Negative mode CID tandem MS of precursor ion m/z 528 from RP-LC- 
MS data frac2 PLS model. The peak at m/z 113 suggests the presence of a 
glucuronide, which would give the RMM of this metabolite to be 353. 
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Appendix D2. Positive mode CID tandem MS of precursor ion m/z 500 from RP-LC- 
MS data frac3 PLS model. The presence of peaks at 2 Da higher suggests that 
chlorine is present within this metabolite. 
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Appendix D3. Positive mode CID tandem MS of precursor ion m/z 299 from RP-LC- 
MS data frac3 PLS model. The peak at 18 Da less than the fragment ion at m/z 90 
corresponds to the loss of water from this ion. 
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Appendix D4. Positive mode CID tandem MS of precursor ion m/z 120 from RP-LC- 
MS data frac3 PLS model. The peak at 17 Da lower than the precursor ion could 
correspond to the loss of NH3. 
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Appendix D5. Negative mode CID tandem MS of precursor ion m/z 476 from RP-LC- 
MS data frac3 PLS model. 
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Appendix D6. Negative mode CID tandem MS of precursor ion m/z 516 from RP-LC- 
MS data ankle PLS model. The fragment ion at m/z 448 could correspond to the 
precursor ion of the same mass and retention time seen in the negative mode RP- 
LC-MS data for the frac2 PLS model, suggesting that the ion is in fact an in-source 
fragment. 
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Appendix D7. Negative mode CID tandem MS of precursor ion m/z 465 from RP-LC- MS data ankle PLS model. The fragment ion at m/z 113 could correspond to a fragment from a glucuronide moiety. 
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Appendix D8. Negative mode CID tandem MS of precursor ion m/z 562 from HILIC- 
LC-MS data frac2, frac3 and ankle PLS models. The fragment ion at m/z 113 could 
correspond to a fragment from a glucuronide moiety, and the very low intensity 
fragment ion at m/z 448 is 114 Da less than the precursor ion, corresponding to a 
neutral loss of a glucuronide moiety. The fragment ion at m/z 448 could also 
correspond to an in-source fragment, as other precursor ions of the same mass and 
retention time were detected in negative ionisation mode data from both RP- and 
HILIC-MS data. 
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Appendix D9. Positive mode CID tandem MS of precursor ion m/z 796 from HILIC- 
LC-MS data frac3 PLS model. 
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Appendix D10. Positive mode CID tandem IVIS of precursor ion m1z 450 from HILIC- 
LC-MS data ankle PLS model. The mass of the precursor ion is 2 Da higher than rrvz 
448 fragment ion (and possible in-source fragment) detected from negative mode 
HILIC-MS data (see appendix D8); this could correspond to a protonated in-source 
fragment from the anionic glucuronide compound detected at m1z 562 (adding a loss 
of 114 Da to m1z 450, would correspond to an RMM of 563). The fragment ions at 
m1z 433 and 415 could correspond to the loss of NH3 and water respectively. 
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